Show UniProt / TrEMBL protein name		View in Fasta format (DNA)		View as list

# Ureaplasma parvum serovar 3 str. ATCC 700970, ATCC 700970

>UU031 unique hypothetical membrane lipoprotein
MAIVAKINGNASEWYHAPIALAFFLRFSLINKIFAIILSCIFCVSIYRFR
KKLVQYENFNEIKSIKNNAILTVIFSVVAILSLTLFINLMIVFINQNYYY
IKRIHNLLIPIRIDEIKILEYSYIYLLRCGFYILLTVFIAKFIHDKRSMI
KVLSLYLFVNFILMIIGTSFTFLEHTNFYNGMLTYWTTFSCGLLYPEIIN
DNFQWISSFNYNLKNTIYENNFIAYLPYFCSFIVLIILIKKVSWKSITIS
SNSY
>UU012 unique hypothetical membrane lipoprotein
MKKLNKKVLFLAIGSVFALGTIITVATSCTQKSTLNYSQFYWTSPTSDDD
EGFQTKYKSMASDGKRALLMPGYQHPERLQNALVNDKFDPNLIALILDGV
YNNDNKAEFYKGADRVADVYFKVDEAAFLGGIAAAYMLNSNQAVFGADNK
LTWGGYVGINAKNTTNYLAGFDLGVKWANEKLKDKNIKQEGTQETKKWIN
VEQVYASESSAGGFQSDSANAKKIIQELITKGADLILPVAIPQVGIAVTE
AIATTSHNVGVIGVDVEIENDQAINKKTDKFINTHLSGNKNGVIRFSITK
RLDTATIKLLENAIKGESLSKKSDQIVIGSEIDPKDKYKLGVNTVGNLSD
GVVGISPSAYHYVIDAFNLAQTNQSDKVSTYDELVNKITNDDLFKTLDKK
PVVDGYLDVKKETDNEASLLNNKTIDPRVNGGTFYKSAKGTYYFYPVAKS
TYISNTSSKKFKEIWDNTKSNDEKQALIGLLLSYAGAKVKDGGYSENTYN
GLKEFYAKHGIKIPQL
>UU146 unique hypothetical
MINNIFNKKLLVYNEKDQRWYNKFDRTKPLFSPSRLLSFKNYIFEKIPAK
NLEYPIEFGTSLMQIIQYYFENQSKLDVILNSINEEKLKEVFLLFLDYLK
TNDYSLIAVELHLFSPKLNHYWHGFADVVVKTKDDKYKVLEIKTHNEIQS
VPSWKFQAGVYDYIISQELSNYEPSAILAFSRKQAKLSVYENDSLDLSFI
NKINELYS
>UU480 conserved hypothetical ATP/GTP-binding protein
MIKKHIKKIVIGALSTLAFITTTVVATACAKHNNSVTKNNEPNVNVKDEI
SSSNSELNDSHYYWKAPKSDTSEGFQTIHKSMVEDGKRAFLLPGFSQSNY
LQDAIKNAKFDKNAVGFLLDTVYNANNDPSLFDGANRVASVYFKVDDAAF
LGGIAAAYMLNANQNIFATDGQLNWGGYVALNAKNTTNYLAGFALGIEWA
NKHLANKKVLQEGSSESKTWIKVNEVQASQSSAGGFDENNENAKRILKEL
ISKKADLILPVAITQMSLAVNEAISTTSHKVAIIGVDTEQENDKTINKEA
NTFKNTNISGNKNGVIRFSIVKRLGVAIEKLLENAVNGTQFQGHVNKIGD
EIDVHDKYKLGVNTVGSLVDGVVGISESAYHYLIDAFNLAQTDETNKVST
YDQLVQKIIQDPLFKSLNQDPKIDGYINPKNLANARGNEGELINGKTISP
EANGGTIYKATNGSYYYYPVAKSTYTAQNASTIFKEIWDKAKNDDDKRRL
VGLILSFAGANVKDGGYSEISYDGMLGFYAKHGIKIPKL
>UU408 unique hypothetical
MSKIVDNIDINALRINHYEEWEQNHIIKVINAYRHHESKKEKFKMIHELI
KNHQMHLTKLIPLFDVSISGYYKWLEDLKIDQVCPIKKRNMDLIEKICKS
HKHYIGCRKIQKILETQYNVKLNYKTINLYMNKMDLCKPCHHEHHEKKE
>UU439 unique hypothetical
MIYKEIVRNIIKHPLILPDGKHYHLHKILTSKDELRKGEVTLVAENGKEY
TVDLSAFVDLLVDGDCIFDDNHSLVALYFDDAK
>UU052 unique hypothetical
MRNKLKIKLKFLASLATIPIVASPLIFSVAANEDGKQENNNGNNHDPNQQ
KKPKIPKNDPNFNTFKTDADKTVKDSLEKGINAAIVYVKSRQEEILENKE
IEFKKKIQQLIYLKNLQSYLEKNKENILKNPNDYGFYLNTPQILGTLKNY
DIKDIEFNGETYKQIKVGKTDPLNYQKAVAPKGKISDVQSDQINDVEETK
YKDTLKKYESEFLKEINKLIYDENDVPQINKDVELTRDEKGQFNTTLPKG
YNDWNAYFISKIKDRVTAFDLKQNQQTNEDKQEEQPNEQKDPDTPPPLPP
PLVEGDHNEIDLPPTQANAIISSLPLLLPYISPIYSNESLSGLKSKFDSL
KPELKQTLFYFNNPINTRYLYSVLDFGVNGSSMINIKVKIIDQVNPKLQR
TYIINKYDPILDINFNSLKLNEVNAIKQIFVNLYKHLGLDEKIDYKKLRN
FYIRNALFTMIEAAQKLILRFNQIDKDNKIIGQKTFATLQNEYLEKYKQK
LVNNTDDKERLLNEFNNLTKENFFRYLNNTLINNDYYWYQLVGAYKQVSL
QFSEVLRLNKDKIKANIASIKGDENTIANLYKLNNQLIYQLSAIVAQRSF
NSQQWYQSYLNVLQPIKENFDLMSILTNQTDIKTNKDKAKDFKNAYDSAL
KSLERQKQVNKQIRRKIGIAFIVISLLVLIINLIIYGLIKKLKNKKVILI
INSVIMVLTIIVLIMGIILII
>UU378 unique hypothetical membrane lipoprotein
MKKINKKILFSSLLFGTVAIGTVAVATACSDNKKTKKTINTGTTQPGSST
GTTSKSLTQEKVLRNEIISEILNAKSKKPDRDKMWVNWWNSSFEQARKLA
REMDKAVDLTKSSNFKKLIADGKYKSTFSAQIEDIITKVKHDIKMYAESP
FWKKWRDEKKTVITLVNNNAPREDLGAMNVTSIDLPADFPIIYSKPDYDG
IPGLGARFPTPKSKVAPEKLLDDGFSFGDIIVEDGSDTQKANLPGQLIES
FEKTADKVIYLYYDSGLPEAFKNNQRQPEKIKQFEDWMKSQNANDFVAKR
MLKNPNNKDDLIVMPMSSLWYASYGILGVNYSLHALSEAFGMPKSELDAL
KAKEEFKVPKQLVTLVNQATDLKEDKQTIKDECDPFKSHRDPNHKIDWKV
WATNSQVLDIAITLGLKPDLLVNGELSTSGHEENQLALYLSDYINGQLKD
CRTITPNDGIRWETTSLTKIKDLNVNLILAGIHGEAATKMFGALMKEHKE
IANFAITNRRFNDETRKVVAPQDRDKYSQNAALVDWEDYLKTKDLH
>UU330 conserved hypothetical
MNSRFKFNYDINNKLALSFTKDLIANKKQKNKKKFLLFLFPFYPLKLFKT
INLIVVFAVLVAIRLGMGFLHIKIPGFNMVISFTWMALMVLGWYFGPLIG
IFAGFLVDTLAWLISGGIWFWMYAIQEPIVGFIAGFLGSVATLRKKTKRP
IIDLIVNQIFILFFSILTLFMILTLVNDGKNSLFSILKKRDKEINEDWIS
IFKYLAIAFLATFVLLVEAFVIIYYLRNRNRSKVQLINFIYCSLLVIFST
MLFSFALGPYVSVAYLKYIKVPITNYLKYGVNYYLLPRIIKESIKTPIYI
ILLSSIISAFDYVFLNIKQINMHKWKH
>UU261 unique hypothetical
MNNYIQQVIDYVNDKTYKNKTYFIKKYAFAFLTSLIIFIFLLVFGLSNYF
NPLVSLVGVVLIFSVLVVFCIHIKIINNYSLNLLKWLRNQKELSYKYIIN
ILDFILNKQLYLNLTIIEVQQICIDLEEFKKTNVI
>UU063 unique hypothetical
MSKKIKIYLAGPLFTLAEINDRKQQASLIRKTFKDELPNYELDLFNPIEV
NDELGANAHKPNIFFYESDIKFIDQTDIAIIDIDNTDDGTMAEMGYFVAL
QKHVKPTLKIYILNTDWRVHKHRNEVLNKFLDGMILSHCQYFTNFTDLLN
HLLIELKK
>UU169 unique hypothetical ATP/GTP-binding protein
MRIKLDFIECFGFYSDLVEFVAKKLPIPFNEINLLGGRSSGKTFATLDFL
SSLVAIKQQNAIYVFRQNISDAKKIFSDYLNFLDQKQLLKFAKINHSERT
VIINGWTVMFEALNETRNNINKGAKVGFRLWTQARYVFAFFEEASQLDFN
LVKNSQQSLRGTKDTQVVSIFASNPWTSEHWYIENFNNHLAENEFSIQQK
PYYEYSVVDKKLFLRSTYRANKFTSQQEIEQFEWWKDIDYSKYRVISLGL
SGSVEGAIYARSLSVMHEPYGEYDNYAMQFFGGMDWGDGTSSSSSDTACL
FGSISKENGIEILDEMVYNNNVNPLTSEQQIELVVRWFIKKQQEVNVKIV
IYIDNAHLRYFYETFNATFKRIAFQYNMYGSELVFAPAIKHAIWDRVVLV
NYMLASGKLRFSKNACPKLYKDLKNCYVVLPKTIKEDTKKERSHEHTHTI
NALEYLMCAFHLYFYAQAPAINEKGAIRYGT
>UU485 unique hypothetical membrane lipoprotein
MITKKHLTKIITILTCSTLIIGLSCLIGACTKSKSKVDDKQVLFKIKKFK
TTTNSIELFLEGSAVLASHSYSVVLKEKATGDLKTINNLKLVKDNDLNKL
IINELKPNMGYELVDLLINNQKQLITKLDFITSTLTQENVDQFSIKKIDW
KNITNNSADLNLEFTKYFLANENQNIFEISLLNLQTQQITKFKFNYQPNS
PSITFNFTQLENNAKYQIHRIVLNNKELVFSNQNLVLSNTNKQNSNPIIK
DLNITKIEKEIYDTSAKLIFYFKDNKLGDLNNQKFVLKLVSAHQPSNTFS
FENYVYNNSKKTLSFNLTGLQTSTKYSLNSLTLNGQPISLANLDLNILTS
TKLTTVQRLENLEHESSDFWFNDENLSVKIKLYFENNVNYLKNKYLKLVY
MDNANNIIVSKPVLFDPTKKEYEFSFDKVLSNRKYTFSKLVFDDLQDFSE
KQALEVNTQGLNGSFNTPQAKIKIKKISYSSTDKSAKLEFHLEDDFDLVD
GDKVSVKYRLKPSSNSIDTTNNTVEGLVHNHILNVTINDLESNKSYEVID
FVINDYKNKQLLNKPEFLKKNTNHHNHPFNIPLDFDTKNSDYKTKFNVNE
ISKSYNKETKLTTIKLKFDNIPTNPTSSNNFTFTIKKRTGYTTNLISPKT
LEYDVNKKTLIAKFENIEDQIVYDFVDVKVNNQNIEFNKSLDKYFSIIHS
ADYHE
>UU316 unique hypothetical
MKNFSKNRNINNFKNPLRVIEGIVREIKNNELQIDFVNSHKKGVCKFINL
TDYHWNTISSRFLINSKHLFLVSKFDPIRHVYWLNYKIIHPIEIKNKRRS
YPTLSHDRNLRIFLNNLLEKENELKN
>UU592 conserved hypothetical ATP/GTP-binding protein
MDIINKKINWFPGHMKKATDEILKNLKNVDFFIQLVDARCPLTSSNIELL
KEVSSKPVINLANKADLSDWKKNFDNNFLLISTKKRNDKNKIIQHLYQLF
DQKIKIYQKKGLINPKFVGMIIGLPNIGKSSLINFLAPKKVLKVENRPGV
TKTQCIRQINQHFYLIDTPGIFLKNIQNERDSFVLTLINCVKKEVLELES
IVHFAYDFYLKNYRNELFIKYKMNKVLNFDDFIHHICELYNYKLTNNEFD
HVRAYENLFNDFSNGLICKVNYD
>UU331 unique hypothetical
MSYYYKSKFRITDHALARFRERAEWTDVNIKNLSGTFIIPIINERILGIR
PLNSLDNNFHIYMDPKNKGYYFLVDKYTNTIISYTKRTNKNDFYHIKKIK
>UU166 unique hypothetical
MESLKMSNIYLDELEGYSQKNIEDSIDSLIEPNQKPIHLCPFRILKGFIK
ITNTGEQSLLVNDKDFSTVWNIKASNEPIIAYWDKSFTYNFKGSLNYISK
DYARIDPSNTTLKNNFKPYYFQAWVQNYSQANNVSTIVFNDKEHTVIKTI
TTVTLIVKYPSVYEDEIYQNEQGNLVSHKAKFKQWTTDMLKEYLFIIPDE
HAQANQWLMVNEVIPFYSTTSKRYEGAQITLTNVNDLLTSSGNDILATIQ
PCQPGDGYLWPVIQNGKLTYDERKEKPLGVKSIQLLTNGPYALNSMLITG
RTYNNDTRELSANKRLLLYKAKIPVASKFFNVSAPTSNYVYLYNAFFEIE
KIYKDQYEKQKDFTFDHNANIKLNGGLLLNHKWDASNNALSYEDNRYPFK
LWDEGFKIHASFFNFKLGGTGAQKGGSLTENAEQKKPLADAVVTGQVAGE
VVSTVFESIGRNVSQGFNLNNLGLWSFNMGFAKTKAEQIKEATKIGLNNI
TMPPGTNLHTFLNHNAFMYDLIKYLPYSYKETIRQNLGELIDNTPLSLGK
VRRGIVDILYPGWTKVEDATGYNMSNIWLNTRGFNFIAPCLPLELEVSNK
LKADLINLDIFTNKPAKTFSPLGIPAIACCYHFDITDRFAKFVDDELKVF
DTELIGQTTYRDGTYIRKDKKPLYWDSFCEALPPNTPLSYEPAVINIASG
KREDVNRVKYPYVIDTIDIKGLGKCDIKLTAFSGFYSPDARLKDEFKNVY
EAIFESNGKYTDDMSQWSNYINFSTLDEINSVGTKLSYPKPPVETDFLKN
TKTNSDDGVNASLQTINETLYKVGDNSLLSATQYRKPRFYFYEPDSSKLA
NLFGYGSYTNKLNYLFGGSNLSDVIVANKVIAYSFVFKWDFNYREWLNLG
SVNKTKRNLKLTFEIESNWIQKGWTNQFNVDNSFNQLITLLVLN
>UU352 conserved hypothetical
MCISKIDMAKVKKFFKEYLFAKFQCKNRELYRQLKDYDPKDDQKYLKWEH
FVEYVEQVLEALDKTSAQIIKEIYIQNKRICELPYSYSTYYAYRKKAIIE
LLAYLDLKI
>UU029 hypothetical
MIDLIIKTLVQKLKIEAKYITNVLNLLADNNTIAFIARYRKHLTNNMDEF
QIQAIAHEYEYLTKLNKRKEVIIKNLEQKGLLTNDLLELINNCQRLVDLE
NLYEPYASNKKTKASIAIEKGLEPLALLILKNNPNSNIKEVAKQYLNEQV
LSVDEAIAGACDIIAQKVANDTTLREMLYETINKHAKLITRINKITNDPT
KNFALYYEFSCPIKYLKAYQLMAIDRANELKIIAFKLDFKKEFLIDFAVN
KYTRKIKSNSYDYIKSAVNDGFDRLLIPSVSNAVYKEKLEEAHQQSAQIF
SNNLQQLLLQKPLKSHVVLGFDPGYVHGCKLAIVNKNNQLLHTDIIYPHK
PQILITQAKNTLISLINKYEVNTIAIGNGTASNESVIFISDLIKEFKLNL
NYCVISEDGASIYSASSIASEEFPNLSVEKRSAISIARRIIDPLSELIKI
DPKSIGVGQYQHDINKNILQQKVDFCIDYCVNQVGVDVNTASIPLLSKVS
GLNKRSAKKIFEYVKKHQFIENREQLKTIPYITDKVFEQAAGFLRINNAN
NFLDRTSIHPEAYLVVNELCKYLQLPINKLINNYQVLNQLNPNELTTILK
TDIYTIENIINNLKNPLQDVRDDYDIPILRSQMVDINNLKIGMLVQGTIR
NQTEFGSFIDIGLKNDALLHISNYCEEDNLHVNKNINVYIDKIDTITQKI
SLKLKL
>UU555 conserved hypothetical
MVLIEKINEQDINTVVAYVVAFRKKLYPKVDHNNLPKELVNFKQTYIINP
LGIWFSVFLEDTHELVGTISCHEYDYRYNNLFYLDRSTKTSEVGKLYIDP
LIRRQGIATRLFNALKDQAKKQGIKCFYLHTHHHLPGAREFWLKMGFKIQ
KEMTLEDDGQDIIHMTLEL
>UU334 unique hypothetical
MMNDSVKQTNNIDENQLKPTTKSFFDDKNNQLTKVLNIPSVVKYTESKIK
KNGKNFSINLIITITTMFIVIGIIITIAIAIGIKLS
>UU323 conserved hypothetical
MLSFVKELNFEINQKKYFIKIYLQPRIKYIKIKIINHQIVCLINHLKLIN
IAEEFIKNNKLKILKIYENDLKKIKYDEQSLDWIILLGIKFTTIKIKNNN
FHCQFNFQKQIIYLYDQNQNLTNTKLLYQKILIYLAEIIFPQIIKNAQNI
TTLTVKKYVFGFYKSQWGVYNKIKHTIGLSYFLVHYDQDIINYVVIHELA
HIKYQHHQKSFWDFVLKYCKNAKIYNNQLKF
>UU386 conserved hypothetical
MEFNQHITVLLNETIELLNIKPDGIYVDCTFGRGGHSQLILKKLSKKGKL
ICLDQDQEAINFANNLFKNNTNVIVIKTNFKNLKSALSAHKIFYVDGFIF
DLGLSSPQLDDPKRGFSYHKNAWLDMRMDQSQNLNAHYIVNNYSFAKLVS
IFKRYGEIKYPKIIADAIVKERSIKEINTTLELVEIIKKYSPKKNLFEKK
HPARLFFQAIRIEVNDELNILEKAFNDAISMLNPLGVVAIISFHSLEDKI
VKKVFNNYAKIKLPKEVPINNYVNKYSLLNQKIMPSTQELNDNNRSRSSI
LRGLIRNY
>UU419 conserved hypothetical
MPFIKTPNKDFGLVDNQIVLSSDYKKRYQRYFAKITGSRLGSILNIGDFT
NPVRTWAMMVKIYNEPIDPIYAQAGVVIEPKIKDYVETVLKVKYKQYEPA
QIGYDVFKDNQIFGGIPDGEPIDENGQLLYPNQPMLEIKTTSIDSFSFKT
IDYVLVLQKDEHNHPIIKKKGDKRAKWFNNDESEVIISDEYQLQLGLYCY
LRKISKGIFAIAFLTSEDYINPQAFDINKNEIILVNYELDLNEFEKVISK
AKTWYEEYIIKGISPKLTKEDLEWYKVWINKYETNNLY
>UU067 unique hypothetical
MDQYKINELIPSEYKLASYFNCGRITIHNAYEVLKVLGIVTTIKGSGYYV
YSSIDHFTNKAFANLYKTIDNIKYEQFLIDFEYHGNKFNSITKFSLIKNK
KIIAVSYYITPNNMDLEQFDTNNINISKQLILSGFDDFFNVKTQINYENI
NLLKSILEDENIKFNTPIILNKLTSSSLKVELLILTHISKEYFDYEETNK
LIIN
>UU170 unique hypothetical
MMKRNELKQLQELQLKINDFYTLVMTTKNLDLCNLSALLEFLGINWGVWV
NLSTQRDEFNKKRYEYITKANYGLRMALNELLGRNASYDKEINNQGLRKF
RTQEYFKRLDFELANEQKSTDIEDTTITFEKVDDNNKLTIKKLINVI
>UU556 unique hypothetical
MDLIFKRLKFISIQNWVLLLFAAALFVCVGAWIGHELVRHNLFDAYTLNH
EKELINMLNPKDLEVYLSQKEQIRLSIGFFGLFLVLWTLTYLISLVVNIR
ILIKYLNDFNENKTKVKKALIISLIPFIHYVSSILLTVVYDKVFNWNRKK
SHTLQEEYISAY
>UU325 conserved hypothetical
MDLWKEQDENGISPNVSNERKVVVASNGEKTLYIFIIVISIISIIGWIFL
LVWWFNTKNHLIQTKNSVNEASSSIQVAQTKRFDLLNKMIEQTKSYYKYE
EKVLDEITKNRSIQMSNDINKNEEVLNKLQNLVNVQFERYPDLKSSNILM
ELMSTSSYLENEIASSRRAYNSRATDWNIMIFQFMTVIVAEKLKLETFPI
YAANKQERKDVDMKSLSDF
>UU572 unique hypothetical
MRNNLSDLEIEKLTKTLVSKNKRVVALYGVPENTSYKLMNDLISLMDVEI
PNWSSISSATEDQCINDIKNFLLSNASLENFKNLPSNNPLINWWKRRRLN
TVVKKIEEINSAFADREITSRSKIFLMPVLTAFSTLGTTLAVPLISVTFL
RGDAIINLWGKDGYIAFLSLLFSLVVAVIISAFVALFSSLKNNKRNYIVS
NMTKGLKRIYDKYFIESNSQEKINAKVTFYSRFLERSKFVVQNNYTFFYD
VVDINSDQYPKILKYFKTLNQLNNTVIFDASGFKYLDERKIFRNIIDLEK
TNVVRLDRYKTKTSGRRLMSFIFYQLSIIANVNTRKLLQKFPFFVNSLYR
FLDYSEKNTELLTLLLDIKKHASKTEIPLNDESQLFFVDFFTFVVFKALD
ELGFETLMNDLTVYGRPSEITKKNITYNSLKLDYIINRNARNFGQQALLF
NLLDYFDETVNKNIFNELGNSNKNMIFSKNHQLNLANEALSKKGFTKREI
DLNNHWYDALYSNLHDDEDMFVKIIEIKDNVDILNVLDELFVRAQNDGVK
NLLIYVFNVKMLYSLIDNEYELVNESII
>UU303 unique hypothetical
MQEGDFYATDRDPFLTYWKELKPSFYAKKSVYIAFLTIIIAFAVSIIGFV
NYFSLKIALEQTQKATLEVQKQKEEQKNQLSNGVYFDQDLNLLNEYDKLV
LYQKNNLSSIVFLAINDQEQILMQKDQVVVNSLNIEQKVKYREQATRIVF
EKQAEHNDHLVTSGNF
>UU016 hypothetical membrane lipoprotein
MKKSKINKKILFASLAGVVTLTSVAAIAASCNDSNKDDGKTNKDGNYISK
LSLEDFYAKPAGDDSLGYHRTYNSLYDDGARMLGLISFSHSIPIKEYFGS
SSDKKDLSAVLIDDKFSGTVGKDRIASVSYRVDQAAFLTGIAAAYYLNAN
QKTFAADGKLTWGGYVGLHFTSTSTFIQGFKLGVQWANEKLKDKEINQED
ANGSKKKWMNVEQVFASKYVAGSFKPDEEGATNIINDLITKKADVILPVA
GPQTNLATSIVSNATDPSVIIGVDTAQELDDVTNRKRITNKTVNDGKTIL
FSIVKRVDLAMKGAIENASKGAQLTNDINKDAYKLGTHTEASLDKSTYVD
DTPLVELSNAGRVYLEQAAKLAGLKAITYAQIVNVIQNEELFKLLSTKGT
TKLEDLATKTSDGWVLKDSEKNKSFSELQKLLGGEVYINESDKKLYPYSL
TGSSYLEEDPKKRSASQEFKKYWDAATTPEAKEKLAKVVLGQNNAVLKDK
SFSESAYNGLAAFYKSKKIIIPKI
>UU504 unique hypothetical
MKKKVIKMINNSPNINYYLQDKKYIPKYAYYVNKKQKPIELFARYKGRPA
LFIRENTMINTSLNSNVLNLDFEFEVAGDFKLPINYFFMDIKSDIGEFRN
LEVYETKHSLYEIGGVIYDLYTYKTNLKINLNQAGFVNKNTLSKKINFAF
FLRINDDKRIHEQINYTCEKSLFFEAVQKEFQDLNFDYFYKNTFLLNKHE
KVNPTNFWETIPLFWIQDKELDNEIKIKNNKRYIFNTKFSLNDDNSWNNR
PTKETFELIKYSLEYVNLAKENKKIEWIEDYQNINITYDYYQRPIDFLLK
MKTKFLYDFKNDQLSINNNYGFNGIWLPNKQIAKLKITVINNYLTPQKFV
INQLINIENDFNSINKQKISVQKAIIENYENFKSLEN
>UU487 MBA N-terminal paralog
MRLKNKNKYWNLLIASLISIPIISTISACSFSETRYKLKVLDYFLKTEND
DYYIAYEFNKLTNEDMQKMPKVIFSTSIINSSNQKIAFYVDIKPIIINNR
IYIRLPQRPKPNEKIIINSSQEFVGVQVIQTNKMLTRSINFNFNKEDHLI
KVVDQSARFTNIKKTEVEFEIKLLNLNLNDIKDKNIEIELTNKKTNKTFK
LHFLKYQFNHLTQQNKKPVLTITANLNADANNQLDDGEYFISKLVLDQKK
LEINQSVYKPSGLQLDGSINNQRPTYLLIPSVFSKWTKINVLDTKVIKND
GIPQQLQLSYDHFINPYNFKDNMLSADIELISTKNNKTIILKSLKFNHDK
NNIVFDLVNNLELQTLILKTPFFKIKSLTIMNDKQTLPLSIREKQLDLTN
KHLSKIIKFTFDDTDPQNMLMKFQLDSDSPIVQNTKKVLLTIKKINTDQQ
EDIKTFSFDILENKITTGSFYDVKNKYFLLNLNKTLNAKSIGQILENDSN
YIITKLTVVNNEASINEIPIEIDDLQNKQFTLKFAEYQSNVIKFNAKNDP
ELHLNIKHFKQLNLTKINKIKLTLKDGKQIIFNRLNNEFSFQQAGFKLKI
NQNTFPNYLKQHQYVIKSISLINDDQSVIELLSKHNHEAIFEIPITASLD
TWEYDKIHNILKIKMKLDSLSLHQSLNPSDYALNFYNLDTNIINRKFTLS
PQTVLSSKVNNSNVIELIYDLDNDENIYGGLEPESTYQISSLMINAKPVI
INTSITMVQTNASASKVEKIVASYDSVTKKTKISLQFSNNWWYNKNADHK
LFAIISSLKPKNNKNANWTFSLSRTFSNPEAINSNKDKDFVLDKATKTLT
YVINYANIDYKDQNDHESFDWYYDDLVLNKVTIIYNDLTTNDISPFSKDD
QNLTIKLPNKINS
>UU110 conserved hypothetical membrane lipoprotein
MKINKKLLKIFAGITSLLVFIPIITACSQKSKLVVGNFDSYMDPDVANEQ
AKRFRKNNLSYSFYDNNEILSSLIKAKISDVQVASAYEVAKLAKNGLIKK
INWAKFNLKDENNQTITSIEGLKKIFTKQVWAISNAYSSYLGDLDKDGKN
DQLLEYMIPYFYQDLIFAYRGKKIPNLDDNKKDVYWSDVFKELTRNDGTP
NRFLYEQKANLGFGVDKRTPITIAKNKTKIIAIDDARTIYDIAKIMQLEG
DNKNNIIKIINHEILGIDNSISQILHILKNPNIKEDIKEENIKKLKRLQK
QLEDRQKELKTNVFLPDSSSVSYIEDKLNNISNMFKNLHPNSMYLKANSN
DVLNDLAMANVAGAIAYSGDIAFAANGGEYTTEADSNYANMKPTSDNFHV
VRPKDTMSVLDGFTISNSINKQNEQAAYEYLNELCFAGLNEKNTDGESKI
LDYGLKIHRNKTPKEIADYENSLDDQNEVGDVLEDSGYLYTPMRNFDYVQ
YSPTLNTIADYVLDENNGFYGKTGFESDLLRQKMVEIFEIDTKYKTKKER
QRKHKYISLLNEIINHIYNTYQKDKKFIFNPTLINDIYEQKPIKNLIYEC
LNNLNIKIESHVFNNYLLLKLEAIFNNINEEVEEHAALNATLRKIFNVRL
NINTLEFPTNDLSISNLKLAYLAFREKI
>UU125 hypothetical membrane lipoprotein
MKKNKYKLLIKSLVITSFLVTTSSVIVACTNKEKEQHLTELKKLSQHAKQ
IYNEIKTNELFKKEASVLNDQINKVLKINEQNNLDVITKNYNDLKKLLDE
IQEKISKEKEKEKQQNAYLNKEINIKLENLNQIVNHNLLKGNKESFFNQI
INFTPITTEIQTIINQNQNLLDFKNEELELKLKNLDLFIKELDHKFKNII
DQLFNIEDSYINKFLKFINNQDFIKDQKYQEREKFNPQEYLELTKSIQSS
FNKLKNVTINSNLDQYLNSLNLVLLSLTNETKAFFTKFEDQIKKYFKWIV
YGRDDTLTKAFNRIVEEQKRNEFIEQTEKALLTFPMEINQKFKMFVDFFT
LKNDKNETEYQKIWKSKHNEVNKVWFGIAECFATGKCTDKNKPS
>UU056 unique hypothetical
MALTIVLILFSVLALIIGLLLSRTSPSGGLSSLNGQDLEIFKKTKDRGWI
KGLQVFMFLLTIVMILIIIFYRVS
>UU383 conserved hypothetical ATP/GTP-binding protein
MRTIAIVGKPNVGKSSLFNRILMRRKSIVDDQPGVTRDRIYDIGNWLTRS
FMLIDTGGIISSKDTYQDNINEQVLFAINEANTIIFLVSAKDGINNDDKK
IAKMLKEKAKDKKIILVINKIESEKYYLNEGELYSFGFGKFFKISAEHGI
GMGDLLDELVKDMPIQNNLEKQERFKFCIIGRPNVGKSSLTNTILGEQRV
IVNAEAGSTRDSIDNDFNYYNKKYTIIDTAGIRRKGKIVESVEKYAVLRT
KKAIERSQLILLVLDGSEPFKEQDEVVGGLAYNANIPTIIIVNKWDNIIN
KNSHTMEMVKKQIRSQFKYLSWAPIVFVSALDNKRIHTIFEAIEFVREQA
MRKIATSLLNDVVIKANAFQEPPPFKGGRISISYIVQVQSQIPTFVLKCN
NPKFLHFSYARYIENEIRKAFGFDSVPITLYWQDKNKKLRGE
>UU351 conserved hypothetical
MKKMDIKAQDILNFLTKKYDLSKAEAWDKNGLFFDEQQTINNVQIALDIT
DDVVNDAILNNANLIISHHPLFTNQDSNDEVNYFVNIDLIEKIKKNKISL
IHLHTAFDASANGMSMQMAKRLGLLNLKQDEQNPYLVVGELKLGVSVDYI
SRIIKQKFLSPIIKYNNVFRLETNLKKIGIIGGSGYKFADDAFNRYQLDM
LITSDLKYHNWLDAQAKKQNIIDMNHLSESIFIDVIYDELTKFYGNDANL
NKSLSIIKINYI
>UU353 unique hypothetical membrane lipoprotein
MRESFDAHIKKKSKILFYFMEWWFQTTNYKLNPEISHAKRSLRSWLIEIF
FLFCIVALIVCILAGVARPIIDCVIKSITLSRGQFKGDLIIDGQIIMKNL
SPSNINGLTGGSSILNVDQWELIPKVWKAYFSSPSVVVLILLVLFFLFFS
CLYIYMIKKIRPRTNKMSLEDYLIARMNLINSFKFILKRKVLFIEGIKEY
NHRFVFNMNADYNLMRIMNYIYSGLAELNIIMVIDMDSDEKIFELQKVIK
QDFDNLDLIIIEKEIAESLKSKYQNGCLNKKTNLININNKEIDQSQQTQD
INIY
>UU379 conserved hypothetical
MSKNPYVINEWFMANVIHNIKELQTLTINKKIKIKDFDYLSYLPLVKDDP
LASYFKSIYEQEVKRTKLVLAHNDFSINNILANECENLFILIDFEYSSRN
LKDWDLFNFLRDLNDVQLNFGISFIKEKLGYDECLIYKYLFLTSYYGFLW
ATNAFLKTNELKIKIYGENAYQKADFYLQKLNK
>UU395 unique hypothetical
MQRIINKNMIYGGFMPLVSGALGFWNKMLFGTIIANTAISMIGGITNIVM
ASSSQQNHDSQDIDSIKIETINVDMSTIVGPKIPYMNIYYLNS
>UU035 unique hypothetical
MRKFNKMLSNKKFLDLDIIKESFDNYLSVGTSRSTKKLKTLHGSIAKDLE
ELLGKEYNIKSQGYRDDKEECIDGRYYNKKVDITIKNNGKSIAGLAIKFV
MSNYSQNSNNYFENMLGETANLRSNSVPYFQIFIIFDKVPYYKSDGVLQK
YDNISNHNLEKYLKLSDDDPKVYFHTPDKTLFILLSLKEISEEIKNKKDY
IRCYKEIMNDEDLLSYSNKIDDLFGNSIILNNYEDFIKRMCALIIGYQKI
KT
>UU299 unique hypothetical
MQYITINNTKSGKILISKSNIKKFIEQKFNLIVNKKFVIKNIDIVQYDES
LVDISIIISLFDIHQKVDLDEVRDVQNHLASFIYSNLGVDTKSVNIGIDL
>UU527 conserved hypothetical
MAKLKFWKISTSINTFIKYLICNENNVKKIFSNEKLHLDTNDQEWKILIN
DKNQKKVEFSFKRSSYELIRVLYYLQIIVDSDKNKTINTYKNDTLKDYIF
TFNVSDNTEKSINKHITNVFVNKFLRNLDLNDFFQNETIDQKNKDFVLTI
FLSLLHYKKHNDYLTKKELFEYYYEPKQNDSNFKHFKQYKEFVENYFKDQ
IISNELITKFENYWAKTNDENKANPNNQTNINKTKNKPDFLRTAKTQQEK
DNKKFNFEEYSDSCELVTNWKLPLISNDNSIEVTKLDGTKKLASDNGDAY
IFNLVWLIKFLNKNETIKMSIPVFQRNYVWTIDNIEKLLEDINDISNKQN
NENHFLGSIISVLVKEESIDNIQIIDGQQRLTTLFLITKAFIIFLYNNRE
EITKFTNEQIKQLSHLKDIFFNREFIIDRFSRIGGNPDYEALKQILSNDE
LDNKNNHIFMNLKDIVEWFEEKPKEFKEWANFANALFNNLILNLVILKNV
DEFKTFESLNTNAKKLNAIELLKNKFCWYENFKESIFKNKEEFQQKYNDL
ITKKFLLKKDENIIEVKRFNEFVDSLSALNLCKDEDLKRFEKNDKDDEYY
NKSWFFIIEIINKKFTLKNNWKACLKYFSKYIDIYNDLTIKDKFTNNNCN
FYLISDYLLILTNKKKKNYIPLLVYLLEKIFTEDVLYDFDNNGNFDKSKL
RINIEEYVSVIANFSLRNVLLNTRGQSILNSVIKLIKLIDNDINKNNINS
IKNINLSKKFLDVFNSNNQMEIKNIKNFYNKMLDEKVSDIHLAYLIRFET
YLTFFLDDTQINKNKDTKVFFYPPSNADNEKADLTIEHMYSQSLKDERFN
IVKNNIGNLIPLTKEYNSALNNKEFKDKKQRYKNAPIIQNLWLYKGLNEE
QITKLYNEFTKINEKLKSNKIDVNEDVFKEALMSLKLSDKEELQPEQIKK
RTQAIALVLSIALFNEDWDVE
>UU376 unique hypothetical
MNFEAASAPSQQPSPTPAPKTEEPKENGGSEQQADQPENSKKDDVVASGV
KISEVKNNTATIEVTFSKFELADANKKDFVLEVIKKADTNPIQASDLKYD
EASKTLSGKLSGLNSNVDYEISKLTLNGKEVKFNEEELLKSYVKNAKLFM
TFNKENKKINVKLQNFDILNSLEENQPILTFDIEIKKDSSLQVVHKSLTK
NQLSNLNGLEIDLKDKMNGNNANYDVKLTNAKLLNVNIETQK
>UU420 conserved hypothetical
MKTINLKKEFNQYCISLKTQDLIKQYFNDEKLKEKLLKNRLIGLISLIII
FIIGVGILILGAFINKGNGANLNNGAITCVIIGIFFLLCLLIPYTIVANQ
NKKIMHKYIEYHFNEVNVGQLIKKISTFFQEFRLLTEGFLNFKQSNQVID
INYCNEKYSLIYSFQQKPQVWLIKSTNGNKISSKEWDLKGNYDLKIYELE
KWNAGFSKFYLENNIESIAFQIESKLSTIINDFEELWIKGGGFLNEEY
>UU266 conserved hypothetical ATP/GTP-binding protein
MAKFIKSAHYFDQYPIDKQFEICVIGRSNVGKSSLINALANKKIARTSNT
PGRTQLVNFFDFNNFRLVDLPGYGFAKVSKEKQTDLAAIIDQYLGYRQNL
CAVFQICDINVLTNDDVEMSRYFENQKYAHFVVLNKLDKVNKSYFNNNKH
KIAKFLNISTDRLLCVSAQNNINIITLFALMKKVVIQAKQEKILSKKEEK
MSSEEEIK
>UU518 conserved hypothetical
MASEDKVVYYLSPNEDKGWKIFKKGGERATKLFSTKKEALEYIKTLGRNQ
NAVVYIQTKDGKFQDVRNYRDK
>UU139 unique hypothetical
MDEQIFIQLLENNLTNSKSYVTQPIILEFKTDVFLIINQILKQYKKGKII
KNNTNEIILEIDNKLISITNLDINKFHSYQIVNINENKNIYNERNSLILF
DLVNYIIEKNQNSIRHINFWTIQMSVVNWIYFITYNFNNSYLIDPNWKKY
VFKIKKDESKGVISTNLLHNYGFVDFVVQSKSQNFLKAYRVQDEILKSVL
NLGDNLNNEFLEEIMRKYDTYKIIDRDHKYLVINIE
>UU405.1 conserved hypothetical
MINNKKFINKTFDNTNQIRLQNNLKTYAPKFLNLIIINNIFVLIMIISLC
IFFSDPHFLYRNDVISNQYRQFIFTYQQTAIAIVLYVLAWYIMVNFFFFG
YLLEYVKLNKFETFNFALASILFNPYAYVIIVKNWTSWSFYWQRSFYHVL
SENNKIEFNIKNSKTIFALVFLIIAIPFIIFSSIDYVPKNPGRLIIFNKN
SLGEKVIYTNNVWFHNMHYFTSQGNWMCIGIAFLYFINPKARCTKNNRVL
LIVLSYILIISSIWLCVLFPMFSRQSTWVWFNNMVGFYNHLITPISFTIF
AYYCIIKNKYAIHIKYFYAWKGFMFYVVIYAMYALFLPLLANVTVYGAIT
NIWPSANGNPIFVTMLFALIGYQILVFSINWTILKFINKYKNNKILIG
>UU092 unique hypothetical membrane lipoprotein
MNKKINLNSSLAYIGFLTRLIIVKKTTYLLPIITLLITLIIGIVVGCVVK
QKTQFLIISYVMIMFNLLMTTIFASLKALNIFKDFSEDGIDILVISKPIS
RKNIVWSKIFFFVLTGIVWSLVSFLGLLIFYLISFNFAKNVNYYWILSYI
SPFICYLIFGLITSLLALKLNAKISILIPFVSFIPLLTIGIIANLVSQVQ
SQAFLRLLKQKSTNNIEAFYLNNNLDQYYLINTGFFNHKFNENQNLEIMN
AYLKTRSLATFWQVSSWILPVYQLADVFNKSDYEPFSDFIKNQVDQILYA
NNLASKQFNYQLEKNSNSLINFSINNDKSFLIPSLLKNDSQNLINNNLNQ
EVIYAIDNWKDQTIEYQKNSYTQLSSDDIVGSLKWMIIKEVLNVRSFNTY
ANNLFKTLDQKANQKQILDLISNSVQKFDFNKWNDENADLFKKDFNKLLI
KSKTEQQIYLAVSLIYYLYFNPHYTNLLKILLVDHQNNLQYKTQLKINLN
NKNYLIGGFKSYLLHQILPQENDDGIDELKKDKKIRYRYSLEQGGNYLFD
YVQQNYSFKRKQQIVYKEAYCVIWLILIFSLLIGTYYGYKRKDYR
>UU192 conserved hypothetical
MYIYYNKTSLNDTLIFLKNNQQYDHQVFLNDDLLLFYHGDELIGLNLFNA
SEYLKNLNEGYLYPTTQLIQKLSDLIKIKLSLDNAFKGFVVGKILEVNLI
PNTHLHICLVDIGDQQIQIICGAQNVRIGLKTVVATPNLLMPNGNEIKKS
KLMNYDSFGMLCSQKELNINNFNSQGIVELNDEYQVGQLFTKVYSNL
>UU138 conserved hypothetical-cytochrome b
MNLKRMINSYLIIFLPFLSVSFVVFVFLGILLEASWSFFYSYLLVIPFGF
GITLLRIFIISKLLNKRLKMNNLGVNPKKYRRLPANFFAFGTIYILFNFL
ILVPLIIGNLVNLYQSIFETISLFVLTFFMFFIQMGMQIYLGIKKDKGEK
K
>UU478 unique hypothetical
MIKDLNSYLKDIDEMSKSSLNEDQKQLIKKILEKTDPQDLDNVFQLLIQR
VKIGFSFDVAPSVHQTQIAILAKNEQLSFMNDAHNLFKNDTNSLIIGENY
DVLKNLLVLERERERD
>UU168 unique hypothetical
MALKTNTIIKSKWNPSNFDINIDIKEMIARTAQESTVNDVILKTKDNVPL
EWMEFIDNINENNEILKLIKGDCRIKSLYGINYVGFEIYNNDILIFNADI
NNAMNKSIRINQQQEYSSTIYRKIALMKDSEYLSLKELHTPYEIKRLIYN
STGVYKIIFNEFEVSTPMYFKDIFKNKNVVHNYGVLCTKEFLNRSFIDFE
NKINEKLPDWYPVNDLINDTNALLNFIKKERELNKTRIVGSIINHNDAQT
YRNQWIDEIQYMSSDLILNTNTPDKNAFEIMQSTFNESIHLQAITEKLNL
IFKGCGYVWNMGDSLSYQNSETATNLNKATFETQKWK
>UU178 conserved hypothetical
MQNLNNKQKTLIIFLGIITFGIFIIYFFTKAKKVSQIRNTHLIVSSNIPF
SLNDFYNCIGSKNNLVNVDATINTLKIELKEINALNNEKLKVLGAKGIMC
NQTKISIIFGDFCLELKELIKKDLFS
>UU547 conserved hypothetical
MSVLHTTNTSQGNGINSWQSILIFLAFLIVFIIFTVIKKIYYSIRFQKRF
YIIPKTSVKGISNIAMVISISVAVIILLTVLSANTASVIFRAWPGTRVTL
EGILIKIGGLLFGPILGIFIGAMTDLLSVAMTAGVFHYGYLIAAMAYGLI
GGLIRIILTTSKKKDLPFAIYSSMATILIGVGIALFLYFAPGIGDKGFNI
QLFGFDIKIARTLMIGIILGFFLLSIIVVWFSLLIKYWFNKKNKAKTKTN
WFIIFAPVLVTILLTEAVVNVLMMPSFDAELSSLKYTQWLSIRAVLFIPM
VVLNLLIIYPIFKIVVPLIRYDYEDDIVEDKHIPIHVD
>UU038 conserved hypothetical
MLNLKQYLGETNFYDKKEKLEKKKIKSWLKSVCTFANGQGGKLIFGVNEN
NNVLGLENYLNDSEFISETIKTKIDNIPEFDIEINEYENKIILILTIFPG
RNPPYFLVDNGSKTPYKRVGNQSVIASINDLLNWCLRSQNRTYDSLVSNK
LLKDVSFLMLKNEYQKHTENLWEDKFLKSFELIDNNNYLTNAGALFADGY
QVYQSGVFCTRWNGKTKTNGLIEALDDAEFEGNLLFLLNSSINFIKRNSK
NMWRKGVLYRIQYPEYPIKAVQEVIVNALIHRDYSIIGSEVHIDMYDDRL
EVYSPGGMFDGNFVQNIDLYNVWSIRRNPILADLFARMNLMERRGSGLKN
ILEIYASKENYREDLKPEFRSTESAFFVVLKNLNYQEQNISKNENQKISP
SQRRKKIIEFIGQNPKTTAYELTKIFFVSINTIERDLAKLVHDGYVEFVG
SSKNGEWKIKTNQ
>UU338 unique hypothetical
MIDKQKIKQLIQNPVYGFFDEFKKNLNSDLDHVILEQLKDQDNNIDKINH
LVTDINNLKNDIKQRKKDEKIKQRTFCNILIAVCFVIIIGLFFLHFYLKN
SKFIKNFKKYEIEKNNQINICNSQKNKYIYNVLSQINSYKISQEIFAKNG
LYLMPEIQYENIKQTDLLISRNAKFVGFFGGLEVKFKSTDTFLVYYKEFS
IKDVVTSGCIQISYRKGDQMVSETIVAHHKEPTPFVDLHSNFVHKTNYSP
NFNFSTYAQTVNSRSKTIFSNLEFSKYYGLGIATQNLEFDTKMLEFFTPF
SQENYENFAKYLKQDDITVPMFTKTATSLIIDDQLLKDNRKPFFINLLTN
NSYVKTCDFLIDTDINADLQTNLNILKYELVKLFEKYILYLTTTSLSSVI
AREWYINNDTYKIGDNYDYESYYYTNQNQLTPLSVSTKLFLKNQIAFVND
CEVIPFAELVNNQTRFGINKAQFNIKSYHVYNRVDNVPVYAHGRTHIVPV
QYKEYIEYEYPFICLYVLKYKQLTEEIGLKYFTRPFNNILLTNFEDHSAC
SIDEILDFNDNESKNNSDNDFKIYLKELDTIVTNANLNKNEFSFLKDNDG
YFITISNKIELDEETEQELSTWLRKVSL
>UU265 conserved hypothetical
MNFSSFIFKVSDVFKSVIHEASDVVTKADLDNANAHTHSLAVGLGIGIVL
FLIAGLIIGYFISMKIMKRQLKKNPPISKDTIRMIYQQVGRKPSESQINE
IYNRAVKQK
>UU287 unique hypothetical
MINKKIKINPNITYFKQKISNYHEHLLVWNDLYDKLISLTNNIIVDKNNK
NIYHQNDKQIFDFTLCLSGLLSKTLGLNHKSSSLYLTNDDEVAHRFKIKV
LHNYFNLYNIEEFFTFMDNQIPLENAKNIARLSLIYDLKQHENILKTISN
EGLENIDLEFAFINFLRAKISINFAYSYDISEVILLLRTGLDLHFFRKWA
F
>UU384 conserved hypothetical membrane lipoprotein
MINNLFKTKNYYISFLILATSIACCFYYNNFWILIVNICQFYWLYSIKFN
YKIIILIIIFSALCIILCLLIHKDFNIHFLVINIEKKYNYSLRTQILIYL
SKKYSNENTLMLIKLMIFNEKINSDFKQILYDLNIAHLFIVSGLHLNLFI
LIINKIFSKRWPKTSFLIGILFLLFYGYLLEFSIGFIRVFIMHILSIKFF
QKISKMDKLAISGMLIGCLSIYNLSILSFIFAYLALFCIYLINIFIKNNS
VLKNIYINLYILSITFVISINLNQKINFLSIVFGYVMNLPILFVYQILFW
LMFIPHFELILDLFTNTLVKSIYFISEIDASILIKAYVKIVTIFYTTIWI
TTSLWIYYKKILKKV
>UU335 unique hypothetical
MFYINLRVKTMMEKLKNNKTLFLNVEQAQKLGINNPLTQEIFLDDQKLKV
HLINSIKDEFYLKKSISKGYAYFNSLEQFKTMELDVLDNYQFAKIAATNL
DEYDQLVYTKTRQYLINKEFWTNDGLDAFIGDDFKRKQLTSKEIVNLKTK
YDLWIQELHFNNARISKQIHNLSIHGQNKLDYEKFYDKKATLESNLDILQ
ILIYLRSSLLELDFDDLFKDDQNKISIRQLLVNDLEYLPFSFQRYDYESR
RNFIRNSRQLVDTSIDFDDLEYDFLHNKKPKQELEKNNESIKIAELKKFE
NSQLSDEQQSNLEKEFYSIGRINCFDEVSENKQELNKEQLVIDKKNGYLK
PRSYLRHHETPFMVDIENRVDFLMAGYEIIKNDDPYAIKQEILKNTILEQ
QKLVEQDDHDFKVKNDDQEANEELLDNTDKLENQDSTSAVEFNDSSEVTQ
VVKTDENVDNLIKTKQITSFNDLKQEQSSQENIIKNDLSSIQIRLDEIIN
VHEKDTKLQTELNSIMIDSNEKNIDDSLNNLNEQIRIQDQELESSDNQNV
IIEEEINTKNLNNKADVGVMSVEKKYEPEEEMVNFEFEIPENQKESVNQD
VLNSNSIDNFKEEKAKENTFLTPKEIENNDLSSQIELTPADFELKTQEIN
DETERLLDELNNNKPKEKKKFWTWFNSKKR
>UU385 conserved hypothetical
MFIGTYNHSIDSKNRMLVPSKVKATLGEAIFVYLSLGFDGNIDMRLESEF
NQFVNNINNLLIGSKEARNLTRLILSQTYKIEIDSASRILIPQNLIDKAK
IKKDIYIIGTNDRYEIWAKEVYDDFSLNQESTLSDLAEKLLINGI
>UU427 unique hypothetical
MVKSQKVIDVLNTHYNLNLELGSIYAQYAHIADDQFSMPFLAKFIADLSN
DKLGVHKNLISEYARKVEIPLHTKFSVDVNFKPANPKELIKHILDTELKV
RKHVANMAKVCLEENDFETFSFVKWFVDDGIKDFDDVRTIHDFFENATNN
LQVEYAIRKYLKQMKVEEEK
>UU475 unique hypothetical
MKHKKYKSIWLKLSMISAIPLLATIITTCAKVDTKQKAKEELQSSLNKAV
LLKEIVDQSSYEDFKKIYNQTLKSNLENINKLSEQKLKQEQQTIKNLITQ
VSVLNELDSIKNMSDLIDVVELENTKKQLQDFLNQYEKLLNQASVDTTII
DKLKSDAHQKRLDTKALIQKTILDLANKIKSLIKTSGLNKNIVELENDIQ
KLVNNDTKANFKKLYEDFKLIYTKLNDINDLINKELKALPFIKKLDDIVN
VINTIYEQNHHFLWFDQTKLTNLRQILIKNINHVLNVKKTLEIKEIKTLT
NQLLVDLQNYLEGLKMIALESENSVNKLISIIESLQPDDYNPYYSIEKQE
NKQKDENNSQATYNGLEHQIKSLKSIINLFDFNITNLSIDAIYNLNDELI
KKFQKANSQINDVVIKIKQTILSNFKQIYLFKYFIKHLKEFNIELNNEND
PIKKANRIQTIQEVLKSYEKDLFLNTKINLKLAPNEVLTVNNLEKIDLTY
ASDSLQKPQELIAYLELNNNQEREFSKELENLSVRVFTIIDKKLYIPKAK
ELIDESKKIIQTKNEHTNNKAKLQRLEKFTSFVEQGISNENVSSYTLNLY
IQRLTKLIEEIKKPQH
>UU191 unique hypothetical
MKTAILIDTGANVLDIKDDNVYFVPIQLIIREQQIWKRIKRCYWR
>UU543 conserved hypothetical
MINQTIVKFTLPNGRKKRIAKDYYSWINYVVSPANKIEINGQFFFIIGAV
DSPEFLFPAINDSDILINKQKSTVLYVNDSGFAKLKTISASVPILEYYTL
KVNTNDLNLLQKNNVYNEIKSELLDSKKGNIYKRTDKDNPYPIYVKRTFF
LTQLRNLIIAIALSLIVLILLLGIYFVTSSIKNMINKNKVMFGAMQAQGV
SRWQVWFSFAPFYTIPSLIVLIIGYSISYEIQPLIMRLFSSYWLIPIPDQ
FVSVGWIFAIPIALTLILGFICWVLIYYILKHSTAETMKGDAGFKINKFI
IKTKAIFLKFGAIRVLKATYVVANLARMLILLVIASSFSIIASIIATTKN
NFSQSASITNAKREYQYAVDLYSPTEQGGFYYISKFDEMGVSNEYAPLKQ
IVKNVKIVIKIKNLVNKKVNVVYINNQTKQKVIIEALINDKGIITFKTNQ
LVKGSFQFEGIYEQETNRVLINSQNLNPSLLNIDNRKIGHFIYSNQKQYI
YLLKSYFNDNDVILDYVDANNQHTYLKAKTLGQYLVFDPSQLKQKQKYQL
VNVINHKGNTWVDLNNISNDLKNLDYSKNGRYLYDYYGRLPYLYFNHLPQ
NLINQKVYLTYTINQNDEFRIYGIVNKEKEVVFDLTKLKINTQQSYQLRD
MRIANSDLLIYDNKQHEFNNNILYFDNNYYGLNNNNQKQINIDYLTPNRN
LYLTLKAMGNEFVNKKKIPFIMTKAMASLVEPDTAILDYNELEKGYVYQI
STATLEGSDTNLYLDNVNSIDKTKDNGLPYSSLKYNNAMREIKNLGTDHP
VYGKMLSNVYYPSISTQPEILQNIRFFDSKVISKSSLDGNISVKATDVNI
EFNPWVFAKTFLPITAIARSELNEKHLLDEAFKTFGYEIINGKKINKLYD
VPNFEDNGIIHQISLWTKNGLPPKSENDENAFFIKQNGQWKINEKPGVLT
EQGAAEFLPEFLRLITQMYTFKTTRYLQYKAGLKFVNIEDEKVQQPYTYL
LGKMQTKTKRFANEIKILGINYEKNKFINGKPSPTTQLSLINDQGVNLID
LIKNDDPNNEIHNIIINKVVAQKYHLKINDVFEYQINNHIKRLSNKFNNT
PENYKTKFKVVGINDSLMDEQLIINQKVANKLIGFDDYRRRIQIENGYPI
IEEREFNGFFTKEKEPIFFNNMASFYSPTGLSPAIDSWPQNLLENIGGNV
QSINIYWIFYYSWDLANSILNASFDKNKITWEPFSEINLDKLLKKIGKIF
GKEANLPSFKAVDANIENEIFASVVDKTSFTLLLNIITAIIPSLVIIIIL
VASTLANESRRLIAIMKVLGMRDFRNVNNFMFIYPIVWLLNILIATPLSF
GIIHIYKLAIFAAFNIVLVASIPWWIFVISYGFVGIVLLFAWLQMLYKTK
KLNLPKALNQFNN
>UU290 unique hypothetical
MAVEKIKISKVKLKIVSALFNLLKTNSFNKIKISQIIEVADVSRPSYYRN
FSDKISIINYFIKNIYNWKVVSKLINNNLNINFDEVGFTKFYEISLQISL
EFKEYFLILDKNNFSGLIVDLTTESGFYAIGNMSNNSIDKYLINYLTGFF
CNIRMQWLKNGAKESIHDMAVFLTNVLKDNVIKKLEKYQSCNNIND
>UU046 unique hypothetical
MKFIKRKTKLLTITIGAVAVSSILLGGIFYGTSQKSPSSFGIASIDQKEN
FINKDNLDYQKARPSIKDNNLKEIPKPKPQPKPEPQPTPFPDPIPTPPKK
EELKKPEIKPEEPKKPEIKPEPIPKPKPQPIPQPTPPVETKPKEELLPPS
PPPPKEEPKPEPDPQPQPQQIPNQSTVRKIELNGVLVDAEVEVPPPRQTF
KYDQDNGLSNLNPYTNISVGKIKKVFVTDELRHKSADLVRGNLKRGDYQS
LVKDLLDPNIKPEEIDSYIAMVDKSGYHAKLWSKFKKLFDTDNVVNFLNE
QGKKEYPNMKTKFVSDAHKYAWLYAHLDFSKFTKLSANSEKYLQEGLTPD
PDNSYVNENGELDSYAYSPAKEYNTVTSRLANDNANRRVFGYNEWYNRSP
NGLANGDYPGWNKSDATAEFKQYGIKDGDGIKVYKLERQKPQEGKLNTGY
IVDIDADNPDGYQKTKELIQKLNNQNKKITGYRIRNMGKSDSGQKFSDIL
KALPNELPLLELFFSAGSHNTSALSALETKHIKELGLYTLGNSLLDEWSI
NPNALRKVEWINSNDYNVSSEYKQGSDIATRITFDTLSFDKNDFNDNAND
LRTKLKRINDGLRMVYWTRNNEPFFQGGFGPGLDPDHKEVGNSYPQGLDF
SRVPQIRSLRGLIFKDEQKASNNRERKLRRVNFFNDKENYEMSINDLNEA
GFSEHIVTNEPMPPKSKITFSNGNATKRIYIKGNGSLTASGIQNLATLFN
LAESLDSKSVVVDSNNSELKSQLEGLGYKVSDASDANYIDI
>UU036 conserved hypothetical
MKINIYDSKMDFVIGNPPYVRIHNLIKEPNLIKNYLFSNKGMTDLYIIFY
EIGIKMLNKNGILCYITPSSFFTSLAGLNMRLFLSEYKLIESVCDLKHFQ
AFNATVYTTIICLNKSKKNECVEYYEFDEKKLKPCFIEKISHNDYFIKNN
YYFGPKQKLIFLKKVLLSNKTTNILVKNGYATLSDKIFINDFDFESKFII
PVIKASKGELKKIFYPYDKENFLIDELVLKKDLKMYNYLKFNKNNLLKKI
MILVQKIVDMHLVEVKELKILIRIKLQ
>UU101 unique hypothetical
MAKYIKTGVSYINLDNARTINILPEDIDSYLELGGDEAYKTSDLGSELYI
NYADFESTNILFDLKKEELQAKIDAFLISNDTVLDLSEVFLDIHFSEDDD
YEEDCCCEDECCSDEENEACCNSEVKVEEECCGGAKDDCCGGHEHEHEVC
CDSETKTSETQEECCGGTKDDCCGGHEHEHHHHHSHQH
>UU366 unique hypothetical
MEEQMSATNKKYDPQISELLELRDLANKVDNLKRKLKTIEYNHYCEHENY
DSDDGETNNVYEQEVSLNHETQIVKLRVDLNDLTNLSNTKIVEVEKPVYI
EKVIEVEKPIEKIVEKIVYVNQDNQVNKQESIKEEKEPKTPVKSGKYVKY
RRLKNNGMSDAGWKIFELVKQTQQDKVAAEKRFDEQQEEKKRQREQKRLE
KQQKLEAKNEQ
>UU326 unique hypothetical
MEKTIIQLEFNEEELASIKKIKDKMDPNNNLELNVFLKDLIKDLARDYLN
FSNQSFESIAKQMNDLKDLIGNVANDPSSFDFNSVMNEFQKFSKSQKDEE
KEIKNDTEIKTATKPTKKS
>UU495 unique hypothetical membrane lipoprotein
MMVKKVINVADLDQKQIIVNKLNIGKIVNNQLVFDVPKNVEEGEDVFVNY
QDVDGNLIKIPAIVNNKHQLQIDLSNNPNFTKDKIYHFDSISIEDEYHIP
KETIISSDDVDNSVKTLNNEVDLGRKIIVKNPSVIQNKPTTLILTVNDPN
KLALNERLKLTLALKNDPKHCVSAYGLIDYKNNSLVFDFNHLQTDTAYYI
KNLVFKNNNLNLTDLNAEAHSQTKINIIKDQVIGYTFRIFSTNTLVLEDY
HQYDTDPNATKLNLNISTTNKHPKTITYRLLDENNNALEPDLVANLNYDL
VKKNYVAHLQNLKGNSKYLLLGFNDENNNKIHYSTPIKTPLIFGTTPHAT
IVNFDVNNPKQIIKSQDARIAIDFVDQDQKLRIGNPVELTYLNKNNQQVY
KTIGYVKGINKTNKSGTLEFELNNLVSNNNYELLELKALGLANDAYQKVV
FAPFDQKHNQFSTKLIGTYIESISSNEVIKKDENKLDVNVKIVFSQKDKT
LNNVWAQLVYISKDNEVCLSQPLLLNVGNSNYKFTLTNNKPNGFLSNRVY
KFVKLIYAQDQNDLQSTDAVIKNSTDLSHGFKTEPTGIISLKNNSLQVIK
RTDDSIRLSIPLVDNDHVLVDSDGSSFTIKISDLDDPNNLFDADNQKIVI
DQNGNRNLEFDVPNVSLNHKYHINNITLINKPINAAFNQNENHEQVYELN
NSQPQLSEFGNELLVNTYNYEPNITDVKTNVLNYKVKLTLKRSLNLMNEY
YLKLKYIDNNGDVVWSDPVSINNVNNEYEFNLPDKNALKSNRIYKFDGLY
YFKDVNTVKITSANKVNMNNITPLQIQTASKINLNSPKVTINNITPASAD
LYLPLVSTDDIFAKDQVIDVTIGNKDNTKNDLMFTSNLEYDDITKTWGVK
IHANNLSPEVNYQIKSVKFRQKPVLGAFNVNNSDDNHVLIDSQKTPGFST
PKASFDLVSVTASDVVDANVKTNSVHIVINNDGTSLNNCKAKIVYNDGEH
DLVSNNFVVLNYGVNEYDFNLDDLKHNRIYSFKKLIYTEPNQNDYKFSFL
NNQKITNTFKTASVNEQLTIDTKLVRKPDSNLNKINLKLQINDPNDFLEQ
DSILEITFHDEKDKTTHNVIGKINVDANNNKTLEFSVENTNTFKIQPNHK
YIVDNINYATKNKIQPANAISNNSNKNSIYDASSNPSKILSFTNELFVNN
INVNQPNTNLNPTASIDVELKSSQNLLKDQYLRALYIDNNHQKIWSDYAS
VNNVDLAHINLNFNHLTPNRKYNFAGIYYFNDQNQNNDETQGKKIFVKEH
SKTYDFSTLASTTQLLEFKTHNVDEDQFNYDFNINNDDQVLEPGMLVELC
FENLVDKNQPVLKTQTTLVKKDEHSFSASGVITNLLADHTYRLTSVSLKQ
KPQLANVNINNNNNNEILLNNIEDNQKTIHTLSKSIVNEISNLADAYPKN
NNGIYDVKFNINIIKNNNKLNNKYVKVVFEDNEHQLISTNDLLVNKLDQT
NLISLQNFSFSNLKPNHLYRLLKVVYGDEQNFDAINEQKNILALNPSLVN
SSFSTTPAKIKVSKNAIDVWQNQALIKLILDDSDNQLHSGDEININYRIK
GTQNIISTPATISDQDKRYTKCMATNLIAGLDYEIVSVTIKNQKTKNVSP
IIFELPSGPIGFYTLAPVFKITSLSMDPVYHENKNTADLKINLRIENIGA
SLFNKDIKFIFKRKNDGKQISFIHKVTSANDANYEWEFKDLLRNREYTLE
RVVYLKNKDFNQSNVSESDYIDLWIYENLNKTFKLLPTKPLGIIGAPIKE
ISDNGAKVQLKFAINDFDDVLKENQTFKFNIQPNENNGANLNEISEHEGK
VEIIDGQKFFVANLNNIKVNKEYKVYKIYFDENQDVGNGVYKINFKNDYK
EPNNVVYDASVNTTQTYVFTNKFAIASFSNNLTDVDVANKQNISINLDSR
VETIQGYHFKAKYISNDNRVVWTNTIPAPTNIGNNKNNIALNFELNQNQL
ISNRLYTFAALYYSKDVNVDENHANMVVIKNNVNPQTISTKPSSTYVDLK
AQNADENKITLSLLLHSNDQIFEDKNNHLKIAKISIDELDAHDQIINSTT
HDYDLTLEKENNEWLLKTQLINLKPNTKYRVKKVWFTSKPSDTIYNGVNK
DNIVYPINNHNTNIDLKTLEKSTLNSVKPTKTNFNKNESIKLMVGFNKTG
SSLENKYAKLVYKDNNNQQIESDPVLLNSDTTTKPFNKEFSFNNNQTSLV
ANRDFEFVKLIISDTADFKNANTLDLTPNFNKDDAKFSIEPTPISVNNVI
QSGSNTYDEIHLSFDYDDQDHNLVDNDQITITYRKKGEQAWTSSKAGEVS
VKNHKINVTLKDLTPNTTYEIGAISTTHVHSPNVKTSPIQYNETTKKQLE
KLDLTTKVAHNFIKDFKLASNSKLVNGVYECAKDENVKFSVGLHKEGHEL
EGYEIYAKFVDKTNPNKPAIEIKSSNNINSNSNQVYEFELLKSQITPNHQ
YELSEICAIKNKGANNEIKKDLNENHLSLALGLAPNKMDVQKPTITITKV
QDNQSVSAHVKYIINDPDGILNSTDCSKELLNVKYALFNQTQNANLINNI
TIKYDQQNKQFYCEFDIDNLTLNQDYGIFEISFANKPIHAAFAKINDTQH
PLALLSTNNQDINQKIALDCEVNKVTINKQDLDYDQNTKISWPIELSSNL
LNNKYIRVKYSVSGHKFKQDDQFSSAFKITNNKASVEIGHDKLIANKAYE
IQAIYFSDQNNDFACTNTNQIPINSSITNKKIVINPSATTISSHEVKNIT
STSADINCSISTNDGDIFKPNSQIIGHFAKGDDLTKTFVANGVVANVNNQ
TKLSFTLNNLEPNTKYILVSVEFKQQPNNAYKHINNKYNDQFYSNDQTHS
IIFTTSTPIFEINSIKTIKNTYASNKEEIKVNAKFNKIDPYLNAKKLKLV
YQSQNNNETFETQPLLVSTNTHDYVFSFDKNASNSIIGNREYHLDKILYL
NEHNQWCELNKNNLVDQFNVEPTPISIAKIVEDDSKRTQNDVKFRIYFND
LNQDQIFNDNDNVNVKLVYPNTNNVWVSHDWPIHFDQQENKWYTEVWLSV
GSLNNQEFEVGAVSVNKKPAKAKFDIHKTNHGYDNFIYNKDIKNQNYLVG
NIFKVNSINVAHPSTPTDSNTTVHVKMQNNMKSAFKGKYLALKYKRNDTN
ELVWSSTKIKIDENIHDDLDFTFTNLAKNHIYSYVGVYCVDDQNKEVFVA
NNITNLNPPQIKVLTNAINTISYINANDKISNLSDNTAKLKLTLNDPDHI
FKVGDELDLVFNTKINPTTPKQKNIHVSVKEIQNNEVILNDVDLSGLSEN
TEYELKTVSLNQENWSQKETYISSKPHFEINNVHFATIKHLFINKIEINK
KAQENSYTLKLTLDGDYSEFIKQGYLRLLLVNNKNEEFNYTKSHKDTDKN
QDNNAVKYFTFDLNNLTWGMQYTIKWVGLAKNNVSDNTDFKKYKLEKGYL
TKKTDDLDQFTVRASKPLKIKQVNVSEIKAHHAKLNLKLEDQDSVLKNLN
YELELRFGVKNNQSSNSWITKKLKTKIVNNEIVLDEIVFDNLTEDMQYEL
KDAKLIFNEEELKKFNKVTAVDNLNVDSDQIVFKTMKSAYVETATINFVN
NTPNATIDLKLNGDLSVFSKSQYIRFEWKLNNSDPNTKPLYYTIPISSLD
LNNLNWKKDFGSDLLWNSSYTLRIGYGDDNKATDDSKWTWLALEKTAKGN
IKTPNAQRISINQMQTPTNYSLLTQEVNENGNKVKKALGALDLCFELNDP
SNILTNQDQFSIKYAMLNNLKQSVSASAHVEIKENKKIVKFHISGIDLNQ
DYKVCELMLLTKPARMGENINNNDKNNYSSIYQNSTNDDNQYKFKILLEN
NDLSTKERPSKTGDVVNNKGKVDITITQAPKLLANKWISAAYVDNNGETK
WTKPRLITTNDNNQILYQAEIDNLTTNRYYNLNGLYFGNQQSDFEQGNAT
YLLSLYPANLLVPTDGVRIQNIKTPATTDAATVWFQLESKDQVFDKQVLH
IQITPFNEDINKKDIPAENIPVFERTYTLNGNSNSAIVLLSLNNLEPNIK
YKITKMWFEQKPTKAYANLNSKANNNVIYENTNDKTQPNISFKTKTVEPK
IISLVKKDQTNDGISFDLKLQHDGTYIGKPFRLIYESSKRKSDVWDEKNN
NWESNDKQLIYSEPINFKAGQKDYLVQIIKDHNEYFKGNREYKILGIEWA
DPSFSQDKHHKKLISKDTDSEAFKNVNSNALSFSTDATTIKWYVATPKIV
YNKNHKKMTFQIRYDDPDDSLFMGQRIGIEKILLPNKRKQIPLNPPLVGE
VDNKKKIIEFNIDNNDDHFKPGNLYQLISIDLVYEPKTLSHKDLNKLMYE
NPQTKMYKDKVTFELDNSQYSSIKIEENQNPYEVKSVKNKLDNKNLTLKS
TVTFNNKDEHLYNKYMFALFTNTKTNAEVWSKPIQLNTNNYSKLEFDLPN
NGALEENSEYQFLGVYYNEKQTHPNKNEIEKQIYMIDNLKIINIDNRITK
TIKTGIHIDVNEVQNLAQFKDGISKQFKLVGKNDSTVLNQILNGDFSINI
EYKRKDQPDNEASFSTGACKLFKKNNNDPFWYFNADFNNLNFNQDYYIKS
ISFVNKGINRIIGSINNADNQIIYTTNNYNSSKYHIKTVGAQIEFDQTTV
VKNDIVFTKGDSGGYPASVVNFKLKGKEANTFVEGQTYNVVLSTWDDPFN
TRDYENKIDNHLNYDIKKDYVIVSIVAHNNCLEFKNIQLIPNQNYNIVKV
LHYQASNTISAKDMGYSLKNAFSTKSVDWKVWKFGHGRNNFTWRYQVALS
LKGPFTGFGGYRKTIFDLGLAKSLGVYARIYQHNTNNLAFKGYDIDGINE
GEDTSLLTDFERASRPTSANVLSSSCTLANYLRRNSDSLKNTIDIGKVWY
EPRINPNLPNSSNATYYSGEPKASIFKIDDQHKHYTDSFGTTNNDAMDTN
NENQF
>UU455 unique hypothetical
MEFDMKFKKILLTSTLSVLGVISIASLATNCSQTKTKINQYKITINKLDS
LNLTSNLTTKQALKDVLFSKEGQNEFLLSNVKKVVYDWAKNNNDPKLAHD
VSEYNTQLDEQLKRIKENVKKSYPNDWQSVLQSELYDTEGGSEKSWKEAK
LIDQAYKSITSSIFDDNDNWISVLNDQNQLIDAYSNDATKLLENESTFKS
TKIGDRNKIVAKTNNFLQKGYANLFNFLIDDYIKYNLPLSFANIEFKYDD
LKNQNIYNKDFFTKIPTSGTSPNFPWFDPKPTDNKSTNTTTNYLEVAKLL
KENKYLDSKDDTNNIDKKFNNNNDINKYLSLNDFITQDNTNLTLSVGLLA
KFLSLFGNENFGIYQLDNLDENNILNNFISKNQSNANTNNVDLFYPLVKK
DKTAFLNDFKDVKAIRQINDLKNGYTLLRNENSVDLWGINNFKRLQQAAK
IGLNALLTELKNDFLYNGALYLNSRKSNSVKKQGYDIKAKIKDYFNNNKE
RLLALYIATHQNDSDFLFKSNLKNDSKVFAFDQRTINIIKENNEIHLLNY
YDNLIDKLNDKLIKFNKKTFIIPSVDSLYDNGINTPIYLIKDQNQQISLF
QTLKIKLVGNKNLIDENQKLSTMINDYVENFDIKKHLVANNKNSQSIVFD
DYVINKVFSKGINSVFANIIKQEQIKKSVAKFFEFNDFNFKNNFLENQEL
LAAFNQIIKNTSVLETTQTNNFSNFDNLKKVYEQALKLWNDNYTKNGPFN
QLSINYQKYQALFETLAIINYLLDFKDGKPTYQNLINYLLKKTANHQPLF
IGWKALNDVTKIPNFGKDSKEDFSFKKYQINLYNGLDLYQLKKADVYEID
QNSQEVKFKKTFIDALTYTNDKNYWNSTVNKDGSVYNNFIGLIDQNNQKD
KLGKAFEKIDLFDKLVYANNPSKQFKGALYGYGSRELLIKTLDGFVSYHD
YQTLAQLLYDLNFNAEANAEFKTILDNQKQIIPGNQKDSKIKNIDLATNE
IKTIMIKGINKIPQTAFQRLDLDLVYNKLDKNATPLVNKEDNANLKYILL
VSQFNANDVQNLVINNQLNQSATGYLGLSKSQFYNLLFDLALNDQTLKIE
AFSQIENEHKIKVYDKRLANNSNLKGWIINNL
>UU374 unique hypothetical
MGRQLREDEWLSIFFWYEQYLNYDISKEFLSYKYCEISNGRQLNKYSLKL
IKTKYKLYNLGMNINSQTGKATKKR
>UU103 unique hypothetical membrane lipoprotein
MKHKTKKITLLIAGITLTSLCTIFAITACSKQKSQPNPKIKPNKIIEKID
QAFFNEFKTKIEQKRTLPNIKITSTFKIPFEKNENTLKSPLFKIGEKSVF
DLKQNEIPITWVQDLKDYFLSQKTILTYYSLANLKLTGNDAKDAYFLEFI
QYIQNMQQKGIISEDFYQQLWYLISEISDYDMQNGILRSVYRIANPKLAI
KDFYLDGSLYGFKKEKSKYMNFTSLFQWPNAEEKATFDVVFKNKNSAQSY
TKKIELIYSKEKKFILDSLINYSEFTPGEYELVSIKKHDDMNAKNLINPN
NPNIAKIFKIKVFKENEKFKPITLTSINQQEADEYDRQRNQIIHKNNSEI
GILDDSNKIKELGTFLYFKKPLSEITINDFDRYFRTYFICPEQDFNDFSR
QYKITKIDKQKQIIELSILHINNKTNEIYSSPINFKFYYKKIYDINKNTD
ARLDLSFDESKKEQKQKLQELVNKLNFDKLTYNDLSELAVVMFEDVDLEN
TKIYVEMIKNKDRSITLKAFVDKAFKNGKLKVSNKPDILIKEFKINYFMP
NYFK
>UU591 unique hypothetical
MIPLNYLTHYFSLKYKGDWSKIYLALINHEDQNEYLFLEKEDYEKVKAID
LTDEKYPNKYKKINQPPFILYYSTTVEWLDKKNIWLIDYENAISNYDILT
LIKAGYGFVIYYDSVVLDTLINRLISLKARICIITDEGIYSSKNIKYLSY
CNVSVISEIPKDYNSNKITQDLKRLACASSDHILCVNELYQIDDYLFNKY
KDCQLDLVLLDKKLAKQNTIYPKYINRIYQFIKNSKLIN
>UU317 conserved hypothetical
MFRNLIKNVYRYLLKSKASFIGLCLLLFVSIFSFSMLTNLSKTLTRSYTN
LVNRQKLHDITVNESYIEDQKDIKQAQFNKLLEELKVFYAQKGLNFDWTR
SNSLIVNSTKDDITYKIVQYSTSKTINTFDKQTSERLIKNSFSDIDLYGI
LNNAKVDVIDLIKTKTLNASFVINNLKELDNKQKSNLVKLAKVDNYDVSI
SQQARLYLLKNIVYGAWPSKTNNLYKKFKKAYEYSLEDKNYDPLIGNIKL
NNKANFDILEAKEISTQFILMLYPSKKGISINGNVNTIVKGHRITFSFEP
AGIPIPVYFDVKSAYALVGLGAFLSNHNKQKYPMYLWQKALVDHEEQQSF
EKWFNSLDEKYIIHIDNTPYLILDSGITPDFMYPIISFTSVIPNPKKEGL
VYVNLNGYARIYDAFRSNPIENNLQIRITNQKHQSVDISILKKIVKNLND
QIKKDAIMNWPTSLDAAYLKDDTNNHITPSPLRLVFINKITNTIQTFSVL
ITLFILILTIFVIVIIINRFLAQNKINIGISIANGVPRWKIILSFAFIGL
IPCVIGGLCGYLTAYFTQNLAINIFSGYWLIPTVLENFNFGALITVIIFP
FLLFFILIVGLGYWSIRKPPIDLMRGTETFKISKIVYVIKFPFKYISGFN
KYLITLSFSSITRIIIFSIMIALSFGSIMFLTGTRGKIKQTIDATLQTKK
YRYGIDLITPTDQGGQYISLSTNQIGSTLNDNDNHELTQKYESSDYKDFI
NSPLFKNLQNLKLIGAKDDQRRIYDLNYIANAFQVKQFLDFNFGIGDVNS
GSSSNPWSITKSLIPENNLQILNETYKKWCSKLINDHSIFSKQLIEKGVN
ELAYDILNIRNSYDPNEYFNYFTFKSIVDTYLKRFNKSFLDQHVTYEILV
RVHNNLFNYKNIYGKLVFKNNQWIINFKDNNFPIDDQNFVSAIYYKKPNE
QNYDLKKYIFKNDDLIYDEVYFERNSKQNYHKLTYQTFSSYFRARFLKFD
PEGDFDYYLPLKYFNATIVRKELLENAINNEILFKNDENKIIKKINFKSD
NDIVVTKINDLTYQVKNIINQQIYLYSPKPIKRSYRIDPAKATNAIKTGL
SIKLDNDFINLVLLTHPSINPSYADVWSGITFNMVGFDYLTKNDKTQLNE
FDEPYIWIDAQINKINNQKYEEAKNPKIIGIIKNSKLVHLLSNKKQINNL
LFNKNDEQVAIINRVAAKYYNLKIGDHFSFVANNQTNRYTKDYIKKQITL
KVVGIIDTYQGIEIYTGIKNAAEILGMHSSPYADKSLYDEYDGAFNGIFT
NKNNPAMLTRIISIYSPSGLYPISETWKKDAPTINLIKNILSDKYTTYEL
NNKWDPKSLVLNSRLSLTKALGYKNFDELKLDARNIYDDNHNYLGLRDEQ
AQAEWVIDKLISIYGRDTYSSTLNNVEVVDVLFAVLETASKTIQTVEIVV
IFLILFIIILVLVLISINSLSDTLKVAKLLKNIGYSDLKNAKLFLMAFLP
SLIIGSIISIPLVIVVMQVFSEIIFNSLNVLLTTSFIWWHFLIILLIVAI
IFLLMWAIAIWILRRSNIADASKRN
>UU083 conserved hypothetical
MNVALELINLLKERRLRLSVCESASCGALSSSIGEVAGASSVFAGGFISY
SNEVKIKLVGVSEKTIFKYGAVSEQTAKEMCLQTNQKFNTDIAISITGNA
GPQGSENKEVGLFYIGIAIKDFAIVKKVTLNSNERTFNRFSIAWEAISYL
IELIKK
>UU437 conserved hypothetical
MHLDIDAFYATVSELLHPEYKNFPIAVGSLNSRTGIISSPNYLARSYGVK
AAMPIFLAKELCPNLIILPSEHNIYQSYSKHFFQIINKYTNKIEITSIDE
CFIDATDLVKKYHNNIRLLATKIQKEIKNKLNLSISIGISYNKTIAKMAT
ELNKPSGISIIDENKIINLIYELNINKIPYIGEIKSQELYAINIFKIKEL
IATENKQKISLVLGSIYQNLVNDLKGLSKIKIIDEDIYKTISHSKTFNED
LNDFYEISNEMNDLILTVTNRLKKCNLMTNNISIYIKYPSFKTKIKQKQL
TYYTDDYQTIFLAIKNLFKIMYKDETIRLIGISLNKLVKKENVKKQLFLF
D
>UU565 conserved hypothetical
MSNNEEKTHHKNKIKKIFNWTNKTKEVLRTENNLLKQISNEATIQQSVQI
EKIRYKAGLLKFAALYSTKKIFLRYLIIVIFSLLASLLVLLLVHNTGIYS
AGIMGTSQGIARILQSIMISNHSSPKEAKLAYDIMFWLFAIFVNIPLLIF
SYKKIGKHFTLMTLTYIITVQVFGFALSQIPNVEKIMIFGDNRLSYPPIN
LFFTNGILDEKIVKNIETGVLNYSNITNSKIADEFMHYVQANPNATIGDL
FHLNQSLTYRQSLYEFAKPLYIFHDLIINKVQILSWVDPDQASKIPSILI
YAVIYPIFDGIFLSIVYIAGGSSGGTDIISFWYSKKYGKPTGSILTYFNV
ATLIIGIVLGSFIPAGMINSRYWDAQYFFSPNMVASILASIVLGIVFNIY
FPKHKSLKIQVYSKNVNAIIENLRANDFNNSITLNSLSDSLTLRTNYSLE
IISPYIELPSLIHLVRDIDKNCLIVIYPIIDIDGEMVVKKSTIS
>UU051 unique hypothetical
MKMIMITMVVFMNHNYNIQITLLENKKFNIDNGLLYVNVNEENTWQKIEN
NTVLAYEIILLKIVDDDYKKTFYLFLKNTHISVLNNIVKIQALNDLHFFI
KDGLNKKNNHKKELVDKYKNITNNILELEAKQQLGLTLSEFLDLDNLKQE
QYITNMQIRLNLVEYKKDEK
>UU263 unique hypothetical membrane lipoprotein
MKINFKRTFLLSFIGVIVTPIPIILSCSLTKIKKEDNKNFFNLYLKIKEE
ASSKVDFVLKNNHKYNYLLNKADIINNYINYLVNLNLNENSENELLAFTY
YELYKLIKDFNYLLKEKTQEYESWLIKIDNFVKLIKKRQADFLNFKNKNK
IIHDIDHIKNNIEEILTNYNQIPDNENIDDIKLRYKKMIESYDGLYKKTI
NDEANKIKNIKSDVKNLKHNYFEKIDNGEEYYKLYNREIMELFHEANQLH
ENISSVLQSILNRKLIENKIDNIKREIQEHKKVSQYIKQNGHKNNQDFWD
TWKEDILGKKFIYQTLMDNTNVAIWYGLALKIEDLAKQKFINTKSLELKQ
LIEKWKLYGQALIRDSLDAANFSGLFFTIKSKTSMLDNWQPSIDPNSLSK
KGKYYLLIKKLKDLTNEIEKKARNANQKLSRFYDSVVKDDVEQIVPYIKA
VGYGFYPQEEFGELMYWSNYYLNQLPDVFQYYKEKIIKPIIDQIKSKSDS
ANDVSKLEELYNFKYHYTNIYEPFNQKRDNFYYYSDYKTDDKGEKIKNSD
EMFILTKQVPNHLKNEYDTARLFFRIERTIGEICKKYALTNPLE
>UU171 unique hypothetical
MIANKITINKIQNGTATIEVTFSKFKLADANKKDFVLEVKDSANDDASAI
SATELVFDANKKILTGKLNGLASNINYKISKFTLNNNEIKFDFKQEDQQE
LLNQYIQQAELNTIIDKANKKINIKLQNFSILNSFQDNQPVLTFDIEINK
KDGITQVVHKSLTKNQLLNPNGLEIDLKDKMKNNIDYWTLAYVVWFLAI
>UU479 unique hypothetical
MKMKNNKKILWKKHIKIASFLICLNLCWSAVIVGIVLRLYDKENSIIFVD
QNNDSYWLKIHNKKDLKTEINTHLPQGNVYRLQKNKLSNSIIGLTLSKID
KTNEYSNTGDIVIKVNLKNKAKKNPQIMGVFVDEKHQYHYIQPTIKDKVA
YFNTSKLANNHDYRLVKILDKTDYNHVLIQQNELAIEHQIMISKPPKTAS
FINQNNQKIYRINVGKWLFNSSLSLQLKDLNNQIYSIDAKVDVEGNVDFD
VSKLANNNFYELVNIYKNNTHPLVKVINPVNIAYHNKTINNLNVNSLNQP
YQYTKNGDINLIAKVAPYYVNQQVYGIFKDQNHKLHKLLAKVDNDGQICF
DIGKLVKPNQYRLEKIVSASDENIEFVHNFDLSSNQKQTLNRPNIVVNYL
KNGDYTINFNDANLINKKIELRFKIDNTNEIKTIQAIVDVNKKITLKTND
NTLFAPNHKYTLIGIVDNKLTVNNNIANLDDILEINKVIIKKPLVKVLTS
SLVEEPRSPNSINSTNIKFEISDEANVLNTNMSATINYDDNKITKAHVVA
ENNKKYLTARLDNLELNKTSFINKIEFDQKPPKAIVNIGYLDTNIIYDDT
KEEKNQPLTINNNFALLPLENQEDYFQRKNEANIKLKVELKANSNILKNL
TFAATFKYKDNKIVKKIKTNAISCTPIKNEINKWMIEFNLKFDDIKTATL
YELDNIYYLDKNNPNNLDEKHKLNQITYNFELQNPLSIALVEKYLKNTLD
VDKKTNHPVCEVKLFILNVKYPWLVNKKARFVFSYTTVDGTKKEFMAYSN
DIGSSDQIINRENLLFKLKNRMYVKIPLPIANREYNFERIEVLNDDNTWT
IFNQSSITIRCRPSQNTILTTASDFNENKENKYIKNISPTQVNLNLELIS
HDQAFHDGLVANLELIDDKGNIKGPYQITLSKTDKEFDGLIKNHIDPNKH
QELQTGLTSWLISENKINNLEPNTKYYINRIYFSEKPNYLTYKWNFANNN
NEIYNRNQAKKDNPQHNDYSFTTTN
>UU195 conserved hypothetical
MKLCDKEYILSVIATPIGNLEEVSERVIKCLNEAYVILCEDTRVTAKLLH
LLNIYDYKKLISYHNFNEIQKLNEAINYIKKYPTALVSDAGYPTISDPGY
KLINECHQQNIGIQVINGPSSLMHALVASGMCSQDFMFLGFLGKTQKQRV
EKLKLYKNLQTTFVIYEAVHRIEKTLMDIYEIWGDILIFIGRELTKKNES
HYYGYLSQLPPITEKGEFVIVIDNKINQDVIKNNNINECLIKIRDLMKQN
FKLKDACKEVSKSSNFDSKELYKLIINQK
>UU570 conserved hypothetical
MENTKKSPTYVYALGGLEEIGKNTYVVEHEDEIILIDAGIKFANASLPGF
DGTVANFDYLIKNNHKIHSLVVTHGHEDHIGGIPHILRHVKIKTIYAPTL
AAKLIERRLSEYKDIKPPRIIVFEDESMYKTKYFEVDFYRVCHSIPDSFG
ICVKTPNGYIVTTGDFRFDFATAGDETNLAKISQISNRGISVLMCESTSA
EIPGFSESERYVIDNIRDYMVNIKGRTFISTFASNLGRVEEIIAIAVGLN
KKICIIGKSMEANIKTSRKLGYLNVPESSFITHKELPFYKDHEIVVILTG
SQGEKMAALNVMANNNHSKITLKPSDTIILSSNPIPGNYAQVEAMVNKLY
KLGLTVYENSPNKKIHASGHATRSEHQLMIKAINPSYLFPIHGEYKMFRA
LKQNAVDQGFDKDHVIIAPNGQKLQLLDGVLSHTNIYVDAEPKFINGYEI
SSKISKLLSERVVLSSDGILNLVLNADFKKAKLNSAVSISTRGCFFAKES
TNLINKISNVAKSSLEEALAKKEFDEKKLKEIVSGNVKSIVWKWRKKNPI
INVTIINNDLVEQFRKDNNYVEFIKQAEVEEIEQEVDIDDLISNGL
>UU505 unique hypothetical
MKILNHLKINWRSHKIKVIVGGIISLLIVITAIILGVILSTQNTNKISKK
EPLTQIEDNINNKKQDAHKVNENITIIDKKGGIIHKKTDITKINQINQQK
EILKDYLKNKEEKNKDQINNTNENLNKPIINVKNVDDKNKQENSTKLKNN
DFISNNDKNNKINENNNISYEEKPFKLKRFNIINVIAKNKDLYQLLDFKT
YFSNENINNDIKFNEKLFIKNIYEIVKSAISSFQEFCNIMQYIKIDIKYK
FNKDAKNIIVIANWLFDNYNIKNETRYYEEFVLSIN
>UU148 unique hypothetical
MDKIKNYLEKLQAFYKLYSLNLTQGTEILIIQIIDKGNLIFDSIEKGKTF
NESKIIEPLLFIFKKINTILAILKLTFTKDDLIGILQSLEEHISEFIIAN
YKYDFEIEEDDED
>UU426 unique hypothetical
MGSSLFKNNVLKDRKIAKQELQQWALKIKNKYPNANYFFKLHPIYNQNQV
LDYIQEITNGIFKPIILDAKTPWENILLKDYLSIKNNKAVLFKNKNTPNF
SLWGFQPTTSALLTSFDFIRNNTKLTNDEAQSIIGFDNFLLGKNYDILRR
DYEPNKDYTNENLQILERIYGQLIFAKILKKFF
>UU563 unique hypothetical
MSIKKQSFPNRLLNYKSIIVLIALLILMVISHLIVELIKDYHQYRMNVFI
AYTCIFMVVFLYIIFSRQVYRRRWAVKLRKYNEYKLSSWEMKLVDRFYIN
AKYELRSIDYATIRLNILITIIILPSFIYALACMIAYIIKTTQSIT
>UU173 conserved hypothetical
MRTGKYITKYDYIGYYTKQKAMWFFTNAEIKAKIDLLLKNVSSYDFEDLD
DEEEHDYEIDAYEIYKEQTDFLSQLEINKNIDVDNPKIAEGILLDKASQE
DIKKTYHYIKKIINFETDPLFKNKSLEELANLTLELIDKNDKIIFFQPVF
INDKLITKPDCFIKKNDEFIVIETKGTSSIKKHHILDVFYQAQVISKHPY
FINKCISYQMCIVDYVKLKKNQVNFTISPYYNYQKSVVLSLPPSAANQFN
KFEINELKRKRKRGEAIYLKKDENKKYYEDIDAYDHCKGILIDDLIDGTY
SSINDYKEAKKIYDYKTEDLKDDVRFNKTMDELIKGIEKLHNDFDEVISE
LLVHKQNLLALPIEQRIPNYFIPSYNDKGDYKDNDFWLELRNLYAYSGYD
VIKYSGKILTIKKFGLDNVTKDILGIDILKTYANQTFFNLYKNNQIKIYQ
AAVDLFAKLKSKKVYFDFESINSAIRAVDNSFPFTQTVTQNSIIIDDGSC
DIKNLKCTNMIIDPREINNEWFKAIIDKIHQGLEYSYIVYNKSFEASRLK
EMAEFINEEIYELKVSEIIKNMYDLADFFIVSMGKQLIVIPELKGFYSIK
KVLPIIEKEFPQIYHDVNCLNYKELSVGNGLVCQTKTTKRFFNTITDLEW
EQFVHDARIYCENDVRAMIAVEYFIKKLIDEAKMKNLILS
>UU049 unique hypothetical
MKKNKSNLTPTTNYFDVFNTYKEKKASVDLITYEELMASVLFDNKLGFES
EVYLDFVKKFTLAFEKKLDIWFENFIINFNLNLKFSTTIMIPILVTKANS
TTDAINFRNDQNPVYNNFLISYNQKIKKLLLQNHPVQILPHLILFKSNLN
GSLVLVFSEKIIASIEQKSGN
>UU085 conserved hypothetical
MGYLIAFIILLILFVLLITIVPVVMVVYLKKKQLKLTFVPKSQTSFKKIV
QKTKDLEEECEDLNNKNNELKKAISDQNLQIDLLKKNNENFLLNATSLTA
EQAKKELFNLLKIKFKKELAQEYAKIKHEFNEAQEIYAQNILVETMEQIA
EPLIVERSLFNIDIIDENLKGKIIGRDGRNKAVFENEGGVDLIVDRQQPI
VGISTPNPIRREIARIVMQKLIDSKNIDINRIELLFKEEREKFEKKVFEI
GKNVVEQTLGFFDLPEGIYSYIGRMKFRNSYGQNILSHSLEVAEYAERIA
KLINIDPIKAKKAAFFHDIGKTIDFESDLDHVEAGLLIAKKFNLDDYIYN
AIESHHNKVIPTTIYGALVKIVDTLSAARPGARVNSYDEYYSRVKELETI
CMRFEGVKSAYVIKSGRQLRVIVDSNLVSDEQLELLGHEIKVAIEENDLL
TNYKIKIVLIKEKRISIDTNIIG
>UU379.1 unique hypothetical
MKNWAKSLLIDFINIDFHNFKSIQIVLDAWTNQVFEVVDIINLSWYIRIK
IKKGNTLEHYLFTKFFKGYFYYDQQSHHLISQKINVKKPLCN
>UU179 unique hypothetical
MLIKPAKRSEKIYTIIAIKDSVVTLKNDYQDEKNIQIYEFDLQNIIPEVG
KFINLIKYDQQGCSVFEEYDKNI
>UU269 conserved hypothetical
MRLRNNANAPLYLKSQHEYIINDPHLLKDNLGKIFKNPELPLYIEIGMGK
GDFIIENALRNQQINYLGIEKFPTVIVKAHKKALKHKLDNLAMICFDANK
ILELLNSESVDKIYLNFSDPWPKKRHAKKRLTHPCFLEKFAVILKQNALV
EFKTDNENLFMYTIYDVLLKDLTKYEILFLTYNLYTLVNNVELLKNIPTE
YEKKFVMQGERIKKVNFRFLKNNQ
>UU224 unique hypothetical membrane lipoprotein
MKKNHKKWLLMTTPILLIGGLSTLALTSCKDGKKSNPKPDKPSTIEEYKL
SLSSVETGFNEAKLIFDNNDSFKTLDNFKVILKNTQNTNEVIEASNLSAT
IENQKLVLKLNNLQDGQTYKINKILYQTNKEVILSNNQVFTTKTKPKIEY
EVQEKILKLDDKTYYVVLKVKDPQNLNEPTKEILKSVTFTSKISNVANLK
NAILENQRPYVKEDYSEIQIKLPRVPVISEKIEITANNSLFKSFTITVGE
KHIKNVEKIIDITKKVFGNQELKSISITKQNSSSANITLSLKLNGNSIIV
GANKLINKKDKAIKFSFFVKNKATNTVKEFNFNEKSKPIGSYQFTLNGLD
ANSDFVIEDIRYDDKSIKITEELLASLSFSTK
>UU445 unique hypothetical
MYWYVIIKKYLDQFEQLYKNSLEQMKKDNHELLFKLQNNKNLPNQNEIFI
PIEKYKKCENMLDLNICDKYAYKDLKEQNHYFDSSTESKFANRFLSLSND
NDKIKNNVELWTKNPVFHGLKYQYFNEDGQISNSYPDFILK
>UU068 conserved hypothetical
MNFKSTIVNKKPIDWKHTIVLEELNVDPKALEMHKERINTVFAKQTEEQR
SQQLHNIIVRENLFNKAMTYLADFYEIDVNEEDIKDLAPRIKQAFGVEDE
KLAYEIAQKIIAKALIFQDLQKEFTIEIKDEELTKILESYYEETNLSIRD
FKENKAQWEAAKSTLLEEKTTAFIVDKFDRDLSILEANIRKKIAEQMELD
KKIKEIQDNNKSKQNADK
>UU165 unique hypothetical
MVDELEKNQVQPQETEENKENALYDEIDKRIQKQFENYLKTNEQLDNANK
LVEAKLKEIKDLENTFKQREQELLNKIATLEQNQQFVNIHQEKPVVEDAN
SHFLKFFN
>UU225.1 unique hypothetical membrane lipoprotein
MHLGIYYMVYSYYGSPYLTQDIATTNVVNAWAMYNAGVAFLVIFALIEIA
SFALFVTTTVNVGLNLKRQENFVLPFVFGILGCLGIIPIIGSIIIYVQLN
KFYKQQNESSLI
>UU189 MBA N-terminal paralog
MKLLKNKKIWVLTISSVLIGVSVITSIASCSSSNIESKLSDKLVEDEDNN
YYVAYQISNYEKLKDFEKKQLEKVTFSTSITPTDKTKNSQVFNAKVNEGI
LFNQQAKTFYIKLVRKPEVGESIIILPNNSILKTHGFVVTNENLNFIKIN
KKGELQRSNTAITKKNNLTNEYK
>UU571 conserved hypothetical ATP/GTP-binding protein
MKKAIKQKLMNLVNLNPHDSIILTRLSSSRNIDLFKYIKKEDLISFVNGE
ISYVELNVGKNLNLFEESLKNALNIGEFLEILVNYNVNLADNKINLLQRD
FHANKKKIIPLAIEQLLAFRKKFISINRLAKNYFEDTTVWPLYFTFNFLK
GKLLPNDPFKSPLTLFKVEIREEADKIFIAKIQDEPIVNEKIQIFLKKGY
QDFKVETTELLTNYELSSTIKMIEDMTGQKININENEFVPFMNENETQIL
DRYTTFEIEPSAVLGLFEPDGGALKADLHKIIEMDVDPFESENDGLNKPV
EYYEDKVIKEQMVVEIGRPLNIFQKYAVASSLSQNTLIYGPPGTGKSEVI
ANIIFNVLLKGKSSLLVSEKRAALDVLTERIGSLSQFALYVYDLTNKETF
FEKISNLNDLLGTQWYREQSRSTKIKEIEPIKFTPEESMFFKNYEDWNSE
LLQLVKKHWSIEDYNDGIYKMDYADYVATKNELGEQIVKEWLTPQQFNEE
NEKRTTLFEEISTIFNEYNLLKIEDLFTAYLRFTSFIKKYKLTDNYSSIE
ILKHLKMITNKIQTNDELVTKFLMHANRITKDIDNYYNFLAEHNLESNTI
FMNKSIRDKRIFIDKIGDYLKFRKDVIDKDFSLQSKTTQELNEIIDLCDN
FFTKHKKLLAKNEWFSFLIKNKDRISAFLSIYNNASDENKQIIFAEFISN
GTIITNADPSDESSLSLKEIKTRNRDSQEVIELFIDFLNNIEYLSKPKMD
QIASYREFINQDVDFLSKLHTLAEIYTPTMQDIIREWSWLSLPYIKTLYL
EPLILFDLEKIGKIMKHVSTLITHDQFKKLKVIVLWDEITHIIPMFSETK
GRLLQDIIIQLRRESMRSAKIVGEIVFKKYINNLRNYLTKLPQQEKDEIT
NALRIASSRSWPSISRYLSKYYTALKRLFPIWVARPDNVASLIPLVENEF
DYGIFDEASQMTIERSYPIVYRCKTKVVSGDDKQLKPTSFFINKLADSDF
EIDDFDKVDSLLERAKTSWWNEYHLKNHYRSDSKELIEFSNKYIYNNNLE
VATRQGAFEKGIDVINVNGVWEKGNPLEAEQTIATLIDNWKKYEKILIVT
FNAIQASLVENLLFERMNIFEKGLCDKIENNEIVITNLENVQGNEGDLVI
LSIAYGPNPEGNLRNNFGPLNAKGGMNRLNVAITRARKKMIVIKSLYGHQ
IQVSNLNNQNALTFKRFIEYVDRINGQLSINDSLESLEQQTYLEFDNDLV
KEIYSELTKKLSNKYQIFPNWNIGTKKIDLVIIKKETKEIVKTILLETWK
ENRSVQIMFEDIDRQYFLEDRSYSTYRIKEYEWYIDKHKIVSRINDSLSS
NNNNNKIDYVLWQQNNF
>UU297 conserved hypothetical
MNNKNNGMHLEVLINKSISLFNLQYQAFFKKRCVDIIIKNIDNSYVQGKI
KQKSETDYYGFYKGDYFDFEAKQTNKNSFLIKQIQPHQLAHLYLIHKNSG
FSFLIICFINYNLYFIITFQQLINYYQKTKRKSIPFQWFKDQCIELEIIF
PGVINFKKMINDLKLKYYDD
>UU367 conserved hypothetical
MKTTANKKIKLINIEKLEFEILEPINTNEILVFKDENSTIYESFNQNLEK
QRDEFIKKIREEEEQNWRNNFLANDRDYNELVKQRYDLEKQRDELKEKLK
NEGNKAIAHFKDSDEYKNLIKAQEKINSLNKTIESNEQSYKKEIENIELK
LKSQFDEETKSLKNTIAKQEIKLDNAEKMAIINFKESNEYQKIIKDKIDL
DIEIEKLKFAIQAHEDNMKAAKENWESKKIVEIKELESKKDKEIHKLTES
IEQLKREKSSNVKLVGEELEQWLKNKFDETYSFSCPDMTFTKINEAIDGK
KADFLLEFFDFGKEMSNDDKKLIFSATIEAKTEFFDNQKGTKNSAHYKKL
DQDRINQKSEYAILVTELEPEDHFVIKKINEYKNMFAVRPQYFIPLVDMI
RNFATLKAKINSQIIRYEDRAKIEENLDELKKDIVDNTLKYINDKTKKII
DDSKAIIKKAESIEESAEDIINKKLNTLKKKINELTIRKIDPNKLLLEVS
DDENDEE
>UU370 conserved hypothetical
MRKLALDLGTKSCGFAISDLLGIIASGLDNFIYEENDFTAVLAKIDEIMI
NYHHEIDTIVLGYPTNVYDGSKNERTYLIESFYALLKQHFLNHEKIKIVY
EDERFSTKIATQRLKNSCVKAAKIKKVKDKMSAVVILESYLSKNHFN
>UU296 unique hypothetical
MSNYELRRRIIMSNIDVKTNFWKLNQKNKKILFRVLGYSSLSVTIITPLI
YKISYNKQYSFITKSIRELKTIDTNFVSSYSDFYILQKSSISNDLYNYNL
INNYHDFEKLIKNDLNFDKYNSALIYEKIKVSLLEKYNENFFKNNDLLYV
SYNSLDSKYFLTSILSFDYNNLYLPFLNTKSIFNDEYDNKNFYTDSALST
TKTEVKFFSINKKYNIKLKQIKIYSIETAKDLFLYKNYVRKNNKPI
>UU144 unique hypothetical
MSLHKTIYIKFNNRDYDVKLTNVKIANIALNNDNVNNIEQNHISFRHLST
NDIKNSNDKVEAKFSIGLGFDISEKLKNIAFKKLDTNTNKLIDISDPTIL
RLTFYEYNKDQKVENNLAAPTDKTKISVVEIKKSQLMNSSIVSFVKKLNK
NAKYHMANIAFNQQLLPYLNKQFNVNADFPIDLEQNPIDFNDNKQANDEK
IKKTKESAIKVATAIAKQIVGIDYKGRDIIKNFIELDNVVNKK
>UU443 unique hypothetical membrane lipoprotein
MKHKKYKWIWLKLSMISAIPLLATIITACAKVDTKQKAKEELQSSLNKAV
LLKEIVDQSSYEDFKKIYNQTLKSNLENINKLSEQKLKQEQQTIKNLITQ
VSVLNELDSIKNMSDLIDVVELENTKKQLQDFLNQYEKLLNQASVDTTII
DKLKSDAHQKRLHTKALIQKTILDLANKIKNLIKTSGSNKNIVEIESDIQ
KLVNNNTKANFKKLYEDFKLIYTKLNDINDLINKELKALPFIKKLDDIVN
VINTIYQQNYSFLWFDQLKLTNLKQNLNKNITNIVNVKKSLDIEQIKSLT
NKLLNDLQNYLQGLNTIALDSENSINKLISIIQSLKPDDYNPYYSIEKQQ
NIQKDKNNSSKATYNGLENQIENLQSIISLFSFNTNSLTIDSANNLNNEL
TKKFEDANTKISSIVDQIKQTILSNFKKTYLFKDFIKHLKEFNTKVNSEN
DQAKKTNKTQTIQDVLNSYKNDPWINTKVSLKLSANQTLTIDNLENIDLA
YSNDFLLKPKELINYLKLDNNQERVFTKDIENFSVKIFTIVDKKLYIPEA
KELIEESKKITETKNGKTNNESKVERLKKFTKFVEQGINNNNVSSYTLDL
YNKKLKKLIEEVKKIQNGTSQKIENNSK
>UU598 conserved hypothetical
MVKNFFIKDPIHGLITFDEQYEWAYELIKTKEFWRLNNIKQLGSSWSIFP
SATHTRFTHCIGVFQVTRKLLDSLKFIKSDTHDLINNKKIVCAAALLHDI
GHGPFSHTFEYATNYNHEKIGQMIITNPKSEINKILIKHNINPVDVANII
DHKSKKMWMQQVISSQIDADRLDYLPRDSHFTGTKYGNIDYDNIFKKAIV
FNDQLCFSKHSWNALENILISRWSMFENVYLNKTPTTYDILMKKTLARVH
FLYQKQKKYIFKNSQLLTILKPWLDNESWDITTVQNLDDYSFTALMRSFA
NEHDFILKTLATNWLQNKDFVTFEYEYGKDKSKDQKIIHKKYFYETITSN
KQIYDFNEPVFLYTENKNNDIKLLKLEDKSLIIAALKSIKQPRIKKWIFY
YKPLK
>UU417 conserved hypothetical
MQKDLLTKLIEQTYGFNKITIFVHTNPDCDALGSAFALARILKLNTFGTR
VKIVGVNALNPNDFKNFFTFDPNEVDDEFIKDSIAFIVDTANQERVLSQK
HRLAKKTILVDHHVKTITYTDLEYINDQSIAACEMIAYSLMHTNLNFDLK
TLNYLLLGITTDSNRLMYDKVSDFTYEIMSWFFKNNVKHYQIYQQLYERN
LNDILFDNELVKTIKTQGQVAYLNIDPQWNQKYHFTRWGDKVYLLSNIKN
YPIWFIVYFDENTNTYKVSLRSNKYKVRLVASQFNGGGHDLAAGCSLTNI
DQLENLLSALDALIKNKIVVD
>UU143 conserved hypothetical
MKRIKNRKWWKFGGVLFLLPLASFLIMCKNQEAPKTNQEAPKTNKENVLD
DFDANIINIENISKPKFINQNKTIINLKLKKFNFKSPNTTITLTYKDNNG
HKFTSDPLSINDEQNYDFIFSNLTPNRKYQIQNLTFNNQKRTDIYLKTNL
NNAIFSIKPIPIKTNNFKIKVFNQNALISFSIPKNSDVRVNEKIALEFEN
LSSNLVPNNEIISRIDKNFNVEFKLDNLKLNNKYRIVNLRFLDTNPPNVS
PNIFEKLSNYESSFIIPGIKTNMHNHKDLNSNDKKYIDSPYNTKIELNDK
NNFNDKVLPDAFEQQNINIQEVENLNQDILNQNELELQKYFSFISDQANL
KDKDFQNYSFNDINKNSKQEIKFKIKHINIDSSNKKAIIELDSSSSNDNT
KLLEANNKQLLIKSYDYNNPWSKIVSYEKKDNNKMIFDLHDFPKDLKTFI
ITHIRFDDNITSLGKIKENSFEYYQNDKEYLLKSLKYYFDIKENQLYGSA
CFNFNNDDFKILKNKTFVFKYEIDTKNNILNKYIPLNKYINVDFKNLAQF
KIVNVFDGLNYKLESIKIVNKNSLLPYNDHVNIQNANNTNFSVWHKVYPK
QNIINEFFDDSLIKDEFNLSKIDFNHLWKNNTDQKNIPYSLRNLISLTLH
EREYAIYKHNATNGFYLYNTITSNKDFNLIKNNKESYHLNSLIAHLAIKD
EGLKKDESAGFFLEKDLNDFDNLNNFKDEDIVFNVDLELDPNLIYESQLV
DKNMRRSHVIIPISYKVIKKQHILEDVEFSLNYALGSEAYENHIYQQIKS
QLKFNVFLNGSKIKVEVKPRNDNIKLYDYVWKHNNSNQPSYFIGRYDFIV
NWLTNNNEVIIDKKLEEFKKKSYTARILKDNENEMSKAAIKQVRERTITF
SLTSDGTWNFLGKVKPNDPNDYRYYMLTDHHVIGSGGSWYNPQINWAGKM
EYESINLNKKTIYDDDGNEKYTYSNFADYTVVIPQTISQNDLNKDKYQPY
YNYSSVNNQDTPGKNQLQYFAFPFKLKFEKVMDFCLQKNNIYKHYNALGR
YDDKISELDWSVVSIDLKPIFEAFKNQDLNKPFIYNNKTLSPEETSVIKY
FLSLKNIKPLEVSPQTRYVRSNQDVDWYIGTFPRYTNTNQNSMGVGELRY
REYNIQKIDSVNTNFVTGGKGVLYKSDIPYTTISTDYIDAAGGSSGTSLY
DEQGRFVGSIATGRTPSKNGHPTWETIGWSLIDSQISGFFGDRENRANNS
SIIQQIKQLAYLYPEKYEDIYK
>UU127 unique hypothetical
MKIIGSAFLGIVFCILLAFAIIFGIEIDYYHQGDYLKYLNFLDKLHQYNK
IDNSFEYSNHYESALIGVIVLTIICFLIFITPIIIIVITKIKEKKVINKK
I
>UU270 unique hypothetical
MINKNKKFHFQYFKKDNDQSISTKETLKRYFNFRSQSVKLIIFNLVLTAF
FLALFLIGRFLTKNLDFLNGFSWQLQMGIFVLAIVCIPNFYYKLMYYIIA
PLVMLAIGFSAEPFFGYLMPHYGFGLILFTDVILIIVKKSCQSIKKQIFL
SYLLIFSFSIIGYFIVWMGYSIQGTLFYNTAFIPSMIYNSLVTFGSMAIN
FVLYIISIPAIVALKNKYLCKLV
>UU149 unique hypothetical
MEKIVGFIVNIINVQKQMIKDLKELKNHKDIMVKDHEKLNDMLNSMIDEA
VKNYKIALKNITEILNVHLNCVLYNHNLKCGVKDEKLLLPLFKRKKAS
>UU294 unique hypothetical
MIQKAKFYAGYISRLRFIQKLRYEIQNEKKTLNKIIKVVNDADISTLYDF
KDKNLTIYTKTFYFHNYQFVNANKKNYFISKKTIKSVITENLLDIGFTWT
IIYNDQTKTYIRPTDFMTKNFIDYKKNENKIATRSKILYDMIVKNESLNI
NHSEYESLLVNNEWKRYYENMINIFLYQYYNEGIKNDIDFLNHFLLKDAL
K
>UU122 conserved hypothetical
MLGLGILVAYLSHFIRFNFLAFDFSLFTLVYLIYKVKYRFVYLVTILLSL
ANLLHGSPSWIGTMVLSLNNLFFVTMVILFKKLFIPKRPKFYLNLWVLVL
SSFLTTVFNVIMNGILYTPLYWYTFKITPTLNFLEVQKIYEKHPTLFLLN
IKSYWLGIIALYTSFNLIKNIIISFISLTILKIFADKKTIITY
>UU275 unique hypothetical membrane lipoprotein
MGLKKEKKDRSTIQLLFGTIKKRKIANYLIIAFAFLTFALAIIGSFEAIA
SKYAIGIGSGLSLFITIAFSVWRILMIHLEKEWNKSEIIWQSVMGAILVL
SIIFWIWATTTTTIQYSSLKEHLLLLKQQDSRANFVVLTQATVDEFGVAL
KGGLWAWVITSCIYIFINTFNNMFMKEKNSK
>UU574 conserved hypothetical
MITDKLIKELNEITRLYYKNDRNQFKKSLINIWSKTMGYTPNLQDPKTYN
EKLLYMYLNTDQSKILEIVDKISFKKWLIKHRLYQYQVPTLAIFNRQNQI
TLLDLNKFPKPYIIKLNNSTENEDLYIIRETTSQAELTQIITHFNNILLN
KKINHPRNFYETWCYSQIKPQVLIEPLLGKQTLVADYKIFCFAQEQFCLY
MNKDEIEKNNWNWDFLKSNIFDLKNNKSILNHEIINFDFSEIKDVCQKIY
EVLKNDFKHFRIDFYYVDHRLYIGEITFNTSNAFFTFWDDPQWKQKDIEW
GKYWK
>UU154 unique hypothetical
MVKDDKLVPSIRLLTPNELSEQWANPNSEINQITRAVLTIQGIDLKAIDL
NQAAQIIYFCQANNLNPLNKEVYLIQMGNRLAPIVGIHTMTERAYRTERL
VGIVQSYNDVNKSAKTILTIRSPGLKGLGTVEAEVFLSEYSTNKNLWLTK
PITMLKKVSLAHALRLSGLLAFKGDTPYIYEEMQQGEAVPNKKMFTPPVA
EVIEPAVENIKKVDFNEF
>UU483 MBA N-terminal paralog
MKLIKKKLLFLFTAALVPIVATALASCSNKSKLNVNVLMKDIIHTKSDHY
YVVYEVNELNTSQGIYKNLTLNTNLFNPLLNKKVDRLENIHPLIINNKIY
LRLARKPKINDHFITNFSNDAFPALHLIFDHNLNFIEQDINEDLNLQPSL
PNTPKIDHLEINNISFTNIKQNQVDIKIKLKTVSFKDDAIHNFSLKIIKK
TNHQIITSDAVFNKQKNEIDATVYNLTSDCEYLLDKLNFNNQKIQLTSIP
NHTFKTLDDSDNLLKNLEITKINDNGANLTLNFKELKIKDDSDEALNNIH
ISLAYNRVYKKGQLELNKKHFFIDKLNKRIIVYVDELERGTHYDIKQIKI
NDQVLNLNNQTHDFTTKGDYAKVEAIDYETAVDKITKAVTIKVKLSEDLA
FYNPNIHNFKFLIRKENDQNPIEFSEVKYDEQERLLTAVINGLDVDKTYE
IDNILLNGKPVSFPNDDDYAGGYYGPINKTFKIRPDRSSIEIFKDKSFYN
SYYSAFNSWFWYLSVSKKDDNERSKEVKKDYKEHLFISDITKNSAIINIK
CEKLLLRKENSLKPKIKLRYHPLNNPNEWAYKEFSFEDKNCFMSIDEDQK
TIKIKLLNLDNHINYEFVSFILEDVDGNYHSDNFNVNVYIGDFFDSHPFH
LDLSFLKFKTNEFKKAVFSFTNTKSTSTDLNVDLQDNQYADSIEHKIKYT
LEDENHNKYKFVKNLSKSETTQLNATKNIILHLFALDKNQTFKLISFEID
DDNYLTNNITVKTLNESSPHLLLNLEFNDIKNTNSTLKLTLNQAVINMPK
RVDVILKNKKTNKLLYLFKTDFYFDKKTHQISTKLDNLNINTDYEISELF
IDKQQINLKNINNKTFKTLDYGFDQFYLDKIDHEINQQQKNIKFKLHFSD
FIFKDKNAHKMSLVLEDENNQQECIDLNAHNQLKIDYEHQTIEFELKYLK
PDIKYRINSIQLNDKNLDLTWVDNQRYFNFPGILNPNLKWKVDNIKYEVN
GSDPKINITFDQDIFLSNLSQDKECNIELNYVYNNSDGDTLESKIVAKIN
KNNNKSVEITLTNENCYWLNDLKDICSNLDSNQISTQFLKSIKINGHKIP
KVN
>UU157 unique hypothetical
MNKWVIGIDLSTTITGVAILRNEQIIKTFAVAFDNFNEKNLYNNVIRLIK
EINLNVWLLADDDYYIGIEVANFSNPKLTQRFSIYAGMIIALMSQVLRDF
NAEFKMFNANAWQLKIPQIQYNTLRKDRKLITKNLMIKTFNIKSNLNEDE
YDALAIAYFYDSINSTLEQEEITKAKKIVKMNKVKQQLSISKKINKLLEK
KSKLKKATAISKVDEQIEELKKLNK
>UU489 unique hypothetical membrane lipoprotein
MSFKTKIKFKQKWKKVLAFFGISTLTIAAIVGTGIGAANYANKNIKTGDF
GDKISARTQVLLNDFQTEAEQLNLLKTTANLSQKHLQALGVNNVSAKYAI
YERINKNTKKHEKFGEIVYQFYPTNSKLDIVNFLTKTKPYEKINSKIQLL
SLFTTANRLELQNISSLFSPKPELSQNRDFDNTNWLTLNNDPKKISVKTT
NNGQQVEILLPKTSFDHQKFNLDFFAKEFDANFNFNPMGNKTRAQAVATF
DRTKQKRKAPVNSWLLWVNRDGLIARFNMLLTLAHAQKQKYVDPKSWDYV
DTVYKNLNTNSEEKAFVDWLAKQDFDKYFINTNSIIEPINVQTDQLLNII
RAFYQSSSHKVKIKNANNQDETQNFKDNEMFYSWNINKLSLVRGFVYAID
YNNFFNYFLAPKKDDKLTPAQQSIVKYTSDKLVLNKDNTTQSFINTAHNL
KQYYLPTYFAQSVFSENNIKKDYAKTFYDLLNNFSTKPSNLKRAVIKTIN
PMDAILIGIAVLILIIAIIISLLYKIPGLIYSLLMAFSFVISLLLIKSSN
LGFSTETYSALIIGICWPLLNLVDFNNHIKHLIQQKFSYKNALRISLNKT
IVNQGMFYLLMIFISLVFMYFGKNNISIFGFNLILITFSCLLISYILFIV
MMYMLWSLAHHLPKLHLWRKYLVATNAINQNRFDDKFEWNDQQKYQRLIF
KIMNQKVYRISFLIFIFILAFIGLFILGFIVPNHSFSFGSVYELIMKSDL
KDFNSHEFKTILDYKINDGVVSMQFDAKKPNVLSEIDLISLNHRFSDAIV
YRSSQYHLINNITNSIAAYFIIFAIILIWSSIWLKPQSIIPIIINLICTS
LISFGIAGLLRLFNNQISIIAINTSFVLMTSFSLHICLNLKRTLDLMKHV
TKKQLQFQIQDSLIKYFNTYNIIYIVILFALLWLMIFTPFVLISFNAIIL
FSLISTHYLSIIIIHYLWMKMVYISKGLLAKDDNADNVYDKFDEQEIMNI
NKF
>UU292 conserved hypothetical
MDKKSKKILGLSVASIIAALAIIAPSTYFGLQKQEEGKKDINLDNVTRKI
PGETKDDIKVEDLNNINDQNTDLKLDFSKVSIKPQTKINYLAIGDSITAG
FNSELGWEAPGRYDPITNKISGLSFPSFIAQYINKVEPNRLASYENLGIT
GSRIEDWLYMLGAGSDEYFKNQEYRFFDFSKQMDQQKDNPFKNRLSKFFK
NFGYDSKLTPKNNHEVNINDFNGLKEQIKKANLMTITLGANDFLRYLDIP
KLVSLTNLKGNDLEIKVKEFENNLQKASLEITKNLKKLIALIRTLNSNVS
ITLVSYPLPLLRLQDVIDSSFKLTNKRRLSDEIINILNSAIKKTYDLNNN
INYIDAFDENDWKENSFNFAKAIFDIHPTELGYKRMAQDIFLKMSLGQNY
AQQKTASIANAIYDAWDSEYFNKDSDSFKQQIGFANNTNQDLVEKTLGSS
KGAAFWAKTALENDEELRKSFSNFKNTSTIVKDWLISNKRRFGSFVNLIT
SNLTSLGLDKNGYISQFLSKKDADNTNNLYKLASALASTPYIDMVISGIQ
NDLDNLDLDKNNIIGTQNISKKILYDVFRKNIINDQNLYELIKGMFHSQL
FNENKSQIKSLIKALLSDLVSSHKLLEIIFGEFATDNLKNNNEFLKNLLI
IQNKLTQTKSLDNIINVFVDALFDNDNEYLLQGPLSNVLAKIVKTNKALL
TTRIDNLFNDLFKDQTTLDATYNILIRVLGQNIPDFIKTPQASLIIKKIL
SKGTNLKLINTLKLNTIDLLTDSKTYAGIFDSSETSIINLIQKSIDFTSK
SFISDVLDLLTSDNVDLNEWKEFIKTILNSSTIKNIFNYGIVNLVSSNTT
PLKTSHFDFNVLLKNLIAVLEEKDWTTNQKTKLKSLLRMSVDELLKNPQT
QNFVTSIEDFIANKLGDLVISANNSLLKSNMSDIWKLIKEVVHDLIHSSE
SYDLIFSIINDFIDHPQNYDNLNNINDLLPLILKSTNKELQDKVDILFKK
LINNENIPNLVGTLTTNLIVKNFFVKELTVDQKQKINNFITNILPTIPNL
TLYKEIRKQAFEFLTNNINKILVDPKNTLLILNDGINKLLSNILPQLSTL
IELIDNDKIKDQDFIDVIKIFIDNLDFNKLFVNIKSNNNQTTDSTTLNQF
YFKFKLNLEPKKLIFDLIKNLLNSPILKVNDNKNNKIKIESNKAKIKSIL
TTSVTNIFENSNLMNFFNNQLSQLFSSIDLFKNLNLSNQQRLNFAKAIVE
LLNKEKLLSNLINVLITNLIDHADEYAEATDLATILSLTIKYNQNELKNA
FDKLLIGTLKNDNLQDLILRIFVKLINPNKSYDSISVVSINKLKTFISKF
ATGISKLDLYQQLKNSIFTVFSNKTKMQQLLSNDVSVINKTLLEAFNIDT
PEKVLKISSLLDINEIDARDYADIIEIILVEIGFNVTSIQNNDVNNNLKT
IDKKTNDFAFQILKKALNNGVSDQQLQKIKNVVNYLLDDIVKIHDSSSFL
RIQLEQLSHVLVDKITAVLPKSLTIKHKYTKIFSSILNNQDFLQKAKTLL
STILNELIDHKDKYKDINSFSELISVFFKNKASDLKTQLKDLLNTILKNQ
TLITNIGQVIIESFKLENKISILDSDLEQNTISFINKIFAHITELPIYTN
LVDNFFNFFSEYTKSSDTKTLNFNKFKSSLFQAIIPKISDFASLLDLFKY
NEISEQEWKSAITFFIDYLPINNLINSKILPTNSLLFVRNISISKTKPEL
NKIENIILDLFKALSQKAKTFDNNTLTKAKNIIEFTFNKLLTSNNIKNFI
NNLLSNLSPIRSFLKSINVQDKSKHNLLNM
>UU288 unique hypothetical
MTVAYHNLDINDPKNVLLATQKFFNHINEIIIDYGLDKRDQWIKKIIPFE
E
>UU088 conserved hypothetical
MDFQKLAQELKKMQNTLSKKQKEFEEKVFDFDYKGYVLVKIKGDLNIEAI
EIKTEIVDPEDKETLQDILRAAINEAISITCKERDAIMNATIPKGTGLF
>UU045 conserved hypothetical membrane lipoprotein
MKKNKLTTLALILPITILTPIVIASCTNKTKVKKSSSLDKIASNLKLEYF
NNKANTKASSVQKDEIKKPLNLPNDVVFSVKDVFVSHKDQSVLIVKYTLK
KGNEIQEYTYEIKGFKSVYEKDKIVNDLSQANEDFKKIVNNIRLKDTFDF
KLAAFPNQNYDQLLPSQIYKNYYQGIEIQQHKYQNELDIKIINFLYPDGD
FGSANKNGTLKLSLMLTDKKNNQVYYKLLEVSGFKSNPYGVDENGTIPGI
GTERLKPKNQDDYFSKTQLQRYEIDNEGYLQILKRQNNDKNWKELRPDLN
ATVSDIKHFDEKAKNVGQDSYESAAYKGFTLPVYESDGKISGLALAGKDT
PKGPSWVDAIGRNQWQIGGLPRTLPNEKYRQEAMQTFSLGILNNDSHKNN
TYNKTAGTTWILDYQKTSDNKYPTKWYFATNLHVADAINENTLSINLMRL
MDSAQIKTTFRLSNLDENIYNFGFRSKEHGKNLLNHGLKKIFDGRDFLKT
KPAEYLINSQKEKYKDVGNFTDFAVFELDFEKLELVNVWKNFLGENNGLV
TKYNNYNPQELAKVITSNYANNKNNQIKFLSKSYLSDYSKIDVPLKYRQE
DAKTWFKKYDELFALGWPNSTEDFFFKAYVDDDQLKYRTRDNFSLWTNSD
YRFFNNLTQQEGGQPAFPPERTERGNYLSYAIGFRSFIQKPGIVDAFIAV
PQIGNNLYTSSDNKKYINMGLEYLPKHFAPAGGASGTSVRNQKNELVAIY
HAKYDSSKTGLAAAFRSEGYDYQGLYGNYNLPQYDLIYGGGKDQTEKKSY
REAMKDIYQNNNIKTALFPDGFDKIPDEFKFNNN
>UU041 conserved hypothetical
MSSLPVIILVIGIFGSIFLVIGYIPQVIKVIKTKRTDGISLTFLISLNIA
CFLFVIYSILVMIFNKHNGIPTALPLCLANTIVGILGLVILIYKVKNIKK
AKLYLMDEKTYYEKYVLNNL
>UU424 unique hypothetical
MVCIILKIKKGMLKIMNNNKSYIKKYFDDILIQAKQVLKKHDYAYAYDLI
SNEFNNPLIDLKTLQEFEAFAIEIKKSAELNFIDENEAKLAKTDFYCKIH
DPKTTYVSLAYLETFLMRFINEMDELDITFLNSLLTNKLINGSTKLDILD
LLATNNIDQNFNFYNKYLKQTKNVNPVNFNNHYQEIDQIQNYLNKYLAKN
PSLLHLANKLLMMYITYYFPFKFAHNHNLIAKTIIDYVKNAMENHVCQYS
EEQKAIVACINKILEEEQV
>UU207 conserved hypothetical
MKTIKLDLFQKMLYAGAKILEIECEYINDLNVFPVPDGDTGSNMKTTTAG
AIIAIKEIEISNFSQLAKIFSRGLLMNARGNSGVILSQIFRGFMDALNND
AYEVSIEQLKQAFNGAKEKAYASVSTPIEGTILTVIRVINERISERQNFD
SVEDLFAFVTKEAQIILERTPEMLPSLKEANVVDSGGYGLVSFLKGMYQS
LTNTFDEKLIIKNEEENIKSKTKPLDLEIIHKEKEEGFGYCSEIILSLRK
KIIPNSPSKSFFEFEKYKSELAKIGDSIVAIQDEDLVKVHLHTLTPYKFL
QLSQKYGEFDKIKIENMTNQFYESLERKGLTTKKENKLTLSMEQKIIATV
PSEKFKKMFIEEHGIDNVIVTETEGAPSIQRFVDEINSTNSSQIFIVTDD
SNIVLAAEQASKIVAENNILVSVIGAYNVFETLLAISHFEQQNDYRTNFK
TMNKIVKKARSGMITTSIKNVKYPHITVNKDDYIGIINKKIIASEKNAYD
VLLKTIEMLIESLKKPEICYIYYGINASQTDVHQIEKYISEKYGIICDLR
YTGQSLYHYYIGIQ
>UU126 unique hypothetical
MQKKILKNLSIGVVSTIILGSITISLSNCSYNKKTFSSSTITNQDTKNLD
IIAKNIKFKYDIFENEDEQIIKINKIKVVGDLGQAKIIIKKVIIEQKSNN
FFVQYQLSLHNQTKEYTQNLEINKKQSVIETKYINDELINNDYRPFALKQ
LLSSPQNIKKTSDLSLITMQKNNQEFNNYFNFIQNEDNFKQLPFNQATLL
TKQNQLTDHHTNFKFEKIEIDKQNQIATVSFSHDSDSQTIQKILNATNKR
LLIKNFDWTNPFSKIISYEKINNNQLRFSLKDFPKSLTKFIITHIQYDDV
VESLGRDLKNLFLYNQIEEELTLKKLNFYLQENEVYGSAFFDFNEQTLKL
YKNKIFLFEFTLDENYSEAKKNQSLIAKYTPPIQYVRVPFKSLWKFKIPH
LYNGYLYKLNRISVRDNNSLTPFAFVKVKELNTSTFFVKNIIYNDRKIID
LYYNNNQFFSTKYQTLKNKNLTLNDLYKLWASNQNNLYLDYSLRNFISLV
QYENTYLFYQNKTNEGFYDFITKKADFILVNNNEIKNLHKTTLKDNPDLI
FKKDKDNYFQLTKKINKIKNLNLVNEKNLVFNITFGLDPNLIKETNLWKN
LMLRSQISLAVPYKTLKNKKVIEDAEFVLNYGIGNQEYEYELYKKIKQDF
RFQISYINDELKIKIISKNNISVFDNIWEHNSSIDSSYFLTKANFNIYYL
NNTTIDIMEDDKSNNQYTTRIYKNNEQNFLPIKNARDRVISLSLIQDGTW
NVLGKVKPNDDDDYRYYLISCAHVLNSTQAFKSINKTGNKDLFESSNSSN
GDFDPLVPQIIHENETLNDKKNPYYNALEKNGKLEANQNQFQFLNFPEKI
SIESIINFDHQVKNKLSPHVNALGFFNPNASLDFSLITINLKPFFQKYGQ
LENSPAFNDLTKEQQSVIRHIINFKDLKPLKLSNQTKYFDDNQNVKWYLS
TFPRTETINEFNAGKLPRYREYEINKYDKIQENIITTNNYLSTVGTTKIS
NQYFDVGSGSSGSVVYDENGDLVGMISFGAHENAKFTAGGMIVFDSLISG
FFGDKNNFANRTSLIQQIKQLAYLYPEKYEDIYK
>UU032 unique hypothetical
MSKKINNNKTPRNKVKNNNVSKDNDDIVISLRYENWVKEERVNSLTTYTK
DENQFLKNIIYILNTLFPYVYKNWKNKGINDHCHPIKQNNVFSKYIKLIK
KLHPNLLKNDNEELELYQLGLGRSVRVICSKIDNILFPLLIDHHHLGYES
QSYNDKDTKKYDYCPLRKYNKNQDN
>UU061 conserved hypothetical
MTSLDITTLVISILSLIATLSISFNIYFIELRKQRERKIERLQQEAKQFI
INNLDEKDFIVLCQFIYKLYKHDKHTRKIHYEFVLLNEPVQKEVFKQLEI
LNIVDFKDNEWIANKFSILKEIVNDYQLGNWDDYKFYENFNFAYTLFREE
KCDAVFEEIKQNKFGGKNLSFHEYLNEYAHRSKESDMLAPIDYFIDQNNL
NNVFDRQKHAIYKLYLLDLILNELCRSMNNDHRINNEFKYFDCEVIYVED
LYLKILYKLYFQLN
>UU037 unique hypothetical
MKELLRLTKVKRYGKVYTPDYLVNIILDKGHYINGNINKKHVIDNSCGDG
QFLTYIVDRYCKDYLINNNDLIELKKTIRNIYTWYRNW
>UU201 conserved hypothetical
MATNYFLMKESQCDLLNDFKNFFQMVIDNQKLICDLLKNDQSSYKETYEK
ACFLEKKVNTTYADMLEEIMWIIQRDQPRASYLRFFIAGINSIKDLERIS
DHSEIICEYFLETEFDEEQKNFFLTSFEISNQILSDLYDFFDKNEFSVNT
IEHIKDLRSKSIMKINKNLIQSLHDQSKLLDENSNYIKLILMYRHIERNI
EHGINIVQNFGNVHITSR
>UU459 unique hypothetical
MNNKKGKKFYDFLKTIEGFKIITIISYVFVAILLAILIWSAVRLSYYIKD
YYARIDEYNEWKQNIIKIFKTKNFHLDSPYNQIKIFKYGSILGISSFLII
IININIFAYWSYSNVYIPELKDKKLVKNWFRNFQKNNKEDQKVIKDQQED
TKKESE
>UU578 unique hypothetical membrane lipoprotein
MKRKNKIITSSLALLFTGVIATISIAACSKQNNQKTKNFNSQEQANKIIE
AILNKKEGKDNFIDWVHWWNSPFQQARKLAKDLDKYIDLTKSKNFKSMID
KNEYKSTFSAQIENVIRIIKDDIKMYANSPFWKKWRQQKKTALFLINYAP
IQKDDSQINAPGILLPAEYPLLYSKPDFEELPGFGAFFPTPKSMDAVDLL
DTWKSFGSLISSKGNSVEKSVLASKLQNSFAKTADKVVYIYDDAIVPNIY
DKNGNRNLKITQEFANWMINQNYKGYLAREFLKINQKNDLIPLPMSIVWH
ASYGIIGMHRMLYTLSKAFGMPKDELEHLKAQEKFKIPTLKKLLTNDELE
LKNGIQTIKTGIDSPFKYHRDQNRDDWKIWATNSQVLDICIALGLKPDLL
VKGELSTSVHEDPNLAYYLNDVIKNQLSDIEQISIKKNHINWTATNYEPI
KNLNVNLILMGVHGLIKNSAFKKMMDEGKQIKNWAFTDRRFSDETRQYVK
KGEEDLYSQNASILGWDEFLKTKNNQ
>UU073 conserved hypothetical
MPKSTLQEIIDNDSNKFTFSEFVKEDIYTNTDYSSTDYKVILYSFFRNNL
TIKIGQKLTWIIKSQNLQIIEFILNGLDYFNNLNIEYEIMFEPDHLNKTR
TNYSLLLWGDLDKLDEILKLFDDANNENFHKDRYCSNFLIGAMLSGGSIA
HPLENYHLEIRCDSNNYIPLLTKALARYGLEYKIIYRNKKTIVYFKKSEI
ISDFLKAIRTQNSLFEFENIRIQRDFNNQQQRLNNLDISNLSKSSKAGVL
TKEMILEIKKNHDEFCKQSTKFLKYCELRVQNPDCSLNELSCLLKQMFNI
EISKSGLNHFNSRIKEMYEELKLKKLVFKN
>UU496 unique hypothetical
MNNKNKKRNAKIATGLTISSLIWAGVITGIVLRFANQHSNQIFSKYYEYT
KDGNLIIKVRLFTRDNDINQKIYAIFKDKLGKETSVLITRNKEVARIDTT
SLGLNNSWVLDRIVDENNNTLINNNELVWQQKILVDRPNVFKVNFNKEGD
KFFEIKLNHELSNQYLTAHFINQNNAKYIQNIQVDHNGNVIVGTKQLPLG
NFYKFVGLTLKEDNKNTKIVNLDEISEPIRGIDKTRSFDDQGNVIINARV
SQNLANQNINALFEDEKHQLHTLKAIVGTDGLVRLLTKDLENHHDYKLIQ
IVDKDNHDVIKPNKLDAAHQNIVHKPNKIKIETDKNGLQKALHIQVDSSL
NDRLLTLSFENENHDKTNIIAKVNNGEITVDLNNLKDGHLYKLDNISINN
TSPAKRVANLDDLNESAKTINKLNTNALNDPYHYDDKGNLIFNAKVDSKQ
FANDQVEAVFIDEKNNEHKVLTKVDLNGNIVINTSDLNLNHTYKLKHVIS
LEEPETNVLNDYELAINQKTKFSKPAAIVGALEDNNYKIQLLNPDLANKS
VVLTFEDENHHPYQLTGKLNDQQELILRTNDDHLLPNNHTYTLTKITNVN
NQPIVNVNDLDRKDRLLEKVDVNKLQQLNTYTYDDLGNLIIDINDNLNKI
TTQDAVAHFIDENNKDYFVPTKVDLNKNKISINTKDLDANHHYQLLNIVD
KNKHEQILLNSNEINPLNRISIIKPLAIIKQDANKNLNLLTFDKNLFNRS
LDATFIDENQKEYHVKAKTIIDSLGQTRFITSDEVLPNHHKYQLIALKYD
GQKSN
>UU558 unique hypothetical
MKKRLKLSAKIAIAFASVGAFAGAVVGFMKLYAVSTGGLGRQTLQVNSSF
DTTIPNRQVDRALLMDQFGKPVADYDFKAKKGNNTQVTLLIDFGKYKKGQ
KISYLEFLDNFVNLNNNNLPNLRLEVGPIVFNNNYINSISPDEFIEFTNW
FFKNVSWGPDLLTLKEFKLSRGIQQNGNAITLGLHSGTRERTVIEFFPDA
FFGSLPIYNINAGPGNAYDSLARQVNKDAMTLEELEEYHQKIPLMISAYN
SHSFGGVKLIDVLKNAKNTYLFNADKYFDLTKDPLNFPNLKNLKASDRTL
NYLFYAQNEQQAKQKVQAYLNELQFVKGLIPKDKKFNPKIDVKMDEINKI
KINEFLEFNASASSPFGGSLDLESIGKSSGNQNYLLIDATIGGQQQKIKY
YMFKDEFTTKSSSNDEFIQNDNSILASSLREIITKNFNDYIDQKQNFKNV
YDVESTFKNKQFYIYDIDGNGKNPHFYKSKESLLESELVNYDEKKVSLVT
ITKTKVEGLNKLILTTKDDKDLILESPKNNPKGYNYDSSFDDAFNTLKVA
ANYFDVFTPRLIKQGSKFVNGKIIKTYTIYVDAYSGLLDKVLNKNRHLLQ
KINGIHTEVVQDKYGKNTYKVVNGEYEGIYVTDRIPYLSLVAQSDPAFKT
TGINYLKYVSTHEYGHHQTLQDMKDISDSNDSVIGGGIDSRSGVSDESYV
NGKALQDYLNARSSGITFRKTDVDYNPTKDGSFFNFSLNNDPKNPVWETQ
KDIFGSVNADDPKAFFYNKKRRFLQKYDELFEAAKLRNVKPYDLFIMNSF
DHESATVNPSFGPDIKDPSRLKAEYYFYNDQNSQEQKNDNFKFGSVIEKP
GLSKYDGILKDGMGTPIKFSKDGRAIVYKLHKKKHPYKKDDIEILIKTKN
NTPVIDLSTCLKSDGTINTRKLNEKVREIQDSINSLIVKNYYNGGWDENG
NFDTSMFNLKTYFDHPMFTSNEKRKWAERITDAMFKYPDFNISKSLKLDE
KANASSVPYYKKVLSQIIGEDITNKTFDQFKYALLTLQYNASKIWDNKSK
EEVSKLDPELIEIKKYYDKQFDRFGVKNVNVVAQTTLFNYFDAGIEGNNG
YKYFVKPKEKELYQNILRTKTKESVESIIGIRPSYLTQNKITSYEQLFNK
SMINLNEFGTIKLIVDRGDGKDNKHLKKLDELTEKEIYPLMILTPAEAQA
INFDYLKSNNGSFTPLTLENNGSKFYTIKFKDIPSLIEFMSVDPAKYTIV
ENALSSSHENVRKWDYEYLKERYDVDKFFNEVIKKQEAYKNLTLEEFKQN
LTGLLFDGFTESNDIFKFYKSKDFNPSELDKYKQVFDGKLGLYGFRSFGN
KYERPGSPYGEPLDTYNFAGNPQNVWKAKPNQKNVRTVDSIIKGIQLEIE
RKHRENNTLNFGQLLQYAFGFTIYTDIPGGSKDIYGWLGSFFGISQSSEI
PNADGTVVSSDYVTLNKKRVQEKLNEIFGDYVFNIAEVLTRDYVQTVFIP
SQNELDNLPNYISGLSDFNTGNEYVFSGDNTKQWNERLIPVNNFLSVSNT
IALNTLFATNNYEKIQNVLANQALNVYQKNQQLFDDYLTKPQELESNFNK
VKESFLSNANFLALTKTHDSDVLNNLNSYSFLTRLSPKSNSYIGKTRLTN
NGFFKDRWLRKIIDWEIYDDNREPIKDDHLNILELDNKTKVTDRARAMWL
YILRSKGIGDRTLAQIYRNKEKDSILMYGFFKKEYKDKVKKIAIKNKNNG
KIEYIDVHTDNTNNLFYLKRQSDINSKWTLEDEGYVSWTSDYAILSNFTN
QLIGYDSINAKGSEFEIYFVDKDLKEVMDLSDPKNPKSLMTLGSRKYVAE
NGKSYTVSPVYARNENTKDKNRTIIRISNQFSV
>UU042 unique hypothetical
MSPISIELIIQISIGLSASLILLFAFLPQTLLTIKTKNTAALTISMFIIC
FIARLCFSLSAILTIIVYIHNQNYGLSLYALTLPVLICHGINMLLNLIIA
FIKINNVYKAKIHKMNENEYIIFAYAQKLKEKVSIKNK
>UU394 unique hypothetical
MVNDNKINEYKNKKFVANKVGYDPESVDVFLDELINELEIFINEHKNAIL
KIEELNEYKRKFEKEREYTTSLNNFIDLLEKVVDKKSTFDVWEKRPVRK
>UU519 unique hypothetical
MTSSIEKTPLVIKRHVFKKHYGIFTTLWEVIKDSSSFIASSLFSSLALLL
ITIIIALHNFSGAFAATSVSYIVVFQFSFIQLGGNIGVVLALWAKKLYDG
SKHKFVPSHSTTNLASFYAFSFGLIMLGVYLATSYTYNLYANIHENTLFA
QLFGEQYIWSSLGIIVLAPVHNYFLISIWTNDRRKILLTIILDFATWTIC
LVTSFLLGKYSILAYSGYGLGLSIGYIISTIAISIIKFSKDWRISKLGLS
LNLLKISIKQIWNQTLISIFSSIIKMFVLLALYHLINQKMTNSVPLNLQT
GRILWYHAMLFIQGIGLGFTDYLFYIFQKQTIRDRRYHSRQLFICVFGLL
FVYLMIAAIIFGFSIKPLSVVYAKEQNEAYINLDAEIPDHFYMSIRQGIL
NNPRLVYFLGAQAHIDPRLILAHLTNHNPEVWKVVIKQLITPIWAAGPNF
KYLYGIDNPITTSFVQISAEVVKKLLIGDNTYIHLTIFAIFYSLSLTLMR
YRDLIAKKQQSPFPTLLLQVLVIAFVVGFGVDYQSSVKFAGLLAWSMPLS
ISSAVILIISLLMFTIVYYKYLNKNDYKDNQITNQYSFKWIRHILWK
>UU319 unique hypothetical
MAMKVNERTCVFSKEKYPKDHLVRFVIINGELIFSLNYHRGYYLMIQKNT
NIQKVCQFLKKRFMIKNEEQVYRILEQLIQSLI
>UU444 unique hypothetical
MKNQKDFYFYGASSNAVLNKKVNFDLLKNTSINKTLEQLVANKVKFIIDI
KHLLDLLL
>UU490 conserved hypothetical
MHFLITNEVKKIFNDKLYSQRFKQITDLVSTKLNIDKKRFFECHFVDEKT
IQEINKNYRNKDYITDVISFAFDDGEIITPLLGEMYICYQKVVDQASQFA
HSFERELCFLFTHGLLHLLGYDHIKIEDEKIMFALQDEILNELKITRNIN
GARND
>UU160 unique hypothetical membrane lipoprotein
MKEYINRRILWLWILTTLWTIFLICSFFIKIGETSFVFFGKESEYTDKAT
LWDWMISKFPKLGSTKKWQLFLVVLFAYIICGCVDFFAISPFFWRFTTEG
KNWHLKTRIEQDKLKSEWKAINEQKRSIKKAQNDLYKQNKESILNDEQ
>UU214 conserved hypothetical
MKLNNHNLKEIYSLSLNELKEELFKLGLKSFISKQIYSWIYQKRIFNFDK
FSNIAKNNVIILKENFSNNLLKINSYQSNSDGSIKFEFLTDKNLIINCMI
IKFKNGFLIKINPFGINFKKEIINLSTNELVLQILLIQQFLDQRKLGNIT
NVIIKGLQDSLLNMDVVSNFINIINNENGLNIGKRKIAVWTSGINVDLIK
WGQLQNQIELIISMNASNSLIYQKIMLKKLNQNWSFLKLIEQIKAYTKIT
NNRVVLEYLLIDKINDDLNYANELVELLKNILCYVLLIPYNLNNYRTSAN
LDDFFNILSVNKIRISKRIRKSNDLDISFKQLKIKE
>UU008 unique hypothetical
MNFTSLLQDGIYEVGNGAIVTDQSPYLGITPDYQGAYGFPTHPWGIFFQV
VGAILVFGAYLPAVIKVLISKRTENLAIGMWIISIAGLGLLAIFAWLGVS
VNPGGFILVALSETLSCIASIIVFALKIANKAKAKAAGMTELEYCNLHYP
IVKKLPKR
>UU336 unique hypothetical
MNKTNQIVDLLTNKQNNSIQRRDNLVFVKNEQEFKDILDSTISLSNVYDP
LLGNGCEQEKIKELTILNNSVDISKIEEYTKTLESKVDDLYNNVSNQLIQ
DYQKNENTSANNIIMKNEELLNSHLKEVEKICEQLIDEWKIEILGEVNFK
FQQQLIEIDQKQEHKLKVKSLINEDSFLTKRQVKNKNKILTEFEKHRSQI
TQNYLNKRSDILKKEYDELLKDDKLFELSSGDNWNNFKKITLFISNEIGI
INDLEDLLNHQELIRTRNYTKRAILNQHHINGHFKDEKKYLKSLYDLRVK
FMYGLGSEIVILKFLIEHYKKLNSLRLRLETLNHPLSNYAVYFDILNRIE
KQTQLLAKIETLKYDNYDFNADVILDDLESNITKINEIKHNSNVLNKTKV
IKTIIEPKYELELISKDDKVDGVKVYVNDQEILSK
>UU262 conserved hypothetical
MSFKTIAYTQKNIKIIKKSKFITIVEPISDKNEVQSLFKKYKEQYYDATH
ICFAYVIGREFNYMKAYDDGEPNGTAGIPILNIIKIKSLTNVIIFVVRYF
GGIKLGTGGLIRAYSQCAKEIIDNCEIIILQKYFYYKVVYKLKNTKFAKQ
ILTSISYEKLIESYEDDRVILKIRINTKINIFMSKIEFIFIKHDY
>UU220 unique hypothetical membrane lipoprotein
MPRINTQVFNENNDKNRIKSNNNKICDDIEYTRLLETKEYNAGFSPNNDS
QDILIKKQDNILKLKPTLNFDDSDQLISIVPTKNYENLRLKEIEIDKKNT
VDYQLKKEIIDQDLTDDNHLSISQKSNGFALKTKQFIPQNISEFIYHNED
DPKTYGSENNLTFSQLEEKVNQKNTPDFYLKEIHAVRNKIIIWTILLAIG
VGLIFYLIYEVIINHFNPWIFLPISIYCVLMIFFLALSCSNFINFKKEMD
YQKNHFDCTKATNFIVGIYRKLIVVHINVNWITAYIYLTSLFMIFGVFVV
SYFMNLYYNAAIGSRFGDLIIKIPVVINNHLSQKISFNKNPLWAMIGLGA
ILGLTFIIHLWLVFNAHHRINRIHSYYVNEIITSEEIISLKKQANRRGLV
IFLVLTVILGLIFYLMYTILKRKYTIKK
>UU089.1 conserved hypothetical
MYNYKEVKHMGYGKGYLAMFKNKKVRFKVVNSFPDLKVQFVTSFPDYKVK
ISNSSSFCEETIKIQVVTSFPDVKLQKVTSFGDFEAYID
>UU211 conserved hypothetical
MIKINHYPNALLVKGHANFDEHGKDIVCAGVSAIIMGALNWFDQQKTTIK
VEQGFILIIIDNNNQLYRQYLELIIIQLKAIYFKYQSYIELHEYKQQYKR
GL
>UU356 unique hypothetical ATP/GTP-binding protein
MVYFLFKVVVYLIIINRVRTNHFMKMKAKKFLITGLLGVVSLATITTVAT
ACTNGNNQKANTVNNKSDLKTNPNINLTQQDVENLEKQRQQWSEDLDVYF
NGGLSKSGKNFDRINTLSSNATEWFKNHQKLAATRDSGSLVQDDAAYSFG
IAPDYVHYKWVSKDGGDVSPSYLKPYWNKNLTEGRNFSKLDPKTLDDNGI
GVLLISDHHYGKWNDNFLSKKTVGGLIMQSRVSGLPSHYPAVLTPKFLFD
PNLNPNLKKYASANYALPNYYSDPLDGIILTGKTLDRIYDAKKFSNVYNA
HVAGKTHFETFTDFAKAMVDETRRGISQWSLKNDKWKDKTVLMVMPNFTP
TAKMVDVNFKPEDLEFLSNVCINEPMYCPTIYSDPNDKYLPGLGAKFPIP
VNHISQVQNYIDDYGQIGGKVLNGTGNPEASKQVGPTLGDAFKDTSDVVV
FCYNEYGLLNYKPGTEEGEALVQQFEKNLTNYVNGLTKETKNQFVPTKVL
KEKPVVGKNFFIERKGKFYDACYGFAGQDLVVNTLNKWTRGANAQNIDLG
YPIFNKNTVKHIRAFKDSLGVKVLDKQK
>UU043 conserved hypothetical membrane lipoprotein
MKKLKLITLSLSPIPIVAIMATACSTTKKEKEVDHKQDELTTINNNLQLE
YPQNKDIETSAAIKEEIKPLNLPSGVVFSIKEISPKANDESTLIVKYTLK
KGNITKEFKKEINGFKKIRKDQNIANLKDMHDDFKTIFNNIKLKDTFDFK
LKGLFNSNFGEYDKLLPSQIINNFAQGVETRINTNQDRLGIEVIDVSYPN
KNFGSANREGNLKMSLLVTDKKTKQVFIKSIIAYGFKTNAMGLDENGSIP
GGGADLVKPKVDENNYFNKTQLERYEIDNQAYLNGLKGQHMGKTWQQVRP
ELGDNEQKINEFDQKAKGVSQDAYASAAYKGFTLPVYDKNGDFKGLSINE
SSYGQARSWVDTRGRDEWKTTGLPRTLPNEKYRDEALQTLGISSLTLKDG
KKDTWDKSSGTTWILDYQKTNDNKYPTKWYFATNLHVADTITDKTTSIDL
MKLMDSVKTKTTLRLSNLDENIYRFGFASKNNKFLLNHGLKKIYDGRNFL
KTKPTEYLTEQQKEKYKDAGSFVDFAVFELDFEQLKLLNVWNNQLNSNGG
VITKYDHSSAQDLAKIITSDYANHSDKQIKFLSKSYLNDYSKIDVPLRST
SYKFEGKDELFALGWPNSTRDGFFERYVDDDQTKYRTTDNFSLWTNSDYR
FFGKLTEQEGGQPAFPTERTERGNYLSYAIGYRSFIDKPGVLDAFISAPH
TGNDLYKSLDGKKYINMGLEYMPRHYAPAGGASGSSVRNQNNEIVGIYHV
SNEFASTGLATAFRSEGYDYKGLYGDKYKELPQYDLIYGGGKDQATGQSY
REKMKEIYKNNNNIKTALFPNGFDQYDEKFKFNNNQSK
>UU312 conserved hypothetical
MNSTYQLFIDVTSRKCILAIYKNFKIHTSIIVDTNNNLTDIIVEHLNNLL
KITNLQYQDLEAIYLNTGPGSFTGIRVGAIVAKTICTIFNKIKLFINDSL
NIIANGKNDVFVYLDAKGNKSYVITITNNIQNEYKIITNKELQNELKNTS
LTIIDANQIDYHDLIYNLKFDNFKLTNILDFRLNYVKKPLN
>UU094 unique hypothetical membrane lipoprotein
MFKKRSSSRKWFIICTSLSISSIAVVSLSACANTNNKIVNAGFIYNGSTT
NDAITGFDVNDYIIKAPENDTNLNQQILRNNNYEQKPILWNDYLKEYDSV
KKQHDQQIKNFYEYIWINEASKYKNLNKVIDINDPYFINWFLKLTPNTLK
NDLYNFINNIRKDNTKPSLVFSSSEPQIKVWKDLGNNQKQVLNPNQAIFE
PLTEQDIKNNINLLEKNKALRVSISFWYALTNQSSANILINDPFYKKPSG
IASNTSEKYFIRIEASPIALDFSQTDRLERDKYSAQTTSIKNTYKMRYYF
NNIRVEKQVTKVKNNAKRGDQNAEENFPKEFYFGANSNEKFSFGTHSYTL
NNEITQASYEQDIFSLDHKIKNELKKLNEQQILKDIEYAFTSGYDVAIDS
IGSIFNILKGVANDLNLKELFLQSSQDFRNLTYNITQQNNLTNLITLITS
NQSLGMVIDGFKPILKEIIYNNPSIDQSVKNTIWSKIDSMDFKNNLIAEI
GQIRTLLDSISLTEIKTYKPIINKLLELISLIEARSKKDPKNYGFIDGLD
ELFSFFLNLKQNDLPSSINFKIGDQNYTLYDLITEVKKIANNLIPHENQY
DPKDQQIISTNYFLTKIKILDLISLNKNDQLDYHKGVEMIFSLLKKFQIA
IPEFIYKIIDELLIQNTNWNKENIKKLLDAILYPKITSNDPSINDLKSYF
KYGISKPEITSKELEYDQNNLLIKKLNIKYRYKVLANAEFDIKPLFDLLP
QKPLSFIDLGGLWEQIKKEFPYKIVLAKNDYVDHTISISQPQELTTLIFK
DRSDHDKYKIGYVFYPTHTVQTHMPNSMKAIIENISLRNDRLLPNKYVAQ
LLNWLFYKKWVFINPLAIYETFEGDKKIPNDKNVKYLIKDNLNKYLKNYD
SNTYCEGFDFKHFSNNLENKVGNQTIRNLILAKIKTIKTDGQELYQDALG
RKIIATSAYDQINLTLQELIDYKLLGFGKKVDLKKDVYLSAVAFNFGLNT
NDSDQTNVLNNNDEIKYNLNILKKVVITLHFTKPMLDLSDPNRTKLVNSY
TFVV
>UU546 unique hypothetical
MSYNLQKLMSSCMFILTDDEIKQVENRLNNLFNEIKVFELFNLQNITPFE
IINKSFDNFLREDEINSCVGNNSEEVLNNCLKVIDHYGVLKNEK
>UU509 conserved hypothetical ATP/GTP-binding protein
MAKINFLSLGGQDERGKSCFVLEVNDDIFIFNAGAKIPTSDVFGVNMIVC
DYSYLEKNAKRVKGIFIGTPTFNNVMGIKLLLGQVGYKIPIYTSPIGAIV
IKKIFEQKVNNKKIEPNIIELDPISDKKIGSIYVTSFKVSNSMPHSYGFV
LKTSDGAIVYVDEFIISNDKNKTFDSQINLLNNITKNNTLALIVGMGQAG
NPYFTAPNHKNKAFYEAALQNTKNRLIVGCYSNDAYSIFTLATIAKQQNR
PFIVYSNNFINTFIGVLKLKLFNSKNLISLPVSEINNSKNAIIVVIENQD
TLFSKLNKILHNEDKYVNLSSDDQLILGVVITPGFEMLAAELSDEVGRLD
IPYKALPKTVLPMTQSDEDLKHLINFLQPKFLIPINGLYKTEVKFSSTVT
TSWIKSDQIISVSNGELFTIEDKVLNPKPQIIELEDKYISSFDALDVGAN
ILFERSQMGENGVINLIVIFDKQFQKLFNYVEFDYCGVVNNDAQIKEIEE
TFKKRMGECLVYDERKRLILKDTKANLKRLLTKLFEKKFNKRPLVLPTVV
DCYKTK
>UU416 unique hypothetical
MSDKKSDFEKLFERSKVQETSIFDINDIDEQKPYEEHSIEELSYILEYEK
IDKKTREKIKKIIKEKQQNL
>UU481 unique hypothetical
MFNDLSINGVSHKFGINPYNTNLSIDYSNWVTNLTENSATINVKVNSTDQ
VFENNQIVEATFVSTSNPSEIKKIDGVLSEVSANKNSAKIKWNLTDLKPE
TEYRFTSAKFKNKPDLAKWMLTINKNNVIYGGNLDTKFKTLVDKLKLLKL
ESNNDIYYNIQENAVNPNRVIGTIKAEFSRINSNYINKKIKLVYEDNNHQ
EWETNELTLSNNKTSYNFDISKLTPNRKYSFKKILISNNNIFEELLNSNN
IADSFIYHHAPTAVTFKTEGDENQLWKSNIGITTAKFRLGLESLDKILEN
GDKIVVTFANKKYPNNQDKMKVYTMSIIDSRNDGLYANIKHDLVNLDEGS
EYYIKEIRMIKKPNKAYEDVNGNKIISPINDAQRRTLENTNFKTNWAIYN
AKKYGNWDQPTINSAKYAFEITTTNDGTMLNTNSKFQLVFKKVSDSTKTF
IQTINLVRKDNKWILEGEISNLEPNTEYILSTIKLSRPTGNDLFDTELNT
NINIIEQNQNKILTKGIDPYIESITYEKTNDLRRRIIKLKIKDIKDYNDG
DRLVLEYRYNNSTSKKEVSLTLNKNQEDYSVNIENLTYNREYTLKNIIKI
NHNTNNITSIDISKLNDKTFVVEPSVTKLTNFKNITNFDEKKQIWSRIME
FNITNDDEWFSQSLLNSYKIRAIVENLSTNKIDDNPIIKIVNDNGKPKLQ
IHINNININDQNNEYKLRIVKFENKPNSYLYKNINNDWDNIFYDTNKNGS
VIYKSSNTSNYAGIVDITNVDHNIYTTNNTSYTYVSFSGSVRKLIFNNMN
NQNDSIFGEVMYKNLDNGQIYNTTVGIIENNVNKNYNTPGQFQLLLDKMP
KSSRYQFYGIKYWRANDKKDNAKIALVPNDKKTKIIWL
>UU190 conserved hypothetical
MLWKNLDELFLKYDRVVILTLSSGLSSYFESLSIIKEDYKDKHLVCIDSR
SVSIGILWLVDEINLLLKNNPSDEELISLVKQRSQKIIGGVIVNNLDQLI
AGGRVKKTKGIIAKALRLKLIVRWNGQLDFMDKTPNLSTAIDKLLDIIDN
QNHWRTNGIKNIAILTDLENESQINSLKTSLQEKIRQTIEIKISYLPGCI
YAHVGLNNFAILIEAK
>UU322 unique hypothetical membrane lipoprotein
MLIILMNYLKKLNNKKINYPMLKKQNKNKEQHWLEKHLRQKTGLIISWSI
IFGVLVLLSIGFGLILHFFNSNNLSIQLSFIINLNKYLVNITKILDYIGF
ALIYLPIIFLLGCWITGINGVHESLYYHVFIWLFYFISVILLIITICLSI
ATHIYY
>UU388 unique hypothetical
MALSKHSIGLIKNLKNKGLTIKNKEKFISFLFNYGVIRVIDGYSFFLKKD
NQYVKGLKSKDLINFVLLDRKIANLMGDCIMLFEQQLNAIVVQNFLKINN
LNSKYVIDMRTDPFIKFESPKHYEILSENIYTYANSSNLLSQFNTNAQEI
PLINLALSWTLNTTIGFYRAVDNNVQISVLEYFQLNHITPLEFIDILHII
KHFRNSISHNDMVITNSFNDNVGAFAKSLKLKSIKKVVGFLDVAAFLTAF
TNDKFHVLNGNLHIKILQAIKKAKFKGVVLEHINNLLGVED
>UU217 conserved hypothetical ATP/GTP-binding protein
MVGDDVEVELIGNTYLITKIYERYNQLIRPKVANIDIVLIVVSIVQPDLN
TLSLNKYLAFYEARNIKNVLIGLSKYDLANNHLKQKINKLILDYKKNNYA
VFILTKENDILLLKEKIKSKTLCLAGNSGVGKSTLINKLDPSIQQRTQEI
SHFLNRGKHTTTSTKLISFANGFLVDTPGFGNLEVNLTKNEMANAFNDFA
NYARFCKFSNCLHIEEPECAIKKAVDEKLIVNWRYDDYLKIIKELPNDVL
KIKTRAQNRKCK
>UU520 unique hypothetical
MVFLYKRGRFNLEEQKQMKVIKKSDSYFKKNLTVFRTLLELLKESSPFIA
ASVFTGLSLILIVVIVAHHKDIGAYAATSISYLTIFQLSFLQLGTTFGIV
FAIWSKRSFKDGKYKFEPTNDTVNAASFYSFIFGLVVLLIYFTTSYIYNH
FANDHQNTVINQSVGSAYIVSGLAVVGLAPLRNYLLMLIRSTKSINVLLA
IVLDFCTWTTALIAAFLLGSYSVLNYWGYGLGMSIGFVFWTIIIGMTTIE
KAQIVLRPLYISKRLFVLSIKLLWIQTILSSLKSVGKMFILLITFVVINS
RVVGSSLLDFQSTRILMYQSMIFIQMLNLGLSDFLFYLYQKQEVRDCRYH
SRQLFFWVFILGILFALITSVIFGFSVKQLVQLYTSEQSPSYIFLEKQVP
EHFYQSLRKILINDEKLLDIITSHVNIGRQEVVNALSSNDKNIWLPMAQK
VIDPIWKLGDKFETIYQMKNPFTHRFVDISASNIYSYLIKNNAYILLSFF
CTFFSFSSILSRYVGLIARRQRPPYVMIVIQLVMVAFTSGFGLTHQSDPH
FIGLMAWSFPLFISSIFILGYSTYKILRIYRKYLKNHKYNDEKLSIMPKK
QLEQQIKVRQN
>UU152 unique hypothetical
MKLSRRLTNMTNWDKEHALSEELRQLKDEFEDLMDDLARINKDLDFNIWE
RKDLEYRKASYETDIESIRLRINQKQNEMMEIIKNDK
>UU155 unique hypothetical
MSSNNFDNNMPRIEFKKMPLTFIRLNTKKSNNAPFVSGSFWLADKVNANV
YFSEYLMERIVPFENNKTNIVILENVSCYINFNWEEKRIIMRVVSFDNIF
YKHQLSEQQTIDFVSAEKEYNYQTQTVNSYSNSDDEIEIINWLESDEQKA
YFDSQLMFIDYKNQGFFKNKTMPDKLKNNANALELYKQIIKLDLEAFSGL
YNGLKPFEAANKLIEKGYITLNDFFKYAI
>UU424.1 unique hypothetical
MSFLASISPIIALNCCKYANDAFHSLMWKVGFLFFAESRICFYRSVACCS
LNSNEFFVIHVLLLQAVATIVVWIIIIVNDNDENKIFYLFF
>UU194 conserved hypothetical
MNKPIIKEVIIVEGKTDAQKIDQLVNAQIITTNGSEINKKTLALIKQAQL
SKGIILFLDPDYQGERIRKIITNYLKDGIIKQCFISKDNMKNNSKKIGIA
EANNDALLKALKSQGTFVINSIESITWLEYLSLNLNNKKIRLMLCDYLNI
SYCNHKQLFKRLNMMQKTFKEIKIIIEGF
>UU047 conserved hypothetical ATP/GTP-binding protein
MKIKKLIASVSIITPIVFVSALAASCVNNKHEDKNIVHNSSDHGNNKKNN
FTNDLNQNLTTHEFKSNLISTSQLDNIAKLINFTYENKANTYLKNILINQ
LKHSPIQNQDFKLEIIGLYPKQNSLQDLIIYYKLTNQKTKEIKGYYFELN
GFKKPDNTIFSNQLTPELKKIIDTIQFKKTFDLVINNQQVLNYENVLPSQ
IKNQLLMGLKVIQKEYTDKIKLSVLDVLFINEGGQINANKLGAFSLLLEV
LDLKSKKTYQILIPVDKFKTNPYGADEYDLLPTQVNNGFAPTSLAQINQY
NNADQQTRYLYDNENYLKSLKAYQRNVNWYQIRQDLINNKQKINEFDQKA
PQVFQDSYESAARKGFTLPVYDEDGKYQGLSFNETEIGKSVSWVDAIGKD
QWKINGLARTLPNDMYKQIALQTFGIQIQTPNGKPRESDVVAGTMWIMDY
QKRNDNKYPTKWYFGTNLHVAEALKSTTTVFGINKIMPTVKTKTTLGLAN
ADDNIYRFSLVSKDNQPNMDKPISNGIKTIYDGRDFLKLNPSDLLTSKLK
NKYHNLQEFVDFAVFEIDFEKIKLGSITKNFYSGSDWSVDKYNNLDPSEL
AKLITNDYAQKPNEQIKFLSKSYLNDYARINVPLDSKYNQAFDTNKYDEL
YAVGWPSSASDYFLDPIKDQKQFESRRESYSLWINSNYQFYNKLNHNPPL
FPLTQINRGDFLSYNIGYRSFTNKPGLLDAFIASPITGKTVHKSTDNQNY
IGFGLNYLPMHYSPIGGSSGTSLRNQKNELVGIWHVGNGFAQTGLAAAFR
SEGYDYHGLYGSYNLPQYDLIYGGGKDQKTSYRQAMMALYKNKNIATALF
PNGFGEDQIPSAFKFKN
>UU259 unique hypothetical
MNKQKRKISVLTSISLFLIISLSIGLGLGLIKNNENSITSKVQKSSNFFI
NDLSKQLFLDVFNQDKLELNAYMYDQNNVSDQQLLDLKFALTLLNPNRLD
INDDDTIAIMKNNAKKIIFQSLSNNWYWLFTNLKSLEFSYTPYKPNFYAP
YINEKQDFTKSSIFDKVININKPLTNYIKIKQKLFDKENYRSVDVYYLQF
GDHLILRLLKFNKKNHFDVRFDTDLFQFNKPIINLELIAKEMQTSIDYHR
EDNFKKDILDYKKNYEDYLYYDEKLNSSIYQQGLDKINKEYYEVNNFNFF
NTKKPLFQKFSYQMFLELKDKLGFKRYVLRNIDQKEVRARDHFNDNEKKQ
QNKNYFRSFDKELNYFQKYIDHNLDININKISKEAYITQKIIKNLLLDAF
NNNDVQITKYLIQQNDKEYQNKLIKQLIEFSNYFKNQKTPRDSNEYKQKL
NDYEKIFSQNWYFILMNLKHFELSFNNWFTLPKQINPITKEMLGPSEKYL
KRLKKLKPYEDYYFINNYLEKKQEGDTSMLIGSFKDLYITKNQSIFNIKI
DFSSSENRLSLNPLIYFFPKTKNKLSVDLITSIFHQAIFHQNKEYYQLFE
TDMIDKYEYGIPAQMLLLWRE
>UU158 unique hypothetical
MTKQEFKAITKELFFFNKKRLMLWIAILIFVIAFAMIIVFVPFFNFNDKI
KSLFDKLKHINWQDPTALFGLVFSVLGYLITALSIPLKVFELMLMLRFRL
MLAKLIKDGILDPKAFIDDIRHSYLSRRKQRKLEEEIEYLKRIKSDY
>UU345 conserved hypothetical
MNRMSEKQIQNSLFEYKFIDFNGPLDTLCVLIKQKRLDINNLDILELSKQ
YVNFVNQLIKTIDIDILGDHLAMASYLLELKTRMLMPTVDEKQIMSIEED
RQNLIDRLIEYNGYKNLSEHLKQRFEFRATMMDLPQQDYEQFYLKDAIYK
PLPNHLDSMILKNIMDKIIYENELKNYKINKIKVHEYDVKQLEQLLLNYL
KQSPNQQASMLSFFDIQAVIDKNKRFFAIMFLIILILINRNEILFEELDN
DYLLKINIERVVDDYNSSSVEQAKNLTSNLTKDTIINFKGEDNE
>UU409 hypothetical membrane lipoprotein
MSANYFLIGLTIFCITCIGLANFLIKPIQIKKHNWLTWNYFINTKWIINT
LISISFLIYFCCLRWAPNIHVFFINHIEIINVLRDKFSDDIDLYEASITI
SRTFLLDWCPCFSVLISCVAIFDKKQIIINHLGFLCFCFGLLTIIGGLIG
DEPIRWNRLITYIFIGDKPNPIYFSLHFYLCLFGFYLFVNTRKTIKIYWI
YIIIHIILITYIIYVNVMILIFNIKNNASGFSFGDWYSPIYAQYGTVAQF
LQLNYRLNALIMCLFMYAIFIVGYLIRYHLQKIYINKYNIKYSQERNYFA
YVKNCR
>UU260 unique hypothetical membrane lipoprotein
MFIFFKKNHLLKLSLFFIPLTLISILITSCSTSNLKKQQILTNNEISFFM
DKSQNCYVGLIVDQTLKNDKKTIFNVSLIDEKNTKLNLLVKDYQIKDNKI
LIRLPRLIKLNDHLIITSNNASFIPIRKIINIDNLIDLNIIRTNNQTQDS
WIAFLNNKVINNLLITIFPNKKDRDEYIKSQQEIKIEYAHEIANWLNYYN
TVQNDANKAAVFNENTARSKLNNNLFNNVSLSNPFAYEQARKFHNTLFNK
NWLWFLFNLKRQIFMLYPDDNLFQESSEETAEGLKDSKINNRSSFYRAQS
NEFIDGLYVVESSNLNKKPEELDEYTDFSKTAKFTLLNNEGFVFTISIEE
NYDKTKKLISRKVSLLPWIKTLPRLMFNDHVIKQEFNLANYTENSYDYNA
VNFHSPLEIKVYEDQFGGKAIRFSFVDIDPN
>UU159 unique hypothetical
MMNNKNKFKNKEWKFSKKQVQLIYLTSSIISGLFLGLALLSTYLIAGLPN
DNAFVLFVKEQKFYFPFFMTIGFINLIISMLTLLPTLKTLWRTVAKMHQY
GDLSKEEFEALDILVEQIRNRYISVENIKAVISSNNYKTLDEELKKLEQQ
EKQLKIQEQEQKVKRLEQEIIKDDKTRVQSDY
>UU340 conserved hypothetical
MYKLIFNLCIYIKNKGKFEYMVENKFLKQIKEGEQIKIEIKGLDKFNNFD
EQNYGLNNISPQIRWSPVLETASYAVAIIDYEAVGGAPFVHWYALNIFEP
ELALNVANLGYANLYQGENSTSKHFSHSILDANYQTDIANNYFPPCPPNK
SHKYEIKVYAVHHKLSTNRNNILYLDDFEAKLNEAKIIATGSTYVCAPQI
SFEDDKLIIGSLEHKHPYLFANCENEYHVIEDVIVTDINKNIYSENQLDN
FKDLEQAKIKIIDSSDALSYAVIITSNHLFKKFGRPVVNYAHVIEKKTNK
RIKFNNSYKLNHAFSEISPSKYDHLGNELLILEDKDANFESGLFTIHVFG
LNKKIKYLNKIDSVANSISDLFEMISGSVISYKAKLFK
>UU090 conserved hypothetical
MLAHFFNIFNLRRGELIMANEYYNMCALDALKFVKNRNMLLPDIQREYVW
DTTDIEKLFESIVDDYPVGSCIFWKTNKKVLNDEKPNLYYFISKYKQGVT
KNEKAPEFVSDETDYYIVLDGQQRITSLNIALFGSFTSKKKGKGYSVKNS
KSWVERELYYNLSFYDSNELDDENPIKRFVFLSEEEAKNGNYYKVKQIVK
SDNLTDYVDTISNFNKNVKTDLMCLYRRIMEASATSVIHYYCIAENTYDE
ALDIFVRVNSTGRKLSKSDLLFSTLIDGWKEGKENIDTLLSDLNSAGDGF
SFTRDYLMRLALVLVDANTNLKIDSLTSKTIKEIRDNWQKIKKALEKLSE
LLVSIGMCDENMTSYNATIPLAYYFYKGGKIDTAESKKEARKFLAVSMSK
GLFGVASNDSLNQSRTALKSVNEKTPFSLTLFSSITLTGNRTFTASKDDI
EYWLTKFEKGKNTFIILSLLYPNLKLSQVEFHQDHCHPYTSFDDKNIKKL
GLTEDKIKEWQFKRNLIPNLQFLAGKENESKNKRPLSNWVKDGNTFEYRP
ENVSLELSNFDKFFNERKSLIKNKLLDIFGLKAN
>UU535 conserved hypothetical
MKKSFLIMTDSSTTLDREWAKNNDVMILPLSILRSDHTLIVDDGIESKPE
RIYEDIDNGYTFQTSCTPYGVLIEAIEQKLQEYEKIIFIGISSGFSSQFN
NAKNLEKEYQDKLFVVDTEDFGYSLEHLVYKIKAMLSNNISFGDILKMIN
KHHDYTSSFLACENITGLVRSGRIPKIIGTMLKLSKVTPIIKAEWKNHRA
GMALNIRSAPHKILENINHVFDNQLNNHTIEKVCILQAGLSSERIDELKN
DVINHFHVDKEKIVIRSGPPIFLVYVWKGALGIQVIANIPKKHVEKKH
>UU396 unique hypothetical
MQKISDNFKKVYYGGFSTSNSFNYMWNNALISSMLGQTVVGFLGMISQLV
YAFNPQPKFNPQQMIDNSVARTYARIAQKPMNSTISLGTPFF
>UU030 unique hypothetical
MNLKTKFFLKVISVIAPIVIIPTILANCAHINSNELDNAKTNLKGSVEVV
NINPYKTKQMLASNINKEQINSYFIFIFNLIKTNQKIEEKILDKNDYEIL
NWAANDNDGTLGINIYIKTTKQSYLINTKPVFLTDKQNNYLQELKYKTPA
VYSIDEILKFSNNPYNLIHNNPYYREQLLRAKIYFNQNEANVDDSKLYMN
KIGYSEFGSDVQKRLENAFKIRYDEQNIYQINSPQILAKETKTLTSYIDK
KTNNNYSINIELIKKLIQINPFGKLPKNFAQLINLIKKEEYPKFLTITKN
ESVDNIVVKDIYYRIIDRYAKLEFILEIYNKKTKQTVYLSANFNQKNSGL
LKNEDYFQYIFDRTISLDLLTTKDGKNVELNSGTGWIVDRIIDDSLPKNK
IKLLIATNNHVMGWSNLAISKDNRMKSRWFNKQEYINYLENNAGFISSNI
YEDKDRYQYLLWGTAPLKSPVSNKYNSLSGISFSNLAKVYNITNQNFINR
AWYIPQLSANGIKINENLRTWYQINQEDIKSIKNGTLDFVLVPMVFDIED
IKEKLPNYYKVLNTKDEANWYIGLGNSKKYLPQLQLFSGGYPGDVNPNSS
AIVSWRGSKSYGSLIQAFDREIKNESILDYYGPKQINNIDGYQKVGEGYL
NKLFNVGTRVITSDEIGDLGSGSSGSMIIDSNFNLVGIHFASLNSRAYGA
PNDSMIGNLFVAQSQDLSGDIDVRAAVIKKLKAENIYTYKLNPKVSS
>UU390 unique hypothetical
MNLKSFEFLKGDAIVDNQIKKAINTSLIKASFSCAIMCILVLIFGFLMRK
YLFYFSDASSLIISSRLIFQIITIIVATLSIVYFIVHLIIYFRQRNNFLA
PKFAWSIILYLLDGITMCFMISYVAAIVGLDLTLIAIGISLSIIVAMGIL
GFIMNHKIAFKLGIANIVLFTIATIGSIILLIVFFTTRYNHTGFNKGVII
ADIVLSIIWLLALSIGFASTIYIIKVMAEHHNLDNKKIMRDFTTWNSYLL
FASFNRILLYVIRLFLLFKRV
>UU451 unique hypothetical
MGLFSKKNKLNQKLTEDKNINITDVLDNNKDIYQLYDETIVTKKVKVRCK
NCGVFMWVDYTKTIKSLRNLALTNIQQEQIPVMDEPQILQDCNDLSSAPV
NNQEDDIVNEHESTPIEPLHEEVEPEPIKNENQSNEEFIQENIVAPVDEV
DNSVKEHTPFTPVSFEFEEPVFENIYSNQKVYAENLFLESLFSEKESLIN
DDQNDFSWLSKYVSVWNKRDEAELAQLVYDECLLAPQSSVFPNNEYFIEE
EYEHIDPDNHHNKHKAQRHHRGHDLIVKKNGKEQIEKAIDDVLPINNGLD
KKQQLLLKTVLIEEEFQSDPISKKTWWETESANKSSKK
>UU575 conserved hypothetical
MYTKLTWNNYEFVEQIKEDINPGQQISTLTLLLWTYYGYDIYFEYLKDKN
IVLFYAQANEELKIIEQNKIATQFIGKFFIIFAYFDAKKYDWTTLIPIAL
EALKTNFKKEFLLAINGIQDENYLNNLSQFNFELIYSWYSNFIYETQSLK
YFCGKILQKKRNNLNFFIKNFKNDYEIIKYNPKFHLHEVCTFLKEWDVKN
FINSKRMLVNSNSDLLLNTQTNPYFMGSLLIKKSINKIVGFTLVYTRPNI
AEILIEQTDREIRGMYQYLLSQNLIINNINNWLIDRQDGAWSDNISASKL
SYAPKIITKRVNVLIKE
>UU361 unique hypothetical membrane lipoprotein
MKNKYFRKNKFWLLIPISFVSLGSITLVATACVKKNFYPNTFADDQIYIT
KNNEKTVKFRISRNDEENKKYFKDDLKWNTFINKLKKTYINVETVIPKEN
AKQNIKQQDLCMRALPVQVLSNNKYVDIYVKIPVLLANTKMLVVGDDLLK
SFYFDTDNLIMNAKHFQPIPIKML
>UU156 unique hypothetical
MRSKQWHLSTQDANLANKKYDYIYFRGVNQLYLKRLKKSSNKFFVYKKCK
IVPRMISKHLNNDHLINVNDYVPLTKEFIKKSVEKEVKHYLRFISYENKT
KQMPELINFLEKSLEDKLFIVAKDYDPLFSVFLRYYIQSLIEKYINELWI
NEW
>UU305 conserved hypothetical
MQKKYIKNTLGFDTNLFIYQDKKMFNYSIDTILLANFISLSSKTKKILEI
GTNNAALSIFLALRKEDIKIDAIEIQIEAINLALLNVSQNHFEKQINIIH
ADFNQYWKDFDKSENNKYDAIICNPPFYKQDKIIPSTKNPLKTLALYEIT
LNFEQIMQGCAKIIKQKGNLAMVIPTTRLVDLLEIMRKYQFEPKRIKMIY
PRIYEQSNLVLIEARYKSGWGTHFEPNLYLHYEDKQNHQYTEEVLNWYKP
IKFKK
>UU389 conserved hypothetical ATP/GTP-binding protein
MQDQGVNNKAIKQKVLNLLSTDTRDSCIRTRLTKYHLDISHTFNKYELQD
FIEGKINILKIRNFININTFENDVKNINSMDELIDYLQDFNLKLKDLLST
RKINEWSQDFVFYKNERIADMIKAIESQPKKFEYLSREARNIYAQTGVWP
LYIAKNFLIGTTPKASNINAPLIFVDVEIKKYNGEIFLKRKNTNFIVNEK
ILSFLKNDYKNNIVSLNEIKNFSYLEIQTLIKKIILKDHLESIINNNEFL
NLKQNEINEQFNNFFLYDAYVLGIFEPHGGAIKNDLEVIISNNIDPFDEE
INNVNQQIYYKNYHFLAEENKLPLIQINRPLNIFQKYAIHSGLVKNTLIY
GPPGTGKSEVIASIIANVINDLKSILIISEKKAALDVLHERLAKINFFTL
FIYDTNNDDQFYNNIFNLIEKIGGLRFIENQDLNQFNDFKYKNNIISNIY
YKKIHELKKEIINITSLIKNLHNEKDNNDNNFANYLYWLSRFNEVEIRFI
NDPLLINEINNLIENYSYNFDEIITHVKASYDFFKKYNYEFSKNNFLKFK
EESEQLNKLQIDFNLITKSLYQSQTFLPRIKLLESFLVKNNMTLTSLIYD
DVNLLSNTYVEANEFYTNFNHLLKDDFKKFIEDNIKSHSLFFSHLNTLKN
NEWTYAFEQYLLINNPFAKKGLFKKIKGDEKKLWKQLDLLKIYINNPFLS
KFSFDFLEDLIKQPIEIFNVENLVYLNNKHLLNKAYVKDLYENAFDKNLS
YELIYGLKDLKLNSEQYDIIKNLIKYQNEVLVNYQFIKNTDFFNLCKKLR
DANIQFSKNADEIIYNNYLDYLQIKLVTAPKQIQTKIKEIAQICRLAKKP
NIVKFILKYYEILRFLFPIWISKPELVSEMLPLISKSFDYGIFDEASQMF
LERSYPSIYRCNINIVAGDDKQLCPTNFFINRQENENDEFELADVDVAES
LLDRAKTALWSEYLLKNHYRSNREDLISFSNDNIYNGDLHFASKNGLFDP
GMEIIDVEGVFENENVIEAQKIMEVLKERAANYQKIIVITFNIKQSELIE
NLILQTFSFNDVVYQRFENDEIIVTNLENVQGNEADLVILSVTYAKNKEG
ILRNNYGPLMKKGGANRLNVAITRAADKMIVVKSIKAVDMMVNINNDNIR
TFKNFIGYCDEIVHLTNQNKFNDCSHFDEEFLTSLEKTILKILKDYKKTN
QQILYKLKIGNFKITFALYNEEKQKIDLLIFIEEFNEWKSYNLLEIYDQF
NFLMDRGYKTIVINDYEICLNYNQVKNNIIKLID
>UU537 conserved hypothetical
MSANAYVFRRSPIHRLNPAIKFISFILLIAMIFLPLGFFAQMIIGIFILI
VFFVAKLPKRTLWNVFKSVVMLFIILLLINWMTYKDPIAIYNVTDQAKVI
LGNNSWINGPINRNLSFNLFYNDISSTHPQNLVSNIWGGEIKNYISPEII
KKLIDKPDYNVAKFLNENNVTVKKLESTFNALNQDVRLNNFYPIYGNSTL
KSGKLEVPLSHLSYYMSTNLWKINGIKYQGLILSGVGDQLGKAQTALFYT
RSPFALSPIAIQLAVYISIKIFLMITLSSILTATTSSIELTNGLEDLLSP
FKILRLPVAEASMMISIALRFIPSLLDESKRILNAQASRGVDFNNGGPIQ
KLKSLISLVVPLFSIAFKKAEDLANAMEARSYNPRYARTRYRTFPLNLAD
YALFGILCILVGFLISLAVIKFYFTPFGVFEASALFAK
>UU209 unique hypothetical
MNINWKSMYKEILIRNSDLNYIVSDPFENMIGGFPIILFENDNYIYYLSG
QNAYLPSKMRRWKNWDEILINKNDLLKENFIYKDIYINLFQIYVTKKNNL
SRYLSNQFNFTLTKNDFKDELWNKLIYNTIKKLINNSNPQILLFEISRNK
KQKYHSLLLFADKNVLKKFYLNSATKDNYEDIIDLAFNKFENLQNLLKTT
KVKNHLKNLKKY
>UU295 conserved hypothetical
MPRKHLIASGINKKQQQQAKIWMKCAKEIKAAAKMGGPNPEANSRLKVAI
ERALNNNLSRDSIERNINGASKDIDNLKELTYEGYGPNGLAIIVRALTDN
EQRTISAIRGYFSKLQGQIAKPNSVSMLFNECGQLLINKETKSLDEWFEI
LIDQSIIDINEDDKIIEILVKPEDFSTVKLILEKNNADIKSAEIKLIPND
FISLDEYARERLVRFVNACENDDDISWVITNYEEEL
>UU328 unique hypothetical
MNLINKELFLITGDNRLKMDQKINEIATSFDELVKINDQEISLISFKNLI
EQDDLFNSNKIYLFKNVNWFENLEHLKNVSDLIDYFFNNHVAIIITIEST
KISTAKKIQETIAKFNHQITFMTYTNENAMAFLKEELNQRNLSLNKSIMQ
TIIQKTNFNINFLNNELDKIELINDFLKNHGMFDINNFICDYGEYQIFSL
LNLLYQHKINESINLINKMLIDKIDELTIINMLATIMSTHYLIKLLHEKK
YNKNVISSSLNQKPYIIDLNLKLIRNYSAKFLLKKMYDLLQLEIKVKENK
IDKYFGLINWVLNF
>UU174 conserved hypothetical
MGKNNKYLIACDLDGTLLNNDSDISEKTIEGIKKIINQGHIFCIVTGRPL
RGSIHIYEKLGLTTLMANYNGSYISNPSDKKFAPINMTFSKDIVSAILKN
RFIAKNIVNAVVEADNVATILNSNMDLNIWKSFIDIFHVPIRDMNEKNKL
TKENDINNLIRDANALLLNVNDKALFDSMVYHIKQIAPTLAVRSWSARVD
DQFEVIEINSSFADKAMAMRYLSSYYGIPLDRCIAFGDGENDLTMLNHAG
YGFAMKNGTRPAKLLARHITKHTNVENGVVWELEYVLNENK
>UU341 unique hypothetical
MIDRKQIHVKTRLTINELNKFYTLIRVQKQSLKEIEDKIKKLDWINFSEI
KNQNLFDEFKFDYKNMTPYVISQVQDLVSVYDVRQISEIILELNQVNIQI
QTKDSEFYIKNNKKLSLISSEFEDYQLKNYDAYEHFKITMDEPKIHTLNH
QMPFDSKLNIKTIIFIVLTSCLLCLLIVIIICALLIAGVIN
>UU172 MBA N-terminal paralog
MKLLKNKKFWAMSLSAIAISTSIVAFAASCSNTNIKSKLSKQLAQTKDQK
NHFAVYEIENYTKLTDEEKKSLENLEFGVSILDKDGKNPINIKVKGVQKE
GKIYVKLPRKPEVNEKLLVVPTKNILKTEALVLNNDNLNYQTVTFEQVPD
QKLEPKEEKQTKAVDYEKAIKDEDYVKQITLSNLEKYISNEYQYLNPNNK
TLDYKNHSFVQKFLDEIDLLAQKLESNDLNLEDKQIYEKIILGLRWLLAE
DNNETKNKALELFKDYFTTIMKATKVNDKVHYDPSFINEFYGSISNLFEE
HDLEPSVEIESNKIRIVKEDKDVIKDKTVTATFNLYNGFDWSTLLKDVVF
KEYKKDSNGKPVIDEKTKMPIETDKIVEDPVVMRLEIAEYPKDWNTSKEN
PKNFSYINFKKSEVLKSPKLVFTKVFNLDKEQKYHINNVMFSHKLIPNLL
KALDIKNNTTNAELIKKIKENMTAIDEKTQTNLNTNYIPLSLTETNNKK
>UU580 unique hypothetical
MVNDKKQKSNKYLTYQDQEYERNLLLEKERKQQKKILAQQAYQQLDLNKK
LIKKAKNDQKLILRLLKEDKSISKTQFNTHRLELKNTIDQMVDEYYELLE
QYSVDFEKISFKLKRWLYGINKEIRRTTWASKRSVIISLIIVIVIVLILA
AIFFGIDTGFYKLSAK
>UU033 hypothetical
MKEITPLIVANWFLTKESMTPKKVQKLVYYAYSWYLTLMNEKVDDLKNKL
FDEKIKAWVHEPAIPMLYNEFKEHKYNSIPKINDFNELEYFNLDTIDILN
QVWDEYGHYSANQLESITHQEDPWIKARKGFGPLDSCNAVISDKEIFSYY
IKQMKNN
>UU471 unique hypothetical
MELAAIAHVCTRMLTPLVSIKLVSDHITLPNSNQEQFNKNLSLIDKWFNE
HLPSIIEAILEIY
>UU064 unique hypothetical
MSDEQKTKLIELKQKVNDLEFELDKIKNEFMMKIIIAVILIFFLTIVGLF
YLIINLSRIISLNQKRKSLELKTKELNHEINKIEISLL
>UU469 conserved hypothetical
MKIILFCGAFDMVHNAHIAMAKQAMKLVNADKLIFLPSNFKFFKAINKND
NLEYEKTKLTPGHHRIAMLKIATKNLVNIEVSDYELKQINKSYTINTIEH
FKQIYGSEHEYYFIMGSDNLERFKQWKDWERILKEVKIICFKRGDVCVKK
SCPQKSCECESFNFFEHEILLVNDFNYNISSTEIKKRHNLTSGIDPAVLD
YINEHGLYALWLLEKHLISYDNFNNLEKKVARINHCRRVAQMCVDLMNVY
DKKLIDQAYCAGIYHDILKCLDEQESVAYFNEHKSELNIGDDFISWRILH
SYLGAHLLQTQYGFKNQLILNAIRRHTRPFDFIKDYSELTTLDKILYCAD
KLEPNRREEIDQINIDYYRKLVFEDLDKAFIEVYQYQQRQRK
>UU226 conserved hypothetical membrane lipoprotein
MRICLEKIMRKIKLNKKIILASVIGIMGVALVPIALVACSQNKTKSDSRN
LTLNNFYGRPSSDGDDAYQAIYASKIQDGARMLGLISFRHKNPISKYFNS
PKDNQQVSAVLIDEIYDLQTGKDRIASITYRADQAAFLAGIAAAYYLNSN
QNVFGKDNKLTWGGFVGIHLPSTTRFIQGFKFGIQWANEKLKNKKVKQTE
NNEEKEWINVEQVFATNYQSGDFSPTSDKAKAIVNQLVSNNVDLILPVAG
PQIDYATTAAAESSKPIVVVGVDTEQELDDNTNKARISENNKSLANGKTI
IFSIVKRLDLAFKGALLKASEGAQLTNDINKDAYKLGTHTEASFNKNTYV
DNTALVELSKAGHQYLIDAIKLSGLKEVNDYKTIVEIIQEDPLFKLLSQI
GTKKLDEVATKSQQGDWVLKSEYQDLPFIQLQKMLGGLVYVDQKNELYPY
ELSNSFYLEKDPNKRQASRAFYNYWNAKDANQINLVKIFLGQSVDVLKDK
SFSESIYKGLEEFYKSKNIIIPKLY
>UU500 conserved hypothetical
MKILAIGDIFSKQGRKAVANELPKLKQEYQIDFVIANAENTTHGRGLCWK
HYEELLGYGIDCITMGNHTWDHPDIFEILTTKTNIIRPYNIINTHQYHLV
GSGSRVFYCNKKMIRVTNLLGNSIDMKGLQTNPFESLDKIIAFNEAPIHI
VDFHAETTSEKNALFLDFKSKLSLVYGTHTHIPTNDARIVDHTAFQTDLG
MCGAANSVIGANPSSIIQRFRDPNKRFILEPSDEKYVFCASLVEIDDETN
FPTNITPIVIYEK
>UU177 conserved hypothetical
MKNNKPICFYDIYCFKPQECFKRNDINLLEDKLKRYSKITFLRNKENPEI
IFLLGGDGSFINFINQQWKKNVKIVGINYGQLGFYSSYDSIKTINLDEII
DENMYYNPLLLKVSINNQNFFYCLNELSLFSNELVSFDISINDYPYEKFR
GSGLLFVTPSGSTGKNKTAFGPIIFNNHENFIMTEIFPVNHLKYSSLNAP
VVFRKDYKISLTNIKFKKSFSVAIDGNIINFSDKINDIKVETIQASSKIH
GLNNFKKYIDKLNKSFIKGE
>UU276 conserved hypothetical
MGPIIPNTRLIDFKFDRDLLNSAYTAHYFIKTCKIIELHAPNHSVIMQFT
HFSKTPIMVCGTSEVLALLEFCLSKKELKQLKIYYVPDGHVIKPKEALFV
IEGPYEIFGWLENIIDSILARRSSIATNCYNVLNLINDEQKVIYMSDRSD
DYSLQPYDGYAAAVGGMQYFVTQKQVEFLKDINYECKVIGSMPHALIQQN
NGRIDLACEMFAQTFPSDPLIAVIDYNNNVLNDLEQLRYMFDRLFAVRID
TAKDLIDESLLSTFNNVGNRDLHGCNPYLIALVREYLDNNGGKHIKIIAS
SGIDLNGIKNFNKHNSAIDFYGIGTYLSHLSVHITADLVCLDNVYGAKVG
RKIAKNFSEMILY
>UU208 unique hypothetical
MLKKTKFDTQLVKSLITSSILKVPGIFSVDINDKLSDFNRNYFVIKIDLH
EDVVNVLSVANEARNLVYYELSKQLNDDNVVINIIINC
>UU380 conserved hypothetical
MKKTLVLYARVCPTKSFHTQQIFEAFQKQTNFVCVNLDANQPFDVSKEQE
FILGFDRIILLFTLNWYNIPWSLSRYFIEVWRTFPFSLENKEVYKIITTG
ANQDFYEKKDPNINNISVEEYLNNVNGMLKKLRASIQKSFYYYGAINQDQ
MRLNQFVNELIKYFKNQN
>UU468 conserved hypothetical ATP/GTP-binding protein
MITNKKCKGCGAFLNDQINTIGYTPKINETKTNLCQRCFKLIHYNKLEKV
STNLNQSIKETINTLNFSNLQIFAVLDILDLEHTIIDELKEYQNKIIFLV
NKIDLLPQRYNSELVNENVVKTLINHGFIDPKIIYVSTHSNTSLKKVMDY
IKNATNKKQKSIFFGKSNVGKSSLINALLALNKIKTKLTISSYTNTTINL
NKINIQEHQILDAPGVCFDENILNYVRDEDNKSIMISYGAKAINYQINPQ
QALMISGLVGIQYLKGQKTTFTLYVSSQLDIHRCKLENFIMNFNKRYLLA
KFNYLNQDLEFVDHLITLNKDQKTNICIAGLGLLVINAHAEQICIRLPKS
VGLKVAKYAII
>UU557 unique hypothetical membrane lipoprotein
MKKINKKIIFLSIGIVGLIPVAAIIASCARTKTTKEQNKISPYLEDGSNF
GLAMDAINTLNYVKFASLRKIVFSLVDGLIKEAPSTNSTIGNLLGISKLF
LNQYKNPVDAGFNNMTDAQLEGMRISPSYVDLSSFGINSGALAPTVSEDD
PTWVFYNNSNNRIVATKFTTNFGASKWSDGKEVNAQDFIDAIQYILDLNT
GSQLRSHLLRFNIKGTNAFNDAQEEYIRKHGVPYKNPFGRAPYILNKQTG
QWEEDPNFVPYQNQTFDKNGHPVDDLEIAAIKKAAYEIGLSTGQAYTNIS
NKELKEALKLPENKDFKFHESKTLTIFNPKYDHKKPDKNTPEKIVINLIE
NPSFNHRQKLASDDLQTLANSKDLFKFKSLPTSRFDLLMEFETYAPKPSF
SVLLTDILGNQALLPVNRRFIETHGGIEKFGSTLENFVWSGPFNIADVVL
GPQGYMTLEKNKDYFSANWTISDKIKIYFNSKNEVTSLWFEQGMISSTTV
PPSYQLKFWAQSKMRDLMKKQAGAGTVAMQFNLDRQSRYDSYQEYLKNPN
KDIPILDPDLRRAIAFAINRENILKLSGWTSSFPVTTWTSFQRIKDSKGR
NLEYWFDNKRFDSEYIDTIKDEKTHETRKQNRSFLIQNNDFSDHVAAKNS
TFENINRKDTGFDPQVAKFYLDKYKKKHPDKKQVVLKFVYPTEPADIGKA
VIAIKDLIDRNLNGYVKLELQALPPNTFVTFANSGKFDISYQNFDKYAGS
TYDSALGLFLTPDGIDLKNNKSSGYELNPTGSWTPKNFFDRYKNKAELDY
ALKRLHISEEDADIIRELVTPTNIKTSEVYNPQHLTNRADLRKLKLKDKA
IPMFDVNYSEYDAKIIHDLEHQINKLNQKIKNEPTSSSKSTWEKEANNLQ
NEIDTMQEREFYLSEEFLNKHDPKRENKPFLLVLQNNVTGQFTTLQIQPV
IDKKTNQYVQATKEDYAKYYNKENIDEINFKKRFKYKFSIKKLPIGSYQV
INLSYINDLKPLLSKYLRNENNEISDKVNNEIYMTKLETVVDQRKRIIDF
FSGNRPGWEDDDSIFRTILNLEKILRDEAAIVPIMEIDTNWTISSLGGMK
NNFTYYLQFAYDYRRPPRPGLPTSPQAEGDN
>UU387 unique hypothetical
MNKPMCLLRLDNYYFTLLVFIYNDVTKVNDLIFIKSIPNNNQNNYESSNF
LQTDLKIQLNTLINCFKKELHINFIDEIIVSYGFSSFQTTHTTFYNYNEF
MKLRSNFNNEHSELLSSDQKSYIAVDFGISHYSKENSYKLISYYILKYDY
QLIIDLCQSFNLKIKQFIVSQAHLNGLKFDNEDNKTSLLLELENFKINFR
TYNEYNLISNVISETKNHFCLADIITQTAQSLNINPKKIESYFNDINYNN
KKVIEINIDPKELFTYSFICGADIENTFLKIFKEHFEKSILSQFDHPLLD
FNPKNLAFLFINTPFNNLNKIFYYFFSSYFKEVKIEVFQNKFFIYSNCYE
YSNSQALAKQDFYNVHNMKNFDSFSNENILTKMHDQTINIKNF
>UU492 conserved hypothetical
MAEIITRGYLVARQDYDVFDEILTFINEYGNRFIMFAPGTKRITSKNARA
LFFGNFLEIQFFYARNDTKLSKLKKVISLDQIDYKYENTYSMLILSELMT
KVVNFNVEFYQFYQLILEYIILEYNDYYISCFLLVKFLIMNGVNFNFQAC
VHCNSSKNIKTFSLADHGLICINCESKIINKIDYEPKALQLWQKLYFATQ
IKKDEDKDNEIIYKGLLKILNSVLYDQLGIYLTIIKNI
>UU499 unique hypothetical
MSLIYLLIGFILLFLLIYSTFALLDIWTLRKYNTFRQNFFNFDQLVNTKF
NDIYTHTDNIYARTSKQKITIINKYLIAINNELDFHKKSLIKLQDYLENH
KLFSYLSLIKFIKANEIKIKNNVDEFVDLIQSFWNDFIIIDQQERKIEDT
HKKLDLMYKDLISKYSIPNLNYQKAINWTTDSFNNLIETKISMNYSKYNY
FLVQLIHRIKNKVHLLKNIIVVLNSIKIIEEANKNSLQKVQEITFLTDDK
IKELRQFNHDFNDFINNQLADFIYNSKFVNLNNLYLNSYYQQALNWLNIS
SQNNIGGAVFDKYKKRFYDDFSFINSTIIKVNNILEKIKSTSKNYQLNQL
NQLILDLDQANQKIINSKIDKNDIKQNIDFIISTQLFYDNLKNLLFYLND
LNVKLANWNHHWNTLVKKTITIYNKKIELESYIKNKDIFFNLSNEIFLDD
FEYIENIFQKINASNSFDPQILTNHELIIHQLNLINERFDYLIEYINQTQ
LWMPKIYDLLYNKINYYGINYEWIKKEFQNLNWNNVPQASKLLNEFIDNI
IIADHALKRLKFN
>UU202 unique hypothetical
MTYMLLTSSDLHCGSCSSNLYNVLEKIGAQNISVNILNSEFAFEFEENKI
ADQDVIKEINKNGFKTNILEKYIY
>UU225 unique hypothetical membrane lipoprotein
MKKWQKILTIALPTSLLVAIPIVVASCSTKSEAQKEFEKTYKEYLSWLDK
LASKMPALKEAFSTLKEEINKQINKSEKLSDEAYKALTASLKVSIDGMKK
TLGQN
>UU392 unique hypothetical
MLKNYFQSSWLYTTFLSRLVLFKKSTYFLVGISLFVNLIFIIINGLNIAN
NIKTYLILFYLFTSINSLLTIVFSTIKAINLFKDLKDEGIEILVFSKSIS
RKNIIFTKIGFLILNIVFWSLITYILNIIFYVVNIKNNNGINFFYLYAFF
NYYFCGLIFASIAALIVSRWSNKVAMIIPISCFLPFLIAGGVANLYSTSK
INQVAKYMNINYDKYDSNTILDVEKFYLNNHNDEVYLITKNLNNPQFSKR
QNYFLKAAFDHAKNASTFFHVLSWLSVPYQLNNSFYKNDIDPFSVNSQHE
NYLDKYFNYHGLESKLYDYKLNKHPHLPQFNINENQKEYFVPGALKNTSQ
FPTLENRNLIYARENVDRFDVNFIEDDNLFSSTNDFVGELKWAVIRNTLE
SKVFNNFAKKFYDNFDEDIDKPQIIAAYNDVINEQSSINFSTIVDENSIL
FAKKINNYYVKNLVEKKIYFIVALMYYLYFNEERWNLLEKLLKNDKVINF
YRPSSIRINVNNYAYDIGGIGSYELMKKVVNNKTLYRYQLQKSNNYVFQT
AKEVYSIKRADQIVNKNYYWLIWILFSTILIISLALIYLKRDYK
>UU271 unique hypothetical
MFMFDQIFKKRKRHLNFQIFIFFFVLILITFLILWIISGNVQTIIDFIKK
KIYDASPQLKYLTNIQIKPFKNLEEIFDFIIKNKNLIKDLQNEPEILDVI
KNNPQILKTLNDNREFLKQIVEYKPFAEILSKQPEILKFVQNNKELIKQI
QNLPELLDLIKKHQNLIDHLKTNEKYIEVIKANPQMLKDLYHVDDNLFNI
IKTSLENDKENNILMLAIKYSVLINNFTKNLTLQEWKQIIEFYKTVDLNK
FIVDDNLFNIIKNNNQLFEVFLNNYDYIKNLEDNQKIIDIIQQNPDLIDD
FKKIDFDLLTQKRNFVRALIKIIDYKQPKEIQFLNKKVFLDFFKNKSEIT
NALNITSLIGFVLFIVIYTIFIFASFISHILMLKQIKDFNKIFKEAKLKK
IYLISTLLLQFLFLILFIINFIVLIILVVDYNKLKAIVLNSGIKRKVEDS
DARLHFL
>UU564.1 unique hypothetical
MLWDYFLFSYILALKSYVKEPTLPLIYFDLLKIHFVNNASTLINFNCINI
HLINNRNANNNKTRAKNTFAIKNANGMIKKFILIII
>UU593 unique hypothetical
MKIVLEELKDYLIGKLYFKYKFIGVFISIFLAGWLISFITNLILALNYGY
NEKLLNYKKYLDFTILTCISFLMLFITIIYLLWINCHNSTARYLILKINK
YPPKKPIKNLPFIFFRLAYYTFNIRQKIQYQQKQIYKYLISFNEYV
>UU450 conserved hypothetical
MDNNINEKTSFWTKKNICFLIIGLIVCLLMIIISILFILDIDFQNLFIKI
NHSLKTIKLAILWLLILISFIFFRAFMFIVIAVIDTYKNQIKIAWWKWIL
YSFSLIFLNAVTPFSVGSEPFSIYFLNKNGYHNLKKVSALLLVSSTFYEL
GQVIVTVPSFIYINYELITYAVNNKTSLPFYYYLAVVGIIADLCMTAIYF
VLGFSKKLHFRSVLIYNWVKKLFKLKYLTKIELIQKNNQNISFKAFYLYY
FKTLRVSLLAFVIGVVYNIGIYALMYISYRLVEPKPHNIFFDLFNYTNIA
VTATNFVPLPGSEGSIQFMLRVFLTNDQNQIRYAMNWLSTQDINNIIFIW
RMFSIYLGSLIGMFGFGYFLIFDLYKFIKKAKVDKKR
>UU549 unique hypothetical membrane lipoprotein
MKKNKSKKLIFSILGISFIGLTPIVAASCSAAAHPQVNVHYVSANATTNN
IGKIKIRAFEGKNQKHEMIFENQNLLDDVYYAAGDLTYTSVKDNKRFDKN
NKEIDQFGYLVPKKEVWTKSLSSSTKLTPIDLSILQNELIRLIGNKLNFD
STSKYANNLEILDQTKKQTVFNQKLYSSDELTKINKVSELINSLVISDGL
YTYITSMTDQLIKWLAEHAFNNHSNKDFELFKGLKNEVAKEFLLALVQGV
GAGKHTYKLALYNFSFDWEYVDAITGLSINKPNFGVKVNDELLVNPSLKN
VLVRLKNIKLQYAWYNSSNKKAGSFMEASSNGSQLNALSSINAALSSVDK
KTYAEIHDDHKPEIRNLVYEIPLKDMVVNFAPSTMRSANINQKATQTLQE
NFLKIKNQKTGLTETEKKRTTVYNEYYTGTLSKIHAFSILGRDLKQELKN
EAKVNKKEYVEDKKLEDWQYYEHDRGLNGVYPYAFLGEKKINELKIDDFI
KSRKFVEAIKASNNSRTILPVTNPENNQILSKQSYSQLAMIALENKDANI
HNLTSFKAAKNNFRKYLFNLNEIKSVNVNYSKWNEKNS
>UU167 unique hypothetical
MKVELYTNDWIDFFKNIAIAWFKTKRYGNKRLSSIEQKQVNKLIRQEFDQ
YVEFKIISNLIKDYNDNMEKVISLYGANLMPLNLAVQKLYPELTPTEQDE
LVKELEHKQKLENGEFENE
>UU476 unique hypothetical ATP/GTP-binding protein
MKLTKSQQKAVSQLVNCYLESVNNNKKEIIDFQAPTGSGKTFIITNTINE
IIKTNKANGSPQKLIFVIATLSSADLPFQLEQNMNEYKYYINGLFDVELK
ESPSSKSAKKDSSYNILAEENKVIIFGSSSFGKGRIITEEGILDAFLDEI
KSQGYTLVYIRDEAHHGGNVNKTKIFEDFDEKIHKNSFKKEETRFEYKIQ
EAASFIIKMTATPKGIHKLVFIDEKDLMDDDTKLLKDEHVYNLEIKELKE
ENIDDELLLTTACEQFLKIKEQYSKAKELKNIRPAMLIQVENEPNKEPQK
SEFLDKIEKIIKILEKHNLSWVKYFSNDKEVQTNILINKKNNKISLKEIS
KKTSNVDVILFKIGPATGWNIPRACMLVQLRNVSSKNLSVQTIGRIKRFP
NPSFDKNEISYNSISNQYFIYSNIISEDKIRQTLILKDKYKNDRFFYGEI
NQEKINNYLNGETYKEEIVEKFEDSISNFEYYVNEEYRENFVKNQYLEGE
TSKIEGKTRVYTKIKNSIELELYIIEQLRKYKHLFPQKIIDFLETKFNEW
EKRWKLNISINMYWYVIIKEYLDQIEKIYKNSLEQMKKDNHELLFKLQNN
KNLPNQNEIFIPIEKYKKCENMLDLNVCDKYAYKDLKEQNHYFDSLTESK
FANRFLSLSNDNDKIKNNVELWTKNPVFHGLKYQYFNEDGQISNSYPDFI
LKIKTHDQKDHYLYIEVKNLYSDYDYEKTKLLIESYQRYIENKNNNDNLI
LDELDKAEITILVCYINMKNQKDFYFYGASSNDVLNKKVNFDLLKKTSIN
KTPEQLVANKAKFIIDIKHLLDFLL
>UU346 conserved hypothetical
MNNDKKNKKNLLNNELDLAKYTLHNLSADNNDDENELELDWDGIDDEIID
NNQQIYQKKHINHKTRLFIEKDDKLNNHEQIESGNEIINQPKALSGQDFL
EFVNSKLVQKNNNFKQNSKFLQNQLTNHELLREKLKPQEDFNKIFKTKDI
NVTEEIKIKDVKKNSSVSFRNSFNINDLNQNQITNIKSIIDSTLFLAGEE
GVSLQDLKRTTGLNESSQLKTILNQLQKDYDVDDSGLVLVQFGEKFKLLT
QSKNKDALSKFVTTSFRTPLSQRNLETLAIIAYNQPTTRAKIQAIRDRDP
KPAIDALLKLNLIIEAGRQDTPGHPILYTVSQKFYDLFGIRNLTELPRLN
KEINEFSPIDESTN
>UU569 conserved hypothetical
MQYKMLVIDLDGTLLTKTKNISKANLQGLKKYISLGGKVVLSTGRSLENT
LKIVHLIHDQIKELIQYISCFNGSYIYDVINEKVLFESTINKDIVNEIYK
FSLKHGLGFWPYNQRFMQTHFLDVYNINYKFLLQLHHTKRKVCLNPIFNK
NDKFYKINILPSNFVKKLKHEVIDQLIKEFSDQVNISFTSKYIVEVTNKN
INKASSLRFIANLYQINLDKVATIGDSPNDIPMFKISGLAAAARTKSKTI
IEHVDVIINYKNNSNSVALFINNYLLK
>UU017 hypothetical
MLEKIKIIDTHTHPNIEPLIEEFDDIIFKCYEQGIGLNIVGVDLKTSQTA
IQQAKKFKFLTCSVAIHPNDLHNIENDFVALEKLIAENIDYISCIGECGL
DYYHEQNYDHDFQKHWFKKHIELAKKYHKPLMLHIRNAHDDAIAILKELA
VQDVIIHCFTDKKEYAQQYIEMGYYISYPGVITFKPTKNNQLHELYEAIK
ITPLDKILVETDAPYLTPVPKRGQTNYPYYVLYTSAFIANLLGITHEKMQ
KILLENSLRILNFKK
>UU422 unique hypothetical
MNIKKIKREFNTHYELIKKEIKNLNEYKKELEFLIATIYFNSKMVFKEIS
LDSWKKFSDYVYRFFLIINKNNQSQNFDLDCWYLEIKELIKVLNISNFLL
NKQLEQIYLKYIIFYWYNINIPINYEIDDFNIICLRNKAFVDCMQILQEY
YHINVDILINLVIKQIR
>UU147 unique hypothetical
MNYILNKNKKVSLTELMNQQPHWYLEELQEHLIKYLDTNGLNDTKKLIKQ
TIKEWKK
>UU308 conserved hypothetical
MDIVIKKNCNFVKNDDHLYSFYTPLIGMQAVALYSWFVNRENIFNKKGTI
NLTHEYLLDELNISINTYNELITKLINVDLIKIYSFENNSQQVIEVFRPL
KFSEFINIEKFNEELKNNVSLNHYNVLNLLNKENNIDTNRLIDLSAQFKT
NHFNNLENKLDKIKKIILKEYGLSLQIDESTKLCLINFFKKYKFSIDQML
NLIKNNLINNIDFLTIDLNKLELTIFSNMEFEKNKTKFQYYNIERDFNIF
NKNSNLDRFKNVINDYNNFKPSDFLKHIRKEKLSLKDKEAINLLTYDKSL
SDPIVNVILDFVLFKNLGRLNVKYLKRIKETVLGINIKDEYEMIKFFQNK
KNDHKELICEDSDNANTFKNTNFIEVKFGDL
>UU423 conserved hypothetical
MQEKKQTKNENFQDLDQLKIGDELMVHAYKLNGWLYRSWNNPKVVYIDDQ
LLILSSTNTLVITSEEKSVRNFPSFTNKMSYWFFFKNEWFNLIATVENDG
IKFYINVASPFIYEEQAVKYYDFDLDFKISSDDKWKEVDVNEFIENAKKY
HYSEDLIQKILSVETKIENYIKEGYFRKLVTRQLLIKLHVLDDIDDFKTN
FNKHTNEWNYNLKKHFNKKNGLHHFKNKKGNVKDNE
>UU474 unique hypothetical
MKVNKIIMKKRVNKIYKHNMFILLATLNLVWAGVITGIVLRLKSKDYSKH
TILKKYYSFDKNGNLILKGYLKPHDNTNYVFGIFSDESNQEHKIQALVND
KKGFEFNTKSLPLNHSYKLKKVTSINDYNHVLLTNDDLVSQQKICFSKPV
DAKVNFINNKKVYQVKLNTLLKNTLIQLTLKDLEHNVYKITAKSNDMGEV
SFDVSQLKNNNLYEVIALQTQDQTKIVNVNEIEYNNKIINNLNIDELNTP
YQYSKNGHLNLIAKIPLRYANEQVYGVFEDQNNQKHLIPAVNKNDGTIMF
DTQVLTKNPNKKYHLQKVVLAKNQNQILIHNFDLVSNQKQDIFLKEYKVI
SISALENDADKTKREINLKLSNIKNDWVNKQIKVIYSSSDGSDVQTQPLV
LEKNQTNYVLKLNNLKANRLYTLKAVELINNNGKTNLPLDTNLTNSFMVE
RTSAVLATSISEISNRLGTALTNAQVKITLKDVDNVLLANQKAIINYGNN
QKSEATVIVNNGVKYLIATLTKLTLNTPTIIKSITFEQKPTCAIENIGLD
KTNNIIYQNTHEAAIPLVINNNFEINGPLASSHESLKSINASDAKKVNAI
NLTLDFNTNEHIYKNLFFKLKYVPIDDQGNENIYDASEAIYSDVLSANNI
IANKIQFSLGNLQTNRKYKLKTIYYLTSKTTPLDDHNVVMIKPNVKSEII
VAPNDSTIVKYGNWNQDSITNGSKAIFKINCNDGDILSEDLSATLVYESN
DPHDLQSYTTKLKKVNNDWVIDFNLNNLKPQTTYHLKSITIAKPNKAYTN
LKIQSLPQVDIKTQLPNLILHDLKATSAVLKWDSTNNGKNNHQTIQATFS
HVSANYDNLNVKLVYEYNYRGDIKAVESDLITLKKDQNVYQINLPISVPN
RKYTFKKVLIQERNNLNNYVDLNKKINLTDSFVVSPGKTTFEWTQPTSDQ
ISQTTLKALKIKILSEDKTLDNNVKVIVWFKSHTDSNDALKWTRGTWEVN
SDGSEAIINQLNNLSGFKAGTQYYLYKIAFVDNLQYGNTQANDNKVIYEW
KANDTKEYEFTMKNAPTILQSIKFENCDANGVINNEAEGIAEFSMTTNKV
NDDFANRKVKFIYHDNNNVAYETDGFPLSRSETSLHFSLSNIPNNRDYTF
DHAEIETSPNSNKYEIWHSQNKIISKFKLKPAQTSVKYIDKQERNNNNVD
FELHLGSRDCAFENNQKYRVTLVSVDALQTEISKEFLLSDVKLDYQDGNI
GILKCHFDNLIPNTGYTLKEIKFLANPNEQQSAKPHKVIKPFNDDNNVII
DKNYSWKWYIYPS
>UU301 conserved hypothetical
MQRYFVSKIKDKKVYFYDSDVHHIKNVMRMRLHDKVIVINKTKAFVAEII
NLEPLHATIIKPYTLNCELATKIDLFQASIKPNNFEWIVQKACELGVNSI
YQTIFKRTYNHSLIKTNRILTIIKEACEQARRNHLVNYYAQFSFNELLKY
LRDYDLILIAYENEKQNLLNNAFKEELTYQKIALVIGPEGGFEQMEINLL
KQFDNAICISLTKTILRSETASLYLLANLVNKLI
>UU502 unique hypothetical membrane lipoprotein
MSDKSTLKQENTIEYPVVGALRRASASVLDYIFISIIAFLLSLLVFINSN
FKISDIFVNNDELAPEPWRLFLMGIIAFFVYSTYYIIIPLFCKSYTLFRW
AFSIRMISLVKQNDKKILFIALIKHSLLTWLIFTIINLLAMGFCFVFADA
SFKSIQAMNETELKEYYHQIKDLKAYVQSILSLKINDNFTNTTTMAILSI
LVKSLYSIMGLVSCIIVIHMFMNSKKRALHDQVAKVVLLWMHYEKPKQAP
KHKTKREVEIQKIDNLIQELDKI
>UU542 unique hypothetical
MKKMFLLMKNMMRLFFKNKTLVTQLSILMIVSTVVIVATTITVQRLQKSQ
SDIKKIGLQSDFLIDTKEQDNINFNEIDVSNNLVKHNEKLIQLATFNQNI
LKNSNNYLQLVDNAFHNHNLFWPTNVNNQKIDVLNLEGNIDWNKINQLKL
QTVFWFENNKENNQNFANNYDDLVYEYHNSKNQLVGFQNLDGGHILFKTP
ALKSANGNYETTFKINAAIVQKNKPFKSFFNFDKYKELGFKNKSYFTNPV
LIKNIDLYSKQVVQTLNDRSNQSIDFKDYQSTFQAIVDTLETNTINKDFY
SVNLHVDFNTLSTKYLLFANYLKNEGIDKNRYINELKIDNYKQKYLDLFQ
NQVLIPKELIDDPKKIEEVQKIIAKAKALLIAKIREETNIFYENSQKSAL
ENKNKIRDYEMQLKQINIALQNSNYSNNELIQLKNEQKVLAANLDQAKFK
HFLYNDLIKQDFRSILNNYNIYYRKHESAIYNDVKSDSNFIVTNASNPTY
TQNGLIAPRNQWIDNMVQINEKNKNSQNPNKKFKRIFINDDNSNKINNFY
DLYSNYIKVIQILKNSYEKDPDTDKDLLVEERDYTPWINTSLINIYQLPQ
FFNILFNQSEWLLSIQYLKEMSDYKKYLLQIFEPYQDKEWIFNLKHKDWQ
DGEQVVAIYKNADSNSDQKEYYFNGYVKNQRAYINVKYNKNLPTRLKLIN
IIKQNQINQKNNLVNVLDQDLNDYAKIINFKKGIKDINTNQQSVYDQWAL
NNPQDYAMFKIWLSKIIKRYYFLRFSNHLMDIQFKHKTFYQKLCYCRLQL
ILLIVVQI
>UU579 conserved hypothetical membrane lipoprotein
MKISVKKTKQIGLFTSIAIMISSVVGIGIFFKNGSIFRFNNFNEIGIIIS
WVVASLIAFFTALSFAYITFSKKSGSGIAGIIDELKAPKCARFISVLQTF
FYNGILMPSISFFAAESLLMTIIPKNSSSPQIYQIFILAIGLFLFFLLLN
FISFKFSSILQNIATIIKFIPIIAIAIIGITYGINNAQNSLFNHNNPKHA
NFSLLGILASLPSILFSFDSFLGISSLQHKIKNAQKNVPITLIVGMFLVA
IVYILITIGQVFVGEGYAYGVINKVFKNNINLLKIITIIVNVFITISIIG
VLNSFVIFSIHNAQYVINEKIIFWWSWIQRVQSKHFKEAQGLISVLFIFF
TWITIFMIISIPLNTDAYIDLLSNYPIVFFFAVYGLIIAFAFYKKVKTKQ
KIKGIKKQYYTSDVTKRPKWFFNYQNSSLKNKNILNKELKIANNWILSVW
IIGITSCLFVFLYQFLYGYTIYAWLDPYNLKLYTFGLFYANNVSVIPWIV
SLLFFVMLIFFIGFPFLNDAILNLNHKKVNKQQKVFV
>UU198 conserved hypothetical
MRLRYKILCASLGVVGVVGVIAAISIDYKQIPIVYANGSSSVLPLIQALS
EKHHKQDIISNAGGSSLGIIEAVEQRTNIGVSSRSPNIDFEQQSVEKSHV
VYDKWKQNQLKTYTIAWDGIGIIYKLNKTNHELVLTKDNIIKLFKAFTGN
EQVSYYDLDPQLPKTPILAYSRTGGANASGTAEAFLTSNPLISKKEFKKK
YHDIYKVIEAGTYGKLIRSTEESNTQAWTNISKDNVDGSITYLSTGFILK
NYDQIIAKGYKIAYLQNKDLKNYLPFEINENKQEIVNVAKTYGWYRPFNL
VFSLNMQGIKNTKEFVWWLLTNKKVEKIIQESGFIPLTFEQKNSMFLKPY
KDEQSFQEAINNQSAKNNFFVSDFELIESNRINILGAKSA
>UU131 unique hypothetical
MNQIKMNKSFAEFSKLPKIKQVFTPWFIAALVIFIVGLTIAFTMVGLLNE
GFENARALVNDQGQIIGKVADVSGDNHSLMSWLGYDQHANYQELYKTIHD
QLINGKTMESLINNTNKNNDPKLYEALHYHAHSKFINHNGTWGFVTKVLS
DWENSWFYKYNQLFSQLANSQNPVLAAQGIKSLAKLSTIIQYQNPNYIAY
NWVFIVFMMPQMITFIIIVVKLATVFSPKKSAEEKQAYKLAKLEVKNQKK
AKKLNNSLQQINLNLEAN
>UU164 unique hypothetical
MADNQNTWKRPDPNAKYTITQYLDVVNANNERVVAGGFEKYMLENQFNAE
FLGSATMTPTKIMDDMRTAIYEVGVIGQVEEYRDDFTQKQVPAIDRLTLH
LSNDYQKEVSISVFDKKTGAQWNDFLAKTLANLEVVKQDQINLINIDAIY
QSCLATGNYIIIPELSPDRVESLTDDERLKIVEKIYRKAKQVTKSRTKFN
LGADPNKLRFVLSDDAALVVLTAKTYKIRDGQAYSDYSTKGLGSSSQYMG
DYLGMPIYSSAYLGEDYLKSTDQKYTSNLIRDYKFSKLSGIITMPETTIC
LKQELMLTTFQSPTSKSHQLIHNSWSMNSAVFPQFAHLNFVILNDKPTKD
EINKARSNLYSQFPSLYAEFKTPISEDSKITEVNKANWRGLSTYK
>UU564 unique hypothetical membrane lipoprotein
MKTKSNLKARLIIFISILLTTIISLVLLTSCSTKKSKKVTINQDTQIKFQ
SITNNNINLANEKQILNQSQNKETKIFLNLYESLKDYFDQTIKRSLYLYY
SYNFALLNLYNAKYHVKLNDFSLIYNTDKNSNNGTFDINYKLGLVIDDIG
DINIQTKPQFYEPIPPDKKVRNDDYHFTKKIKRFWFGSKKAIIDYFNEAI
SMQINYSNVKIYHSIIKYPDSKEHYEGYTITGGSLYRWVKQAIPTDDNQN
KVRYMISKINDLNIDNDVKLFNLNDLVLKQIFIVDRPAQTSIKPERDLVY
TNIWNNKLDDFYFSPIAFLAPTFIKKNGKKITPFNLKTNKEYLDNLYENL
LIQGQKNNNALIKGMYVIYSMYSYFDLTLEPKKPGSIHHCHADGFCH
>UU309 unique hypothetical
MFEQVFFLASINDKKIIRWLYERYHKIFLKYINEQLNFKFYTLEIEANDL
KTIIYEIFLKIFQVTRIKSLNQFIGFVKRQIYFYLVYLLRKSLSNKNLVN
HLNNNNFENYELISTNSDEVGAELNNRFLIYEFLRSIQKENLFLYHFTIL
IIKGYNTKEISEILKINSAKIYYYKALLKKYIKKLL
>UU150 unique hypothetical
MAMLCMCDECQAIINYYVVQIEQLCNEIVKTRKRVEPYKKLGKLFFEIIQ
NDLFEAIAEEVFRIDEKPKRKTNKRVCK
>UU441 unique hypothetical
MIVKIEKVHLYSLDINAKDETSENSHIKIWKELDWLIQNDVKIINHSYGW
SPNDFLNIGFYNFINGKEINDDKDFKRELKKYIDTLNKDDIVNNTINKYK
FKNYIYDFISYYFDIINIFSAGNSYNDEIRYRNKNGHILEINWFDISKYS
FMDRFNQNSIYVGSTNKNNEKVSNFSDRHHLNDVKNKYGDLLMPFLVAPG
EGIYDTSIITKFIKNKGDKNINLGTSFSAPIVTGAISLLQSYYMVNNANK
TIPLTHIRSILAASSIPLKNNENYDFYKNSFSHLYGAGHLDFKRAIEAYK
NAKQTKILTKHKDKQLVKEMDISIDNDQTNFNFALSWLFKPTSNSFSKKH
DYNSVYNEYKKLTYFKNDNYDIYLVKNEDLKNIDYQNFDNFGEILRTINI
YRSESDSNVELIRAPNLNKGEYKILVYQKGEVRNEQTSFSYTFIKEKAIH
>UU350 conserved hypothetical
MNPKTRIAFIADLINDAQNVVDVGSDHAYLAKILLVNNKAQHVTNIEVNQ
GPLENGINNLTKNNLLKRTTNILNDGFKGLILEQTFDYCVIAGMGATSII
EILEQNKNQIKNYILQPNTQSYKIRKYLNNHSYQIKVEHIFVEKKIFYEI
IICSKTINVPKLIEKDYYISSQMHKDSLNLYFKFLKRRYEYLKALDISLV
SENIVKEYEYIKEFINEKNGY
>UU472 unique hypothetical
MIYKEIVRNIIKHPLILPEGKHYHLHKILTSKDELRKGEVSLVAENGKEY
TVDLSAFVDLLVDGDCIIDDNHSLVALYFDESK
>UU440 unique hypothetical membrane lipoprotein
MNKRHLVTHSLKKKLFIKTSLLSLFLIAPLIIGCTTNKSKSNNSNKLSKQ
IEIKENKQQEKPKTKELSPIIDIPKNDYYKVLYANNIKSFVYDGKVWDDQ
KQTYDLEFVNKLLAYIDQHISNLVDFELVKNNQNKPWFKWLIDYYMFLNV
TYFIDNKPKFLANSIKYISLRDPEHYFDEATRIFKKYYHPNKLSSNNKDY
FYSWYNFIYFAHINHYYNARELYKYYNQKFNLDLPSKYINHSYPISRIYK
NDRYYFSNVNRILFKIKTYDKTRINTLFLAFKKLNQSNDENKNLIIKYLK
QENLIDQNYEITNKLDFNIFLEKSFLNNKEYSSTKNELKRFFENINDQLN
KFNLFVNAYWYDNKYYSISTSNTKLMNDKIRFSIINMLWRDYDITDYIKA
KKDELIETNPINSHYEDRYLNLLKQLYENEWQISINKDKNNEEINQLKTK
NESLKTRMQNIKNEFLQYLVKMGIIDDAKELADFSVSEFYLWSTYLSTK
>UU464 conserved hypothetical
MLDNQEIIESILQADSAKGGNGNFLMILIIIIPIVLVVVFIMRKKRKQNG
ENQTSVNNKDKSDTNEVWTTIKKYLRSIDDKGKEVIDSYVVKRAEPHNLV
QMTKQQRIDYKNEQKAIKALKTTNPEQYKIEMERIKKEKRAKPKELYVVL
FTTRNAKTLIIDEPRAIECEVRLVKINKKENRREIDVVRALDYEEEMLWI
EPIKAKDDEIYNKRLEADKKKQQKAAQRRQKQLEKQKNKTN
>UU510.1 unique hypothetical
MMKKWISISLLGFLLSLLIAIGVMFGFKNKKYFKTTLNIQTKLSIITKNN
YEKIKTKKQLEIKIKNLTYYVKFKFLKQTHDYCLIKIFLSLKTDQKMIDI
SIYTNTQPLIESIINNFKLYN
>UU077 conserved hypothetical
MKILIKLWTNLINRISNKKYLAAVSGGPDSMAMLNMYKRNIRVVCHVNYH
KRESSDRDQQIVVDFCRKNNLIIEILDVDEKVYERYGHIDNFQTKARLIR
YDFFKEIGKKYNIENLYIAHNFDDFLETAYMQRARQSKALFYGIKESNVI
NGIIVKRPVLFVRKQTLQRYCDENKIKYGIDETNELDIYERNRVRKIISS
WSLNEVYDFKKFVIKYNKEHSSFANFIDLSYIEFKKNKYKYDYFIRQDDM
VQYYLIYYFLIDHKIINPSENKIISLIKFFGKQINKEKAYRVQENIYMHV
NDDELISLISYNKSDNISNSNVDIIDDHNVIEK
>UU405 conserved hypothetical
MDQVYNIVMAYILTLIISPLYSYLIGSLNASIILSLVFKKQDVRLFASKN
AGMTNMIRVHGKKLGILTLFLDIIKPITTVSLTYIIYKYALDAPFDLSNG
FNQAILVYFGGIFTIIGHCYPIFFKFQGGKGVACYGGFLITVDPIVALIG
IITLLVILLITKYMSLSAMITATFTCFLVLVPGINYIPYYNQNFTTYFFD
LNYVIKGIWYVWFFLLVSASLLIYRHKTNILSIATKQERKTILFHTKSKD
NLSDVNK
>UU398 unique hypothetical
MKFKKFDSKKSILRFLQVDETKREINLSFNDTTDFIFFLKEIAEDPNIAK
KNAKKLTSLYIEISNKLGNDDNTDLSVYETKCNNLIEACVIDEAIYLVNM
AKNIVIFLAHNKLDLLQKDFFDKLLLIESHFNFDQNLTYSYIKNSSIALL
IFHLKQFINIYDEFLNNFENVINHSLENSISTKNKLTQQINHFNTIKRRP
S
>UU142 conserved hypothetical
MLNKNKRWYLIALYDIYQGLLTTKQCEYFNLHYFKDLSFSEIAELKEISK
SAISDCLNKVCDQLLKYEQALLIYEKNKKRNDLYTLINDSELVKKLKDI
>UU425 unique hypothetical
MATSNDLLIYSNLKQTPKYQIDNKKLKEDFVKNNNWLSENVDYHLSIFKD
IKYDFYLSHWCYQYWIDQNRLDVILKLIYNANKIILYPNGNAELYYVANY
YAQAIKNLIREDPHLSKQKINDHLNNFINMKSFLEAKNYFSSQLNNNKDW
LTVFVLNKLFKIFTIGESWVDSKYFSFNKELMPKSYKIRTNYASVLNSLN
LSLDAKNQFKKKILSTLLEYTIKHF
>UU162 unique hypothetical
MNNRLLLSVEEYLSLFPLIVRNENLEDNQLQLERKKQALTTFILRAQSMI
DDCVASNGGAGFIYSWFDDLKTTDYQKTKFKEAIATLTNYLWLQGHFIDK
DYTSAIGDGLSLSFKSENADFEKKRLDIINKLRVCGLYKKSKFANFNDDG
IYVNYDELKINAINNVHEELRDHYISKNNPVVNNNFDLNHHNINNVSSIN
ASGNLATLNGFILNDCTLPNDLTTDKSNKVYDNAIANYVDIHDVKNLAWY
GQNNNNAITRQELYEYCNKINSKMYWDAIYDYKAGELVYDLDEKTNTIKV
YKALVNNGVSTHNIVDPSKQINENVWELINIQQIDLNKIKEGVQDAVDNK
VNEVKKAIDTKENTFTKNLENKVNEAKQAVLSSYEQDKASGVFKGEKGEP
GIQGPIGPKGETGPKGEKGDSANVDALTSNLESFKNTALNRNVRFPWKIM
DNLNKII
>UU007 unique hypothetical
MLNILNNVSNSSLYSAASNATAQTGSNLINDLVPETLTASGISIAISVFS
VIGTIVIALSVLPQTIKTLREKDTASLSLLLFLLNGIATAFLTLYGIGLV
TVHPNSFSFLVDIKNGMFIYNREEWVAGYLICGIFLIMGEALCSVTSFIV
LFCKVNNMIKAKKMGMSEEEYYEKQIKPFLKVKGAN
>UU050 unique hypothetical
MQLKDLINKKKNLNNINLKVSNERNIFLINIMKLNQRLTFFSKNAFEIKE
SILSLKRIYNIKHDMLRHEERKIFKFLNKINDRVLWIYLTEEQKYSTDSY
SRYEQKILKTIKSNRDDFILIGQGAIEFGKNHNLNVLQTFNDSNIKNLTT
QLTKMIMILYTFDNYKKVNFVINSNKNYDGHFTILPMNEFSFDKFINLQK
CDSNIIDFQKVKIYPNLNEFINVQINVFLVNIINTLITESSFYKTKNGLV
ATNNILKELDDNLSKIQRKITRVKTELQIEEINLLARQNMNEDDNDNDGG
VYES
>UU153 unique hypothetical
MTNSIKREILSALNDETKKVISKLQQTNNLIKQLSDEKKTLEQYLKDNVN
NHEIVDLDSDLKIKIYDLTSKDSIVLDYDKIITDYKVDTKKYETIKKGTT
STRITWSGADK
>UU180 hypothetical
MMIKIISVGKLKQKAFVDLINDYLKRINHYLKCQEIVVSDEPEPVQISNK
SLEQIKSKEASKIFKNINQNDFVIALIIESNIISSETLAKKIQQWLNTFS
HDICFIIGGSNGLHESIYERANYHLSMSKMTFAHGLAKVMLCEQIYRALS
ILNNGKYHK
>UU048 unique hypothetical
MMNTKTFTSVNRVIYDDNYSLKQQQKSSFINQFLKGLLSAITLLFFILLL
IFAENTLFGLGFGDENKSMMISKSLNAFFDLHSPKYLQLNFLIVFRFFIL
SFTLFYTLIKNFTNLYWHRATIKKYLPWFVLYLVIATISFLLFFTFFSVW
PKEVFNLVFLLLVLFLLNLSYEIFNYFISKKTNPLLYDNYKNLIIAMVFQ
ALLLLFVIITPLVWINTGKSPNFLFVDNRFYTRIVDIFTVQSGKNFIILI
AFFFFLITFIVLANTNFFALVINKRYDRNYVKNNLWFILLLFSAIFIWLL
RVFAYKHENENLPVGNNHLLWVYILQSFFAIIILILYMVFTLKKRLSVKS
SLNTLLNLVVTQTILSLSLFLVTLFNSKSVVSLINVFITITVQMSVFGIY
IFQNKNISTKLLVLLKVIMILIILTAAIVGFDYLLTSDHHNNYLFSNIQP
KMNLVQIMLLLNFSLNFTLISYLTIKFAMVIFKINKLNKELNNEKK
>UU482 unique hypothetical
MNNKKSKKIQTIKNDNNKKSRKQRLFLLLATLNLAWAGAIIGIVLHSKNN
NELSNNDFYSFNDDGDLIIKGQLPKTYINKDVYGVFVDENNQEYKIKTQI
DSYAKFEFDTKYLPKTGKYKLNRIIDLNNNIVRENEKLKPEQKIEVLKPV
PTNVYEDQKNEKHIQLKVNKILANKILVAKFVNQNNEVYSIEAHVGLDQK
IDIDTSSLKDGNVYYLKDLILKDSNPLTKVVNVNDIDEQFKKIDKTHTYD
NEGNLVLKVDLTNKTKNQALPTAVFKDENNKEYLIPALSVKNNVGYFNTK
KLPLNHKYELNRIVNNNELNDVLVPNNELMLEHKVSVNKPTKAKVNFIDN
KKVYEVDLGVQLKNTPLELTLEDLNHQTYKINAKTDEKGRAVFDISSLGD
NNLYEVIGIKKTNEVDVVNLKQIPYHNRSINNLNSNALNTPYQYTKNGDI
NLIAKVAPYYVNQQVYGIFKDQNNQEHQILAKVKKDGTIAFDTGALNNNS
NYSLDKIVSVSNPQNVLVSNFDLTSKQKQLIKKPAANASVDSTKKTQILE
NLNNDLINQKLVATFVDNNDKEYKVVANVDQNNKIIFDSNDLPKGYIYHL
AKVENNDLNKVINLNDFELKDKIIDKRDLNLLDSHPDFTYDNDGNLEIHT
QLANDLNDDLKQKALNNANVKGIVVDQDGIEHEIDVSIDANGKVIIPTKN
LANNDPTKPNIYTLKKVVLKQNNQPNIDLISEEQLSGDNHISFKKPTITA
KTKENDDYEISFSNPSLANKKIKLTFKTDDNNTNTKTVEASIGLDGKAIF
KTSDDAIFAPDHKYTLTKIEADNKKVANIDEISPLDRIVNKQKNGNVNAD
NKHEFKIPDQKNKDLTAVYKDKNNNEIHVPIKTDDKGKVIVNPNNNLFDP
NKIYDFDKIVDLNEYPNKTILDRNSINKDVSAINDGVDQARKLVLKAPAV
SNVTVNAINFQVNLFDLNKLSYNRQFALTIAKVNDLNDTQKYIATYDPKT
NNYKLNFDFTHLDANTKYKVVDVELLELNNKEKPIKLIKDDVLNFEFTTS
SATTINPPIWTKFDVVVKTNNDTTITFEIDDKDNILKNDQKIYAQLALMD
DDLLDTDVINPLVNFSKTNKIASINGLDLKGNSKYSIKNLYYLNDQNQKV
YLFKNDVTKYEQHFITNPHKINLSFNKSAVEQDIFADHANLFIDYKDYDQ
KLRINEDVKIYYQNIDNTKNELQIGYGKVVANNKIKFNLVGLKEKTTYVI
KKLEALNKSASSIVNSEFDLLDPNTNFSTSNKNTTLVGLNSIDNWNNDQT
PIINAKINIGDDFQDNQQVKLIYVSNDNKEIKSKAVTLIKGQRNYQFEFS
NLIKNRLYTFSKIVYETNNQTLHKLDTLTHQFSINPSNNAVSLKNNTNIE
ITKRILVNNDQSLISAKIEVDDIDNVLNTADKPNIVYQLENSNDANNNLK
LATNAQVVVENNKKFLKFDLVSLKINQNYVIKEISFNSKPTNAYFNFTNN
KTNNIVYSYDEQNKISLSNNINPTSYKPQTINKNDKSVNIDVDLQVDKQL
LANQYLRLKLKQLNDNKTVWTDPILFNNNAKISFKLSNLIHNRAYELEGL
YYFDDQNSVNDMTNNQISFNSKIHKPKIEFEPSLTTINYDTNNAIKTVSA
HNAQVHFKLKTNDEALENDQIVEAVFAPTNNLNDQKVVEAKLNNVTNSFN
EGELEFNLSGLREETTYRLIKVTFKNKPNKAYELLNKNGVIFEYKNGSQA
YEFTTQKFEHKVIDVVSSTSTNTTQQEITVKIDGIQRAWNNKKLELVYES
NILGDPEIKTTVDNNNNSVHLSFDKKEYNLVLNNLKPGRRYSLKKINIKE
VDNGQDHEFVKEINVNNSFDVNLQSEITASSVEEINDRAPDKLNQTTIKI
NLKDDNDILKTNDIATITYDNEQKVDAIVKTNAQNQKYLEAIITNLVFNK
NVIIKKIEFKNLSQTFIKVGKNNTNVIYDESNLNKLIINNDFQIIGPLST
DVNSTQNIVANNKHVISSTLDFKVNPHISKNLKFKLKFQNINGEVVYSPI
LTNSSIIVNNNKNVINFTLDNLKSNQLYRLVDVYYIDDNNDTINDKNKVP
KANNVTRIIDIAPGKTTISKSNNTWNTTSTSSQFEFVINSDDGNEVLDNL
EATISFKKGQTLLTPVKVNIIKQNNKYLIKGQITNLEPENRYVLESILLA
KPNKTKKPLVVEILNKDDISFQTQAGNYKVIQIKSQNPSTVDTKQRIKLK
LDGIQNAWNEKQLEITYSANDNSTKTAIIKLEKNKLEYEFELTNLEKNRT
YTFTKIELINDNNTKTPFNKSDSIQDKFIVLSNNQVGVGNIIEIQDRDVN
HLNSAKIRFELNDLDNVLSNDEQATITYNNNQTTSAKVITDQNQKYLEAT
FSNLVLNKDTIINKIEFNTKPKNASKNIGINDTNVIYDATNLIINNDLKI
TGPLHTLKEFEANNKTNISVSLELDTNNHISKNLYFIAKFDSNDGQSVLT
NPIAADKIVTNNNNNKKELTFNLTNLTSNRQYIFKGLYYVNSSNQTNIDE
NNKFEKNSNVDYKITVKPTITTIQKNGNWTFPQPNAQKFKFNINSDENVD
FSTDLDATITFSDQHDTKKTITTKLKQKDNQWYIEDTISDLAYNDTYKLD
DISITKPMNAFANLKIQIENKEQISFTTQSGPTQLVSITSHDLMWNDQPN
ASNQQTITAKVSGVNDLYNNRKIKLVYEYRSNNQKSLVESNELTLQKDQT
QYIFTLPISVANRQYSFKEIKIKTSNNNFETLNNSTNVTNSFNVNASKTQ
IVIDNTNLATNITSTSATITYKLKSKDHVFQVGDSIITYLKSNDDERQEI
SYTKTITSISSDGSEATVSFNTDQTLKEEANYKLIKVGFVRKPTLAYTNI
NNDANNVIFEDNNSNYNFKTLIVDHKVTNVSSNDSINTTTQTVNIDIDGI
QRTWINKKIQLVYTSNDGEEILSDQKTLLWANNHYSFELSNLKHNRKYTL
KEVRIINDDNKTSIIFHLKNGIADWFIVNKTQSISISSIIEPIARAKNNL
QSTQIRFILNDPDNVLSNEEEAIINYGENLSVKAKVKIVGSQKYLETTFN
NLALNQDTIINSITFINKPIKAATNIGIDNSNKIYNNTNNINPLKIDNNF
SVIGPVQSDTNKRITLEYNNKTNVKVNLELKANDNILQNLYFIATFKDQN
NETVKSSIVSYSSIKKEGKKQIIELRIPNLKSNRLYHFDNLYYLLNQDDK
DLIDNNKLIRSNNVVNEIEVKPGNTTFKKNNVEWQINSNSVNFKLQVESD
DEDILDNNVMADVIFSSKSNQNDTKFVNNVKLKKEGNIWFIEGIVNNLKP
ETEYELKSIVLTKPLNANSNLKTINPTNISFKTKPGNYGIINIESNQTLT
NSQNVNVTIDGIRSEWFNKEAKLVYISNTNDEVEAKVNLEENKLNYVFNF
NNLKYNRKYTLKSIKWFDGQNWIDFPNKQNLQNSFIIKGKTPISVNKLNE
ISDRVINNLNVAKIQFSLNDPEDVLSNNEIAEITYDTNKKTNAKVITVNN
EKYLEVSLSNLEFNHDTIINKIEFITRPNKAVDSVGINNSNKIYELTNLI
EETRKLKINNDFRISGPLSSNNLHLEIKNYNDKESINSSIEFTINKHIAK
NLKFKLKFRNEFGHEVYSELIDGNNINKTGKQEVLFSVKGLKSNQLYKLV
DVYYLDNIHQNIDETRKIFKDHNVSKEIEINPGVTMISKHGNWKSPTDTT
ANFEFKIETQDDNDVLNNIDATVKFKDEHNNIKQKIVRIIKENNDWLIKG
QIDNLNPETKYKLENIELSKPLKTHTNLSVSINDKENISLITETGNPVLK
VIQTQNDTINDTQQTINVTLSGVNSKYNGRQIKVVYKDNNNVIYESSLIT
LQKGKNDYQLLLSNLNSNREYRFEKIEINHISNTNNFEDLEKLNGVSNTF
ITQTKNTTVQWNDSSATIVGTRGVNFNFKIKSEDKILENNQQVVAWFAPK
ETIRDTNTWLQYTRPLKDVTSDFKEGTWAHDLSNSVNFKEETTYKLVKIQ
FVNKPTKAKNNINNSENNVILDNTNSINSNYEFTTKVGDHKLINITSSNN
VNTNSQTINFTLSGVKKSWVGKKIKLSYKSNDTSESIHTNEVLIESNKTQ
YNILLNNLKRNRTYTLIDVKLIDNNNVSDFPKEGNLTNSFITTRTSAINV
LNIEEISNRASTNLKSTIIKINLNDPDNVLRDKDQATIVYGNNKQAMGFI
TVSGNIKYLTATLVDLNFNDKVNIVNISFNNKPSIAAENIGIDKSNNIIY
NNDSIPKLEINNDIIVNGPINKEIVVKNANQKNNIDVDLGLQINPKIAHN
LRFIAKFKSTNNDIIETNVINGSSLVNNDGKTSIRFTLNNLKANKLYSLV
DVYYLVNNNSNTIVESNKLPKLNNINYQIKINKSHTIISKNGEWSNPSDT
SAEFNFLLKTDDNDGELDANATATVTFNKNGGTLKQVNVNLLKENGKWLI
KGKINNLEPNSTYVLNSINITKPSNVYEDLDVSIENKRNISFTTQFGPSI
LNELLSTNEINVDSQTINATFSGVNDQYNGRRVKLIYRDQNNELYESNIV
NLKKGMQKYNFTLSGLIANRNYTFIKIQINDDKNNSQYIDLKKQNTVNNS
FKRNPSTTSIEWSTPLNITYNSAELNIKLKSVESNIWN
>UU453 conserved hypothetical
MASYNINDNLLLRKIIMQHYEHPKNKVCFVQDEINYLSYHNTTEGCGDDI
TVYVKLNHQKIIDVVFLGTGCAISISSTDIICELVKNLDLNNALLLINNY
LNMIEGLDYNKDIMQELIAFYNVKKQMNRIRCARIGASALKMCLKQFTDK
HKTIV
>UU080 conserved hypothetical
MKKIFISTEYVTLNQFLKIAGLINNGGQAKFWLLENKVMVDEKIENRRGR
KLYDQMIIKIKNQLYQIVKTNE
>UU302 unique hypothetical
MKQRLINYIIVLIGILCIVSLVVGFAVWFSPNKNFDTLTQNKIDGNEVKR
LYNPNNGIFLEQLEGFSKYNIAGYVVPIVFVILSFILLFLYYFLNKKSRS
KADFPISEKFIITLQLPLFI
>UU600 conserved hypothetical
MKVKSFAKIDLGYSVYKKQKNFTKHDFESIFILVENIYDDIEITKIEKNI
DDVHYYNETNEIYVYSRLVHKTLEWIRHTYHIKNHYRINIKKRIPIGAGL
GGGSSNAAAIMKYILEFEGIKEINYKDVVNKLGADIPFFLSGYKTAYISD
YGSVLEDLTGQFKLNYEVYLMNVNVNTKIVFEKFDDNSWHVIKNNFKTII
KNLKENIVVNIHNDLQEYCFELYPNIKYKYNELLSDGFYTILSGAGSSFI
RIKLKNKEDLIINEN
>UU165.2 unique hypothetical
MNKIIKFHNERIKWLWILTAILAISFFVICFNNVKWIYTENTAKYELLTS
SLEKIVKFYSFSLVDKPFARGVPNSIDVFSRAIIGVAFGLGFVGTMLIDY
FIISKVAYIVKQKIKQSKKVGM
>UU111 unique hypothetical
MNYKYSAEEKQIIYNYILREYGQVDHIIFLSNEHIRVPIEYDILVIKKQN
LQILMTFGLGAFKSHNHEENTQERAEIFLELPVDWDFNKHENMWPVHFLI
NIVKYSYSNHLTLKWLQTFINPSYFNKSNKIAGFLDLSWYGENSLECKIN
NDFFVSFYQILIIDDEELFYAKTNGIRALSKFFDDGKSRIVDLNRKSFVK
>UU196 conserved hypothetical ATP/GTP-binding protein
MLDKLIKTLKNPHSIDDIVGQKYLLDEIGIIRRMVNHHQVFNLIFYGPPG
VGKSSLAKVLAQDLKVPFAFFNPVVDSKKQLMQIIEQALDLNNFIIIIDE
IHRLNKDKQDILLPIIEANKIKLFATTTENPFFVINPALRSRCQLLSLKP
LTSSQISERIKTLINVEEVFEPQAFNLLINKTNGDLRAVINTLEIIYLLY
KEHKVDYVLLKRIMQESYALGSSDGDEIHDLKSAFHKSMRGSDCDAALYY
LARLIIIGDFEAIYRRVSVCVHEDIGLANPNLCLRVDQGINSCRFLGYPE
NQVILANLVLQICLSNKSNSVYLAYQKAFEDAANGKQYSIPNHVRDAHYA
SAIKLGVHGYKYPHDFKNNYVNQQYLPRELTNKKYYVPQNNEQEFKLNQN
QQKFKNNN
>UU044 unique hypothetical
MKFIKRKTKLLTITIGAVAVSSILLGGIFYGTSQKSPSSFGIASIDQKEN
FINKDNLDYQKARPSIKDSNLKEIPKPKPQPKPKPQPTPFPDPIPTPPKK
EELKKPDIKPEEPKKPEIKPEPKPEPIPQPAPPIETKPKEELLPPNPPPP
KEEPKPEPNPQPQPQQVPNNSNSRIIEINGVRVEAEVEVPPPRDIAEYDK
QNNLVNPNPYINDSVGKIKNVKVTDELRKATGKLVQGNLGRWDYKHLIND
LLTLKPEEIEKYVKNDKSGYYAKVWYRFSRLFESENVVNFLTEQGKKEYP
EMKSKFVSKDHKYAWLYQHLDLTKFTQLSNESESYLKEGYTPDPDNAYVD
ENGKISSHAYSPAKGYNSVTSRMENDNWNRRVFGYKSWYGRTPGNLVEGN
YPGWKKTNVTQEFHQYGVSDGDGITVNKLTREKTEDGRLNEGYVIDIDAD
NPQGYEKTKKLIQTLKEKNINITGYRIHNMGKSDSSQKFVDILKTLPNQL
PLLELFFSAGSHNTSSLIALKDKKIKELGLFTLGNSLLDEWSINPNALRN
VEWINSNDYNVSFNYKQGADIATRITFDTLAFDESDYNDNASDIKSKLKQ
INDGLRMVYWTRNNEPIFQGSFGPGLDPDHKESGNSYPQGLDFSRVPQIR
SLRGLIFKDEQKTSNNKDRKLRRINFYNNSTTYKMSIEDLNEAGFNEHIV
SGEPGEKSKITFSNGSGTTKIQIDGDQELSANGISNLSAMFNFAESLQRT
IVVNNTNSPLANQLRNAGYSVESTTNAGLIDI
>UU473 unique hypothetical
MKSNNKNYKFLNIKKRKYRIFFMLCSLNLIWAGVIIAIVLRLKNIDKRFS
ENDHKIARPTWEYDNDGNLEIHTQLANDLNDDLKQKALNNANVKGIVVDQ
NGVEHEIDVSIDANGKVIIPTKDLVNNDPTKPNIYTLKKVVLKQHNQPNI
DLISEEQLSGDNHISFKKPTVVAQINDNNDYIMHFTNPNLVNKKIKLTFK
VDDQDDHTKTIEAIIGLDGKAIFKTSDDAIFAPDHKYTLTKIEANNKKVA
NIDEIPLKNRIVDKNPIKRINLTQLKVAKDLILWNNTNQNQFITATFKNI
NNDFDDYIVKLIYEYNYRGEMKEIASQPFKLEKNKTTYNNILLPISIPNR
LYHFKKVVIQKLNQPNKSIDLDHDPNLKSFFIVGPGKTDFAWKKPNDDQI
TYDGLKRLNIEITSQDYALQNGKKVMVWFKSDAEPNNDSLKFIGELSQTN
ANGTAAVINNLNNLYGMKEQTEYYIYKIQFIDELEYSKLPPNRNNIVYEY
NKNIARNYAFRTKTAPLILEKIEKDDNGSIGGQNFYFYLNKASDDPSTIK
QVTIYCRDNNNELYTSDDQEIDSVDLVYHSWIHDLKWNREYVFDHAEIQT
TYPDDPEYGGETNDLEIKRGLTFKFYTPPSKTEIQWKHPIKITNNGAILD
IQLQSKDRAFEDKQKYRVTLVEAENQNNAVVGDFLLAGTSINKNDSPIGD
NNDKNKDIATLSCNFENKLKKGTKYLLKEVRFIANPNEEISAKPTRAARP
FNNDNIIYSLNLRINDPYDFTTLKN
>UU161 unique hypothetical
MANHEVIFKWYLSLNFNNSSVDWSDKDYSLTFSFDRNTDRNNMLSDSGET
QQQILLWNQYQPQFLVVRVNAEKSGVNVDLWLIDIVNKTFATNFEVGLNY
EWSVRTIYVGE
>UU307 conserved hypothetical ATP/GTP-binding protein
MNNNQVDDELDLENFNYQKALEIPNIKAINLTEEEFNLYFWDIVEVYRSY
LNNLNNQNDSYYIYQLNRNEYNHLCLVVVKKENKVDKIKRNYILNTIKNM
DYNISLADDSQIFSKKTEILDANLLAERNKLINFFLEEARKNKKNTLIKN
NNQQPKSAFIYGDFSVGKSIITQAYTNTISLKYNLKIAYITLNDLFKNVI
QFFNYKDTSDLVINELVNLLSNVDVLVIDDFSSVNLNYWSISTILMPIIE
NRLKSTRQTIFISNFSIEQLINSTKNTTNIEEQKTKLRLFNRIEYLTYGN
IFKITGPSVFKVVNNS
>UU273 unique hypothetical
MEQIRNLIDLQIKLKPIQKAFYDAWSKTFINGIDNNKETHEQNKKIILEI
YMILKVFLNKNRDIISKIPLNQVKKIANDILEKEIILEQPLVDYYYQSSS
CFILIPYLIQILYQSYHLNKPIYKIMCKFIIRNNLALFKEWDLIERQTLE
IIKLKTNLIEDNNKAINLFSCEQRELQHNRFVKLFNNFILVYWTKREVKY
IEAIRFLMYFIWIPIIFIVLLILILGLYFGLSNSESLKSSTQFLLDLFII
N
>UU163 unique hypothetical ATP/GTP-binding protein
MGILILILRFVGRLLLSKIKSLISTLINLFSRMLKMFKFDFFKMFKNKTG
AFMKKGKTVFHDFNLKPDDILKKFFDNSSLEKIFNSKELKIIQDNKDLAK
KLKDAINEAIKDIAKQTSKYTTKQKDSIIKHLTDTLDNASKTEKKNFEKV
RKENQFKDVDNVDIDFNKHWIDYGTWYASDGVGKIGYLTLKLMKPSKRNP
LARYTWRNIPKRIATMLKFAPTGTTFWNIFYHANRKNLIHLQKESIYWFD
ASRKYFEGVK
>UU329 unique hypothetical
MLNAELSSAQKDLYKSIKLYLNTIFLNQKLNYAIKNDNDYRNQLNKVMNI
FEYYEDNYEIANKNFHSYWQAFKSYVHYEKIVNDYNDFDELKDIVNGLKI
YVLNTFQIDLDQESQRIADIDFKYDEKTQASMGFYTPRNQENNTSTEYEK
VSAESISDEDSMNHTYQPTSDFTTANIDNLTNMVFSARVMNGEIYLYETK
PKVIPFLKYVFFAVSLALVFFTTLTYAFLMDFGTHMSSVINVNGITHIVR
LVSPTFPTQLVISIFIMIYAGINAFKRKISENEKFHFKNFIWIILFGALL
VVALANIFTGNLRFSSSSFDEMFRQAQINDVLANLARNNSFSFDYSYLQS
IFYGYSIAQILVFVVIILGTILIISTFILNPKRDIQRIKLLLQEIHDDIL
TGKIDPNTYLRTKNPFRDLFGF
>UU602 conserved hypothetical membrane lipoprotein
MSSVDKQNLTNRMRISVSHFAGASNANSIKKERKKKIFNVLLKVFKIIVY
AFFLGIGLYGCFQNMANHWTINSTIVGNGFELGFHVDPILGANDIRFDLI
YSGTGPWYPMSDFSFDYGPFYALFVWPIAQILLHFMYATRDWPAGLNAIL
GLIIILLIIRVITMLISARATIQTERISEIQGKIAEINAKYKDAKDMQSR
QKKQMETKELYQKHNVKPLAPFESMIITLPIFLIIYRVVTILRPLKFISI
FYIWDLSATPISEIFSNFTTSGWPYIFFLLIIIPVQILSQKIPQLLARKR
NRNATTVGAKNKQQLKRVRMTQNIIAIVLAVVVAISASGIGLYWFFNAIF
TILQSYIIHVIIMKRRSNSATRIESKLAKLGIS
>UU293 unique hypothetical
MYNDLLDSLFTKLSDKSILNKLLNDDFLSIGSILKEIFNINQPSQLIKVI
DIFSIKDITAQDYVNVLNVIFNDIGFNNQQTKQNITNDQKYDINIYFEYL
KALVEHNFSELTKTKLKEIVKLFVKDVMNDDHHNHLWKKMTSFISHKLSD
LLIKKIQVLTPQKNEYQQLVNNLLNGIDFKNVVQNLIVEGFAKIIDHQQQ
LKNSQNFGDLIQKVINIDDVWIKKQLKQLLSAITKDINLTKATSTTIINS
YLNYFEIKNLTEEDKRNLINIFDKILKQIPNLLYLQNIVDQSVDFLKVNI
EALINHQPLKNTTWNDFINKNVTDISALSNLLEIFETNEITNNEWNQLIT
ILINHAPIDKIEEIIRNITSNSIINNKAQKQDIKKQIDKIYLLIKKVLQT
QTLNKSHAKTSVVKINETIKTLIDSLFANQEIKTLISNTLSNWIFSSNLA
KILNVDEDQKNSLIKPVVEFIISSNDLKTILKTITNSFILHASELANTNS
FEELIVKLISFEQTNLKSNLNNFIQKILQNDKIDELLARVIFKQISPQKK
YDQIQQINKDKVVTFIKKLGDNLTKFDLYNKLLDNLFSSITNQTNLTKLL
SEQQDSVINFIKTIFDFSDPKQIISLIDVLKVNEITSNDYIEVIKSILDE
IDFNHFFNQAVKNSNLSNYPLNKHENDNDSKLDINKYYIYVKTLFAHEMD
STSKEKLKTIIDELTKKIVENNNKGLLYNLGNGLGEKLSNLIINTFPGLT
NLKQNYKTLVQKVFTNQNLFEQVQNLITYAINSLIDHKNEYQNCKTFGEL
LTTYINKNQTQIIDKLKEAINKIISGSSSLIDEISTSFANTIKTYFKLEN
LTVEDINKLKSFINFVIKNIFNLEYVNDGLVKLITTLSSNAIKIVDQNTN
FVTVMQNDVISYLTSPQQIAKLLQIVDLDKNDDILNFLKVILSHLPQNAY
TILFGNKINLITKNTNQKTNRSVIQKYTILDYVKTILNSSYLKKQDTIVK
IKHIFKDLLVTISKSSQLNNYIGELISNTFAQKLSNLSGVDKQYSESFLK
ESYKFIISDEKLIKIIDEVVNDLVDHKDEYLKEITNNNQPSINIILNMLI
KRNVDQQKVDFVPFIKRYLVIDSSTQFMAQYLFKTLKLENTNDQDVKIVQ
TFVKELINQIDQLDFVNLFIDKIFTLIKENGLDLFTKEEGIKKVNEAMKT
FGLTETTNLLKIAKLVEPNKIKPQTIGDLINLVFEKSPLAEDFESITQDK
NPLYYGLKNLKEDSLNAVLFASGKKKIGEAAKVSEINMLDAIQHLINKLW
SARAEYAKNHPNLEYEQDNPYMRSLIHLGIVMQWYVHETYFRNVSGGLWW
TGSDSLSGEGRVYLLLKADMGSESEKRVRSMIMGNRGAMLWNTPKEWNYN
KNDFLYMITYWKWRTNSRFNDSKEKNKATYIFKALKRGYGEKVKTMK
>UU373 unique hypothetical
MSREQLEYLITDIFYEEILKRNNSKNLEEVVEKN
>UU497 unique hypothetical
MKKNTHKKLLPLISIFVLIPLSSLVVMCSKTKTKIVKEQKQITASSLRST
DIDLTSINLEIYFAKFDVNDILVKKFSIELEDDKGNKINVDINPEYNKNL
QMLSFKLENLKPNTTYKITKFNITGHEVDLTQIKDSLFTTKAENLLPDIP
NLPNSVGIEIKDIKTNSLSNDATKVNVNVNLEINQSTLENQYARLVYKSN
DNSWKLSNTLKIAEIKNSNFVLDGLISNRKYLFKELIIGSQSDLNLTNAQ
TKITTNNELSFTTAPKPVEIKSVLIDTKFDNHPSSLINLKFNDSENNLKE
NDILKIKYKKVGPNEVIFEKTVRLANNFELLFEIENTKKNEKYEILSLES
NTKHGYNVAPSIFNFISNDLRTFEIKG
>UU176 conserved hypothetical
MIYVLYSPNCAVCKKVVRFFRNNQIEITKIIIGEDKIERSMLLDILSLCE
DGFGTIISFKTESSKRLNITSKTFLDLSTKELLNLIQNDLNLIRRPLIYQ
TKNNRPYRLQIGYDSEEIEIFKRAVHEK
>UU183 unique hypothetical
MDKKAKIYTWSHIILIVFSLVCLHWFFILSITIPNQTGFLINRVGQWINS
SSTYAYKIDPRSLFYLNYTLNFNIALNASGIASIVLFICYILTFIFNLIM
IGIIRSWRPSLLHLIIAILIWLAILYLFIIIMIKPNFNQIINNSYYTWLK
NVIFNDQTLTLNKKNVILNTYINHYHLPIINDPQVALLDISKHQINNENL
TFNPSYNYNANLYFTKAKLIYCTYTIIGIIFIISFIYYLSEIIKRCLLVN
DNWKIKQHERKDGLNIKKRKNKQEIVAPDPILEEIFKELDL
>UU526 MBA N-terminal paralog
MKLLKNKKFWAISLGSIIVSTSIIATATACTNSNIESTVSSSFVRTQNGV
YAIYEITNWTKLDDNQKKSLQNLNFKTSVIDKDNNAEFTSSTGILRDGRV
YVKLAREPKKDDRVIIKPDDANLKKGAVYVTTLNISNIELNDGPKVQISH
SNEKNEIKSYNSAESIIYNQRWLANIWNTLSAEKDGMLLTEYNSAKHQFD
AMIKQSDFDTSKVKVEKDSNGNITKVTVSNPESNKAIPVVFMDIDETILN
NYANQNYQLLNNKAYNPKDWDAFVNDKVSKRLAGAFEFIKYVWEHGGVVM
FNSNREQENQVDPTIENLVSEGLERSLLPKWIFWMQGVDFSSDKPWANIK
KDAQGKRVKSTKEDRMNAMNKRTQGYDLSEFGSGNAVVLKTVMRIGDNFD
DFNDNASKGKLNSERVALLKEYGKLFGNFDINNKGVKYEKNQNGQMVKSD
ETWSESYVLIGGNSSYGGFEAGIAKGYYGLGKEGQAKALKDYIKQLYWEP
KSK
>UU403 conserved hypothetical
MKKAILISISSLIGISAIVATSTFLSLSAKTNIYAKLIKSSDLNQSLNYT
NLSDANIGIKEMLLGTNKINNGNYVLYIGTQSNLDNLNFVYDNQTNHINS
ISDLKYNDNLKFNGSLAKSINNVKNYADKGVYEHVPEFYSFIDLMDTNVF
KQKQDYENLIKQNKSSTIKEDQNWANNAPTDYSFDVNKKYKDKSGREVYF
RNDTQAVKFREILNFLKKYLSKEKLIELSTSQTPGIVLFYSQDNLSKGPQ
VYASSKIYDKSKNERKESYVSGDNVYNSSRFEFGGDLNAAIYSVYGKK
>UU112 unique hypothetical
MKICDNISEINDDQDLVFIDIEATDSKGEQRIIQFSGYRLNIKKNKIFNF
NKKFNPEQEINSRIKTLLNFNKNFNNIEQMPKLDKQAAREIYCFVKNAIV
ITFTDFDIKKMHELFTYYNFDFEKIVYFDVYKFFEKKLQTKSVPSLFSLG
ILSGIKINFFKLHNALYDAFILKEIFMCIRHKTNEELYEMYRYYEFLPKI
ISSSYFVTNEQEKNRGIIKKEIKYVMYIKEFDFSNKFNLDFVVYKKDHHF
YSKPIYDSSLELQTISSLTSKSNFMKVKLANIFFNYLSKSAVFSIKKLSI
KQSEKFLKFYKTQTNKRKVIKVLNLNLKKEIKPENFVIKAQIICEILFKN
PIIHHFVHEYLKIFQNIFSQEEKDN
>UU343 unique hypothetical
MNFDINLINENDYVFSGYIILKKHNEEIIELLTYLGDDPINDEAKIITLY
NNDHIDLKNLNDGDLIIVKASLIINNKNNKQLLLKDINKLELSIN
>UU442 unique hypothetical
MKFKKKAILLSTISLSSMVLGSFSLLAKNKSQQTISSKLNQQVNLVDNQN
QNKISYSVIEIDESNKDYFKDKLIIRLIFNTTKASKTEIFEQHLKIKTWI
KNAKISGVDQYNEFDYLPFMDLIIFNNKLDLKQLESLSNSDFINQVIINK
IKFILFNKKIDQKPMAVFGECKNLVLKNEWGFDQDVGEFCQIDSSSGTSF
EPVYSKDLLELREEFIENVEDRLSDEFFADFYDNTNLFEQTPTPNDHLLI
KTNPIKDDFESLLSKKSGLQYKIMRLVYQHEHGKVIKTLPVNALTFLNHE
DLKFEELYSGNYRFTGIEYWDKENKIWVFEELINHNEQYYQMQVVFNNNI
TVHDLISKVYFDAHFNKPQEESTSQSLTLSLNPNFNNINKDESIEIKLMN
LNDRENWESPSLFTRY
>UU034 unique hypothetical
MLISKHEERVKSILSARMENGNLRSRENTQVEFKQSFNKGNIAIYAKTMA
AFSNNSGGYIIFGIKDSPRSIIGLQNSNFENIQQEDLTDSINNLFSPSIN
WELGSFILKEKEINSNGDVIIVQKIIGWIYTEESNIKPVIAQKNNSSEKI
VNGDIFYRYRARTEKIKYAEMEQIINCRMKQERDSLFKVFEFIRNNGATN
LGIVDYNNGKLSTPYGVDVVLEKNLIAKLLKKAKFIKEGSFSENEGIPVI
KVTGNINLAEEVPVPLENLDETYPYIQKQLAEKLNITPQKLYALIWYFKM
KESKKYHLEITTSKTNKTHKFSKFALLFLKEKIIELDENKNELNNIISKF
NNRKK
>UU151 unique hypothetical
MKNQNEKQIKEYVNKFKDLRNQLTKNNDVKKVCDLINDLFFEVYKNNLID
EVIKEINKHD
>UU462 unique hypothetical
MNLRHSKTTWFRKPFETNTRFKSPLLYKFLITSFFVVIPMIVFFILYGEI
NLLGFNGIIGVNGRWYGKGFKLDENQQWIVGVKDFYHWNPIVYDQLKPKP
GPLMIERMQKLVNEITNQYNHGVEFGTNIISSYPVWVAMFSTLGLAVIVC
IIFAFSTPKIRWDILTPVVSCWFGMFILIISGFIPSQIWGYLVRFLILVV
AFILPIFIMTKITNAIMNRSKHFETYAADLYNELKDSEQYYNEFNKKRLE
LKKRNKANERIKYKVEDDQKGK
>UU118 ABC-1, ABC Transporter
MRNKKENDNVINPLSNPDENKKINIKDLSKDERKELKKRIKEVEKLNRNH
KGDIDMPSRDPNNIIELRDVKKIFTNGYLINETLKGVNLDIRKGEFVIIL
GPSGSGKTTLMNIMSGLDRATDGDVRVCDKQLINMNQNKLTDFRKEYIGF
VFQQYGLLPTLSVEENVEIGADLQVDKKRRIKPQDALKAVGMLDYAKKFP
HELSGGQQQRVSIARALAKNPIILFGDEPTGAVDETMSKIILKEFVKVNQ
ELKTTVIIVTHNPIFAELGTLVIKVKDGNINELIRNDHPKSVDELKWDEQ
>UU510 ABC-2, ABC Transporter
MKIVQQTSDNECGVCVINMLANYYHNKTIDKNIILQKANLTKNGLSLQEL
ENLANEFNLDAQSFECSFEELIDEKINDYFIALINKNGLNHFVIVKNYNK
NFFRIYDPENKIYELNNEEFKKIFLNIIVRVSKNHQIFDLPIFKESYLKN
IKLSSLIIILFIELLNIPLNIFLSKIVNLLIDLVLIDTQIKNLTYLFIVF
SLFYISNAFKDLLITIYINKISNNIFSNINNKIVNNLANKSIIFFNKTNL
GELSSIQIHLNNIIHFLLVSRIKLLVNTLFAICIICLLGLQNWSLLLISL
GFSLLNFIIGLINWKYFKIHSLKIINIENSLFIKYQNFIKLINLEYNIDK
YNNYINSYKKQFDELIIFKNKITIFKSNVNFYLSIINNIGLLILLTYLII
NTNYDYKVISVITYIVFLHQNLNNLFFGIFNFFNELLNFKNGKQIVEKIL
YIDNYEEHDGIQINKITSCKITENQKEFEFSKSCLIIGKSGVGKTTLLKN
FLNFNNKNLFFNNLNVNNINLNQLKELIIYHPTNPLINDFDINWFIDKNE
EIINALKIVIFITKIDWSLNNNFEHNINLSTGQQQILAFLNLLKYKNKLL
LLDEPLAHVDNDNKKIILNSILPIILKNNFVIYVSHDHYLKKYFDQIINL
NDEKMDKY
>UU515 ABC-3, hypothetical ferrichrome ABC transporter
MNKIKNAKSSFLYFKKMHNLKSFNKKRNRLKGIQIIFIVFLIIFCSLFFL
IDLFFTGNHLNVIKRMFENSSLSNSTYIFVPVANIITGFSLGIGSISIQI
TSKNILAGPSTLGFTPMAILASTISFIITSSGIFSTILIYCLGLIFSFII
IGVNFILVRNNFLENSFKPILVAFGIGALVTGINIVLIATHDNLKIVGWW
RFITINNTLINNYRMIVSSVLMIISTIILLFLSPYLNIIRKDYILAKSLG
IKVNLIYWLVAICVVTITISSSILLGIIALLGVIVGIIIQTIFKKTHVLL
LMILAGLFGSGILSFSSYINEYIPSAREMIICVFAIPVFAYILSKRKGFI
K
>UU538 ABC-4, ABC Transporter
MQKLMDYFFKRKLKVPRPISNDISVRVKNLYAVYDEKQENQLVALNNISY
DFKKNKIYFIIGNSGSGKSTLVTHFNGLMISRYGFVQVGDIVSGDHFDFE
RQLLGVIDSYDKKIINLLWRNQLDQWTFLVLFSNEVNIQQARILFEANFK
QKPISLKFIKTKNNHELITNPYVRENTKIAVVRVDKNVILEINDKMNYEE
LQRFEFIKKEIKTNYHLSKKIKRFKELRRRVGFVFQFPEYQLFKDTIEKD
IMFGPVNLGVKKSEAKKRAKFYLNKLGLGDDYLERSPFGLSGGQKRRVAI
AGILAIQNDILVFDEPTAGLDPAGEHEMMQIILDAKANNKTVFVITHTME
HVLEVADEVIVMDEGEIIKTGTPYEIFFDQHIINSTSIQVPRVIAVINEL
IKKDLKYEILKQKQPRTIEELADAIIEFKKGEK
>UU539 ABC-5, ABC transporter
MSHNDKNTHNYQISSLDKIINDSSVAIEFENVYFAYTEERMILKNVSFTI
NDNEYVCVIGHNGSGKSTISKVLTGLLKPKSGVIKLFGIEISAANLKYLR
NNIGIVFQNPDNQFVGITAEDDIAFGLENRKVPPNKMWDIINDAAVATGI
EDLLKKESLELSGGQKQRVAIASVLAINPKVIIFDESTSMLDPKGKNELK
ELMVSLRDVAKKTIISITHDMEEVVKADKVIVMSNGEVQYIGTPQEIFAN
EERLLKMQLDIPFTLKLAKTLKEKGLKIDLTLNNEELIEKICKN
>UU024 ABCsbp-1, putative ABC substrate-binding protein-iron
MVLIMKISFKFRLINVISMLGLSIIFTTLSSCKNLQQQKPYDTNWLFKNK
NWRLNNFFRDPYKIHLEFARQLDNVLNFNELKKRLPKPMQNVHSFTEWSL
KIARLLKNDINNVAMLDSIQKMRNHKATVLVIENRNELVNNKENYNKFSI
LTPSDFPLIYSNPYTEVPGLGLNFPKPINNDISDIIDRYQSIGYNALRTN
PLESVLKQTSSFYKTADYVFYMYDSNLFTNNKYKTDGQKREDLFKEILSN
KNFYAHKFLRNSRSKIIFIDRSLFWWGSFTMVGQSLIIKELLKIFTNKKT
IKKQWSYLPFNKEELINLFDHKPTIKERNLIIKPHYINKNFKLTYGYKIV
GTWADSIDHLISFGLKPDAIVDYESFNNINLKTQGVGNYLKELINYDKLE
KINKAPNDSEKAEFVDKNFAIYMGPSHLLNSMNKLIMIKNTGSWIISSTQ
GINDPKTQFKTRINTAKSDF
>UU027 ABCsbp-2, putative ABC substrate-binding protein-iron
MNKKIKTVFISSLIVGLLGLITTSGVACSSSIKSKQENEIYPTIKGYDQH
DFSKILASEFIKIIKTNIQFLAPNKDIKYELYDARLNELDEDVIDLIIRY
HFKGQTHTYKKILKGFKNAKQYRLFLENKKYLEDEKNHNTLYLMPIVNSS
INISKTTVDEALKWQNSYLNINNSNNDLKYEILKITKSKTANSIDIEIKI
SKGNGENLASITYNKTLNGFISEADKKIYLANLEAIKQDKNQLEPQLIDE
KTKQKTIKEVIENYKTLFKLPFQTGFIYEIQSVEPDVNNKTAVVFKILIK
KGNGSQEAVLEYLKTIKGFNQNK
>UU028 ABCsbp-3, putative ABC substrate-binding protein-iron
MKIKLKKIIMSFLGLPILAIPLIVSACSQFKINQDVILTYRPTVSLAKEF
ANDNNTIDDVLKKVKINKDGSNNLLVYDLSRNPKNVQYKIVDIKKDSEQI
LKVTINAKIQKYKESINYDFYFQPFLTPKQKEDKTILQQNLNIIKSAWDY
DQKQKIGFFNLRIKPEYQKRSLVEIKTLGEKAFNFGEDLIPQLKVDSKFK
DINIKIIDINYFEPLDERQRELVVEIMISKGKNEQQAQLFKKIKINLD
>UU071 ABCsbp-4, putative ABC substrate-binding protein-iron
MHKKTKKYLISMLATISIVIGTTTIISSCTKKTSANVQEQIKYDIMPTYT
SQADNLLALGITPDYYPQQMYWKKNSPYDYLNPQKPNYQKWFYEKDDFAN
KFKEKLINLEKNIKQYGTTWWSFSGNTYGEGVSEEYWNKNKGKLVYYDRY
LIDNSHFERAKKTLVAHGGPISNQKTAIPVDFKMSRDFYLTLNKNDILNF
KNDPNSLLRKSLLLGLEYKDKEKGELNELYNYSYFADKLNKNYFNAETFD
GINFNNSAFKKRILEGNDIPIFYTETKWKDPKSLNSKIYEAFKTVVLTKK
VRESGLNKLNYDPFLSTTKQDSYVTSILQHHPIYEQNMRWDGGTQVYLGT
MRDSLLYLYDIAYATTKYAYSEEAKIDFKDNLAKLEPLKKALFNANQIAN
NLINRLNKMRLYFQAIGVVDKNYNPNIKQFDNTNSKTLGLLTTSQNSGSS
TLQTQSKYGFLYYDLGFKAPKPILKKDEWTELLEDVNGKQLLCHRHGNGQ
IHCFGGDNQDGTQIDKNIVGSLFNMDDNGWWWNLGEGSLSASNFAKFNSE
FDYLIKISYQNLEDFHSNNLSRPQKELIMSLIKSDYDDPAKRIFDDNYEL
WNDGIKSPIGYNMILDSVIKIINKTIDPQLIQQNKQLLKEANDWGSYWKT
FVNQK
>UU359 ABCsbp-5, putative ABC substrate-binding protein-iron
MKYKKIWITSIASIAFITTIVSTTTACSKVNNEVKSSNDIFKQILPTKEE
LTNLIKRRKDWANDLQVYFEGGKSASGKEFERIQTLATNASIYYQKNQKI
AMTRDSGSLCQDDAAYSFGIAPDISNYRWKAGDVEEVVPHYLSYLYNPKL
TKGMELKGVKAETLAAENVGTLFIADFKFGNYKTNFLDKNKIGGIVMQSR
SSGLPSKTPALFMPNWLFGKNNPYLETDVNASAGITDFFVDPYDGLIFTG
KTLDRIYDAKKFDNVNKAVIDGKSNFQTFTDYAKAIVSVVRKNVSNWAKQ
HSYWKNKTVVMTMPNVMKGARIIDPNFSKDDLLFLGNIFIPQPVYFPILY
ADQNDEYTPGLGAKFPIPKKDINEVQRYVDNWGWIGGAILSDATNPDAAK
RVGPTLGEAFEGTVDKVIYSYNEYLIKGYKPGTAEGEAIIKKFEANLAKY
VNSLDINTKNSFNPTRILKEKPVVGKNFFIERKGNIYDANYGFIGQKTMV
NILNRWMNGENSPEVDLGIPNFTKDNVKHLRAFKDELNVKNTDE
>UU360 ABCsbp-6, putative ABC substrate-binding protein-iron
MKLKFKKILLSISTSLIILSSIITIAACSNQVKSKTNFSKTTPTLEELTE
LKKREEAWKADLEVYFEGGVSKSGKKFNRIETLSSKASSYYQKNQKIAVT
NDSSSLCQDDALYAFGIAPDYSGFRWKTSELEEVHPHYLNYLYNSKLTKG
MNFTGKGALPENFAKLNVGTLFIADFKFNKYKENFLDKNEIGGVAMQSRS
SGLPSKTPALFMPSWLFGKNNPYLETDVNASAGITDFFVDPYDGLIFTGK
TLDRIYDAKKFDNVNKAVIDGKSNFQTFTDYANVAVKAVRKRVSQWAKQN
NKWKDKTTVMISPDVMPNGRIVDPNITKEDLLHLSNFFITQPVYLPILYA
DQNHPYTPGMGCKFPIPKKHLEDVQKYIDNWGWIGGAILSSSAENPDAAK
RVGPTLGEAFEGTVDKVIYSYNEYLIKGYKPGTAEGEAVIKKFEANLAKY
VNSLDINTKNSFNPTRILKEKPVVGKNFFIEREGTFCDGCYGFMGQKTIV
NILNRWMNGENSPEVDLGTPNFTKDNVKHLRAFRDELNVKNTDE
>UU401 ABCsbp-7, putative ABC substrate-binding protein-iron
MKLFVKTKQYYFKNEDNKNMFKKNKKSLAVLLVGFSTVLISSIAVAATAC
ARKDNNVKEEGKTTLNKLISKKAPKQNATKSSEKYILSDVNNSSTFFNSL
TDPYKCFEMFAKSLDDAGYEITSHEPLKNSGKTSFLEYAKELNNKIREYV
RKVANLPTIKKLRDNNTTVLWAESTQSFNSSDASKLDLYYFQQEDLFPLL
YSQPDDSNVPGFGLRFPKPKNHNADKYFDNWHGIGASQNNASKNDYDWML
SMQEAFYGTADYVFFNYDSNNLEGNEDGEILKSNFEKFFKKTVNNNKIIP
VDFQFEYSSIWGPIGTVRLVQSLAKRLGVSDSELASVSLDWTMPSKQTLK
HIRPKNSNNDHNKFAIWFYNLWDHCVALGIQPDYASFVKEKGKTYTKLPG
FLADLVDETKTEFKDFTGDAQKVAGMNLYALGGNNSHINRSFKTLIGNAI
PKAVPTERGDSNNSRSPINFEFYDRTTNTLQSVEGTKVVSWTDPAKENKQ
K
>UU517 ABCsbp-8, putative ABC substrate-binding protein-iron
MKKWKLVRTSGLILITGISIPVITTSCSLIDLFKSNNEKQNEFTHGKLKS
NLDYNVSTAYLNKRSIALKFTIPLDKNQAINIFGTGWIFDFQEDPFTKNI
RTYYLATNIHVINLISAAKQNASLTLGQYDLESQSQDTRAFFNENLSFKS
AKKTYNPQYYVNYNPVGTFSILPVGLKNQLKNYGIKNPAALASLNNLTTA
VDLAIIKITPDILQKNNIDALRNFDKEVGIGFGNTISNHQRFYAAGYPHD
EKYSRWNQYSNQPDELFNSFSTSNYRKDNPINFSYNEEYMTVSNRNTIGK
NNPTKYEAYDYATKNFDLHSGASGSPIIDDNNNYVGIYWGGFKIQEGLKT
TFYGNFSPLFVHKDNGLSQDLLAYYLAYTANETTYLDTNFNTNLRYSALS
KENKEIYDKFVQSLEKQFLSDDNQYGDKNILSLKTVDGYSKNKQDLINTL
YNFIFKDINSPSFNEKYTHENLKLKDIIDVKVEWNRNKNIDLRITFITKR
PLNFNVNHIVNFNTSFTFFKEISKPNENNNWIDQLL
>UU375 MBA, multiple banded antigen
MKLLKNKKFWAMTLGVTLVGAGIVAIAASCSNSTVKSKLSNQFAKSTDGK
SFYAVYEIENFKDLSNDDKKSLSNIEFNAALTSAENKTESTLEKGHLVGE
KIYVKLPREPKPNEQLTIISKSGLIKTSGLLISDNLNYQTEKVNFETTQP
GKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGK
EQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQ
PAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPA
GKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGK
EQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQ
PAGKEQPAGKETTGK
>UU484 ackA, acetate kinase
MMLIINIGSSSWKFCLFDMNLKQIFSGKIRLDVSPHQLKYIFDKNEYVYL
LDDDHNNHVDLIIKFLINKKIIKKLEDITYFGIRAVYVKNFYGASAFLNN
EIYNDLNQHTDLCPIHNQNTIMLINDIKHLNTSAKIIIIFDNWFHRSINK
NKYTIAIDQTIAIKHKIRKYGFHGISFSYSNKIMQNYLGKQDVNLIILHL
GSGSSVCAIKNGKSFDTSMSYSPLSGIIMNTRSGDIDPSVLLTLKKVKNQ
SLKQLILFLNQQSGLYGLTKHHSISEVANNLHNKNNELALEMYTDSIVDY
FIKYLNHLQKIDAIVFSGGISEFEHLVLEKIISKIHLINLEINDHLILTN
TLNKISTSKSQIPIYLCLVNEEHEIAYEMLNLINKTK
>UU506 acpP, acyl carrier protein
MSINIKDLIMKIAKENKIALNMDNLNIELKSLGIDSLSAMNLIMKIEDQI
GVQLPDEKLLKIKNLRDLINAFEDVLK
>UU393 acpS, holo-acyl carrier protein synthase
MKLVHGIDIIEWNREELNNPLFAKRILIDNELEYYFQLNSSREKKRYLAS
VFACKEAVMKALKLKYGYGDILILKTENQRQVYLNKILIKELELSISYTE
TYIVASVVGLINNMN
>UU251 adk, adenylate kinase
MKILLIGPPGSGKGSVSELLTKNNTLKHVSTGNLFRAILKEDSELARKIK
EINVSGGKLVPDEITNQVAKSAIDELIKNEQSFILDGYPRTINQALALEQ
YCNLDYIFYLDIDHQELMKRLTGRWMCPKCAGIYNIHFKKPQVHGLCDND
QATLYQRADDHADAVSIRLDEYDKLTLPLIKHYETNPRFIKINANQPIED
VYKNINNYLKQNK
>UU369 alaS, alanyl-tRNA synthetase
MLKLSTNEIRKKWIEFFESKDHLFIEPKSLIPKNDPTLLWINSGVSTLKD
YFSGKVKPPHKRLVNSQKAIRTNDIFNVGLTSRHHTFFEMLGNFSIGDYF
KKEAIDWAYEFLINVLKIDVKKLWVTVFEDDQFTNDEWIKLGIIKEQIIK
CNRDRNFWDVGNGPCGPCTEIHYDRGERFDPNKIGSKLILEDIENDRYVE
IWNIVFSQFNNDGHNNYTELLQKNIDTGAGLERIACISQDVPTNFDSDVF
MRITKSVEQFSEYKYDMNEYFHPNVTQNKINFAYKVIADHMRATVFAIAD
GAIPSNKERGYILRRLIRRTMVLVRRLNINNLLWVDAVVDAIASTMGDFY
TYLKDEKTLTKIKMILNKEVQLFEKTLQLGLNIFENSIRNQELDKEITFK
LVDTYGFPIELIKEICEQRNVKVDLEAFDAMFKHHQLISKANKANLKVME
SQNESLMQLDVDSTFHYEIFRWENAKIITLFNEDFELVDGLDHEDGYVVF
DNTCFYATSGGQQHDTGYIIKNDQQFFVDDVFKAPNRQHVHHVKNASLSM
NEHVILQINEQDRKSITANHTAEHLLHYCLKHVLSPDIKQEGAAKYPHKV
TFDFTYHAQPTKAQLDKLENVLNEMVQSNFDVQELHMDLDEAKAVGAAAY
FEDVYKKLKGKLRVIKMGPSIELCGGTHAHHTSEIERIKIVECASKGAGS
WRITMVTGHDNLAKYIHDLYVDYLNEINHLKVNLDINDHKLNDLYNAFAN
WKNLSIDDYDLLNEKFAELKQSLINFKIEFDKQNAKQAIIDIKNTFNTQL
TNKRVHVFKNTDNKNIFNALNELINENQDTLFISFNLDDNKIQYLLAINE
KFATTNQINLNKYIKELNTISNGKGGGKPYFVQGGTSEQEKLDELLTVVD
KWVINA
>UU507 ampL, cytosol aminopeptidase (leucine aminopeptidase)
MTLNEKKEFVYELKAVEKNHNLKGFEENTTEHVVFGGLYQKQQYLILTPD
FDSNELSRSLISFLEKSPKSVSVDLNSFLSLVPESRHASLLNVVISALEY
VEVTPFSLKSKIETKNIHNLVVDQKYHDLINKLHVIAQSQTITRTLQDTP
ANLMTPGDFEERIKELFKDLPEVKVSVLYRKDLEAKGMNAHVGVGKAAVS
DKAQPRLVVVEYNNNPETNEKYAFVGKGVCFDSGGYNVKTGSHMRWMKFD
MSGSAIVSMTVRALALNKEKVNVVAVCPLVLNLLAPEGQKPDDIVKSYNG
KTIELDNTDAEGRLILADALTYAVRDLKASKLFDVATLTGAMIYALGDTY
SGVWATNNDIWNEVVVAADYAGELVWRLPFHNDFLKMLNSNVADIANSVS
DPRGGSSRAACFLKEFTEGVPYAHFDIAITADVGHKGTGVMLRTFYRIAQ
NQKFN
>UU218 amt-1, ammonium transporter
MRIVSTIITTSWGVDPNIYFSKHELTWVPATADANTLALTNFNPTSTLLV
ALAIAFVLLMTPGLALFYGGLTRRKSTLTIINQCVASLGITTLIWIFGGF
SLAFGPSVGKGIIGDISTYFAFRNLLFADGWSGDVGIVFANFTNGVPLIL
FFAYQLAFAIITPPLMVGAFADRMKFKNYLVFLVLWQYLIYIPFAHWIWG
QGFLAAAGVIDFAGGIVIHTTAGFGALAASLVLGKRVLLKNDKSRPHNIP
MTIIGATLLFFGWFGFNVGGSGFVAGGNAATWSAATSAWINTIIALAIGM
VGWAVLETIFNKNHKATGVGLVTGAIAGLATITPAAGYVPIWASVPIGVA
AVLVCYTSAKTLHHFHKIDDTLEVWGVHGMGGVTGSLLIGAFASKSVNPS
IMYEAIGPTTTGVLFGVQLGAVLLAAVYGFVFTILLVYITRPRLSARQQL
GHIDYINHGEDAYSFDIEIPSEKEMEQYELADSTWHSSTGVKYSLLNNKN
QQNHKVANDH
>UU219 amt-2, ammonium transporter
MKIVSTWGLNKDIYFSTHELTWVPADASQSTLNAIGFNPTNTLLVALAIA
FVLLMTPGLALFYGGLVRRKSALTIINQCVASLGITTLIWIFGGFSLAFG
PSVGKGIIGDISTYFAFRNLLFADGWSGGAVLVFANFTNGVPLILFFAYQ
LAFAIITPPLMVGAFADRMKFKNYLVFLVLWQYLIYIPFAHWIWGQGFLA
AAGVIDFAGGIVIHTTAGFGALAASFMLGKRTTLITDKKRANNLPMVVLG
AALLFFGWFGFNVGGAGFVKENTNHISQAISSWLNTIIALAIGMIGWVTL
ETIVNKNHKPTTVGLVTGAVAGLATITPAAGFVPVWASVPIAIMGVLVCY
SVSRLLDYFRFDDSLEVLPVHGMGGVIGSLLIGAFATNTVAHGIKYDAVG
LDNNGNPIYGILFGLQLGAVLLAATWAFAFTCLIVYITKPRLSVRQQLGH
IDYINHGEDAYKFDFIIPSESEMFEYESFDQTWECKASGCKKSNLAAKKN
PVFIENENDCTWQSKSRECTK
>UU488 apt, adenine phosphoribosyltransferase
MINIDYIKSKIRDVPDFPKKGIVFKDITPLFLEPKIIEKIVDDFADFAKS
LNIDAIIGAESRGFLFAAPLSIKLNKPFILVRKPNKLPNDVYSAEYTLEY
GSSRVEMHKDALKPNQRVLIVDDLLATGGTVAAIENLVRQAKGIVAGSVY
LIRLGFLKGEEKLSGKVHALINY
>UU311 ard1, N-acetyltransferase complex, probable ribosomal protein-alanine-acetyltransferase subunit
MLKNLLIRPADQKDLNDIAIFENRFFLNDCYSMRNLEEIFHNSNYQIIIV
EYEQKNIAYLIYMKSVDFNEILKIGVDENYRNLKIGSLLIDLLKQKKQNI
LLEVSDLNTNALNFYLKHGFIKQNIRKRYYANGSDAILMIWKYNQT
>UU278 argS, arginyl tRNA synthetase
MITQKISEELNKALAKMGIHDTQETKILVDKTKNIKFGDFYTNIAMILSK
KNNKSSLEIAKEIANNFEQDLFLEVNLQPPGFLNFKLKAKDHENLLKQIY
YEKDRFGQFSKKNITYNIEYVSANPTGYLHIAHAANAIYGDILANLLKIY
GYDVETEYWINDAGNQIDKLAMSVLVRYLQLQNINIQLPADAYHGQEIHL
VAQTLYQTYKNQFINVRLNEKYEIDDDIANQEIKNFAVKYLLNEIKNDLA
SINTFIDTYTSENWIRNSGRILEVLSKIKPYTYTLDGALWLKTTTFGDDK
DRVLIKSDGSYTYFTPDIAYHDYKFNKTNTTKLIDVWGTDHLGYIARLKA
AMNALGYDPNNLEIVCAQVMKLVKNNQEFKLSKRSGQSLTIKDLVEIIGK
DALRWFLGSSSMNSHVIIDVDIALSKNNNNPLYYVQYAHARANQVLNKQV
YELDFKTDLLTETRERELLNQLHFYKQTIANAANNREPHRISNYLYDLAQ
IFHNYYANVKINNDNNKVLSAQRYTLVWCVKQVLANGLAIMKITPYDQMY
>UU363 asnA, aspartate-ammonia ligase
MDQLQKAKINQTQKAIVEIKNSFQKHFAKNLNLSRVTAPLFVEGQSGLND
HLDHKQKAVSFYAKKLDKTLEIVQSLAKWKRLALLDYGFSLYEGLYTDMN
AIRADDDIDEIHSIYVDQWDWEILINNQDCNLDFLKSIVNKIYSTIRIVQ
LEIDQLYNPKQIILPDSITFISSQELEDLYPHLSPSRREYEFAKIHKAIF
IYQIGYPLKSGYIQSIRSPEYDNWNLNGDLIVYHKLNDQAIELSSMGIRV
SKQDFIKQTNFANLKNDQENNFYHQMILNNQLPQTIGGGIGQSRLCMFLL
NKKHIGEVQVSVWPNEYKDELLKKGIKLL
>UU365 asnS, asparaginyl-tRNA synthetase
MQLKIKEIFNQDYVKLEGQKIQIKAWVRSNRDSKKIGFLVLNDGSSLTNL
QAVYRVDKIDNYEEIAAARMWAAVVIEGVIKLTPTAKQPLELEVLNAQIL
KQSDEDFLLSNNDLNLETLRLNAHLRPRTNLFHAIMKVRATLAFAVHEFM
NQNEYSWLAAPLFTGNDAEGAGETFSIQKFDNEEFFGKQTHLSVTGQLQA
EAYAQAFGNVYTFGPTFRAEKSHTNRHLAEFWMIEPEMAFVDLKGMQDIV
EDLVKHVIKAVLEKNQQELEFLAQRNDENLIKKLQKVVESKFERIEYKDA
VKILADAVKNGHQFENNEIFFGMDLGSEHERYMCETYHQGPVFLQNYPKD
IKAFYMKLNDDQQTVASTDLLIPGVGELVGGSQREDSYEKLLKRCQELKM
PIESLQWYLDLRRFGYYMSSGFGIGFERLVMYVTGVNNIKDTIPFPRSHG
QIEF
>UU286 aspS, aspartyl-tRNA synthetase
MKVYCGYIGEEHLEKNVILNGWVKKVRKMGNLVFVDLKDRFGIVQIFATK
SDGVFNELTQLSREDVINVEGLVLLRKNPNNDLKTGRFEIHVKKILIYSK
AKTPPLIIEDETDANEEIRFRYRYLDLRRDVNLKIFELRSKVYQAFRNYL
YSQDFIETETPILAKPTPEGARDFYVPTRTRKFYALPQSPQTFKQLLMVA
GFQKYFQITKCFRDEDLRSDRQPEFTQVDIELSFADEIEIQTLIENLLKY
VFKQTINVDLTTPFMRMSYEQAINDYGSDKPDLRFDLKIKTLNTYFENSK
TLFFQKALLNNQSIRAILVPNINLNKKQVQTLEKFAKDKGAKGLSWISIK
DEKIIDGSLLSIQEDHIIYKTIFKDFNLSTGSILLVADTFDIASQALGLV
RINLASILNLKKPNIFKFVWIIDWPLYEYDNEAQRFVAAHHPFTMPTLET
LNTFDVNKKDARGRSYDIVLNGYELGGGSVRIIDQQIQRRMFKSINMSDE
EANLKFGFLLTAFEYGVPPHCGIALGLDRLMMILVNSEYIRDVVAFPKNN
NGVDMMLDAPSNMNDEDLKELGLKIKND
>UU053 atpA-1, ATP synthase alpha chain
MQNTKANPRIKSIFNYIVTVSGIYDYQHHQIFVLKNDPTVKLFVISAKED
LAYLLISNEHANINIGDEIIETNREENVVTDLNYFGKIIDINNNFIWPKP
LNNLPSAKIAQTNPAFGLAHNLMTVKTLNEQLNTGIVAIDLLIPIGKGQR
ELIIGDRQTGKTHIALNTIINQSRAGTKCIYVAIGQKRESLTTVYETLKA
HDALKNTIIIDAPLTAYEQYLAPYIGMAHAENLSYQDDVLIVFDDLTKHA
NIIREMALLTNKPVGKEAMPSDVFFSHSSLLERAGSFKNRKTITALPILQ
TVDGDITSLISSNIISITDGQIVTSTDLFAAGKVPAINIDLSVSRTGSSV
QSRMITKVAGEINKIFRQYKRHLKLAMLDYEFNKETSLLLHKGKLIDKMF
LQKGFSLFSYRFIVLSTKLIAWGILKGVKDEQKAFMLLDYAINNYEDAQK
AFNTISTTQNYDDKIMKNYFAFILKQYSDYLNLNWEVELEHSFIPLQNEF
LMNVAKFLGDK
>UU132 atpA-2, ATP synthase alpha chain
MTDNKNHSLISDIKSQIKKFSEKALTLEVGNVISLGDGIVLVDGLDNVML
NEIVRFENGVEGMALNLEEDAVGVVLLGDYSNIKEGDRVYRTKRIVEVPV
GDVMLGRVVDALGKAVDNKGNIVANKFSVIEKIAPGVMDRKSVHQPLETG
ILSIDAMFPIGKGQRELIIGDRQTGKTTIAIDAIINQKGRNVNCVYVAIG
QKNSTIANVVRELEAHGAMEYTTVVTANASELPALQYIAPFTGVTIAEEW
MHQGKDVLIVYDDLSKHAIAYRTLSLLLRRPPGREAYPGDVFYLHSRLLE
RACKLKDELGAGSITALPIIETQAGDISAYIPTNVISITDGQIFMMTSLF
NAGQRPAIDAGQSVSRVGSAAQIKSVKQTGASLKLELANYRELEAFSQFG
SDLDDETKRILKLGKAVMAVIKQAPNKPYNQTDEAIILFTVKEKLIPQVP
VERIQDFKEYLLNYFKGTKLRADLEDKKAFDKENTPAFRCAIQKAINSFL
NNSQDFKPCEEAEQTAFDKFFNENESIVVDGENDFNFINEEVSLKPTTET
SEAVQIEEKVQDFVEPQEILETNKMEENHIFEEVEPEKIICEHHEFEIAE
NQEKIEGQQVLEDTNHEYSIYETVEQSGEVDNDESKDDDLEVLVPVAEIE
HDEAILDERENRNWVFSDSAVSEVEKQTIMISISSNEAEQLFDNAKSVVF
FKVTPKYPVEKVLVYVTSPVQKVVGEFDLLKIDVNSVNTSWNKYRSSSVI
SSRKEYLEYFNSHKEAHALLASKVYKYRKPKDLASFNMNKGPSGFTYLK
>UU137 atpB, ATP synthase A chain
MENYSPLDIMIALPHIAAIIMVTLIIGTVSLIYFSMVKKLTVHDVPNRFV
IIIGMIVDYFRGLVVDTMGAKHVKLAPYVLFTFCYIFTANLVSLFGFKEA
TTASAVPLAMALGTVIGGQIVALKYQKASFFLKFAFKIKGFPIMINPLEI
VSKLTPIISLTFRLWGNISAAAILLNITYWAFAGFTNVVPWVGVSLIAAV
VILPILIGYFTCFAGTIQAFVFTLLTSINWGLEIKEGEEHHAHLAHKKAE
KLAAKKLAELDTQNQIQNNEAQVVL
>UU128 atpC, ATP synthase epsilon chain
MANLTKLKIVTPYAQILEKDVYSVELKTSEGRITVLPDHNPLMSTIENHV
AYIRELPNTPRKPLLLLDGIVYIEQHQVRVFSDYFKFLDEIQIDEINSSL
NQLKHDLNNEEDDKKKLQLKSKIKLNESILIAYKDR
>UU054 atpD-1, ATP synthase beta chain
MNNGRVIKIWSDIVEIEFKNSLPALNHLLTTHDGNTFLLVKRLVDATHAR
AIVVYASKDLAINDIVINTNKSFMVPVGNDSKNNIYNFWGHPLLETNKTP
KYVEMNSTILNERYVDKSIEIVETGIKAIDFFMPILKGYKLGIFGGAGVG
KTVLMKEIIFNLNRHKQANSNIFIGSGERSREAIELYNELTASNLMPNSV
MFISKMNEAPGARTSIVPIGITAAEYLRDQNKENVLLFIDNIYRFIQAEN
EVSTALGKKPSVGGYQSTLESDVTHIQNRLFRNKNGSITSFQTIFLPMDD
LSDPSAVAVFNHLDGKLVLSRAQAAKNIFPAFDPLASSTNAIDPKIIGER
HYNAIIETKKVLKAYKDLEDVILILGFDELDAESKIIVKKALQLEMFFTQ
NFFMTEHFTKAPGQFVPLKETVESVIRILEGKYLKQSPDVFAYIGSNKDI
SQDH
>UU129 atpD-2, ATP synthase beta chain
MTEVKKGKINQILGPVVDVRFPSEWLPEINTALELNNHGSKLVLEVSQLV
GDNIARCIAMDTTDGLVRGQEVINTQKPITMPVGKQVLGRMFNVTGDPID
EQPAPTGKRMPIHRPAPSFAEQAESIEILETGIKVVDLLVPFAKGGKIGL
FGGAGVGKTVLMQELIHNIAKNHGGLSVFAGVGERTREGNDLYYEMAESD
VLDKTALVFGQMNEPPGARMRVALSGLTMAEEFRDAFGQDVLLFIDNIFR
FTQAGSEVSALLGRMPSAVGYQPTLAFEMGQLQERITSTKKGSITSVQAV
YVPADDLTDPAPATTFSHLDAKVVLDRAIASLGLYPAISPLQSTSRLLDP
LVVGVKHYSVARRVIEILQRFMELQDIIAILGMDELSEEDRQLVMRARKV
RNYLSQPSHVAEKFSGQPGLSVKLEDTIEGFRKILDGECDDIHEQHFLYV
GKIDDVFEKAAKNK
>UU136 atpE, ATP synthase C chain
MSSFIDITNVISSHIEANLPAIASENVGSLANGAGIAYLGKYIGTGITML
AAGAVGLMQGFSTANAVQAVARNPEAQPKILSTMIVGLALAEAVAIYALI
VSILIIFVA
>UU135 atpF, ATP synthase B chain
MKLNKKHLVAILSVLSLSIIVVPLLTSCTGDIPELNPAEIINTLFPNVWV
FIAQVIAMCVVFSLVLWLVWKPTNKMLDKRREYIAKEITDAENAKQEALQ
YLENAKSEHLAAQAQTLEIIAKAKSESLTLRESLEKEAREAADKIISSAK
ISIANERRENLERLQSEAREAAYIAAEALMKKELSREDNDKLVDQFIKEL
ENNEK
>UU130 atpG, ATP synthase gamma chain
MSLDAMKRKINSVQTTAKITNAMKLVATAKLKRQRDRLAAIKEYCHDYYD
VIGLLLSVVDDVEFLKIPNAKDRTLYITINSTMGLAGSYNYNVNKLISKI
VNETDITFTIGKKGHDFMRLSGRVDQVNTYLNLNDNDLTFDMSLQIAREA
LELYSQGEVNKICIIYTKFINAITFEVSVIDVLPFDKTALIKDHLAETIE
LAKDNIIFKPNKFELVKKILPTYIATVLYGSLIESKISENASRRNAMDAA
TKNAKALAENYKLIYNTLRQGKITREITEIVAGSDD
>UU133 atpH-1, ATP synthase delta chain C-term
MQSNTKLAKYSKIIANRLKAYSNQTRFIEIKTAFELNDEQKQRIKKTVIS
RFGDERPIKFIVDPSLIGGISLKINLEIIDSSLKTKLNQIINTKEKEGA
>UU134 atpH-2, ATP synthase delta chain N-term
MKSSLKPVEKYAYSIFEIAKEEKKLDLYKHNLETINSIIEEVPAFFEAVG
DPARDRNERKQIVIKNLEGEIDIYLISLIDLLIDVKSVKLLKKIVLKALD
FVNEALSVKKVLITTAYELTKNQIDRLLQSLKKKYVCEKIEPIVVVDKSI
IGGLSINFESQVLDNSLKTKLFNIVKKVN
>UU093 bcrA, ABC transporter
MNNEFILEVKNLTKIYKKSNQGVFDLSFNVKRGEIHAFIGENGSGKTTTI
KSIINAYTNYKGSILIDGFDNKTPKSHEKIGYVPEIALFPSELTTFQYLY
SFARLSNLNKKQAIERIHNFLEKFRISDLKNKKPINFSSGQKKKVILIQA
LLHDPELIILDEPTANLDPSARHEFNNILKELHEQNKTIFICSHILKEMD
TYVDSLTLIHKGKLVYSGHKYDALEKIYYDSVLKNK
>UU291 bsaA, glutathione peroxidase
MERLNMKLSDYPVLDIDKKLFNWSKVKNKLVLIVNVASKCGYAKQYEQLE
YLYKKYKNKGFIIVAFPCRQFMFQEFDDNNKIKEFCSTKYNVTFPIMDLT
NVVGSNISPLYKQLITEYPWSPKAKAVKWNFEKFFVKNDEIIGRFESKCE
PNDLEEFIKNNL
>UU531 cdd, cytidine deaminase
MKYNDIYMGLLELLKKSYSPYSNYPVAAYVDTDLGFISGVNVENGSFGLT
SCAERNAIFNAIANGAKTFKTVYIITKNNGDIASPCGACRQVIFEFFKKD
AKIVVFNNDGTYKEYNVEQLLPFGWDPNISL
>UU511 cdsA, CDP-diglyceride synthetase
MISVNKINEKTKNTFFKRFYSSIFIFLYLLIYFVLALLADRNYNWTPLIN
NLYIQQGIAIVLLIWLLPLICIGSYEMNKVIFDNNKITLIILTIVFNICI
YTTTISYFIYQYEFLNIKYLLTINYHYVIKLFGACLGCSYFVTLVILFFF
LAFLKKINFKNCLYTILIFSFLSGFFIGLLYFTFIRSWITSLLLMMIVFL
SDTFAYVGGVLFGKTKLAPKISPNKTVEGLIFGLVIATIVIMLIIFGLSY
VPIKPKNGIVLKSQNVLYNIFGLDFSSSNEKNLTLHKQALWWICTIVAFL
FLSLISTSGDLVFSAIKRNYHTKDYSNLIPGHGGLLDRIDSHSFVISIMF
IFTLLITGSLQDENLFPNIQKFFIQLIV
>UU280 celM, Endo-1,4-beta-glucanase
MSKFNEKEIRNKAIEYMEIYGMSRHEERVASKLKASLKDAGVDYERDNLG
SIIFKKTNSNKGPKILIATHMDEVGFVVQQILDNGQLLLSMVGGVWPNIA
IGSVAKVYVDEQRQYTGVFGHTSIHILEPEARSKAVPVKELFVDCGFNSK
QQAIDLGIEIGTEVYMEGPTLNFYDENYIVGKAVDNRVSVAVLDLLIHSL
KDKVIPNQTYFAATVQEEVGLRGAKTVVSKVKPDIGIVIDTTTSHDTYKC
PEGDTKLNDGVCIRIKDGGTLVNPKLVKYFEELAIKHNIPLYKYVARGGG
TDAEELQYGPNGGVLTIGLSIPQRYLHAPIGVATVKDIKAAFDLVREFLE
VFDENEFEKVKFK
>UU391 clpB, ATP-dependent serine proteinase-heat shock protein
MEFKQKNSNNPLEEFGRNLNKEILDNKIDPIIGRDEEIRRTIEILSRKTK
NNPVLIGEPGVGKTAIVEGLAYRIVHKDVPSNLLDKTIIELSLSSLIAGA
SYQGQFEERINSILKEVKKADGNIILFIDEIHQIVGMGRNQGSNMDVANI
LKPMMARGEIKLIGATTLDEYRLYIEKDQALERRFTKVLVNKPTIQETLT
IMRGLKPRWEAFHGIKIHDNALIAAVNLSERYINDRNLPDKAIDLIDEAA
AKIKTQINSQPIYLDEIKRDLQHLQTEKAALEPEKDEKSIKRLNEILEKI
KLKQDEFNNLNDLYLKEKKQIDDLKNLRQKIERIQHDIEFYQSEGKYEKA
SRLLYSDLPLFEKQREELENKINENNNQKMIIDSLTENEIADVIARATGI
PLSHLLADEKTKLLSLNKRIASHVIGQDEAVKLISDAVIRGRAGINNPNQ
PIGSFLFLGPTGVGKTELAKTLAKELFNSEKALIRFDMSEYMEKHSVSKL
VGAPPGYIGYENAGVLTESVKRKPYSILLFDEIEKAHPDILNILLQILDE
GSIKDAKNNEINFKNTIIIMTSNIGAEALLENNKTKALLDLQKTFKPEIL
NRISEIIFFNKLSKEIIFKISENLLKELENLLAKQDYLIKFDDNIAQIMV
EDAYSSNYGARPLKRWITKHLENEIAKLIIENRITKNINYKINYDRELDQ
VLIK
>UU588 cls, cardiolipin synthase
MKKRILAKFIITFICVLLIINICLISIYFHHRPTVIVTDILISFYILNTS
IGLYILSSRHRQDRSKKSWLFIFLFLPIVSIIFFWIFGSRPFKDKKINDI
ITNRRALFKFEDYEFYHSFQNMIINNNGLNLIRKIGQYNYQLFRTPIYCD
NQITIIKETNEMYEQTIKLIRKAKKTIYLQYYIIENGRWLQSLVKELIKK
SNDGIKIYILYDPIGSLNKFPKKYRQQLINNGIEIACFKARADYKFRSTI
NFRSHRKYLIIDGEVAISGGSNIGDSYLNIDPKVGHWVDLNYILTGGIVH
TILLEFIHDWYYYTPFSKKNNFNVVVDSMHPQPYLCQGKDDLINNSIKNK
TITTLLHTGPDQSTSSLNEILVMAIANAKKSITIFTPYLFPTEDILIGLK
AAANTGIKVKIILPGRVDSWSFIISMNRLSYESLIKSGVQIYEYSGFLHT
KAILIDDDISLLGSYNLDNRALVINYESLLTIYSIQVNHDINEIFNQYLR
NSQLINLEDLDNKFTFNELVQTVFINIFQLLL
>UU342 cmk, cytidylate kinase
MKKYISIAIDGPSGSGKSTAAKELAKKLGFLYINTGLMYRAYAYFLSINK
LDINVNEMDCINAIKNANFIFNGDNVKINDNDVSLILRSNDVAMIASVVS
ANEKIRDLATNEQRRIASENNVVMDGRDIGSIVLTNADLKFYLNTSIQTR
AKRRLFQNKDIENLDYESIYNDIKERDHRDMTRKIAPLKKANDAVEIFND
NMKLDECVQHLYEIYLKKIKKLNF
>UU529 codV, integrase-recombinase protein
MKKFINYLKNVKGYSDGTIAIYQKYVKVLIDNNLDYLKAIKKYEHNANVT
KRVVLSAFKAYLKFINHKDAILIVMPKKEIKVKEFLTWDNFLKIINNINQ
ATFLGFQKYLILRILFETGIRSCELLKLEIKDIYENKLKIHGKGKKERFV
YLSNDLQNNIKKYIGQIKTKYLFNFSYKNLYQKVTRIKTNIRLTPHILRR
SFANHCINNGINIYDLSLVMGHNNINSTSLYLNKESKLVELDHLFDNKKV
N
>UU203 copA, copper-transporting P-type ATPase
MLKNNLIKKFQLLPINKRRYLISLMKTSIALLISIPLMVFEMLFMFKSNL
ILSIDGYFIYGWIVFVLSIFIVFGLGFSFFKGAFFEVFKWKKPGMSLLVV
ISTCVAFIYSTYSLISNTIIYEPKLHGFFETACMIIATMSVGQLVSDRIK
LKANQDLQSLNNLQVKKYNSYDLNTKQVSEKVVFQAKINEYALVKKGEIV
PLDGVLYSQIAEVDESSLTGEARPILKTINNDIIAGSINVGDNFIFKITK
LYNDSTIKKIINGVNQIASSKPKIQVVADKISLWFTPFILLMAILAFLLQ
AFVPSIQELPIAFLNLHGSNNDSNLYEKAAYVAVSVLVISCPCAFGIAVP
LAVLIGAGHGAKSGITFNNSNIFEKIKKVNAIAFDKTGTLTYGKLQLKQV
IGNDQFLDLIYQMELISLHPLAKSFVTYAIINNIVMSTKLIDIKEVAGVG
IIAKDVDGNIYELTSEHYANENQFDFSLINQKSSTSTNLLASNIIFSINK
KVQSILVFEDEIRADAYETIKVLHENNIETYMITGDSFNVAQKIAKELGI
KHFYAQVKPEEKANIIKKIQNDQKTVMYVGDGINDLLALKQANVSISIGE
TNKATNAVADISLIKPDILNIYKVIKLTKITKMFIVSSLLWAFGYNLIFI
PLALIGIIPPFISVLIMTTSDIAVVLNSLIFRLLKMRLVNKKQIHKLNLK
IINEAMLHK
>UU530 cpsG, phosphomannomutase
MENTNKIFNCWLNSPKIPQVIKEEYKNKTQKEIDHIFDENYRFKFGTSGV
RCIYEEGTRYLNAITYTQLTLGFIEYLETKKNFNKIIVIGRDNRFGSREN
LKLVAEIFSSFDYTVYINEDYGMLSTPITSFLINQLQAGAGIMITASHNP
KNYNGFKVYNANGAQPLVDDTNLIESLMPSYTEALDFNFEFKQDNIRFLT
KEQIQSYFDAVKAQLINTDPNIKKPFKIVFSGHHGTTTKDMIPFLESLGY
DMVSVSEQNFEDPNFNDDPSSNPEEQCSFDLSVEYADNTNAEIMIASDPD
GDRMAIAVRHENYWKFLTGNQTGVLIAHYLLEHKKFTKPTYIISTFISTR
YPELFAKNFDCDVLYVDVGFKNHGNLIANRKKTHNLVVGFEEAIGSLPSD
INNDKDSYQTASILLEMINYYYEQKLDLFTVLKKEIFAKYGNWYSKTTQF
VIDGDNWKQKALIILNNLRNFEFKTVTQYTIHNIIFHEQGSYLEWKLDEY
STIKFRLSGTEPKFKVYIDLYDFSKDQKRDFYQELKIKAEDILDFLKNYL
GL
>UU123 cysS, cysteinyl-tRNA synthetase
MKLYDSYSNQLVEINDELISIYNCGPTVYNHIHIGNARPLITMDVLYRFL
KKHNIKTKYVLNITDIDDKIINYALANNLKELEVSEYYFNEYLKIKKALN
TLEMINPKVSTHMDKIIDYIQKLIDKQAGYFIGDDVYFDTKKALNYGQLS
KRDLENDIVGMRIESAANKHNPNDFILWKKTNKGIMWNTPWGIGRPGWHS
ECSCLINTYIGEQVSIHGGGIDLKFPHHENENAQNQVLYNKNLAKVWMHF
GLVNINNEKMSKSLNNFILVKDLLAEYDYQVVRWFFYQADYKQPIKFSHE
IMKQNEKEILKIKNAIYNAKNYLYFNNQLKSLTQIDHFELFDERINDDLD
FVGIVDLIHISVKKINILIKENKDMNELKLNLTQLLYMLDILGINFVDLH
NDENLALLNTWKNYVDKKDYVKADELRKQLINIGIL
>UU528 dcm, cytosine-specific methyltransferase
MTGEQLIKSVGNKGIDLLTYSFPCQDLSTAGSFSKKAFGMKKGSGTRSGL
LWEIERILFDLQKLNQLPQFLLLENVNNMLSKQHKLDYDMWTKSLKQLGY
STCTFQLNALDYGSAQRRKRVYAISILNYDGLIDSNGNILDLEAPIFDGK
QKQLKDVLKTNYKIEKYYQEAYLAQPNRTFSRIKYVIPKYDLLNPNCYCT
STITTRQDRFPNGGYINLKNTILGDDYREKDHNNLPKKANFRLLTNREAY
LLMGFNEKDFEAIQAKGISKAKMYQQAGNSIVVDVMVYLMKLIQERFNK
>UU582 deaD, ATP-dependent RNA helicase
MKFNSNYQKWILDSLINQKIFEPTPIQLKTMPLIAKRENIIGVAPTGTGK
TLAFVLPILNNLDLSQKLQVIIITPTRELARQIFSKIIVFKKHQPLLQVK
MLIGGESIDQQINSQLNKSQLLIATPTRLKQILTRQILDLHHVNALVFDE
ADMLMDLGFISDLEFINSQFTNKDVQKISFSATLHEMLSIQLKKYFKNTK
IINISNSIYENKKITHYVIHNHDKWHSLSIIMKTIKPYLCIIFANTKKEV
EAIYQYLIQQNKNVCILHGSLLQRERKNNYRDIKNNKFQYVVASDIASRG
LDIDGVSHIINWNLPTENEWYIHRAGRSGRGKYSGESYVLYDQKEHDKLL
NLSKKGIVFHHKFIKENELFDKEFLFKKKNQFKDLKTQNEIQKIISTTST
KIKPGYKKKIKEAIQKINQKNKRSHIEKKMNAHRIRGYKLKNS
>UU465 def, polypeptide deformylase
MYNIKFLDLLNSNLKPNPQWIFKDPHPILREVTQDIEGNELSKDDIYYLK
KMVRYIDVCYHNQAKKYKIRSGIAIAANQVGWNKRATYIHFNDEAKEHHY
LLINPHIIKRSSEIAYLNPGEGCLSVDDDRSGYVIRNKKVHVKAYDLISE
QFIDQEFSGIIAICIQHEIGHLDAGLYYDNINQQQPFYADPSWTKIGR
>UU368 deoA, thymidine phosphorylase
MLNVVEIISKKKNNIELSEQEIKFVYDGFVNKTIPDYQMAAFLMAVNFCG
YSENEQYYATKAMVESGKLLDLRVENKIVVDKHSSGGVGDKVSIILTPLL
SALGLYVGKMSGRGLGHTGGTVDKLESLNLNLDFDLKTYMNQLKDNGLLL
TGQSDDMVVADKYIYALRDVTATSDVFDLMIGSIMAKKLALITDYIFLDV
KVGEGAFCKNVAQAESLATKMLKLSKKFNRNTIIHLTNMDQPLGKAIGNA
IEIKESMDYLLGKPVPQDLYDLINQFALDILIDTKFAKNKEDAQSKIDNV
IKNGLAYQKFVNWVKWYKGDYISLENDTYFNPKYKLEILAKQDGYLDFKS
TKELGMIAVDLKAGRKVKTDQLDFQAGIYLNKKNNDFVKTNEVIATLYAS
EPINDEVVNKYHNNVVYLKTPKQIAPSIIKVMR
>UU585 deoC, deoxyribose-phosphate aldolase
MNKYNIYVDHTLLKADASLEEIHKLCEEAEENEFYSVCINPCFVKVAKHY
LLETSVKICTVIGFPLGANTIETKVFETKNAIDLGADEIDMVININQLIN
GNREYCLNEINQIKEVCGDKILKVIVETAFLNREQKEFAAKIILESNADF
IKTSTGFAKEGAKLEDIILWKRILGDVKQIKASGGIKNFEDFKSFIEAGA
TRIGTSSAIKILNNH
>UU281 deoD, purine-nucleoside phosphorylase
MTAHNQAKLGEIAKVVLMPGDPMRAKWIAETFLENAILVNEVRGMLCYTG
TYKGKKISIMGHGMGIPSIGIYSYELYKFYEVETIIRVGSTGSYKKDLNV
NDVVLVEKSYSDSTFASLIGAQVGDDKVLLPSREVNNLIKNTAKELNLEL
SLATCHASDVFYNNDFQTLDEIIHRTKSDCVDMESFGLFANAQILNKNAA
TLLTVSDSLITGDALSPAERANTFKKMVTLALESAIKLL
>UU086 dgk, deoxyguanosine kinase
MSDKKLDFLTPSFKKNRVSNSIAIGGMIAFGKSTLAQALHEKYQPSNVVY
EMVEGDKLMDLLLAKMYERENNVLFGSLFQLYFVLNRFANYKNNCNRKSL
TIFDRSIFEDWLFAHANIDKPSVFSYYDGLWQGVCKELIYEHGVPKLYVI
LDGDWELFKERIFKRNRKVEIDNFSINETYFKRLLEMYKNYMVNVCKDFG
INYVVLDANNSVEQNVDEVTKILQKLENEQDK
>UU583 dinF-1, DNA damage inducible protein-MATE transporter family
MRFDFFKKSQKIKPNWFINQFGDKIFMKTAAKLFFPAILEVIILSSVNYF
DSLFIALFTPENMGTAAKTATVLATQLMFLPTIFFYSIVAAAGILAAQYY
GKKDYLKFKETINFMLLFSFIVVMIFIVIYMAAPLQMIQLYSGNNLDVSA
SEEAKRIYDLTNHWAASYLRWQSLTLIPYMFSFSLATAYRQHNNAIMPLI
SSSIAVTVNVILDPILIKYCAVTPFEAILFVAIATIVARSIDALIMLILT
LFRKQYPYYFLNYLKLSKKVVKLIFIHGWQVLLNEILFSVGTTIILMFYT
RYSQDHRDAISTVALIIQFTNLIWPGAASTVAVLVLANLGANKHDLAKEN
TRKLINWGMIVGISLGIILLVLSSFVNKLLNPPLDYTEQGLKHAAYTATI
AMYLEWIVIMVVLTQGPYSVIYFCIRGGGSRWLLTIDCLSTFIWLIIMGC
ITHINVPEDYNDRLHVVLLFFIMESQNISKLIMAIIIFKKTKWAQNLVDE
EKEITNEINDDKKEKNKQIIKLENKLMDTDIEAR
>UU584 dinF-2, DNA damage inducible protein-MATE transporter family
MSYQIGFKQKKLSFLNFKKIFGDKQFIKKALKLFFPAIIQNIIITAIAYV
DNFFLATYTPQSQGLDAKTATILATQLLYLPTIFTVAVCYACSVYSSQYL
GNKNYHKFKETTNYMILGSVILNIPFLIIYLTFPHWSITIYAGSINNFSK
DMSMVTSNELTNFKKVNEWASMYLQYAMIGQVFYAFSYPFAIAHRQDARP
AIPLLGSIAALCLNCILDPVLMILVAKTPKQAILLAAFSTIASRGFDLLI
VLLCVCIFKKRATYVINYWNLTWRLLKNIFKRGWFIAINEIIFSISVILL
TLFLYKYHPDIRSSISTALLIAQFTKLIWPGMNTIVAVLVLSYLGKNEIN
TAKQNSRYTVAWSLIIASILAIILFILSLFINPLLNPPLSNSLLDIKDAK
KVAKLATQLEWVLVVEIIILGPYAAMNNCIRGAGVIYGAINDTMVMIIWV
MMFALISTFAYNPKIPHLLTFALLESNWLLKMILVSILFTKVNWAKNLIG
SNQFEIRKNSFKFRFNYNKK
>UU001 dnaA, chromosomal replication initiator protein
MANNYQTLYDSAIKRIPYDLISDQAYAILQNAKTHKVCDGVLYIIVANAF
EKSIINGNFINIISKYLSEEFKKENIVNFEFIIDNEKLLINSNFLIKETN
IKNRFNFSDELLRYNFNNLVISNFNQKAIKAIENLFSNNYDNSSMCNPLF
LFGKVGVGKTHIVAAAGNRFANSNPNLKIYYYEGQDFFRKFCSASLKGTS
YVEEFKKEIASADLLIFEDIQNIQSRDSTAELFFNIFNDIKLNGGKIILT
SDRTPNELNGFHNRIISRLASGLQCKISQPDKNEAIKIINNWFEFKKKYQ
ITDEAKEYIAEGFHTDIRQMIGNLKQICFWADNDTNKDLIITKDYVIECS
VENEIPLNIVVKKQFKPEQIIEIVAKELNIKTDLIKSSIRKNNIVWARDI
VCYILKNKLNLTLTDIGKLLNGREHTTISHSISKVQKILDDENSQEALQI
NLIINKF
>UU550 dnaB, replicative DNA helicase
MPTKDLNDAILDLFCLIINNNDFWKDVVLRLEVKDFPEKIQQNIFNTIAN
LNEQKYKINESNILNALANYVIIDEQDQNYLLHKNYLLQILDRTDYLVDL
KDCIEIIKNASIKNKLDVFANEILATQISLINAKDQFKEMHEKFLEILAS
RTEDTIENMELIANRYFEKLNKIGNSGIIPGVIKTKYDNIDKFTNGYKPG
ELVVIAARPGIGKTTFCLNVMVNNVNEIIEYNENIQPNQKEKIIVMFSLE
ITKEQILQKFISIKTGISNREVIENKYRITKGYDTRSFAMQAINDIKSWP
IFIDDRPNISIVDIEAKLYDLKKRYDIALVVLDYLQLVSGGNANKNMTRT
QEVGRVSSALKIIAKEINAPVIAIAQLSRKAEERDVSNNVNMKNNPLVKT
IDNSPKLSDLRESGSIEQDADVVAFLHWDRKQRNFMQNDNQETRMRDDLI
EAKFIVEKNRNGSTGETDIIFSKLNSKFIRATTSKE
>UU415 dnaE, DNA polymerase III alpha chain 2
MFINLNVHSHYSLLNSTLSIDDLIKYALDNKQPYVCLTDLNNMYGCIEFY
DKAKAHNLTPIIGLEFEYQNATLVAYAKNYNGYLKLIKWSSWIMTSKEFE
IQDDFDDLIIVCKKGTIVFKSPNFYQTHDQNAPNAIALQSVFYANKNDKI
VFLAMLAIKNDLKLEDFKNCCDFDNNHFLNDNLAQSFFSPIALNNLNKVL
NELKVQIHDLPINIPVYDKQNSIISSEILKQLCISGLKKRLNANDGQVNK
IYVQRLKYELDVINEKQFDDYFLIVYDFINFAKSNGIIVGPGRGSAAGSL
VAYCLHITDIDPIKHNLIFERFLNPTRKSMPDIDTDIMDEKRDLVIEYLF
EKYGNDHVAYILTFQRLKAKMAIRDVGRILGIDLKVIDKICKNIKPEYDE
DLDLAIKKNTILKEMYLLHKELFEISKKLINAPRQIGTHAAGIILSDSLI
SNIIPIQLGINDRPLSQYSMEYLERFGLIKMDLLGLKNLTIIDNVLKMIY
ENQNKKIDLFNINYNDKFVFEDLAKARTNGIFQLESPGMKKVLLKVKPQN
IEDISIVSALFRPGPQQNIKTFVERRFKREEFSYWNEATRKILEPTYGII
VYQEQVIELVKTIANFDIATSDNFRRAISKKDEKILIQLKDDFINGALNN
NYKQPLVNQIFEYIFSFAHYGFNHSHSLAYSYISYWLAYLKHYYTLEFLS
VLLSHTSASKDKLLSYLNEAKEFNISIKGPDIQYFSNDFVIDTQKQIIRF
GFKTIKGFGDELLKKIKSALQKSTLSDYISYIDALKKGNVSLKNIEILIR
VGTFDSFGINRLFLLNNLNEIFEKTGLNGHFFDLNLVGLDYAKDMSVNDR
YLDDEIQYLGIDLNSLNYANYKTEIDYNKLKYTIKDFYEINTNYETNILA
QVLNIKQSKTKNGNDIFYLETLIDNKKQTLTIFQNSKYLIDEISIGGIYV
FGVKLLNHFNFIVNIKQRI
>UU494 dnaG, DNA primase
MSKITNNVFLTIRNAINISDVIQNYIKVIKKGNNYWAICPFHNDTNESLS
INDKKQIFKCFACNHAGDVIKFVAEYKKISYALAAQEIVQLMNLDLNLLN
HLQKISPQEIKKNKVFDLNKQIQKWFINFLNNKNNIHVIDYLTKRNLNKN
DLAYFKIGYAPNNDELLNLIKSNYNNLIQENDEFELNKLIENSFLVIDKN
GNYHDFFNDRIIFSIYDHLNNVVGFSGRIITNEKTPKYLNTKTTAVFKKD
EVLYNFHNVITIENNHQLFIVEGFMDVITIHKSNKPNVVATMGVELTNKH
LELIKSYGIKDLILCFDNDQAGFLATKKQIMKLINSPFNIFIVNHKDNDC
KDMDEYANKHGYSATSKLLDQQLHISEFLLLEISNTNKSTPSLKHSYKQE
CFTIIKKYGDIFYVDKYVDFMKQTFSIEENLLKKVIEELLINKQCNSIQN
KKNIQSYQKQTQLTNKLTTSNPKVILTKIDKHFNHLVVIILMNRVFLNRL
DTQVRNRLTKEQSLVINIIEDFYLYHFKINNILKNTDSFIEFINKNYSKY
TNVINQLTKMVQIIKYNPKFDNIVAFELAKNNFIYEWLNNQIKRLKLINL
NLNMNNNQEQIINNEKLIKQYNDEKILLDNLINASLFHKNQ
>UU019 dnaH, DNA polymerase III delta subunit
MKYSFANLLIQSPKTSLESGIEEIMLAFIYEKNHKEQSFYVTKVKNKQYF
DLKIYDGLSMKKSDVIDLQNTFLCDGVEDINLKFYLIKNIDLASKYVLNA
LLKFIEEPPKNTIAIFSTKNLNQVLKTIKSRCQLFYLPTNHDLYKKLINQ
INQPIDLVECDLMFDDLDELKILLENKEINDVLTYYGKLSDLRSFEILND
LKEIFKNLSTLQIHYLLKLIFIRINNVNSKEIILDLMRANLKININKNNL
FTIIYTIINKNKGD
>UU407 dnaJ, heat shock protein
MAKRDYYEILGVSKSATPEEIKAAFRKLAKEHHPDRNKSADDTLFKEINE
AYEVLSDSKKRAQYDQFGHDGPQGFSSASGFSGFSGGFGGVDFDINDIFG
SFFNNASSSHNSSNQYETYDIHLRLHLDFMEAVNGISKNINYDRKITCHK
CQGTGAKDPKDVKICTKCHGRGTSIENVHSLFGTIQQEVECHECEGTGKV
ASSKCEQCYGKKVINERVNLTVEIPAGTREGEKLLVSKKGNIVNNQEFDL
YLHISVKPSKYFALDGLDIYSETYIDPIKAIVGGIIEVVTINGIKTIEIP
SNTPEGKKFRISGSGIVNKKSNIFGKKNGDFYTTIRYAKPVELSKDEIAY
LKNISTRTNQNVEYYKNKVLKEISK
>UU339 dnaK, heat shock protein 70 (hsp70)
MAKEIILGIDLGTTNSCVAVIENKKPIVLENPEGKRTVPSVVSFNGDEVL
VGDAAKRKQITNPNTISSIKRLMGTKEKVTVLNKDYTPEEISAKILTYIK
EYAEKKIGAKVNKAVITVPAYFDDAQRQATKNAGIIAGLSVERIINEPTA
AALAYGIDKLDKEQKILVFDLGGGTFDVSVLDMADGTFEVLSTSGDNHLG
GDDWDQVIINWLLKSIADEFNIDLSKNKMAMQRLKDAAEKAKIELSGINT
TTISLPFIAMDSSGQPINFEKELNRATFDNLTKNLIERLKKPVLDAMKES
KLSLVDIDQVLMVGGSTRMPAVQNLVKELTGKEPNHSLNPDEVVAIGAAI
QGGVLAGEIDDILLLDVTPLTLSIETMGGVATPLIPRNTKIPVSKSQIFS
TAADNQPSVDIRIVQGERSLAADNKLLGNFELSGIEPAPRGVPQIEIKFN
IDANGIMSVNAKDLKTQKETSITIKDSQGLSQDEIDKMIKEAEENKEKDA
KVKHERELVNRADSLINQLEQVSKTENVPQEQKDVFNKQIEDLTNARDAQ
DYVKLEAEVKKVEDLLTNAAKFAQQAQQQNPDNQNNNKDDVTEATVTDDS
TKK
>UU079 dnaN, DNA pol III beta chain
MEVFISIKKLIEAIKFSTTIANTNNANALLLGVLIEVSQNKISFKTTNNQ
VSGYKEITEGFEYFNSGKVLVTAKIILGLISKLKDKSVLLKQIDTNILLI
KTENFETQINTMNIEGFPNLNFSLEDYVKISLPHQIMQEINTKVLPNVLN
SQGIEKIQPISGILIDTQTLENKLIAIGTDKIKASCLIREYMGEKFKFIV
SYSTMKLIIEILKNVEYSNNQTVDFYVRSRSLIFKINDAILQTRMIDGVY
PNIYSIFDETNEENTYVFDRRLLIEIIERGMNIVMQEQNPKISIRIDKNE
AEISLTTFEIGNMKEKMSIVNLNNKSAEFILNPSLLAHVLKNFDNNDVTF
KVKDEILRPIIFIDTKDVGFKQILSRIKN
>UU087 dnaX, DNA polymerase III gamma-tau subunits
MSESTLYRKYRPHKFKNVIGQDLIKQALMNACLNNKITHAYIFSGPRGIG
KTSIARIFASSINCLNPNKGDCCGKCSVCESILKEQSVDLIELDAASNNG
VDQIRIITDNINYLPTFFKYKVYIIDEAHMLSTSAWNALLKTVEEPPQHV
IFIFATTEYQKIPLTIISRCQRYDFKRLNNSELQELIDSILTKEDIKIDN
NAIDKLIQLADGSGRDCLSILDQLTTVKKNIDLDLINKTFGLVDNFKVIS
LIELIQKNDILLLREFIYELYNQGVNLEAFCVQIINVLIDYLIYLKTNDI
NNLKKVSVDELKKMLLINFNGNYLLNNFISLFNNLKKSLNQVFEFEIYLY
KIINANNDKLENKKIELSINPEENKINNSQIITTKKIDCFEEINKNTVDF
DKLYKTKIFYHKKINNQNDKESGINQKEELSTELVNDNKLICNSNDILDN
YELAKQAFFNKDIKLSKEMSQKFKDFKNEETIENSYIDIIKQADLVLWCS
PNALVLGVEFLGLINRINKVTHSFEFIKEFVKKFDSIKLVIAISKKQALN
IINIKKQGLKTNIINDVLIDDIKMLLKQEEQRKQEQTALLNEIEDEE
>UU298 efp, translation elongation factor P
MATIIQAKDLRAGHTFLYKGNIYQVIENSFNKTAMREGIVKCKVKNLRTG
AITIEVLTGEKLEQAVIEKSKMTFSYDDGSGYVFMDNDTYEQISIPYSQL
SWEKNFIEEGTEVSVMRYDGELMGVSLPDQLVVTIIEAEEAVQGNSVQNA
TKRAWLESKWEFQVPQFIKSGEKVIINPSNGQYVGRAK
>UU184 eno, enolase
MKIINLLAYQILDSRGQPTVAVKLFLENDQSVIAMVPSGASTGAKEALEL
RDGDVNYFFNKSVKLAIQNINNIIRPHLINKNVLNFFELDNLLINLDGTE
NKSKLGANALLGVSIAIVKAGAIAASKPLYQYIKEDLMHNYDVNYYAPIP
LMNFINGGAHADNDLDIQEFMIVPLNAISFSQAIQIGSEIFHQLDKLLKS
NHLSTTKGDEGGFAPMLKNNYVTLELLVHAIKKAHYLPSKTQGVCLALDV
AASELYENGKYFFKKSSSHNITLEQTSFSSDEWIKYWSKLVSMFPIISIE
DCFEENDWNSFALFLKNNPHIQVVGDDLYCTNLKYLQKGIDFKATNAILI
KPNQIGTISETLDVIKFAQKNNINTIISHRSGETEDTFIADLAIGVGAGQ
IKTGSLSRSERIAKYNRILEIEQELKDKLIYEPSKFFKFR
>UU503 epsG, glycosyltransferase
MLLTIAFYLSKTTHYLKKNFNYFLDLLNQNQKNIELIIIDDASDYNLFKT
LKPLIENTNAKIKYFYLNETQGNAYAYNLATKYAHGKYIWYLGGHVELNL
DASSLLFSVLEKDYDVISFNLNDNVNQNPSLVFDSLNKEILVGLWESVSN
KIIALDFIRKNKLAFYNDKWYPALFIYDLFTKFNSWRNVNINFISNNSGE
VGYNVYDLLQQINELYIRFSNDDLLDLYKDELCYWITGICFHSFLKKIYE
LYTININSKKQIKERTMIISHALSNAKKYLEIYFANFENNLYVRKFKINI
LKYYLKSKQGLN
>UU491 era, GTP-binding protein
MVLEMIKKYGIVAIVGKPNVGKSTLINAIMKKKVSIISNKPQTTRNAVKE
IYEDDESAIIFTDTPGFHEPSNKLDLFLNHEIEISYKEANVILFVTTMDK
ELDANDFEIINLIKEANKENIILVISKAEMAKNQDQIDERIHFLKKHIAF
KDVVQISALHVINIDKLINTIKNYLHKDVVTDYFRQKAEKEDKFVITEII
REQCLLNLNHEVPHGVGVEIDESKYNQEANHWIIKASIIIEKNSHKPIII
GQNGTMIKKISMGARKQLHEIYDCHISLTIFVKVENNWRDNNNIIKSLGY
KIKK
>UU022 fatC-1, ferrichrome ABC transporter
MSIKIKHDQNLKHQFEQKLFFRFKKNKFFLSLSLLIITIILTLIAVAGAS
RFINVFSYLSDWKIITQLLFSGIALGISGYILQRLTKNRLADSSLLGMGN
INLVILTILFLIFDFGQLQIQKRMEYVLPFIYLIGSTMICFFIHFLCNSS
TGYIFKRIIVSGIIINLITIVIAQSLRILMSKESSMYLKTILLGNIESRS
DFCFYFCFGMLTISVIWLMLNATKFKIMVTNQQISGQLGINNKSLTIQTF
ICISLLVSVSYSLSGNVIFVGIVAANFSFNYVKNNISNGIINAGLIGGIV
LLISYIFVVLILNLSTDQTILLVPIISGPYFLYQVILLKN
>UU358 fatC-2, ferrichrome ABC transporter
MKNPSRFIFIIKNNILNTINNASFIENGNFKKKFRVYARKQHLAAWVISI
VTILFLSLLVMFIKINNQGQLLNNRTPLDLFKVNYETILQIWITGASLGA
SAYMFQRITKNRLVDTSTLGIGNVCLIGLFFLAISINFENYGSQKLFENL
LPFIFIISGVCAGLILYWFSKKRTGFSHTKLIVSGVFINFIAIALSISLK
DNLTLVASNYIDDRLLGNFSNRNSTEKYLSYAVFLFLMIWCFLRSAKFKV
VITDTMIAEQLGLKVKLLNLEMIFISSCLTAVSYIMGGNVLFLGIAAANL
GYAVFGNRFSSSIIFSSFITIIFLIFGQFILDNIVQNLTSLVFDAPIVTP
LLVAPIFTFIILFKNNI
>UU516 fatC-3, ferric anguibactin transport system permerase protein
MINLNTWNKTHSFKNPLKYQNKIAYLKTMITVIISIVVFIITLAWTYDFN
FKQDNIALAYIIMQIFLSGFILGFCAYLIQKLTKNRFSDTSIMGISSVNI
LGVIIIAFQVDFNNFSADKLSTLEHTEPIIFFIAPIILCMLYYFTCKEQS
SFNYKKMLISGVIVNFLSVALGASIAKNLPKLANAYVSRYTYGSIEPQQE
SFFIALVLIIIGLLIVLFNFKKIQIVSSNQDLANQLGINVKLTSGLLLVA
ICLMVGASYSLNGNLIFIGLMAGNMGSVISNNRFKSAAISSGCCGSLIYM
LSFLLFIKILNFDSQWLNLAIPLIISPYFIYIIVKKNKSDL
>UU023 fatD-1, ferrichrome ABC transporter
MKIKLKFENKLNFKKYLIYKWSVFVVLVLLTSFIFIFNIIYTNKTFIWES
FYFQNASFEEVFLLFFYSPIVLLVCGAGLVCSGFSLQSTTRNGLAGPSTL
GIFPLAALGNILSQLITKSFSNIFIGYVFGIIFSLFALGINFLFIRISPH
KKTFKPIIFGFSLGAIITAVNILIANFNSSIVASPIQLLGSIGVYNSIER
FYIGTPIVFISTIILLCYAKKIQILDTDHYLAKSLGIDVNKVFWITSTCS
IFIAISTTFLIGGLSLIAIVMPHLVRLLFKRTNYLFQMIIAIFLTTFLLE
LLGIIVEFFSKFNIVFLVATVFAIPMIVLLKWELGWKVNKN
>UU400 fatD-2, ferrichrome ABC transporter (permease)
MFKNKSLKFKNKLDWKTHFRRLITSLLIILSICVLICYCLFDGKELMNFK
NVGEEINEGSAPYIRKFIATPIAIFLSALTLSFSGYSMQVVSRNPLASPT
TLGYLPAAILGLAISKLAINQILYLPFIIGIVFASCLIVINFFLVKGNAL
EASFKPILVGFAIGGIITGINVLLEDLVKDINIKITGFVEPPINFQWQQL
CIGGPLIIISSLANLFMAPYYTIIAKDYLLAKSLGIKVNLIFWLTAFFAV
VATVSSIILIGVLTLLGMIAPHVARILNPKGNSFKQLLLSFVISLLLLTS
SRWLINVYNQFDINLFSAIAALPVFAYIFVSKQYRRNVE
>UU025 fecC, ferrichrome ABC transporter
MQNYTFRFKLFKQIKNQQVKKLKPLILIGATVFLIIAIFSIWVWNISYAN
FYDQQLNKYVYFPLHESLKLIFNGHFLDPTNIKYLNLQATFWASISSILS
GISLAIAGCVTQALTKNPLADSSTLGIVQSSVFMIVIAFSYNMISFGELF
GFAIIGGIIASIILLILVFATRSRLSYIKITLAGLAIGVFFNTISYFIRI
QSAKGSSINFKYVLGGSENIYTTHIDPFLTLWVSAILILIGVILACFLAY
KLTLLEIGDEKAKNLGSSIIIIKILAIISTIFLVSPTILLVGNIAFVGLF
GPHIVRKIFSIRDYRYVMPLSGLLGAMITSLGLILYRETIYINSSIWMSF
IGAPVLAYLGWKHWNRA
>UU357 fecD, citrate-dependent iron transport, membrane-bound protein
MQIKQVNINKKDLSIYKKLIEAKKFVSTQIRRPYMITIIVLTFIILAVGM
FFMNVFYEKSTYFDANYNTHVTYFRTWAKVVADDKSILLYWYPPIVKLFV
AISMPVAGYAIQITTQNRLSSPSTLGYIPVSILAYVAMLMIDQGKSWLVY
VFGFIFSSFIILVNYILQRQKSSNRSFKPVLIGFAISATITAVGLVIAVS
RPNILNRVTIWTGELPNVYEWLKLYISMPLILICLFAFLVLSPKLKIMQR
DFALAKSLGIKVNLIFWVVTVLTAIVTIATVNITSPMILLGLIIPNIVRA
TFNKHEPLFVFFVSIVFSLALLEVSLFLSLNYRFGPNFLMAIVSAFVLIF
IMRKHG
>UU069 fecE, iron(III) dicitrate transport ATP-binding protein
MFKIFAKYFCNHQLDRNQIINASKNDALIINNLSYRYHKKLPEVLKNLSF
SIKKNSFTTILGPNGCGKSTTAKAIVKLLKLKKNIIKVFDRNINELSFKQ
LAQLISYIPQSIEIPQGTRVIDFITFGRNPYLGFSGILGKEDKLIIDLVI
NEMQLHDLKEKFMQELSGGQRQKVILALCLVQDTPIILLDEPTTYLDIKN
QYELLESLKKLQILRQKTIIAILHDINQAIQYSDEVFVLKNGQIYANGNP
NEVITKELLKNVYNIDAQIDIVDNQKIVHKIKVKDYLSNSE
>UU091 ffh, signal recognition particle
MFKAMIGSIVSKQMSKKLKNATIVEEDIKELLSEIRIALLDADVNLLVVK
KFIKNIKEKTIGLYVEANQKPADLVLKIIKDELVEILGKENKPVNTAKSQ
LKIMMVGLQGSGKTTTTGKLANYFKNKYNKKPLLVAADIYRPAAIDQLRT
LAKQVRVDFWEEGTQRPDLIVKNALNKADENENNLIIVDTAGRLQTNEEL
MQELVNVKKTLNPDEVFLVVDAMAGQDIINVATEFNNWLKLTGIIVTKLD
SDARAGAVLSLTSLLNIPIKFTGTGEKIGSIDSFYPERMADRILGLGDIM
TLAEKAADVIDEKQVRGSMQRMMAGKMDLEDLMRQMSQISKLGSFSGIAK
MIPGLNNISENQIGDAESKMKIWTILLSSMTLKERRDPRVFKKEPSRRIR
VLKGSGRSPDELNKLLKQWEVSRDKMAELGKMLQKGKNPFSKSGGLFS
>UU435 fhuC, ferrichrome transport ATP-binding protein
MSFFKKKNDLQKEEHKHVSVVDMNEILSYEDSEEFKNDEIDSNEPIFKLN
NVSLGYGKKMIIKNLTATIHRNDFVVVLGPNGSGKSTLIKGLCRINNPSS
GYIMYRDKLISRPLLPFLWLEKAWSSIVNIFTKDRKEVIETIDWHIQNYK
KIHAYKSKELALNLAYVPQLAVFPEATSIYDFVKMGRFPSSNALGINTNT
EREKQIIDEALKNVGIYEFRHKNLEDLSGGQKQKALIALALAQDTETIVL
DEPTNHLDIRSQLEIIELLHKLHHEMKKTIVLVIHDINNGLKYAHKVMIM
KNGEMVRYGKLKETIDHEILLDVFGVESIIVKNESTYPQVSVTDFSLPKD
YKINEIKENEKTNSIYNDGDEVEIENELEKEVDKTKK
>UU463 fmt, methionyl-tRNA formyltransferase
MKYKVMFFGTPEIAKIVLETLFNMHEVDLIAVVSQPDAHFDRKKNVIYSP
VKQFCLDHNIKLFQPEKIKEIEEEIRILGPDIIITCAFGQFINQGIIDIP
KYKIVNIHASLLPKLRGGAPIHYAILNGELKTGITLMHTIKKMDAGNILF
QRSLEINDCTTTKSLTLELANLSALMIKEHFLELVKPNLVGIQQDENSVS
FAYNIQKDQNIINFDQPAFFINRFVNAMYDKPIAIMQYNGVSIKVYQVKI
TNQKSCQKPGTIMIFKNQLFVSTQDFDIELLLIQLPNKKPLSPKVLLNGK
NPFIN
>UU114 folA, dihyrofolate reductase
MLKLIWCQTLNGGISKNNKLPWYIKEELDHFYKTTKNHKIIMGKNTFDSL
DQKPLNNRTNIIFSSIMQTPEDESYFVTNDFQQVLNDAKKEDIFIIGGKE
LFDIFLAYADVLIVSVLKDYYDCDLYMKVDYNNFNLDKQDVYDNFIVNYY
SNKKEK
>UU337 folD, methylenetetrahydrofolate dehydrogenase
MKLKIDFLYEKVLTELLTKKNKTKKRIYVFYDSDLVNFNSAYIQSKLKYA
KLFSVKLIIYDLNAYQIQENHHFLSKLKQANKDFLFFEFPLSKKHLDQNY
FQYLTFQNDLDGINSHLFLNKKQENQIIYHPATINAILTLIKELDVNLND
YRICIIGRSPYLGDYLYKLLNPKNNKINIIHSQTKNPLRIIKESNFIISC
VNKAHIFNSNALSDNSYLIDVTTEYINNKLCGSFLINKNDALNRNIKYTP
VPGGIGKLTTLFLFLNYFK
>UU413 fpg, formamidopyrimidine-DNA glycosylase
MPELPEVQTIVDYLNHHVLDIFIKKTIVHLPKILKNKTPQEFEKLLINHK
IVKIKRLGKYLLFFLSNNLVLSVHLRMEGKFYYQAKEEWFNLAHTHIIIE
FNNGMQLRYNDTRQFGTFHIYEQQSFLDSKELKKIALDPLDNNFSAQYLY
EKLKKSNKAIKTALLDQSVVSGIGNIYADEILFAAKIFPTILAKNLTLKN
YEKITKEAQRILLLSIKNKGTTIHTYKFGNDETGLFQKMLLVHTHAKEPC
QICGTIIQKTKVNGRGTYYCPNCQN
>UU512 frr, ribosome releasing factor
MNFKIYETKIREEFELVLKWMHNEFIKLRTGRATPAILDGILVNYYGSMM
PINQLANISVPEPRVLAIKPYDRSSIKDIATAINASNLGVNPQVDVDIIR
LTFAAPTEEVRKNLVKKAKQVGEEAKIRVRHIRQEAQDLFKKDSTTIEDD
KKFFQTELDNLTKELNKEIETVVSHKEKDIMTV
>UU221 fthS, formate-tetrahydrofolate ligase
MAKIIEEMINKKGLLIDDYELYGNEIAKIKSIKKLNKKDSKLIVITSMNP
NPAGEGKTTTAIGLVDALNKHGYKAIGALREPSMGPVFGMKGTGSGGGLS
FLKPFDKINLHFSGDFHAITAANNLIVAVIENEIHNRSSMQIDSQKILIK
RCLDVNDRSLRNIEYDINHQQTKSGFNITAASDLMALFCLAHDHKDFEDK
LAQTIVAYNIVNQPIRICDLELTKAIMAILEDALYANLVRTNEDNPVFVH
GGPFANIAHGCNSIIATKNALALGDYVVTECGFGSDLGLEKFMNIKMASL
NLKPDLIGLVISLKSIAYHAQTNEKDYVKQGFANVLCHINHIKKYNVSFI
VYINVNTNTDSEEDLLTLEKLLDEHQIEHARSYAYSYGSKKSEEITKKTI
TLTNQINDHELKLIYDIKDHLSYKLKKICENVYGADGYELSYEAKEQLNR
YEHLDFYLCIAKTPYSISDDAKLLNNPKNFKIHIERFEINYAAKLIIAIT
TTIYRMPGLNKEPAAKNFVMK
>UU105 ftsH, ATP-dependent zinc metallopeptidase-cell division protein
MYFLKKIVNLFSSKIESEDNNVKKDDLTQPRKQSPEARKRRNRRIIFWLI
ILLIIGTIIGVIIYFSVRKEYDNVIVKSAQTEVVNNKKVLYLNTIRPNST
QITRYTIDEDQLLTARVNILNNTNFQIISNASSLGLSRISFNIVREGVEK
FKLGETNIYAPISGNTNNQWNWLTSIITQNAGIPSSGFNPQVIISPLISI
IFFIIFLYIILRVSKAQSDSLLGTNKANAKLTKSGVRFSDVAGIAEVKEE
LIEIVDFLKEPKKYVAAGARIPKGVMLYGPPGTGKTLIAKAVAGEANVPF
FQTTGSSFEDTFVGVGARRVRELFEKARKSAPAIIFIDEIDSVAKKRGNS
LTAVQDQTINQLLSELDGFDTSSGVIVMAATNRLDTLDDAILRPGRFDRQ
ISVNLPDILEREQILRIHSRNKNLSAKVSLEDIARRTAGFSGAQLENVLN
EAALLSVRDKATSIHMNHLDEAIDRVIAGPSRPNKVISEREREQVSYHEA
GHALIGLYSPGADVVQKITIVARGRAAGYTLQTPERNENILQNKTELISR
VRTALGGRAAEELIYGPNEITTGAANDFYKITNIVRAMVASFGMTDVGLT
QYIATEGVDNPYRNSYSEQTALAIDIEIEKIIQREYKIVKEMINEHREEL
ELIVQTLLELETILKPQIDYIHQYKQLPPEVIANKNKREASQKQANSSVE
EAKVVDDEESIKDKEKDQKSN
>UU508 ftsK, cell division protein
MVSDNKNTLNKETISFYSYDNQLDAQKTESNGKEQEKSNLKTKKFKVQKN
YFFNKKKLIGICFFILSFLILILAFLKAPYTGAILDNVLEFFFGWVKYYV
YVILLLFLIVFYIKKVRRRLFSKWMIVFYIITLILFALIIGAVGYGIITN
SLTYKFIINTNQQMINKEILNLHKDNFEYISLVNLHSKKLHLCEWWAYSW
SQEFLKAIDEKHYYYTSVFAYGGIIGYANLDLYRANAWIFTIVIMFMVLV
LISFILITFGTKSHLGLKFKKWLVNKIITNINNYHKKDYQLSEQNFFEEK
LGEDHHNIDKQLEQKEVIQEQNLQIKNFNDRQTNSSCITKNDKLKTTILE
PIVNDINQFRENPSTIKNNKYNFYPRIDIIDGKSQDYLHELKSKGENLKL
IIDKFLENNQLEYHFNAINPYFSNVEIVYQFTRSSLNNFLKNFLNLMKQA
VNDTDDYEINIYNDNDFLIIQAKVKDLNPQINIKDILTNLEYNDKLCLGI
GKLKERKVVWLEDTQAGSILIHGSQQFSGKSMLISNIIISALYTKSPNEL
ELFIINNGSKSLKEFAKLKHTKKSVDHDDFENVINLLREIMNDINKQNTL
FADNNVDNLDEYNLKNQNQKLPKKLIIISEYVEIVSSQFNTRFDTLIRNI
ANIAKKHGIVLIISSNITNESTVSFKNVFDYTIVLKLNNPYESILLTDRN
WCNNLVGFGDMLLIRNFDNLPLRLQTAKITNEQFANIINEINSADYDIDE
YRHETRLTSRTQNFFNK
>UU141 ftsY, SRP family of GTP-binding proteins-cell division protein
MGFFKKIFNKILGKKDTEQISQEISQKNEENRILKLEDNSINKFNEGLRK
SSSALTDAINELAVKYIDIDERWYEHLEEVLISYDVGYVATNKIIESIRN
EMIYQKVNDPDLIKSIIIDKIFIYYIQDTEINTAINLKENQTNVVLVVGV
NGVGKTTSIAKITKKFIDENKKVLLVAGDTFRAGAVEQLKVWAQRLGVDI
ELPNKEGQDPASVIYAGVKKGYEQKYDLVICDTSGRLQNKINLMNELKKI
HDVIHKFDEYAPHETLLVLDATQGQSGINQAKAFNEVTKISGIILTKMDS
TSRGGIVLAIKDAFNIPVKLIGLGEKLEDLSVFDLEMYVDSIVLGMKLDV
K
>UU523 fusA, translation elongation factor G
MSKELKLFRNFGIMAHIDAGKTTTSERILYHTGKNHKIGETHDGAATMDW
MAQEKERGITITSAATYAKWKGHSLNLIDTPGHVDFTVEVERSLRVLDGA
VAVLDGQNGVEPQTETVWRQATKYNVPRIVFVNKMDKTGADFYYSIETMK
NRLGVKATAIQIPIGAEADFVGSIDLIEMKAYIYDGKADEEYKIEDIPAD
YLTKAQVMRSQMIDDVAVFDDEVMEKYLSGEELSHEDIKKCIRKGVISTE
LYPVLCGTAFKNKGVKKLLDAVVDFLPSPIDVPPIKGVDDHGNPIEYHND
PNEPFAALAFKVATDPFVGRLTYIRVYSGKLDKGTYIYNATKDKKERISR
LVKMHSNNRDEIDSISAGDICAVIGLKDTTTGDTICDEKKPVILEQMVFA
EPVISLSVEPKTKADQEKMSLALSKLAEEDPTFRTYTNEETGQTIIAGMG
ELHLDVLVDRMRREFNVQVNVGAPQVSYRETFTEVADAEGKYIKQSGGRG
QYGHVWIKFEPNHDKGFEFVDNIVGGKVPKEYIKEVENGLIEALTSGPIA
GYQTIDVKATIFDGSYHDVDSSGMAYKIAASLAFKEAAKVCKPVLLEPIM
SVDVTTPDDYFGTVMGDISKRRGVIEGQEQRGNAQAIKAKVPLSEMFGYA
TDLRSNTQGRGQYIMQFSHYAQAPKSVTEEVMVARAKK
>UU362 gapN, NADP-dependent glyceraldehyde-3-phosphate dehydrogenase
MNYKTLINGAFVDAKEKLPVYNPSNNQIIAYVPNIHNENEINTIFENAHI
AYLKFKDTPIKYRCDLLLKLADKLDEHKQELAQIISTEIAKGLKDSLIEV
ERSADYLRETVFEYQKLMQKPIIFDETVHHVKNKVATYYRIPVGVVLAIC
PFNYPINLLISKLAPALVSGNSLVYKPSTQGSLIGIRISELVHEVGFPKG
VVNCLTTEARITGDLLVTNKYVKAISFTGGPKVGNHIAEITSKISLVLEL
GGKDPALVLDDADFELAANEIVKGAYGFSGQRCTAIKRVFVSHKNHDLLV
NLINKKVDALTVGLPQQNPIITPLINSNSLKYNLSLVEDAIKKGAIVHQK
IVYNEKNNLLHPLVIDNVTKEMRVAWEEPFGPILPIITYNSIQEAIDLIN
QSQYGLQACIFTTNYASIEQLALQIESGTININKSSSRGPDILPFFGVKD
SGFGVQGIVDAILSMTTIKGIIINK
>UU545 gatA, glutamyl-tRNA amidotransferase subunit A
MKNKTILALHNQIKKREVKIYDLIKKSIDHDLKIKNLNATLANNYEQALK
QAAFLDEKISSDNLEIDYLFGIPYSLKDNISTKNIITTGGSLFLKNYNPP
YDATVKTLLDQKQAILLNKSNLDEFGLGGTGTDSAFGPVINPLNPKHVSG
GSSSGSAVLVQQGVVPFAIATDTGDSVRRPASIMGIVGFKPSYGLISRYG
VYPFAPSLDHVGIFTNNIFDTQIVFNALAKRDFKDFTSLSFKTQSLSMLK
TKNKYKIGVLKPSFDLLASKYQQELTNLIVKLNDEHEIINVDYDINLLKA
ISPVYKLIAFSEAYSSYSNFTNITFGKHDIDYDNYEDLIIKTRTLYLGTQ
LKQRFMIGAYVTQESQFETLLVAAKKMRTLIVDQAKNLFKNCDLILNLAV
HDISETIDDVNNQKPTTNLVEDVMQIANFGGFPSIVIPFLTTKLGNLGLN
LWADYLNDNKLLNGAYLINNLLGNEEK
>UU544 gatB, glutamyl-tRNA amidotransferase subunit B
MQNFEVIIGIEVHTALNTKTKMFSNAATSHKSIPNTLINEIDLALPGTLP
TVNQEVVHKGLFLANALHMRTNHQFIAFDRKHYYYLDLPKGYQITQNYFP
IGQNGYIQIIDEYNNLKRIRIKQIHLEEDTAKQTNIGNQIYLDYNRAGWP
LIEIVSEADLRSAQETVLFLEELRKILLFNDISDAKMEDGSLRVDVNVSI
RPQGAKKFGTKVEIKNINSISNVAKAIDYEIRRQLNLILLNQNVEQQTRR
FDDNTNTTVFMRSKNDAINYRYIREANIAPIHLSDDYVKKMFLTKSCSIN
DLRQQLAQKGLVSSAIEQLLSDGPLFKAFKYVDKIVNNPLSVYKWLCLEF
IGLINKNTQNIEEITPELLQKIARMILLFDQTLINGKQTKIILEKIYLTN
KDPQILIKELGFEQITNENEITKLWHQILAKNQEMLLQYNERPDRVEKFF
MGEIMKLTKAQANPTISFNVLKKILQK
>UU411 gcp, sialoglycoprotease
MNDNYLILSIESSCDETSLALFENNKLIAHKISSSASIQSLHGGVVPELA
SRYHEQNINHLFNEILNETKINPLTITHVAYTAMPGLPGCLHVGKVFAKQ
LAVLINAELVPINHLHAHVFSASINQNLTFPFLGLVVSGGESCIYLVNDY
DEIKVLNQTHDDAIGECYDKIARVLGWKYPGGPIIDKNYQENLATLEFIK
SQPAAKDFSFSGLKTAVINYIHNAKQKKISFDPVVVASSFQKFAINEIIK
KIKYYLNLYKLNHLAIGGGVSANSLLRKKIQSLDVISYIPEMIYTGDNAA
MIGAYAYALIKNHKKSILIK
>UU039 gidA, glucose inhibited division protein
MKKYDVIVIGAGHAGLEAAFATSNLNLQTALITLDEKGIGMMPCNPSIGG
PAKGIVTREIDALGGIQGKAADATTMQMKILNSSKGPGVWAIRAQIDKIA
YQRWFKQQIKQQKNLDLIIAEVSDLLVENNIVKGVVLSDQKIIQADYVII
TTGTYLKSITHRGSVCVDEGADGTKNAKFLSDALVKLGFELIRLKTGTPA
RIKKDSIDFTNMILEPGTNQKIAFSHYHPVYKPYDEQLPCHIIYTNEQTH
QIIRENLNKSAMYGGMISGIGPRYCPSIEDKIVKFSEKPRHQIFVEPESY
ELDSMYLGGFSTSMPIDVQEKMIRSLPGLENCEILKYAYAIEYDAIDPTQ
LYPSLESKLVNNLFFAGQINGTSGYEEAAAQGLMAAINVNQKYQNKEPVI
LGRDQAYIGVMIDDIVTKGVVEPYRLLTSRAEHRLALRNDNADDRLMKIG
FEIGLLKPEVYDQYLNNLKQIKEILNWLKTTTVGQIDDLKFTTLKTNSYL
IDYLKRPEIKLNDLLIYCPIKIEDEQIINKVQIQVKFEGYIKNQEENLKQ
LKRLNNIKLHAIVDYKEVPNISLETIDKLNKIKPLDLEQASRISGVNLTD
IAMIKYYLERIKND
>UU040 gidB, glucose inhibited division protein B
MSFEKYKTIIQKYNQIFNLTRLDSDDKIYQNFFLDSLAPYKELDFFTQNT
NLKLIDIGSGSGIPGVVLKIIFKNLNLTLLEANQKRCEFLKILTQELGLN
DVLIWNMRAEDLTQSMRESFDIATSRAVASLDKILEISAAFVKVNGYLIQ
PKSIKFYEEELKAKNIIKTLYLERIALKDFWENDYHHLVGVYLKKQITPL
QFPRPWNLILKKPL
>UU599 gltX, glutamyl-tRNA synthetase
MKIRTRYAPSPTGYLHIGGARTALFNYLLAKAYGGDFIIRIEDTDIERNV
EGGINSQLDFLAWMGIIPDESIRNPKAFGPYIQSEKLKHYEKLALDLVDQ
KKAYFCFCSKEQLDADRELAEKSHQTPKYKRHCLNLDKKTIESNLLQNKE
YTIRLKINENMEYSWDDLIRGKISIPGSALTDPVILKSNKIAMYNFAVVI
DDYEMQISHVIRGEEHISNTPYQLAIAQALNYDITKIKYGHLSIIVDETG
KKLSKRNLSLKQFVSDYEKDGYWPHAITNFVALLGWSPKNNDEIMSLETM
IKNFDINNLSKSPAFFDINKMNWFSTQYFNNITQEEFINFIKKHSLTKEL
VLNDYTFINKCLLFKSHIINLKQLIDLVIEQFNCDKKVLASDVDYIKKNQ
LITVVRVFYEQLIINDEFNEEFIKEIIKKVQIITNNKGANLYMPIRIATT
FSSHGPELAKTICYLGREKVLKNLINILKILD
>UU493 glyS, glycyl-tRNA synthetase
MRYKFKTQEDLVNHLKSVGFVFANSEIYNGLANAWDYGPLGVLLKNNLKN
LWWKEFVTKQKNIVGLDSAIILNPLVWKASGHLDNFSDPLIDCKSCKTRY
RADKLIESFNKDIHIAENSTNEEFMKVLNDHKIFCPTCKQFNWTDIRHFN
LMFKTHQGVIEDPKNIVYLRPETAQGIFVNFKNVQRSMRLHLPFGIAQIG
KSFRNEITPGNFIFRTREFEQMEIEFFLKEEIAYDVFDKYLNQIQNWLVT
CCGLDLNNLRKHEHPKEELSHYSKKTIDFEYNFLHGFSELYGIAYRTNYD
LSVHMNLSKKDLTYFDEETKQKYIPHVIEPSVGVERLLYAILTEATFIEK
LANDEDRILMNLKYDLAPYKIAVMPLVNKLKEKAEAVYNKILDLNISVTF
DNSGSIGKRYRRQDAIGTIYCITIDYDSFGDEHDPTFTIRERNTMAQKRI
KLSELSLYLSQKAHEDFQKQCQK
>UU213 gmk, guanylate kinase
MKRGKLIVFSGPSGVGKHTILSKIINRKDLNLAYSISMTTRKKREGEVNG
VDYYFVNDEEFKKAILNNELIEWAEFVGNKYGTPRTIVEKLRDEGKNVIL
EIEVVGALKVLDLYKNDDLISIFLLPPSIDELKKRLLKRNTETLETIKKR
IQKATHEITIKDYYQYNIINDNPDHAANQLAEIILNEIKQS
>UU115 gph, phosphoglycolate phosphatase
MFMIILLLIIIQIRRKNKRFMTKKLIVFDFDGTIMHTHTTMSLSIIGVLE
FYNHHIPSLKEMNDLLGNLSMVNIFKKYAKHDLLNIEIEMMISKYYEIYE
SSLFMIHSYFFDGILDLIKKLKSLNNNVKLAILSNKRSSLLATMVDYYNL
RPYFDYIFGAEDVEQMKPDPSGLLKIMNNCNVDHKNTLLIGDSIADLKAA
INANCHFILVNWEPQYQKHMETIINLKPLIVKTIDELETQINHFLY
>UU382 gpsA, NAD+ dependent glycerol-3-phosphate dehydrogenase
MSKILIVGSGAFGSALTQVLVSNSHIVDVYGINENELNDLKENQKNKKYF
QDQKLDLPINNTYLDINLALQNQYDFIIIAIPSFAIKNFVDNIKIFNLSK
TIVVNAAKGLNLETKSSWCDYIKQNLKIKALVGLVGPSFAIDVFLKKPTV
VNLVGNNSNALIKVKEEFENNWFKCILSKQFDAANYISCFKNALAIGCGI
IYGLQNSNNSLVAFLTKGINEMQLILEKIFHKKVNPLEYFFIGDTILTCT
DQKSRNFSFGLLIAQQGVQEALVNKQQTIEGLNNIKVIYEIIKTNQISAP
LFQNLYKVIINALNPQDLFDKSFC
>UU304 greA, transcription elongation factor
MAKYTISKHRLEELQLELREILDVKWPAITKQLQDAREQGDLSENADYDA
AKNEQAALKKRKDEIEEILENYELIEDVLRSTDEVSIGSTIEIYNYQKDC
EEVITLVGSMDSDPFANKISIDTPLGKALVKQKKGTEVTVHTLASPYKVK
IIKIID
>UU406 grpE, heat shock protein
MSKNNENIKHQNNDKVNNQVDKKETKNHNKQEFKYKELYEHELKKNKELQ
NINTLLKDKNQQLEEQISQLNQDFIKQLETKAKQAQQILEQKVNELEARH
EAKVNDAVFKIFKFKMEPLLDAINHFTKIVNQNYDDPKIQAFIEGFKMFS
QNMIDGLDNLKITKISPQVNDSLNDEIMEVFEVVENTNKPSMHVVEVISD
GFKYNDKVIKFAVVKVAK
>UU595 gtp1, GTP-binding protein
MSLSAGLVGLPNVGKSTLFNTITNSRVEAANYPFATIEPNIGIVNINDPR
LKRLASLVVPDKIVPTTFKFVDIAGLVKGASQGEGLGNQFLNNIRDVDAI
CHVVRCFDDKSITHVHNKIDALSDIHVINYELILSDLDIIEKRISRIKKK
ADSGDKDARREYLILFNIEEALKKGQLASSVKLTKEELKIINSFNLITLK
PILYIANISENEISNPDLNKEYLKVKKYAQDNDARCVALSAKIEYEISIL
DEESKSIFIQDLGIKTTGLDEIVKQTYDLLNLKTYFTYGKQEVRAWTFIN
GMSAPECAGIIHSDFEKGFIKAEIMHYDDLISLGSEQAVKEAGKIRMEGK
SYLMKDGDICNFRFNVTK
>UU082 gyrA, DNA topoisomerase chain A-DNA gyrase A subunit
MALKKPKKSRLTTEEIKQQLEGSTIKEQSITKEVETSFLDYSMSVIVARA
LPDVRDGFKPVHRRALFAAFENGMTHDKPYKKSARWVGDVIGKYHPHGDQ
AVYQTIVRMAQDFSMRYLLVDGHGNFGSIDGDSAAAMRYTEARLSKISYE
LLKYIDKETVDFVPNYDASEQEPSVLPSGFPNLLTNGTTGIAVGMATNIP
PHNLTEVCQAIKAYAKNHNVTISEIMEYLKGPDFPTGAEIYGDSGIIKYF
NTGRGSVTIRSKYEIEDIGQGRVAIVVTEIPYMVNKANLIEKIVELVTNK
QIEGISDLRDESSRDGIRIVIEVKRDVIPEVLLNKLFKTTPLQTNFSVNN
LALVNGVPMVLNIKEMIKYYFEHQIEILVRRTNFDLKKAKERIHIVEGLV
IAVNNIDEVIKIIKASGDDDIASKSLIQRFDLTELQTKAILEMRLRALTG
LNIDKLKKEYEDLILVIKDLEDVLNNYNRQVNIICENLDYLIEKFGDERR
TEIMYGVSSHIDDEDLIPVEDIVVTMSKRGYFKRLPIDTYKNQRRGGVGV
QGLKTYEDDDVEKILVANTHTDLLFFSDLGRVYRLRGHEVPLGSRQSKGI
PAINFLPIEKSESILTILPIDNYDQGSLFFTTSKGIIKRANLSDFESIRA
NGKIAITLKDGDKLFSVMQTLGNDEVFIGASNGNVIRFNENDAREMGRIA
TGVKGINLENDEYVVGTGLSSHGEYVLAVGSKGLGKLTDINDYRLTKRGA
KGVNTLKVNDKTGNLVSIKVVNREEEALIITTSGKVIRLSIKDISVIGRN
TSGVKLISLENKEEVKSIAIFKKEEINDEQLLQENDYNLK
>UU081 gyrB, DNA topoisomerase-DNA gyrase subunit B
MNDSNKEKKYTAESIKVLEGLEAVRKRPGMYIGSTQSEGLHHMIWEIVDN
SIDEAMGGFATIVRVILKKDGSVRVEDDGRGIPIEIHEKTGLSGVETVLT
VLHAGGKFDNDSYKVSGGLHGVGASVVNALSKNFKVWVNKNHVQYYVEFI
NGGHAIEPLKPINNKDVKEKGTTIEFIPDFEIMEENEWDELKIMARLKQL
AYLNKGVNIEFESELTNRKEKWHYEGGLKEYITDLNAEKEPLFDLIVYGE
EEKEVRVPGHNEQTYNIKCEVAFQYNNSYNNSTHSFCNNINTTEGGTHEE
GFKLAITRLLNKYAVDKKYLKDTDDKITKEDVSEGLTAIISVKHPNPQYE
GQTKKKLGNSEVRPYVNEITSIIFEKFLNENPEESKKIVAKVMQAAEARR
RSHEAREATRRKSPFESNSLPGKLADCSNRDSSVTEIYIVEGDSAGGSAK
TGREREFQAILPLRGKIINVEKAKIDKIFANEEIQNMITAFGAGIGPEFN
IEKLRYSKIIIMTDADVDGSHIRILLLTFFYRYMLPLIQNGNVYIAQPPL
YKVSYAKTIKYAYSDQELERIKSTISNIKYNIQRYKGLGEMNPDQLWETT
MDPKNRLLLKVNIEDAAIADKTFSLLMGDDVAPRKEFIEKNAKYVKNIDA
>UU274 hemN, oxygen-independent coproporphyrinogen III oxidase
MIFNKKTKHLYIHIPFCNYICIFSDFKRILKTPQTKKFFKNFLENIKMHI
NNFKIKQFKTIYLGGGVPNCLNNQELEILLKTISPYVDDNCEYTIECNPE
LINQTQINLFKKYKINRISLNVQSMNNDVLKQMNFIHTNQDSKKAINLLH
KNGLYNVSCDFLFCISILTLKDLDDVFNFILNHKINHVSFYSLEIKEQSL
LKKYHITIDEEKEIEQMNYIINKFAGLNFHRYEVCNWTNNFRYIAKHNLA
YWRTEDWAAIGWGAHGYEKNIVYFFDGSIKNPILIKKVLTKHELYQQILM
MGLRLKDGLNLNKKINYEAYSYFKNQLKHVSINKKNHLLIDDLNLLNLTI
LDIF
>UU285 hisS, histidyl-tRNA synthetase
MINYSKPRGTIDLYNKEMNDFKLLENFLLSTTKRYGFQQIKTPVFEFAEL
FMKSAGESSDLVSKEMYLFKDKSDRWLALRPEGTAGVIRAVVENKLLLNH
PLPLKLMYFEPCFRYERPQAGRQRQFHQFGVEVLGTKNIYYDFELIALAD
TILKKLMISNYILEINYISSPHNRSLWVKSLQEYFHLHRTELTPLSQERI
TTNPLRILDDKLESQKLVVKQAPKISHFLSNEEKEEFNLIKKMLDDYNIK
YYVNEGLVRGLDYYSGLVFEFISTSPKLLGQSTIIGGGRYGELIKQTGGP
NYEGIGFGIGIERLLIALSETNKNILNTDDDKYLIAFFDKELENEAIKLT
QILRINNQLNVDIILSSTKADKIFKLAQRLNVKKLIILAKKEWSDKKIIL
KDLLNFKQDLLSLDEIKGIR
>UU536 hisT, pseudouridylate synthase I
MNYKISLRYDGSLFYGWARQPQKRTVQGDLEEIFKSIFKINNIRIIGSGR
TDKGVHAYEQTFSVKHSALKYDSHIIYQALCSRTSSDIQILEVQKVDDSF
HAQYNATSKTYQYVINDYEFDLFRNNYELFVNQKINDQKILEALELFVGE
HDFKSFSTSELTMTIRRINWVKIKRDTHLIIYINANGFLKNMVRMIVASC
LDYAFNKISLAKIHELLIYPKKGASIKLAPACGLYLYKVYY
>UU272 hit, probable HIT protein
MQDCIFCKILKGEIISKIIDENEFAIAILDIQPASDGHMLIIPKKHYRNF
SLTDPIYLDGMMRLAKNMTFVLEEVFPNVLGFNYLMNSNSSAGQVIMHTH
LHIIPKQSNGRGFVFKAIKEEGDISNIDEIYKKIIIKTQKLKKSRLSKHY
MV
>UU436 hlyA, hemolysin
MNQRLDHYLKNTNQCETRSKAIDLIKRGRVFVNNFQVLKPSFLVKQTDSV
EIKNDEMYFVSKGGYKLLKIIKEINLIIKNFVIADLGSSTGGFTDCCLQL
GAKKIYAIDVGVDLLHPSLKKSYKIINYEKTNVKNLDKSYFLEDLDLIVG
DLSFISLEQIFPIIKKISSPKTLLLLLIKPQFELGKDVASKYKGLIQNQK
LQQLAINKIINLAKNYDFECKHLTPTDIFDEKKQNQEYMIFLQKHEK
>UU072 hlyC, hemolysin
MIEDSQETISTQANFSVGILVILAIITLILICFSVFFSAAETAITSVTTV
KWKTESNKIKSKTITNVVYKMINNYTITLATILIGNTLVNTASSTIAGLF
FAGIMKSFSTTSNAEAIGTGIATGIITLIVLIFGEFIPKNFAKKNPIKVL
KLVAYPLNCFYILFWPLTWSLNRIFNKKSQNIITATEEELKSLIEVIRHE
GTLDSQEALIINKAILFDDILIKQKMVPWTQVVKINENKTVLQSFEIFNS
TGFSRLVVVNKNDEVVGIIYLKKIIKYLLNEPNKIIRTIMQTPLLINQKD
TLYDGLRTMQFQRIHLGIVVDNITEKNPIGIITLENITEELTGNVYDETD
NENEIKEIQIVNETTWRVDAKTNAKLFLHQYIDKDIEVNDDISMGKYISK
INKNRAFKNRQLINTPNMYIETFKDVRTNQFAFLIEKKINQS
>UU070 hmuU-1, hemin transport system permease
MKINQKTNLKQKHFYLIKNLNYKQSVIIKMAGLILIAICFVFLTLAIYFD
TTNGFEASINQFNFNIRGPKTLMAFFSGGAIAVAGLLLQKVTRNHLADTS
VLGIGSLNIILMTVYLILIKDKTSSYLNPEMRILPLVMFLSSIFGTSIVY
TLSKLGRANNEKFIIIGIALNFLFEAISVVLINPANNSLFSNQDKNLMIA
FENIKNYTLGIIPNSQYIDLSLVISCSVLIALTLIPIWFLRKKIDLYETS
AALASTTGINIERLKISIYLLVALLAGLEIVLVGYIALLGVIGASVARQL
FGNRTGITMFAAFLIGATLVCFALLISVNFNTQVPVGFLSTTIITPYFMY
LIVRGK
>UU399 hmuU-2, hemin permease
MKMKFNFFKDKQNILGQNHILELNKKSFIPYHFKPLLITITLLIALLVVI
ILIFSVTLSNKLGFSELAKVIWQEVVQLIITGVALGVSSYVLQRITRNRF
ADVSIMGIGTINLILLCALSIPVDFTSANELSILQKKEPWIFMFMSCCLM
VLYFFVSRQKENFNYKKLILIGVILTFFLIAIAQSIRGWLNYHANDYVVG
HIVGSVQKAPLNSLIIAASFVILGLLWLLFNSYKLNIIATNQQVAKQLGI
KINFQIFIALIFVGIMVGASYSISGDFVYVGLLAGNAAMRRRNNSFTYGI
LNSGIYGMLSTLITYWIGISLIGMSVYHVGAILPLLIGPYFIYKVLRS
>UU076 hprK, hpr serine/threonine protein kinase
MEIRGKLFVSQVVRKFNLNVVANSDYIDREISTTGITRVGFELAGEILFK
EIWNIVYFGSKESNYFNKFSETIISKKLGKILDLNPPLIIFGKNFKHAGI
LLKLAERYKIPIVEVKYSFYELNFTINSYISQKLSHQSLVHGTLLSVFGI
GVILMGESGVGKSELAIELVKKGHIFVGDDAILVNRIGGNLYGRAEDSTK
DFIEIRGLGIMNFSRSFGIERMIESTKIEIVIELIKPAKHEKIKFERFGR
EIQHKEFLETKIAHYYIPVIEGRSISDIIETAITDYKLKTSGYNSAEEFI
LQINKKGI
>UU104 hpt, hypoxanthine-guanine phosphoribosyltransferase
MIKNQKTRNDGIKMKDIDPRIKEVLITEEQIDQKITEAANWINKEYEGKE
PIIIGILKGCIPFIGKLLPKIKIDMKLDFLAISSFKGATSAQTEPEIITD
LKFEVKDRDLILVEDIVDTGRTIKKVYDLLKIRGARSIKLVTLVDKKDGR
LVDLQADFVCCDIPLVFIVGFGLDYKEIMRNLPYIGVLKEEVYQNDLNNK
NEGDGE
>UU421 hrcA, heat-inducible transcription repressor
MKNTKTSQEQVIELKLSDRQKKVLKSIVDEYTISATPVSSKLLVQKEFKD
QSSATIRNEMMFLEKNGLIEKQHISGGRVPSLKGYDFYNKNLINKNNNVS
DNFKMRLHKILSKRYSNIDEILNAAVSIINETTQLPAVVTKTSSDELLKR
IDLVKINDNSALVLIVTSSENILTHSIKLDKNTKFNDLQTCFSVLDERLV
DTKLSLISSKLDLIVDIVRNKLEEVEYYFSKIVHRVFDFYAYKPNIDSKT
YGVKYLTKHSEFEDQQKLNDLLNLLEDSTIWQQIALNKKTDGLAKIMLGN
EIGHEHLAIATTQINLANTNHQITVVGPTRMDYAKIKALLDFLKIEIEKI
LGSTNEH
>UU098 hsdM-1, type I restriction enzyme M protein (fragment)
MFGDAYEYLMSMYAANAGKSGGEFFTPQEVSELLVELTLIDFNNENKDVR
RKIGKVYDPCCGSGSLLLKYAKLNEGVKFYGQEINLTTYNLARINMFLHN
IGYDKFDIKLGDTLLDPKHNDDKPFDAIVSNPPYSTKWEGKSNPLLANDE
RFHVTQLAPKGKADFAFVLHILHNLSSSGTAAIVMFPGTLYRDHAEQDIR
KYLVDNVNVVDSVIQLPDNLFFGTSISTCIIVLRKNKNNNDNANGILFVD
ASKEFVKSGIKNKLTNANIKKIVDTIRFKKEVTYFSKLVSREEVKNKNYN
LSVNTYVEKEDTSEKIDIKLLNMQIKEIVAKIEKLRKEIDEIVLELEE
>UU100 hsdM-2, type I restriction enzyme M protein (fragment)
MDNKKEIERNNLHATIWKIADELRGAIDGWDFKQYVLGILFYRYISENLT
KYINDNEHKIGDHDFNYETCNDDDVDEEMKITLIKEKGFYIKPSFLFANI
VKNAEKNENLNETLETVFNNIEGSSSGYDSEKNLKGLFNDIDVNNSRLGS
TTQERNKRLARILIRIIYKNMDLLILKPYINKKEIPN
>UU095 hsdR, type I restriction enzyme R protein
MENKVLLAEHENSTVVAEFKSIKVHSNKFESEAELEETFIKLLIAQGYEY
LPIKNNNDLKNNLRKQIEKLNNYQFTNNEWESFLSTYLLNPNDGIEARSK
KIHEDYSYPLKKDKDSITKNIKIIDKNNIHNNSIQVINQYQNNNLDNQQK
TRYDVSILINGLPLVHIELKRRGTNLKEAFNQIKRYANHSFTDLYLYTQI
YVISNGTQTKYYSNTTRETSIKERNNTNSKKTSNSFEFTSYWADSKNNQI
LDLIDFCQTFFAKHTILNILTKYCVFTSDNTLMVLRPYQIVATERIINRI
KISLNDKKLLGTTGAGGYIWHTTGSGKTLTSFKTAALAKEIEGVDKVLFV
VDRKDLDYQTTKEYEKYSKGCVSANTNVNELAKQIGNQENKIIITTIQKL
GIFISKNPKHPIYSKNVVLVFDECHRSQFGDLHKKITKKSFKKYMIFGFT
GTPILEENSNVKNKNIFFTTEHLFGACLHKYTIDKAIRDGNVLGFRTEYY
KTLSEKDDIDDETSSTGIDKKEALENPIRISEIVDFILKNYNRLTKRNEE
FFEHNKIANINEVITSRNKLSENKVLTTLNGFNSILACSSINAAKIYYSE
FKKQQQKFPQEEKLKIGLIYSYLPSEQESNDNELSNFELLDENNENTNQL
DLDSRNFLDEAIKDYNEMFGTSYSTDNANFNNYYKDFSLRLKDRSLDIAI
VVNMFLTGFDATTLNTLWLDKKLKYHSLIQAMSRTNRILNGVKSNGNIVF
FINLEDEVNEALRLFSSESNINSSIAILRSFKEYYEGYYNEDNQYIQGYR
NLVEELKSNFKIPFNGTKEEERIFIKLFGDILKYKNLLSQFSEFEQNDDL
IGTEMQDYQSIYIGLRDKYQDKKRMETDSIVSDLDFKIELISQQDIGVDY
ILKLMNEKLKKDLKEVKYHDLERDILSSLKARKKKDLIIEFVNEINKLPN
KDEIDIFNEWSKFIKNKKESELIKIINENKLDNKKTFEFMKKAFENNEFN
ENGVDIVNLMPPTSFFKKSNQNSNRSKIKENATEKLLEYFEKFRG
>UU096 hsdS-1, type I restriction enzyme S protein (fragment)
MSFKHISANELKRYEKCNFGNVKLLSTGLYDGYIKYNENDNNINYGEIIA
LPSGGSPIIKYYNGYFIDSLNIIFSQKNKKECNLKFIYYFLIANKMLIEE
NYRGASVKHPNMIEIIELLIPIPHISIQNKIVEILDKLEAYTKDIGVGLP
FEIKQRKKQYEYYRNKLLDFKKY
>UU097 hsdS-2, type I restriction enzyme S protein (fragment)
MSNVMQEIIIPIPPISIQNKIVEILDKLETYTKDINTGLPLEIEQRKKQY
EYYRNKLLDFDNIARERES
>UU099 hsdS-3, type I restriction enzyme S protein (fragment)
MNKIEKLINEFCPNGVEFKKLKNIITVAPKSPFGVTKLLKMEKGNYLTIT
SGKKSFYVDNFLVDGEYIFVNDGGQADIKYNFGKTMYSDHIFAFKVNEYN
TKYLYFYLLNISNFINKKLFIGSTLKNLNKKEFLNLAIPIPPISIQNKIV
EILDKYTELETELETELETELELRNKQYIYYRNELLNFNKNQTLLKKIMD
SDDIKSIDHKIEFKKIEYVCEIKRGQVYSKEFINSNKGNYPVYSSQSLND
GVLGNINKYDFDGEYVTWTTDGAYAGTVFYRKGKFSITNVCGILKVFDNS
N
>UU446 hsdS-4, type I restriction enzyme S protein (fragment)
MINLNIITRDNYYYEKIGNNKPKKLENLPFNIPNNWIWVKLNNISNVISG
YSFKSSKYTSSGIRIIRISDFDSKEVDNNEPIFYEYNEKFNSYKIENNDI
ILVMTGGTVGKNIIIKKANDYYLNQRVARIRTFNVNYNYIYYLINTTYI
>UU447 hsdS-5, type I restriction enzyme S protein (fragment)
MPPLDEQQRIVDKINLLEFFIKQYDEIEQKLSKLENEFPEKLKKSVLQYA
MQGKLIKQDPNDDSIKDLLKQIHKEKQKLYKEGKLKKKDLEESIIYKSDD
KSYYENIGNNEPKKLENLPFNINV
>UU282 hupA, DNA-binding protein Hu-alpha (HU-2)
MNAKIKAKTRSQMIDELSKMLNIEKKQTKAFMDTYEAFLILELSRAKEVR
LGNIGKFKVSVRAERKGINPKTGETVIIPEKTIPKFTFTKGIKEIINAGI
SIDNERVSIDDNDFDDDDEFVEEYIVSENN
>UU410 ileS, isoleucyl-tRNA synthetase
MKDYKSTLNMPTTGFEMRANLNVKEPKIQQFWVEHQIYEKLLTKNKDKKP
FILHDGPPYANGNIHIGHALNKILKDFVVSYHNMNNYYSPYIPGWDTHGL
PIEVALSKKIKLSNLSVNERREQCKKYALEQVNNQIQQFLRLGMISDFKQ
RYLTLDHNYEIDQLKLFTYMLKKGFIYQDFKPVFWSWSSQTALAESEIEY
ADRQSSAIYVKMKVVDHNDLFTDKPTSLVIWTTTPWTLPANLAIAIHPEL
VYSLIEYKNENYIIAKPLVETFVKKVGFEDYKWIKDFKANTLEKIKYISP
ISKKHAFVIMDEYVSANDGTGLVHNAPAFGLEDYYACKKYGIETVVMIDQ
FGKYNALVNDLELENMFYEDANQVILNRLMNEHLLIHHEVITHSVAHDWR
TKKPVMYRATKQWFVSIEKILPNILQTLNNDVKSTSFRGIERMHEMIVNR
KEWCISRQRVWGVPIPMIFDENHNAIMDHELVENIINVLNEKGVNAWFDL
DVNAFLTPKYLSMKNKTFYKEKDIMDVWFDSGSSYNILGHYNLNYPADVY
LEGYDQYRGWFNSSLITGTILNNRAPYKYLVAHGMVLDGEGYKMSKSKGN
VVDPLDVCKIYGADVLRLWIANSDYQNDTRISEEILKQNAEIYRRIRNTL
FKYSLSILNDFEPSVDFSFNVRQEEQFVLNEFNELHIKVIKAYENFDYQT
VVKLFNKFILDLSSWYFENIKDDMYCLAINDPIRKQIQSAVYWILKNSLI
DLTPIIPHTTEEAYSFLKDANKKESIRLEDFYDQSQFQFKKGIAHVKAFF
SIKDQIFNELENARKNNILKKNNEAFVTIAKNLILDDYLINNPKLLAKWF
GVAKIEFANNTNVANANFKKCLRCWNHFPDEEMYNDELSMNCYKVINKIK
>UU253 infA, translation initiation factor IF-1
MADTEKLKMLGKIVEVLQGGNFRVQLENGITIMSHVSGKMRVNKINILPG
DTVDVELSPYDLTRGRITYRHRDN
>UU320 infB, translation initiation factor IF-2
MAKKNIKQKKDNRIAIDVKKHIKKVDVGVFDGTFVFTSPLSISELAPKLN
KSPNEIIMRYFKKGVVYNLNTILDEEQIGELCLEYDLDFKIEKNVNTENL
LENIYFDDLEIDLVARAPIVTIMGHVDHGKTTLLDTIRKSSITASEAGGI
TQHIGAYQIIKDNRAITFIDTPGHEAFTEMRARGANLTDIVILVVAADDG
IKMQTEEAIDHAKAANVPIIVFVNKMDKYEANPEKVLNQLSAKEIVAEEL
GGDVVFVKGSALKNEGISELLDSILLIAELNNYKANPNRLAYGTTIEANL
DKGHGPLATLLVQNGTLRKGDYLVVGSTYGKIRNMFDEYDNEIEIALPSK
PVKVSGFEEVPTAGDKFLALADEKQARAIANDVKQKKMRLERAMLQSSDI
RTKIANGELKNINLIIKADVQGSLEALKGIFSSINIEGVTTTLIRSAIGT
ISESDVRLAQTSDAIIIGFNVRASRIIKDLADSVGVQIMNYDIIYKFKED
LELWMKGTLDPIIIEEVIGEAKVLKLFKHSQVGTICGCRVINGKIKRNAL
VRVLRDGIVIYNSKIATLQHNKDSVNEVIADKECGLTIANFNDIKENDII
EVYIKVEKKHDEVK
>UU227 infC, translation initiation factor IF3
MSSNNDARKNQPLINDQIRFRTMVVIDDHGNNLGEMNRIDALNLAASKNL
DLVVIAKKGNIPVTKILDYGKYKYEQKRRQKESRKNQTIIKVKEIKIKPM
IGEHDLKVRAENAKRWLEDKDNVKFVIEARGRMCTKDEFIVQAYEKFIDL
IKDYGTVVQANKKVSNYRYETIIEPIKK
>UU573 kch, potassium channel protein
MTNDERKEFIRKNKIIYFNRIRYFFYEWTDMKAYQRMLVPETFFSFFYQL
FVLMIAFCSVTIIIYNQIELKQANEEHIDFIAKYFEVYYAFNIFFIIDYL
IRISYADYTYNSISRLKAFLIAPFRFVNLLDLVSFVAIVIIYNTGLLDFV
AKMNETTSYSQKFDYYYQIINNNAYMNVVPCMFLIKILGAHSKIIKNVIL
SSEVNFFWQIFKRRWRVLLSSFLILVLFTFLLSFIIYRIEQNYYEIKHIL
PGNPLYKLKNFGETLWFSMGTITTIAYGDVTPVSPAGKVFAVILGVIGVT
YYGFLTSLFASALISVINEFGKRRDSRRLLEFQNENERLLHEFSEQIKVD
IVQELIKNNVIQDPEEIKRIEDLQNQEREALKMKAKRRKKIYFSDDLFDD
TKRISVSNVKVRSASNVTKVLGRSSTKK
>UU601 ksgA, dimethyladenosine transferase
MGQNFLLSNNIKNKIVDVANINKDDLILEIGPGWGAITEILVQKTNILIA
IELDKRLYAHLKTYIKTSNFHIINNDVLCVDLDNLILDYNNTQKIQKIKV
VANLPYAISSKIVLKIIQSKLINDAYIMVQKEMAERIGAKVNTRGYNAFT
VLVQLFCKTKILFEVNAKEFHPQPKVQSAVIHLENLHNSVNFNIEELGKF
LRICFLNKRKKLKNNLSNIYDIKIINQMFIDYNLDMNLRAENIEPKMFLK
LFNYLNR
>UU006 lacA, galactoside O-acetyltransferase
MIKKIYFGNDHAAYEIKDQIITHLKQKGYQIIDEGAQAALGSVDYSTYAL
KVANDVVNDTKNDSIGILLCGTGIGMNIAASKVHGTRVALVYNESSAKLA
KEHNNANIITIGARENSLNQILKMIDDFLTSKFLGERHQKRLDIIAKYEK
EQNS
>UU324 lepA, GTP-binding membrane protein
MDKKFIRNFSIIAHIDHGKSTLSDRIIEFTNTLSKREMTNQILDSMDIER
ERGITIKLNAVQIKYHAKDKHEYLIHLIDTPGHVDFTYEVSRSLAACEGA
ILVVDAAQGIEAQTLSNVYLALENNLEIVPTINKIDLPSADPNRVKKEIE
DVIGLDTADVPLISAKTGLNIQDVLEAIIKHVPPPLDAKDDAKLQALIFD
SFYDSYKGVVCLVRVKQGTIKVGDKIRMMANNKDYIVSELGIRTPKIVNK
TELVAGEVGWVAAAIKTVKDINVGDTITHTNNPADKPLPGYKKILPMVYC
GLYPIDTSQYDDLKEAMAKISLSDAALTYEYETSQALGFGIRCGFLGLLH
MDVIRERIAREFNIELILTAPSVIYKIELTNNQEISIDSPAKMPEPTSIK
LIKEPFVKLAIITPDNYVGAIMELCQSRRGIYDDLEVIDGTRRKLIYKMP
LAEIMYSFFDSLKSITKGYATMDYELIGYQAEKLVKIDIMLNGNKVDALS
IIAHRDFAYGKSKIICERLKEVIPKHQFEIPIQASIGSKIIARETIKAVR
KDVIAKCYGGDVSRKKKLLEQQKEGKKRLKAIGNVDVPQDAFVKVLSEN
>UU371 leuS, leucyl-tRNA synthetase
MYNHNKIEKKWQKYWLDNKTFKFVDNPNNPKKFYVLDMFPYPSGKGLHVG
HPKGYTATDVISRFKRLNGYDVLHPIGWDAFGLPAEQYALETNNHPHTFT
QQNIKIFRKQLQMIGFDFDYDKEVDTTDPQFYQWTQWIFVQLYKHNLAEI
QDIDVNWCENLGTVLSNEEVVLNDKNERVSERGGHPVVRKPMKQWVLKIV
DYADKLLDGLNEVEFSESLKSLQRNWIGKSIGTSVQFKIKDSLLTLDVFT
TRIDTIYGVQYLVVAPEHPILKSITSEQQINVVQSYIEQTKKISDLDRIA
DTNKTGVFSGAYAINPINQEIIPIWVSDYVLMNFATGAVMGVPAHDERDY
AFAKKYALPIKSVIDTKQKLPYAGDGLHINSAMINGLNIKQSQNVLNDYL
IKNHLGKKVANYKLRNWIFSRQRYWGEPFPVLFDENNQIKIIEDLPVLLP
NLNEFKPSKTGESPLANAQEWLYVEIDGKKYRRETNTMPQWAGSSWYFLA
YILKNEDGSYTPLNSEEAKKRFAKWLPVDVYIGGQEHAVLHLLYSRFWHR
FLYDIGVVPTKEPFYKVINQGMILGENNEKMSKSKGNVINPDDIIASHGA
DTLRIYEMFMGPLTASLPWNPDGLDAMRKWLDRVYRLYHNLSELEVVEDL
NKLNEEIIIAYHTLIKNYTKAINEQAFNIAISEMMVFVNVLYKNKVINYE
LLDNFLILLSCYAPHLAEELYSLNHSESVCLQKMPIYDEQKIIAQNITIP
IQINGKLKHTINVLRDTNAEELVNLALACEQVKQEIGDQPIKKQIVVVNK
IINFVI
>UU075 lgt, prolipoprotein diacylglyceryl transferase
MQLEIINPESTLVNDVVAHRVAFSIGSNFNIYWYGIIFVCGFLIAILTYS
LRLKFHYKVPYDPGFYYIFLAIPMTIIGARLWSLAIGDAKDFFDFRSGGL
AIQGGVIAGVLSAAVYFPLILRMPKYHIRDIDADGNVVIRQPSMWIYADA
IIPTILIGQALGRWGNFINGEIFGAESTVNDLQWLKKAMPAVFEGMKHYF
IEGNKTLFTIYQPLFLYESFFNVIVFVFIYFGLSYIKQLKIGFISMSYFF
FYGVTRFSTESARAPQFSFEGTYIINSLLLIFGVLGALYVQFIAPLLRKK
FLLDAIIEMFYKKKDQIHKFGELRKPEEFLFYCHK
>UU121 lig, DNA ligase
MDKIKAKIDELKQKLDQWNYEYYVLDDPSVPDHVYDQTMRELIELENNYP
QFKTNNSPSVKVGGFVSEKFNKVKHKRPMLSLSNAFNDDDLKKFDQDNQN
ASVDLKGYVVEPKIDGLSISIIYKNAKLHQAITRGDGINGEDVTSNILTI
KDIPHYIDQKYKDYEIEVRGEVYMAFHDFYEMNDNLEESDKKFANPRNAA
AGTLRSLDNSIVAERKLSAFMYYLVNAQELGIKTHYESIQFLRDNKFKVS
DLIVKVDTINEVINQIDCYTKVRDKLSYMIDGIVIKINNLEVYDEIGYTS
KFPKWAIAYKFPANVVSSQLLEIINDVGRTGKISYVAKIKPILLDGSMVE
YATLHNFDFIKEKDIRINDEIKIYKAGDVIPYVDGVDLSKRLANSVPYEP
IINCPSCQSVLVRENDEVDQRCLNIYGCKKINIEKIVYFVSRNCMNIEGM
SDAIINKFYDANLIKNIADLYYLQKHKEFILTSDFKIKEKSFSNLINSIN
NSKKCSLEFLLTAFGIRHVGPNLAKKIAKQFKTMTALMHANFDELTNVDA
CGEKAALSLINWFNDEHNVSLVNQLQQVGVNMEYIDDFIYDDNINIIDEY
KNKTFVITGSFSISRDEIKTILEKYYHAKVKNSVSKKTDYVLVGTEAGTK
LEKAKLLGVKIIENEFWKKDNNF
>UU021 lip3, triacylglycerol lipase
MIMELIKTNTLNFYFEPSKSELKKGSIVFIHGLDASPHYFFLINKDLSDY
DCYFVGLPAHGLTPINNKKDLNIKVFAELFINWINEIDLKEFHLLGHSLG
AGIASLVSFIIPQRIEKLILVCPYHYQYLNPFLNKKLFNAWVLFPNPFLK
FKTDVVLKKLYIDYRNNYKTLIETRWESISREYPRIARDVLFLCLSLLNI
KINHELKMAQRNLIMPTLIMVSRHDQLIDFNLAIKVFKNNNKVNQYIFNN
SGHIPFIEEPKLFTNILLSFLEDRFVEQEENDNNDINEK
>UU348 lon, ATP-dependent protease
MKKPILISRAIVVLPYETTTIEVGRPKSIQAIDLAKQSSSKEIIIISQKD
IDTDEVVNFDELYKVGTLVKIKSIIDNFDEGYSIEVEGLKAVYINNENDV
IDAIEYEYEDVITNPILSNKDEIAINGINSEIFNIINKRSRHKNINFDNM
HALISLEKEKFAYLAAATYINDYDNEISEKTIEDRINILLQPNLLLVHET
ILHLLFDQLVDKRVIEDEVEKTITDKINNNFQKQQREFYLREKLKVVKEQ
LGELSSREEDADKIRAKIEDLELPPNVKERALAELNRFENAMSSNESSVI
KSYLDWLLDLPWTQQGVDNTDLMSVRTHLDDNHYGIEKVKERILEYLALR
MRNPNLKGPIICLVGPPGVGKTSLVTSIAQALNKKFVKVSLGGVRDESEI
RGHRKTYVGAMPGRIIKGMKKAGVINPLFLLDEIDKMTSDQRGDPAAAML
EVLDPEQNKNFSDNYIEEEYDLSKVMFMATANYYQQIPYALIDRLEVIEL
SSYTAIEKREIAKSHLLKRIFMDAKLNENELIFTDDALDFIINHYTKEAG
VRELDRQLGHIVRKYIVETYKNKNNQSPLNLKVDEAMIIKYLGKIKFDFN
KKEETTIPGIVNGMAYTAAGGDLLPIEVNHSTNGKGGNVTITGNLEKTMN
ESVSVALGFVKANADKYGIDTKKVSFKEIDIHVHVPSGGIPKDGPSAGIA
ITTAIISSLSQRPVRTTLSMTGEIMLRGNVGIIGGVKEKVISAYRAGVRE
IILPIDDERYLEDVPKYILDDIKIHLVKHYDEVYNIVFGEK
>UU314 lspA, conserved hypothetical protein (possible signal peptidase II-lspA)
MLQKIKNSNFYIIIKKFNQSLRKINFFEKIILKINNKSIRDYFLSITSLD
VIFYKIINFIIVALIVLLSGFLVREWAIDLVVKTKETHHGPIFHFTLNNG
IALGRINNHSGIVYTLQSIPIILGFLSFIFLKNSCYYVPLLFLLFGGLGN
IIDRSIPEFELFNALPNIFHNSLINPNSVGGGDDVINGVVDYWKFVNSII
NLFDVYIVVGVCVLVVILVIRFIIKWKNDSDNQDIIKKVADENDLEINEI
SNKPFGYDDLKKS
>UU062 lysS, lysyl-tRNA synthetase
MERKFSDQELIRRTHLQELKNQNKNPFLITKVDRSMFLKDFAEKYKNFSK
EELHNMDLEKLTLAGRLIGIRQTFGIIQDFSAKLQIYINKKNVAPEVFST
FKSLDIGDIIELEGVAMKTNSDEITLNVTNIRLVAKSLKVLPEKYHGLVD
EEIKARQRYLDLIVNDETKNTFIKRSLIIREMRNWLDNKGFFEVETPVLQ
DILSGAAARPFITHHNTLNKEYYLRIATEIALKKCIIGGFEKVYEIGRIF
RNEGMDSTHNPEFTSVELYIAYVDLWYIMQLTEDLIRHIATKLNLLNPTF
RGFSIDLNKPFKKAHMVDLINEYVGVNFFEVKSDEQAIELAKKHHVKLLD
HQKNFGHIVNAFFETFVEEKLVEPTFVYGHPLQVSPLTKKNQSDPRFVDR
FELFICQKEFANAYSEINDPIDQYERFIAQLEEAKLGNDEASELDMEFIE
ALEYGMPPTGGLGIGVDRLVMLLTSNDSIRNVLLFPHMKDKTK
>UU252 map, methionine aminopeptidase (map)
MVIVKTEKDIAAIKEAVRIWKIAREAIYKQAKAGVSLKELDLLAKEVIEA
NGGIAAFHNYLGFKGHICISVNECVIHGVPTDYVLKDGDKVTFDVGVKYD
NHYCDAAFTIIINNSNVEALKISEICKKSIDEAVAIIKPKVTTHAISNAI
QKFIEKNGYFVLRDFAGHGCGNEIHEDPLIPNYRSLLYRNVTLEENMVIC
IEPMILSGSNAYYIDPNDQWSVKSKNHQMTCHWEHMILITKDGCEVLTD
>UU412 metK, S-adenosylmethionine synthetase
MKYKKIITSESVGAGHPDKICDQISDAILDECLAQDKNSRVACEVLACNR
LIVIAGEITTHAYVDVVKTAWEIIKPLGYNENDFTIISNVNKQSVDIAQS
VNKANKDLIGAGDQGIVFGYACDETPQYMPLTTVLAHELLKEIEKQRRNK
EFVKIQADMKSQVSIDYSNCTPVIETMLVSIQHDEDYNIEYFNKKVSTIM
DQIAIKYGLNTDFKKIINSSGRFVIGGPIGDTGLTGRKIIVDTYGGIGHH
GGGAFSGKDPTKVDRSASYFARWIAKNVVAAKLAKQCEIQLAFAIGEPQP
VAMFVNTFKTNLVDEKKIFEAINKSFNFDIKTFINDLELWTTKYLPVATY
GHFGRDDLNLSWEKLNKVQDLIKYSK
>UU197 metS, methionyl-tRNA synthetase
MLKQKKFFISTPIYYSSGNPHIGHAYTTIIADVLARYKRLFGYDVFFLTG
MDEHGQKIQQKAFEENISPKALVDRNSIIFLNLWKRLNISFSKFIRTTQM
DHEESVQKVFSYLYKQGKIYLGQWTGYYCVSCEENYNPAEIIKSQDNIML
CRMGHKLETKSEESYFYKMSDQAPFLKTYYQNHPNFIIPNERANEMVNNF
LNNLEDLSISRTTFDWGIPIAENPKHVIYVWLDALMNYLTATGYLSNNEE
LFQKYWCDNETEIVHLLSKEIARFHCIYWPIFLNDLQIRFPSTILSHGWI
ITKEGKMSKSLGNVIDPNVLIDTYGVDALRYYLMADLSLFRDAIFSEDNL
IETYNTQLANSYGNMISRTLGMLKKYRNNIVPKYVGCVLKNDEKLENLIN
KNIELVQENINKYSIDKALNCIQEILVEANKYIEDNKPWELAKNQQEQEL
DSLLVHLVKVIQVTTTLLSPILIEGSKKAVEQLNFDESFLTLASLASYDI
FNYHKVNDSKPIFARIIVEKQ
>UU015 mglA, methylgalactoside permease ATP-binding protein
MEIKTNQCPYAIEMHEITKTFLNGTVIANKDVNLFVKKNEIHAIIGENGA
GKSTLMSILFGIYKQDSGSIKINGRIVNFSSAKDASKTGIGMVHQHFKLI
DTLSVLDNVILGSEGATQLGIINRKKITKELKKIIQEYGLNINLKSKISK
ITVGQQQKTEILKLLYRDIDILIFDEPTAVLSEDEIQAFLQMLKDFKAAG
KTIIIITHKLNEIKEVADSATVIRRGHYIDSFDVKQKTIAEMAELMVGRK
LVEVKNIDPITSNEKVFEVQNLDIQSIVKKQKDIVKVKSSPKGDDVSLLS
TKNNNFINFSIRKGEIFAIAGVEGNGQSELAQIISGLLKGNKEAKIMLDN
QEIEHASIRKRYQLGLSHVPEDRHKHGLVLDDTIAMNAILQQVDDKPYSN
LGFFNNNEISKHAINIIKKYDVRGTTRGTSDARGLSGGNQQKLIIGREFE
RSHKLILLVQPTRGLDLGAIEFIHEQTLEEKRKGNAILLISYELDEILSL
ADTIAVIHNGYFISVGDRFSMTRQKIGELMAGEKI
>UU009 mgtE, Mg2+ ion transporter
MENKQSTLNLNNNTNINQNFLTQNILKTYEHKDITGLKKLLKSKRIDKIV
ESLETINDTQIILFVLVATKDGICGDIFKYLNTELKSKIINDASLQQLRI
ILFELYNDDVIILKNDFPMYTKKILLSLDSQQRAAIKQLSEFDEDEAGSI
INSDFFTINQNLSIKEALIEIKRMYNDFEQSNIIYVVDNYNRLKGYVTIH
SLLFADSFELKISNVIQEDVFYVRSDEDIDAVLDIFRKYQIEQLAVVDKD
NQLIGYISDNDILPVINAETTTDIYKMYGISELDFPYIKSSVFVLFKSRL
LWLAVLMISATCTGFLIDKFQDVGQLVTAGLSTLVIVPIIPAMTGTSGNA
GSQAAASVIRALSVGEITLKEYNKVLAKEFLVGALIGLVLAIINFARLII
YFAIIKPDLQQYNVLYENITNNPHTKMIVGAIVSAGSSVALFFAIVISKL
LGGTLPLLATKLKIDPTIMSTPILSTLLDMVTTIILFGFGIIFLLIIVDK
VKVEQLNNIREHIHAIKNVNSWLPNQNFLLNNLNYSKHFA
>UU055 mnuA-1, membrane nuclease A-hypothetical
MVCKKNKLKMFGFIAIGTVLTSAIIPFLVTCAKEKKIKQEVIKPKQISNL
NLEAKNIDIVLKNNVFNKETAKFTLDFDINKELNLQMVAVFDVFDKKNNW
LKTIKTAKTNLVDKKFVFDSLDENVKYLLKQIDFYDPKAPNQIIYTKNNQ
TFSFDTKMDDSIARTVELIIISGFNGFVDEQIVPDYNKQTTYLKAPGLIR
LLNEVNKIKKERGANNVAVVMGGNNYYENNISSLTRAQYTTAALKFLNPV
ATSIANTDLNWGYDLIDEKTKHFKEYVKALYGNDGILSVNSYLKDGDKNI
QMTNNSKIINFGGFKLGLIGAMSNLINFESNLNLTKNIQWFSNEQTANLI
NDEADKLKDQGVKNIVLLSSFLADKAKENDTLTNDEKSFYKEASRMSKLI
DNNVNLMSVINPYKALNVIANNKNNQPLNVVQSKPNSGFVRYMITLNPYN
RILKTEIKLVDKLSTSGDNAGYHYITQQDLLNPQKNPDFNQNLITLNNFL
NNYKDHEYEQLREKILIKNDKKVNLYSSTYSLSSLGAFISDILAKYYQAP
FYNKQTHTFEFKQTQAILLAPHAIRSLVSAKPIKLENLNQILPFNDTLVS
GEISVKNLKEFLINKNKSQNYNEPYQFSNTLKIEYENLQETKTKKKSRKK
QSEQSYSDNEKKDGLILSHQKRVIKVFLKNSDGTYTELNDNQKIIVSVMN
SILKFNKKFSEALLNKTYADQTNIRDLLRTYLPKETQIDQKYDQSVFSKN
DARFYKKKETDQNKSLIYNHINESINNKQADHLRIGHWNVLHQTGLNDPK
NYALAKTILFNKYDIIGLTEIWPAENNNQEQNNLPLIGIIKYLNQLSGSD
DYDFLISDNLKGSENDKLATNEHTSTERIGIIYNKKKVKPIPFANNKIGY
IYSNPLQPGKYEKAETDYSRPPFAIKFASIGQIKNDFTLVFGHLDSPGTY
PSNTEYQKKEHLLKRTELVNKKVISTNQMINKYEQGSREVDDAERLVKVM
EEIKKIDNNKDDDYFFLGDTNIRLHNQQWVFRTLIQNGYSSVFSDNDLFK
SSLSVNPGEFSNPYDKIFSQVNGLTISNPSIYNLWNVYEDQIVDQEWLKK
VRSLYPNEYHDKLFYIRNDISDHAPTFFDLGLNKNDTK
>UU486 mnuA-2, membrane nuclease A-hypothetical
MKNNKSRKWVITISLTLLIILIASAVIGVVFYLKNKKKNDTSVNNDSYII
QNNNNSLKEQPNSTRSFLNQKTICVGHWNVLNQGGINQLKNEALAKVILK
SNVDVIALTEINSAKNNEHDDLPMRAILKELNLHKNQFDQTANWNYVLSK
NLFSKGNESQTERIGFFYKANIIKPVQEYIYKNNDNKDILFEQYFKNWND
NTKITYSRPPYAYEFQTLDNKFNFTIVASHLDSPGANEHKTSKHDHTYGN
KNLKINIKQGSKELNEAYQLGNVMDYIDRLDGNNDDLIFVGDTNIKTKNE
LGAFASLYKRNYLSNFKDDNENNKTTLAKTYLKYAQHYDKIFTSPSIKVL
NTYKYDLWSVSLTNTLLDKNWKLAFLKTYFRSLSNQQMQNIVDNWDEIAK
SNDVYIKKATSIISDHTLVAVNIKIDENDIIDEN
>UU477 mod, adenine specific DNA methyltransferase
MMNERLKLAKNLLKNDGVIFVSIDDNEQAYLKVLMDEIFGEENFVTNFIW
QKKSGGGLNKLIYEGHEYILCYSKNNYNFCLSEKNKKMSGFIKYKDKNNN
SFFINSDIIRNNFGKKDNKFEHRNKAYEDLSKEDKEKWNLKLDNKNYILV
PFKKEPGKHLVAKIFNDERKTTYSIIKLPFTFVSGIWTKDGNNEVDSLNI
DFQNPKPIQLIMHLLDLHSNKNARVLDFFAGSGTTGHAVLELNKEDGGNR
TFTLITNNENQIGTNVCYERLYRINNGIGTKNEIDFDWVSKNKPYLNKLN
VYDLKYFDTNPIEVDNSKIKKVFAKMLVDFNNTSQSSLFENNQRELLINL
STLKPIEKKE
>UU059 msbA-1, transport ATP-binding protein
MKRVYFNIKGGIIMKSVWKILLIKHKFLFFFILFLNLVQVLLVIGSPLLL
SILNNGNYASTTADAFIYGGVLIAMAIGWAIFSIFTNYISTVFQIIVESR
LQKKIFEKTMFLTYADKQKFNQSILLTTSIKDVEELSKTIIFLTRPVIMG
IFYFIGAIILLFIISGNLWQIPLTVVLMALSTIIIFMIISKFNAKNWNKM
RVANDELAKVSLENVSGVKVIRSFLLDAFFLTKLDFKWKDNVSKSIIANR
ISKVSIAIVTFIIYVITPVILIIGICTNSMKATNILSIMQSTNLLVLGIA
LIGFGSEQYFRSIVSIKRINDLIFYKNQIVYNGTKEINNNNIEFKNVSFR
YHNSKKWAVKNISFSIKDTDRVGIIGTTGAGKTTLIKLLMHQLEPNSGEI
FIDNIPLKDIKKTSLQAAFSLNEQVPLLFYGTIRDNVLFGLEDIDENKIN
EVIEIAQAKDFIESKNEKLESLIAQRAQNLSGGQKQRLAMARALLRDART
LVLDDSTSALDMITEKKFLTALKQQIKFKNSIIIAQRINIILDCDKIIVM
DKGKIVGIGNNETLLKTCAVYKNIYQHQINKGAEYEPTTTNQ
>UU060 msbA-2, transport ATP-binding protein
MSQQLQTNKPVSKLYLIYYYFKDFKKVFIGLSIAIIFWLSTTIAATFLLQ
ETVDKYAIANGIVDTVVKMCAGLIGIYFFSFIFLLIINEFAIRISFKIES
HLSMMVINRIRYLPMKYFDINKSGEIFTKTLSDPTSVQDGIVNFYIELNK
AIFGAIGFGTALLITSPYIALIGIVIYVLVMLFNILIFKKSHQLMRIKRQ
NFGEMNGYIEEMIYGQNVVANFNEQVFFIKKLDNMIKKLYKNWIKAQYSS
QIIFPWSIFSMRLMNAVLIVSYLLISIKGIHLPGLINNIDPTTNIISFGG
LVSISLFGNFFCDNFSQLSNTIPIFIVARTSLAKIDEIVKTPNEINWNEK
LIIDASQGIEVRFENVNFNYLKNTPTLKNINFVAKRNQRIAIIGPTGAGK
TTITNLINKFYDINNGFIYFNDVDITNKSRESVREHISIVLQDPFLFSES
IYENIKKGKMNATKEEIIAAAKKAQVHDLILSFPKDYATVIDEKQNLSQG
QKQLITIARAIISDAKIIILDEATSSVDTQTEHKLQLAINNLLKGRTSFI
IAHRLSTIINSDLILVIKDGEIIAQGNHDYLIKNSPFYQELYYANFNE
>UU289 msrA, peptide methionine sulfoxide reductase
MIKSIWIAGGCFWGIQKYFDSIIGVNHTVVGYSQGNVINPSYEQVCTQTT
NHTETVQIDYDDRFVSLISILEHLYQIIDPFSLNKQGDDVGSQYRSGIYY
VDHDDEFIIKDFLLKKQNQTPKKIMIEVERLRNFNIAEEYHQKYLDKNPN
SYCHVDLSLSKKEFR
>UU460 nadE, NH(3)-dependent NAD(+) synthetase
MNNDLIKYLQWLKNDFIKFLNDAQTNNVILGISGGIDSTLTLAILNDLKK
EYDLNIYAYFLDIHNSSLDYECINELKNIYPNIEVINLVDIYDSYCKMIN
KKTNDKYVLYNLKPKIRTNYLYAMANAYKGVVVSNLNYDEYILGFFTKYG
DSAADYYMLIGLLKKHIYELGAYYHLPNKILNRAPTPANEDDEHKTDESF
FGFTYNDLDQFLLYRKINPKIVSMIKKRYETNAHKHFVFDKKKLFLNYKL
GNKHE
>UU306 nfo, endonuclease IV
MDKYNLIIGSHVSLKAKDFFYGSVKEALSYGSNTFMVYTGAPQNTKRQPI
KSFKIEEAHNLLKKHNINLDDLIVHAPYIINPCSSKKNVRELAKEFLIQE
IQRTESMGITKLVLHPGSRLEQNEDIALEQVYTMLNDIFSTINTNVIVCL
ETMAGKGSEIGVNIKQLKTIIDNVHSKKNIGVCLDTCHMNDSGLILDYYN
FNQYLKEFDAQIGINYIKVLHINDSKNPCGANKDRHENLGYGTIGFANLI
NIIYHPLLNNIPKILETPWFNVNDELIPLYKHEIKMIRDCKWYDIKNKLL
SKK
>UU454 nifS, nitrogen fixation protein-class-V pyridoxal-phosphate aminotransferase
MNDYKQFFPWFKNNKDVIYLDSSATSLKPQVVIDAIVDYYTKYSTNPHNT
DSNFTFHTHEIMNETRANVAKFINANFDEIIFTSGATESLNLIANGLRPH
LKKGDEIILTYIEHASNLLPWYKLRDDLGVKIIFANQKNQFPQLSDFLKV
ISPKTKVVSFASGGNLIGNVLDENLIIKNIKKIKPDVLVCVDATQSIQHR
MFDVKKCKSDFMVFSAHKLLGPTGIGVAYIKNDLIKKMQPLKYGGGMNFS
IDLNSYQLYDNYMKFEGGTPHVAGFYGFNAALKFLMDIGYNKIHEHELKI
TKYARDQLALIPEIKTYVQDATSSTITFSYNGVFCQDFANYLGSKNIIVR
SGLSCAKIINNVIQTECAIRASFYIYNDFNDVDRLIKAIKEYQKGDELNG
IL
>UU318 nusA, N-utilization substance protein a
MSNSFKSKEFIEYFKDTAKQNEIEFEVLSSIIKEAFEKAYLRTHPGENFE
TNIDLKQGTINCFRNLVVVENEKVHNEDLETCLDDAVEILLDDARKINAN
AQIGDLIKQHISIDNFKSIEVGQIGSLLRQKITEIHNKRVADFWKPSLMK
MIRAKVAEVNYNKQRNEITGVKVELDDQWKTLGYLSRKDRIGDEKFKVGE
TYDFLIKEVKEQSRLWPILLSRTEPELVEEILKREVVDIKNGNIEIKKIA
RIAGFKTKVAVSTNLLNIEPVAVVVGNKGLTITSISKQLNNERIDIIRYA
DDKRIFIANAIGLDKLKGLLVQENESGQRSAIAIVSKDDLPSVIGRGGAN
IRLIAKITEWNIDVKTIEQAFEENILYEKFDEKIYRSWNIESINKKNVTN
DEMLALIDSIEDDKIEQDVQLNHPLKQQEKKVVSSNDEDGENDETQLEYL
EGFEDFKF
>UU300 nusB, transcription termination factor
MKTQWAKRVKLFQFIYHWLITKKNKPIALKCALVDFDLDLNWINVGEYIL
DNYEQLTKMIKPLISKDWTFERLSYVEQALLLSAYGEYLVLKTPKKIIID
QTLITTHNYSNNESYKFINAILDQLLN
>UU581 nusG, transcription antitermination factor
MAYKIKDLDSKLLSDLKIDFNHRHQWYIVTVVSGNEQKVIENIKDKLNGY
GYGDKLSDLKIIKEKIKEVKIYEPSEAPRSMKNRANTKWETIVVDGATKY
RCTKIKEGNKFNGYIFLKAEMTDQIWFLIRNTQMVTGLVGSSGKNVKPIP
VPEDKILKLIADNDAKRALISLNEKVDHEENIEVIELHEDENFTNFEVDQ
EVKIIADTFFGEIAKIAKIDQNKKIATVEFEFFGRINTLDLNFNDIQLYD
EESDKLEN
>UU461 obg, GTP-binding protein
MAFIDKCKIVLIAGNGGDGIVSWRRETHVPEGGPAGGNGGNGGSIWFVGN
HNETSLEFLKYKKIIRAKHGEKGDIKNQHGANAEDVFINVPLGTVVYNPI
TNEILADINIDQQKYLVAQGGLGGHGNTHFKSPFNKAPNLYELGELGENV
EVLLELKTIADIGIIGLPNAGKSTLISTFTNAKPKTANYMFTTLNPVLGT
IYRDQNRIIFADIPGLIEGAHTGVGLGHDFLKHIERCFLLIHLISLDPND
NPDIINAYETIVNELKQYKQNLVNKPIVLVANKIDQIGALENLQILKEYL
KNNQEIKIISALTNLHVDNMLDDVIKIYFAQKKIYEQRLKEQLPVDQILK
WTSDIPKSKELDKTIEIIKVDDHIFEVFGEYLKYWAHRIPLKTQDNLIRF
NQKLQSINFNQQLLQAGAVAGDSIKIYDITLEFEE
>UU562 oppB, oligopeptide transport system permease protein
MNQKNSFEANSSQNNYGELPILNQKKRVNYSFSNNFIIFGGGRSLKTAAD
RDRVVDPLIDFFTFDSKFMTFIIKSLKLIAEFFLLAWIVITITFFLINSV
PGESALTIGITSPEAKKAILAQYGLDRPIGVRYVNYLANIFRGEFGVSTS
IRPGVEINSFIWSRYLVSFAVGIFSVLLTLVIGIPLGIFVGRKPGGILDS
VSTVIISVISAVPSLVFGLILLLIGKEVGLPFTFDINNFVTYILPGLALS
LGSIIVYVQYIKVEMNRELNSMHAKFAYLKGATVNRFVWLHALKPSLFPI
ATFFPFVILGSFVGALFIEQIFQIPGSGSLFFEAIISKDYNVILLLVIIY
SLITIIGYTIRDALYQIIDPRIRRGGK
>UU561 oppC, oligopeptide transport system permease protein
MAKFGEYLKQKSKSITSSFIDELTSDAPNKFLQPFQHQQWKIIGHLIEFR
DNAYMGGRPRPFREFANRYGRSFSGLIGLAIIIILFILAIIIPFTTGSPT
ELRPNKRYLDYFTDGFIFGTDNNGRDLWAMLWWGLRYSLGIAIIVTAIEL
VVGVTLGILMGYFEMFDKIMTFIIKILTNVPTIIILMILTIILKPSFGVM
IFAISFSGWIAMANQMRSQVKRARSFLWVAASKTLGTKAWKIILNFLPIL
IPMMITQLVFSIPGAILAESSLAFIGLSLPNTPTLGNLIADGSSIITLYP
RFTLIPSFLLVCLVASIQLVGGATQDALRRQR
>UU560 oppD, oligopeptide transport system permease protein
MKQKNNRYTYINYLRSQRAFIQTLKPQILKLTSNNVCLNEQEVDLEPQLN
NLEDINIQLTNEKVNIQDIVTLEEEINVKDNNQNQNLNEEILATTLINEQ
ASGINEISEQKETTIANKKHKKQTMAFKAANSRKNFDFEKFEKNVKYKSF
KDGTVKKIAAEIENVRLTFTNPSKPNDRALVLRNTSVQFYEGEVHAIIGE
SGSGKSVITSLLYGLAGKNANVEEGKILLYNNEVQDFSFKDWEKSRYLGK
VISAVFQNPMSTLNPTMKIGKQIMEGMLINGIVKTRKEAYNKSIEYLKLT
KINNPEEIMELYPHELSGGMIQRVVIASIVSLHPKILVLDEPTTALDPTV
QALVLDVIRELQEKFKMCIIFITHDLGVVASIANYISIMYAGQIIEEGQR
DEILWYPQHPYTWGLIMSMPDVNKGDRLATIKGSVPSRLNDIVGDAFAIR
NDYALTRDFEHEPEMYHVSETHRVKSALLDERAEKYTPPQIILDKWNNFK
KRQENN
>UU559 oppF, oligopeptide transport system permease protein
MSDTNQKKAFFNHKKRFCLPDKITIRPVTEGLIERLNANPEKKRLVQVRH
LDVTYGHGFKKFRAVKDISFNIYQGEVLGLVGESGSGKSTTGSALIGLAR
HSFGDIIIDGIKLPKQGEKVTKELTDFMVNNVQMIFQDPSNSLNPYVNIE
TVVSEGLNNIKDLKKSFLRLIYKDYLRGLKKELKAKNFLNNEQVQIFLEK
AQDLKFDYLNETAQQELIQLFNELELNHLSLDNNDEKLQKAFNDINTWKS
KTRTDITRHLILDVLKSVGLDETVLRRYPLEFSGGQQQRIGISRAVALRP
KLLIADEPISALDVSIQAQVVNIFKELKTKYDLTILFIAHDLRMVEYISD
RIAVMNKGVLLEIGPTKEIVNNFLHPYTRSLMEAVPSIDSEKKSLLGYVY
DANMHEYTPTKQPKWIHLGNDHYILGTDEEIANWKAGKY
>UU140 p115, p115 protein
MIFLKKIEAHGFKSFGEPVVIEFKHPMTGIIGANGTGKSNIIDALKWVIG
DQSLKSMRAHKNDLLFSGGRYAPKAHIARVNLYFNNVNNVLYTQHKEIKI
SRVLNIKTNENTYYINDEVALLKDITDMFLDSGLSKGSLGIISQGAVSWF
AEAKPNERRKMFEEASGIGRYSKRKQEALNSLSRANENLARLNDIVANLK
KELAKLQKQAMRFNEYKQIKDELTKLDLVIIVRDIIHWQKQLNDIQENLK
EYKKEYNKQKPLIQSKKNEIESLRVISDRYAKEYTNLEFEYKKLEDTIND
LNLKLSLTKNTLETTAFNATNTQERIDAFATLIKTTEIELNNNKKNINEK
KDQLKDIQKQKLELESLKTKQKNNLDTIIWEIASKNLKKEMLEEQFKRQT
ENERGVKTIIDSQKALVGVYGTVAQNISTKTEHELAISTALAKGINNIIV
KNNQAAENCINFLKKNNAGVATFLPIENLQAKSIKPEFYDVLKELEGFVG
VANELVKINVNYKISIDYLLGNTIIANNLKNAIILSEYTYKNYKVVSLEG
DIVFGGGAISGGSNSKKNIILNLEEKIKELDLKIKKLNEEQIELNNLHNQ
TKKQWQEYYNSEQIINGILNNLITTNNSLSDNLNNYKSQYEALSATKLSK
EEIESKISDNWNEYNKKKNELINLKQKIQTLKANLNTANLNKNELEITYN
KELEDFYNLDKNITSCESNIDNLNYSIQNVQTRLVDNYKLSVENAIETYQ
NQEIDMSESAARLRIESLKIDLEKYNDINLNALEEYEEKQAEYDSNFLEY
ENCKQAVDQISSSIQELDKKAKADFMRVIRETNKLMPEIFEYLFGGGSCA
ISLNDPNNILESGVEIIANPPGKRDVPLSALSGGEKTMVVLAVLFALLKI
AKFPLVILDEAEAALDASNVAKFGAIIAKYSDETQFLVITHREGTMKSCG
YLLGTTMMNNGVTTLLEVDLNDTKIKYESEL
>UU264 pacL, cation-transporting P-type ATPase
MSFDPENINPSTGLNDEQVLKSRQIYGFNEIKKKKKSHIITKFLKQFLDF
MVILLVIAAAVTLALVIIKPPHDTAELVVQYVEFGIICFILLLNAIFGTI
QEVKAEKNTDALSKLASHQVKVLRNNQIRIINSNQVVMGDVLILEAGDQV
PADALLVNSSSLEVDEAILTGESLPVVKNAKAIVKKNTVIGDCLNQIFSG
TYITNGTAKAIVTNIGMNTEIGKIAKLINDQKTKLTPLQKKINKLSKIIG
LFASILCIAVFIIYIYLIGDGNWNISWHPALIMAISLSIAAIPEGIVAIV
TIVLSFGIKEMAKQNALIKRLPAVETLGSANVICSDKTGTLTQNKMTVTK
VFTNKLKITDLIDNESVFNLIKWATIANNGIKNFNEKKQEYEFIGDPTET
CIIEAALKLNIDKYKLDQEFIRIHEFPFDSTRKLMSVVVKHQSDYYLITK
GAIDAIDKIVQNPITKDVYEANDFLSKQALRILCVAIKKLSSIPTNFNQD
ELEKCLEFVGLIGMIDPPRPETQEAVKIAIKAGIRPIMITGDHINTASAI
AKQVGILNEGQEVLNGNELNMMSDNELINNIDRYSVYARVSPTDKIRIVK
AWQHHDKVVSMTGDGVNDAPALKAADIGCAMGITGTDVSKASSDMILIDD
NFATIINAVSLGRSIMDNIKRIIVLLLITNLSGLVSLIFGIIILGINPMS
SLQILWINVIAETLPGIALGLHLADVNLMRHKPLKKSAPIVNKRMWATIF
TNGFFVGLISILLFYLGASSHFNFDFMLMRNEFKELTNLEKIYQDTWSWF
GQNHEISNIIHEKILTIKTAIMAGSSLTFVFMGMSLTFNALSLRTNHSVF
VNFWENCKYVVYSILISIVMIIVIAYTPHLNQIFNMNPYNINGYEWFNIL
PFVLFAIPLSIFEIIKYFRYLKLRSTFDYKNKTYALLNQEIQSTNLKINN
TKISYEKQYYKALLNNLIIKRKILINKCHKEI
>UU467 parC/gyrA, topoisomerase IV subunit A
MSVNHQKIINTPLDNIVGESYAKYAKYIIQDRALPDIRDGLKPVQRRILY
AMSELGIFYDKPYKKSARTVGEVIGKYHPHGDSSIYEAMVRMSQDWKNNL
CLLDMHGNKGSIDGDNAAAMRYTEARLSKIASVMLANLKKDVVKFSPNFD
DSEKEPSILPSLFPNLLINGATGIASGYATNIPPHNPNEVFDALIYRIDH
PDCSVEKLIEICPAPDFPTGGEIHDLNGCANAHKTGEGKFIIRACIDFKI
NDNKINQIIISSIPYETNKALIIKEIEDIIYNKEVAGLIEVRDESDAKGI
SIIIDTKKDINLENVKNYLYKKTNLEISYNTKFIAIVHRTPTLVNLSTYL
DAQINHSLDVINKVDLYDLNKILLRIEIVEGLIKCVDLIDEIIKIIRASE
SRQDAKNTLIQVFNFTNNQAEAIIMMRLHNLTRTDIFDLKNEWQTLQDEA
KTLQERINSLQVRKNYLKQKMIEFKKTFGFERKTKLFDELVKVEINEDQM
IEKQNLNLVISRDGYIKTVSKKSFESSKYDELGLKTNDILFYHNIINSHD
KILIITSKAKLINLVAHKITSMRWKDVGEHLNNYVKFDANEKVIAVYIWN
EQFKIDEYQLVLASRLNLIKRIELSELDINKNSKQISIMKLNDNDNLISA
NLIKKGHNQFIIAISKLGLALLFLVHEINCLNRLAKGIKIMKLKPNDEVS
AILITPNNGYNVQLFLERGSKCFNISELKLSKRAATPTNLYPITKKVQNV
LAAFLVAHENVFYLLDQQQKINPYYLSNPKPTKLDTKISIYENDQMITDV
VKDCFLSDEAISDFKKINMYANEFDNEMLKINKNHDDSQLELIDEEEEKK
>UU466 parE/gyrB, topoisomerase IV subunit B
MANKYDGNAIKILEGLEAVRKRPGMYIGSTSSTGLHHLIWEIVDNSIDEV
MNANAKNINVILHEDNSISVLDDGRGIPVDINSQTKISTVETVLTVLHAG
GKFDESAYKTAGGLHGVGSSVVNALSSWLICEVYRDQKIYQAKFINGGHI
NQSLKVIGTTKKTGTLIHFLPDPLIFKNLVFNPNIIKERLHESTFLIKDL
KIIFEDKINKKKYEFINNQGLIDFIKFINEAKKTFSDVIYFRSNINKIDV
EIAFQYSDQNNEIMVSFANSVKTSEGGVHENAFKNALTSVVNNYARKHNL
LKEKDKNLEGDDIREGLSSVISLRIPESLISYEGQTKNKLFTPEANEAVK
KTIEDNFSFWLEENKTQALDLVNRAILARDAKLAAKRAREETKKVKKIKE
ERGMGGKLTPAQSKDPVLNELFLVEGDSAGGSAKLGRNKKYQAILPLRGK
VLNVLKARLVDVLKNEEIASIFTCLGTGIGAEFDLKKLKYHKIIIMTDAD
TDGSHIQVLLLTLFYRFMRPLIENGNIYIALPPLYKLTNKNNKKFFYAWD
DVELDQLKKEQKNYEIQRYKGLGEMNADQLFETTMDPNNRLLLKININDI
LQAERQINTLMGNDVSIRKQWIDNNIDFSVIDELQINNEESK
>UU065 pepF-1, oligoendopeptidase F-zinc metalloprotease
MENKKYEWDLDDLLNNKSLDDLYAEFEEKKAKYIKAFPTFLDSKQNFAQW
QILEEEFTIVANRFYNYVSNNLNTNVVDPKWNSWSQKLSASFYELETALS
NYNSVVLANEAKIKEYLTDSQLNVYTRKYNEIFRYQPHTLNNEQSKLFST
LIRADEGFSTIFSTYTNNDMKFSDAIDAKGKKHPIKNEAEAFVHLKSKDR
VLRKSAYLSMYRAYYDSRESITKMLYYNYLSLNQQAKAKNFDDYIAKAAF
DDVVDKSLITLIYDQVKLYKDTNEDYKKVRNTYLKKLIKVSKIEPWDNGL
PLISKKIDIPIEEAKQMAIDSLSILGDEYVSNIKRAFDEKWVSWLPQKGK
RGGAYSIGGTKGISKYYILMNYTNSLRDVQTIVHELGHSMHSLYSNRTQK
IYSDYKIFYAEIASISNEVYLNYYLLEKYKNDLEMKLMILDEMISGFFAT
TTRQVIFSNFEWIANELINSGAPFTADVVMKEYQKLELEYTNKPIVEDLN
SIYSLSSITPLRIPHFYVGNFYVYKYAVGQVAAIISGHRVFTKVTGAKQK
VFDFLSSGGSKDPLDTIKLLGVDLTKPQAWQEALEIVKLWIKDYKQTIAL
LNKKRSKK
>UU521 pepF-2, oligoendopeptidase F-zinc metalloprotease
MNDINDKKYDWDIDSLLKGKKLDILFNEFVESNNELIKAFEKWINSLNDF
INFHEVSEKNLLISNRINNYVSNKLQTNLIDNEMLAWSQKIEHEQHRVAK
IFINFENLAIKNKDLINSYLKNSSLIKYQLEYEELWRYEKHILNEQQQKV
VTAISRFSSSFGDIFDVLLDSDMQYQDGINYKKQKVCFKNQTDLYVASKS
NDRALRKSAYESHFKAIYDLRNTFSKLLYYEYVKQNELAKLHNFKDYISA
DAFSDKVDKNFINHIYTQTKKFAKGINRYTKYRTLFLKQQYQLTKVEPWD
KNLDIIDKKNMFSIESAKNLTLEALALLGSEYINVVQRAFNEQWISWMPN
NNKISGAYSISNTKGLDKIFILMNYDETYNSILTLVHELGHSVHTYFANQ
SQEVYNEYETFYAEIASITNEILMNYHLLKKYENDDLMRLYILDEMISGF
IATTTRQAIFSNFEWVANEWINQGEEFSWNKIVLAYLEINHDYTGYKYNK
NKISKYDEANALILINIPHFYTGNFYVYKYVIGQICGLINAIRIFNNKAN
AKEKYFCFFKSGGSLSPLETINILDIKINENDVWEEVNIIFNSWIDDYIK
IIKKFLINKKI
>UU532 pepP, XAA-PRO aminopeptidase
MSDFKLQQVLKTIKEHEAQGADGMILFSNYNRYWFLEFASSDGFVFINKD
GKAIYLVDARYYTAASETVKNAKVILLARTPQKSTFDLLKDAMVELNITN
ALVEADYVTLDVHEMLKKLVKNTTPFTSATLRAIKTEKELEYLQKAADIA
ALTCNWIREQDIIGRTELEIATLVSKHMLELGGELNSFDPIIASGPNGGS
PHHHPGNRVIEDGDMVTVDIGCTYKGYCSDITRSFIVGNKANPQMQEIYD
KVLESQTAGINLLSTKVTGQEVDKVCRDIVDNSKFKGYFTHGTGHGVGLQ
VHELPNTNAGNPNKLPLNAVVTVEPGIYIPNVGGVRIEDTIVVKDGQALV
LTRLAYK
>UU185 pfkA, 6-phosphofructokinase
MNQVNFLNLDKNILIITSGGDAPGMNASLISLIHRLMNNNFNVFIGIEGL
LGLYNNLIEPIKDKRVFDVYFNEQGTVIKTSRFIKLDINDKKTQIIKDNL
LSHNIQKIIILGGQGSMQAGLVLTKMGFEVFGILHTIDNDFSETQMCIGA
LSAASFNQKLLKCLNYTAKAHCAFNLVELMGRECSWLVNNSVGKLKPILM
LTNQDNKYTVDEVIDLIKDKINSIKEYDPLIIVQELIYDQKWYELLVKTF
EQKLHKSLRITILNYLQRGAPVSDFDLQLAKDSANVLVDFIVNQNDIKNT
NNMYVVINKFDNKLEVIKFNK
>UU470 pfs, purine nucleoside phosphorylase
MIGLIVALNSEIKTFFKQIKKKVYQINNIDFYLCTHQNIEFVLVFTDVGK
TNASFITALLINNFKPKVILNVGSCGALNDQLQVLDIAIIDQCQYLDVNV
SAFGYLKNQIPRLDNFLF
>UU279 pgk, phosphoglycerate kinase
MNSLNKKSIKDLDVNGKTIVLHLDLNVVVDYENKRILNDRKLRASLPTIN
YLINHNAKIVILSHLGRIKTLADKQSGKYSLEIIVDELRNRVSKNVNRVV
FSPLNYGETVVQMVNDLEERDILILENTRYCDISDEGEYVGLEWDGSEIL
GQFWGMLGDIFIDDAYGVAHRQLSSNYQTAKFAKKSALGFLIVNEINHLD
IALEVPKSPYLALIGGNRVADKIAAIEVLCERADQVIIGGGLVYTFLYAQ
GYNVGLNLVERNMIDDCNNILEKYGKKILICFDFLCNNDFSDTRPIYRKI
DEGLEGLYGLDIGKRSLKFIKHEIYRSKTILLNGPFGVIENIKNYAQGTT
EICKSMAKQTTRGAYTIICDIDTSSHAEYLGLDKYINFISTGGGASLSYI
EEGVLDGLETIDNVPLNVLKKE
>UU182 pgm, phosphoglycerate mutase
MKLNKKIGLIIIDGLGIGKEDNTNAVHLANPPTLNYLINNFPTLQISAAQ
QNIGLLENQAGNSEIGHLTIGAGRIILNDNANINNYMKSVDYESAVLSNI
KNEIVHIVGMYSNGLVHSNYEHIHWIIKQIIKNNNQVVLHLISDGRDDYP
YGFAQFIEQINALKKQYNIIVKSLSGRYFAMDRDQRWERTQKAFNAMFVK
QDKICEKTFLEVAQSIANSYKSDEFVQPVVFNDDEKYNLKPHQKVILANY
RSDRMRQLAHLLKPNKKFHYNNPFLVQDVNLITLVPFPDVDAIALFEKQN
LNNTLGDVFNKHQIKEARIAETEKYAHISFFFDGGVNKYYSTKTQYLIPS
QKVATYDLCPQMSAHLITKTIIDHYFDHDVFIVNYANPDMVGHSGNMQQT
IEAILSVDHEIRKLYDFFEKNNGVLMITGDHGNAEMMLDDQKQVITSHSV
NDVWFIITDNKVILNSTQKFSLANIAPTILEYLNIAQPIQMTATSMIKKI
CE
>UU458 pheS, phenylalanine-tRNA synthetase alpha chain
MDVINLIKNLKQILRTANNERHLIELKNIFVKQHLLPLYDELKKSANKKE
MGLLINNFKQQIEFVTDQILKELNDKDDQVDLKKWTNKTLFAPFINNGHH
HILNSIIDDIASFFKKLNFEIVSGSEVVSPIYNFDHLNIDENHPARASAD
SFFINSIKMLRTHCTTTTAQFLENNVNKDIRIMSFGNVYRKDDDDATHSH
QFNQVDFVWVKEGLTVANLKWLIDSLIKYLFGQNLKTRYRLSFFPFTEPS
FEVDVQCFKCDLKGCAVCKKSTWIEIMGTGMLHENVLKAANINDIRTGMA
FGVGIDRIAMLKYEIDDIRYLYSNNFKFNAQIK
>UU457 pheT, phenylalanine-tRNA synthetase beta chain
MILSLNLLHKISPKLKKIPLNELCAALMDLGCEVETINSIKPSTNLVFAK
VLEKTRHPNANHLNLVKVKANQKVYEIVCGANNFSVHNWVVLAKLNAELA
NGLKITPRELRGYVSNGMLCAYSEINPQATSFLTSTDLDGILVLDDNYDH
YKTPNQIFNLDDVILDLSIPSNRNDLNGYFWIAKELCAYFDFEYVVDATI
NHRPHKEIIDVRILSDDVNSYGIIEVKNIQNYILKWNTKSILINNQIKVL
NNFADNMNFLTLLTANPLHAFDARKISGQIVVKNAEEDAILLGLDQKEYL
IKKGDLIIVDDQKILALAGIIGSNDSKIDATSTTAYIECANFNPMLIANT
ARRLKINTAAAMRFSKPLTNYVTKVTLKKLLANFKSDAKLIYYFKHSVHN
VIKNKINQVSDFVGAEIDLDTAQTFLKRLGYKINKSNLITPSHRYDVLNE
FDVYEDIMKKISIQEIKPQPISFDILNFENNLAYDFEKKVSDFLVDQGLF
ECKTYNLKNQTQAHEFNFFNFKQAYEINNPTSNMRSHLKLNNLNSLLEVL
EYNQNQKNELENIFEISKINPVDSSQQTVLSIILCKPLINSKINDSLIVN
NFVTTKALLHALLTKLNIDYAYDKNHVVNELYDNNQLALINANKQVFGFI
GQLKNQVKKTYGLSNDIFIINLNLTSYLNQKQVITKVIKPSMYHDVIRDI
SVKLASDVDLNNIIANIKKIKNIRKVEISDLYIKDDGIIYTFKYYINDHL
SNLSSEQIIIIEQEVNNYLKQF
>UU216 pkn, serine/threonine kinase
MREEIKTNSILNYKYKVVKHLADGGFSKVYLCCFLSDETKFIVIKVLDIN
DEKQQMVVYDELRISNLIKNSDSDKKNYIMEYYEYFETGSLENNDKRIYI
VFEYIEGLTLREYLDEFKTITYVKAVEIIRQVALGVSFFHSCNPQIIHRD
LKPENCMINKTLTKIKIIDYGAASVFYNREDLTKDQEIKCTIIYASPKLL
SLGQKVKEQANKGLNKRALSLINDALGVSYDIHSLGVMLYELITGTNPFS
EHTITDDRDYLEKWITYDVEPLSLINKTIPKGIDNILMRCFAWKKEDNKL
LYKDIYTLIDDLSNVMDPESNLNQEYIKPLNKLRIYRKNLAGLYEIKEKD
RKWYLQKWFIILISCLSVILIILLIIILFFKKSGAI
>UU344 plsC, 1-acyl-sn-glycerol-3-phosphate acyltransferase
MNFLKTLLWFVAYPFVALYIIIQMILAAMMANKYKNDPESVSVNERYKKI
MGIIDAILYLKNIKVDLIGKENVSIKSMLYIGNHKSNGDPIVLLKALYQI
SPHNVRFVAKIELKKSFLKFLFNLIDVIYIDRNNLRQSISTINEQVNALK
QDYRGLVIFPEGTRNFNHEFNEFKSGALTAAYNTLSSIQPFVIFNSQGSF
EMKNDQKQKLRSNPFKTQHIKVSFLEPIHSFNYININKDILMRKIQSNIK
KNYDELLKSTIKTN
>UU206 plsX, fatty acid/phospholipid synthesis protein
MEKIKILLDTMGYENDLEHVIKAAKDFYYQHEDDLEIILVGNEQLIKPLL
DNDWRLFPIVHTEVSIEQNDTILSARKKQNSSMHLALRYLKDKQADGMLT
AGNSAVFVYNAYATIGLLEHIKKPAFMPFVPTIDGGVTNLLDVGASIDVD
GTDLFNFAIMANTIAKMRTPNPRVGVLNIGTEDHKGLPYHQEANELLKTS
NLNYVGFVEPKTILEREVDVLVADGFSGNIALKTMEGVGKTISNFLKNEY
KKPKNLFAALLSKPIFKKIKKAFDYKEHAGAFVLGLDGILVKTHGSADYQ
QFMSALKILYETIKADVLNEIKKDLNNYYGQ
>UU414 polA, DNA polymerase I: 5'-3' exonuclease domain
MKKAIVIDGNSLIYRAFHATYKQAEWAVEKQLMPTNAIKLVASMIFKILN
QEQFTYGLIAMDASKQTFRAQEYAAYKATRKPMDAKLIVQLPYLKKLFVA
MGFRIISQPGIEADDFVGSFSNLMNKFDVDTTIYSSDRDMLQLINKNTKL
KLLKTGTSVMQEINLTNFSLLNNGILPYQIIEYKGLVGDSSDNLIGVKGI
GPKTAINLLLKYDNIENIYTNLEKIAPSVKNKLIEHKDMAFLSKKLAAIQ
TDLLFDEKLENFVLKPYNTQELDELFTSLKINNMQNYYK
>UU377 polC, DNA polymerase III alpha chain 1
METKNALFKKIVKISDQLLNKISIKKLTKDKKNNLFVYFDEFVDVTIIDE
LHQLSKTTLMHDLQIWYINNLKEVDHKKILTFFKKISEQNANLIFLEQIN
DLNTKIEYNSNLNSLILKINDKLIYDHFIANKLEILNILKVWSLPYSNFE
IHFENLSSLLNEKHEQAVNEIISHHIQQQKHLEQQISQQQNFYNNQKANF
NYYKNPSNKTITKLIDINPLMNNAKIRAYVFLKKIDILKSGAIAYKLNVI
DDSETLTIMTYLPSGEHPLKKFLDELKIDQLIEAEIDIVLDNMSKSGQVP
IGKIKKICCVEDKHVKKQITPRLELNFHTKMSSLDAIISTQELIDFAVKN
QLKTIGITDRNVVQAYPEIAKFSKKQDLKIIYGLETEELEDQIPLVLNVR
DQNLDNATYVIFDIETTGLFPNFDEIIEFGAVIMQNNKQIGEKIQFFIKP
IQQINENVTNLTNISQEMVNNAIDEKTALLKIKEIFDDHILVAHNGINFD
INFINQRLLKWGLEPLKNPSIDTLMISRAINPFKSHRLGAICKKYEVDYN
DESAHRADYDAIVLADVFKVMKNNLFNDFGITNLSEINTKLQTTMLKNRS
FGNWINLYIKNQANVKDMYELVSISHTDMYYTRPTITTSFLANKKDKLII
SNSIHESDLINALYSKNDEEIKRLIQRYDFITLPSLGSQKHLVYAKKITI
ENVQKAFKKLIYLALELNKIIIYSSSPYYFFKDDKKFYDVYVNTKGLEGK
AHRFANEVYVPDLEYIDQKNAIDELAYLEDEKLINLIINENPVHINSWFD
DSIQPLKEGLYAPKMEGVDQKTIDYVYHTAKKIYGENLPTIVEQRIKKEL
NSIIKHGFSVVYWISHLLVEKSMQDGYGVGSRGSVGSSLVATFLNITDVN
PLTPHYLCPNCKKCEFITNADDGFDLAPKSCEQCQTPMLTDGHNIPFETF
LGFDGDKVPDIDLNFSGVYQAVAHNFIKSIFGETHSYRAGTIGTMAQTSA
ENTVKKYFENRFNENKIIRDSTVSLYVQKCIDSKRTTGQHPGGIIIVPKE
YSIWDFSPYNFPANDINETWKTTHFAFEYLHDSLLKFDILGHDNPTILKL
LKDYTGIDERDVPMYDPLVMKSFSDISALNIKPSDVLNETTGAISIPEFG
TRFVRGMLVDTKPKSFADLIRISGLSHGESVWLGNAQSLIKSGKLLKDVI
ACRDDIMTYLIRQNVEPKTAFLIMEDVRKGKKIKPEHQIILKELKVPEWY
IESANKIKYMFPKAHATAYVMHAWKFAWYKIYYPLEYYAAFFSVRADNFD
LFVINQGKEFIEKTYNDIEQRSKSRDPQKKVSSRELALQPIYEIVIELLA
RGFKISNISIEQSQATSYVIDKENNAIIPPFIAIQGLGETVANSIIEARN
QKVFSTIEDLKNRTKISRTDLKNLRVLGVLDHLSETEQLTLF
>UU107 potA, spermidine/putrescine transport ATP-binding protein
MEKTLLHLRDITKIYDDGFAAVNKFDLKIKKGEFVTLLGPSGCGKTTMLK
IIAGFEQPTNGKILYNGIDIKDMPIRLRPTSTVFQDYALFPNMTVKQNIK
YGLKLMRKPKDNVDQSIYLQADKVYNSASKKANEKIKELKKQRRGLLAEI
KKMDLKYQKNKNIFEIKEMRKNQYLGTLDELYQKQGINKNGKPGFLNYFK
SWFSHEKLNLNDPIDREIFNLKKAYKEKSGLDKRYDKITYKYNDLDYWES
YWATYPQLKKEQFENKNITRLLTKEEVEKEANRVINLVGLSARKDSYPSD
LSGGMQQRVALARSLVIQPEIILLDEPLSALDAKVRKQLQDELKKLHKNL
GITFILVTHDQEEALSLSDKVVVMSNGQIEQVGKPSDIYDSPNSLWVANF
IGKTNIFEGHYIAKGEVEFDGITSKTDVINGFSENEACYIMIRPEDFDVV
KKDEGSINARVESVLYKGLMWDIKCKYNDMIISVEGVNKVNEGDEIGLDW
DDIDVHVIKKDYLNNEQAI
>UU108 potB, spermidine/putrescine transport system permease
MNKQFNFNFAPSKLSDINKKNETVFFLKEVKVIKKNNRKHYKQTLFDKLK
MNKALILTIPYFLVTIFLLIIPLVSIIVKTFINNTDSTGVTTNIIDNWSV
ITPTIGMKIFNSLWIAAVATIFCLIIGYPFAYFLSIGKSKFLKAIAIALI
TSPIWMSMLVKLIGIKTFFDVVNGEINSTHGHIFTILGLVYINLPLMILP
IYTSLSTMPKNLVNASYDLGRGFFYTFFHIVIPYTKNALISGVWIVYLAA
FTSVVVSGFLNNDNAGGLIGGEIFAQGQDGISSGVQLSRSSTITLVISLI
LLGIYLIIVIIPKIVQLIYYKRKNLKKGVKNNEAD
>UU109 potC, spermidine/putrescine transport system permease
MKQINWLSWLRNFYIWIILAIIYIPLIIIVLLSFTTPSIKGNITSAFNWN
DGSNYLTLTTNQFTDALINTIIISVIAVPISTIIATITCFGVWHAKIFYK
KLMTASSQTNIMIPDVISGISLSLLFAATFIPIGFSFGFGTIILAHISSC
TPYAIMIIYPRMLKMKKNLILASYDLGYTKIATFFRIILPYLLPSIISAT
IIVFAMSFDDFIITKLVGGKVNTIGTEMYSMAKGIKAWAVCFGALMVLLT
ILIAALISANKIIKLKLINKQTNKRKLKIWNRQV
>UU315 ppa, inorganic pyrophosphatase
MKLNVTIEIPKNSNIKYEYDRATKEIMVDRILHGSMVYPHNYGFLKEALD
YDGDELDVLVFADQAFQPGIKVPARVLGAMKMIDGGETDTKLLAVIDVDP
RYKHINNFKDIPLHWLAEVQDFFENYKNLQNKKVKILGFEDEIWAQKEYE
ECVLLMKEYGHLKKDEFVTKMMKERPEKYIK
>UU003 prfA, peptide chain release factor 1
MEYNKKLYEAIERVAIKNDALKKELETVVTDFKKIKEINIQLKKTTKIAE
AFAKYKQKLDTGIAAEKILNTEKDLELIELAQMDLDEAKINIPIIENDLK
IMLLPTDPNDDKNVIVEMRPAAGGDESSIFVGNLFDTYRAYAENNNWKMK
IIEMTPNAVGFSFISFMISGEEVYSRMKFESGVHRVQRVPATESKGRVHT
STITVAVLPEQDEVDVVINPTELRIDTYRASGAGGQHVNRTESAVRITHI
PTGVVAACQEGKSQIENRETAMKMLRAKLWEAAQEQQNAEFANLRKNQVG
TGDRSEKIRTYNYPQNRVTDHRINLTLNKLDQIMMGELDEIIDALIADEQ
TGLMANLDI
>UU452 proS, prolyl aminoacyl-tRNA synthetase
MSKKLEKITTRKENFADWYTSIVNNAKLIQYTDIKGMMVFQPNAWAIWEA
IKNQIDVEFKKHGVRNLAMPTLIPLSEFQKEKDHIEGFAPELFMVNQIGD
KKLDNSYAIRPTSEILFCNYFKNIVNSYNDLPIKNNQWCSVMRAEKTTRP
FLRNAEFHWQELHAIFASENEADSFAKVILDVYTDFVQNYLCIPVIKGLK
TPWERFAGAQKTYTIEAMMQDGQALQSATSHYLGQFFAKAYDIKFQGQDN
QMHYVHQMSAGLSTRIIGALIMVHADDQGLILPPDIAFNQIAILTIFSNK
NPQLLKISQQICEQLNNYRLFEDHSDKGIGYKLAQQEIEGTPICILVGAK
ELVNQQVVIVRRDTHEKINVDLTDLKLIIPKLLADIKRNIYEKAKKDLED
SIVFVNNIEELKQVIAQNKMAKAFFDGTKEDDEQIKLLTNASTRCIFDET
QNGQCFYTNKKTNKLTLFARAY
>UU193 prsA, phosphoribosylpyrophosphate synthetase
MSKNDDILLFSLSNSHQLANKIANLLKIELSPIRIDKFADGELIVAPQVP
VRGRRVIIIQSTSKPVNDSLMELLIAIDSIKRASAKAISVVIPYYGYARQ
DRKAKPREPITARLVAKMIESAGATSVLTWDIHSLQTQGFFDIPFDSLEA
VWVLMKHYFSAYKDSSNITIVSPDYGGVKRAREISIATGATLAIVDKRRS
GKNQVEINNVLGDVKDRDCVIVDDMIDTGGTILGAAKIVREKGAKSITII
ATHGLFNNNARQHFQQAIKDRIINKICIADTIENEPFDGLEIVSIAPAIA
KCIEIYSEGTGSMSFVHDENSKVLFAKKIY
>UU364 psgA, phosphatidylglycerophosphate synthase
MAKLNFKKNISSSPFFRNIPNIITIFRIFLALICIILLLVDFYTKNLNIV
YEVLDANISALRLSATIIFIIAAFSDFLDGYIARKYNLVSNLGKILDPIS
DKILVNGVLICLTLDHTALAYLTIINILRDIFIDGLRMFASSKKIIIPAN
IFGKIKSILLFISICFILFLLSLTSSWKNVYLFNIPLFFATSLSVISGII
YYINFYKGVKKRGSITKS
>UU199 pstA, phosphate transport system permease
MSILNLNSQQTKKIIFNKKIKDKLAKTLVISFAWLFSICFIGLVVFIIIR
SIPGFEAYGLKNIFWSKNFNLADYAAGSSVWFPLAITLLVSFGAIIIAAP
IGIKTATFIKFRIKNKRLQKFFRVTILALAGIPSVIFGLFAIQSLGPAIS
FVFHIDTVQNITTSMFMLAFIIIPTIISLTLSTYDGIDMRLIENGIGMGS
SYTRSIYKIFKKEARGGIIIAIIIALGRAIGETMAISMILSDQGYQNIFG
TGFLQIMHSALRPLGAVISANMFAENGGEGLRGLLYIYGIVLFVAIMILN
GLVTYLTRKRSKKTYAWFIKLEKSLAYIVCFIPDQLKILYEKITHRSQYK
LHVNNLDNLNNYITDRIQNRKLKRLYTVHKLFFESLAFMVAFAFLAWISL
DILVNGIKAINLPTSTVVAYTKNTTGQATINTLIIIIVAILIGLPFSLFV
AIYINEYAKNKWPKKVLLFFIDSFGSTPSIIFGMFGLVIFIEIFGFTSMG
NIGKSLLAGALTITLVVLPTFTRSIQQSLKAVPMSIRENAYGLGCSKWET
IVKLVLPQAKKGIISAIVLTIGRIVAETAPLYLTAGLSSAQSITILNPGQ
TLTTRIYAQLYENNTNIAHNVMYESAFITLWLVIALIIIAHVIVPYFEFI
KHDIKKWFKILKNYLRAPYMRDIKVFKPQIYQKHLYLTHNQAKIMGYNES
VNKVAKIGLKLYEIRYVDDEQIQKELLKVRG
>UU200 pstB, phosphate transport ATP-binding protein B
MNDQKDNKEIQTIVPLNQKTNLNELDAKAIYDEFQKLNKYQRAFAWLKLP
KQKKAELKQFLNKKKTQVDLLKEDFNHANVFEIRNFNFWYMNRTKHVLHD
LNLDIKRNKVTAFIGPSGCGKSTFLRNLNQLNDLIEGTSHEGEIYFLGTN
TRSKKISSLELRTRIGMVFQKPTPFEMSIFDNVAYGPRNNGINDRKILEK
IVEKSLKSAALWDEVKDDLDKAGNALSGGQQQRLCIARAIALEPEVLLMD
EPTSALDPIATAKIEELILELKKKYSIIIVTHSMAQAQRISDETVFFYQG
WIEEAGETKTIFIHPKNKRTKDYISGKIG
>UU066 pta, phosphotransacetylase
MLSSINKLKNKLKNLAKKPIKVLFIEQSLEIDKAKKMLSQDTLINIVDLS
SFKTPEIINECEEIWYELRKLKGESRNDAQIAVNDNLNFAVCLSYLKKID
VLIVGANLSSKTCFSSILKILKNPNGSIAYSTMVMINKRELIFMSDCALN
LNLNKQQMIDAAKYSCTISRNYFDVLNNHVGYISYLSQNDVIYQNKNFDF
IGPIQFDAVVDLKVRNKKVPNIHQYHINHYVFDNISIANTVFKIYQTKLN
YLTVGTYISNILTKVSVISRSASSDEIIATTYLLCVAFLTDLT
>UU215 ptc1, protein phosphatase
MNFGFISDIGSQRKHNDDCALVIQNQYQQTLLIVCDGLGGYKGGAAASHI
TLETIKDNFLTTDFSEYDKQQIQKWYIKVIKLAQVEIDRTVLLDKDVYNM
GTTVVASIVVNDFSYTLNIGDSRAYLLSNEQFLQISRDHNLLQVLQERKA
NPEVYKKHEKNLFSLTQFVGRTSNIFLSYDLFVNKLNPNEIIVLTSDGFH
NYFELNTLYEKLIKSTQETKNELLQQLIRQAIINGSNDNLSLAFLIF
>UU078 pth, peptidyl-tRNA hydrolase
MEKYLIVGLGNPGSNYAKTRHNVGFMVINEICNKLNLSLDSSKFNGIFTK
TIYNNSIVFFCQPTTYMNLSGEFVIKMLNFYNIPIKNLIVIYDDVDTKLG
TIKLRKKGSSGGQNGIKNIINILKTDEIKRIRIGIDKDPHIKLDQYVLSN
FKIDELVIIKPAIIKGALATLAAIGEDFDKVMNKFN
>UU587 ptsH, phosphohistidinoprotein-hexosephosphotransferase
MISKEFTIVAELSAFIKAITYFVNAASDFSSSITIKANGRQADAKSIINI
MALGIKQGTKIELSAVGNDANKAINKLEEILIEQKLI
>UU186 pyk, pyruvate kinase
MFSKTRIIATVGPATTKLFSNWLEFNDLNNINDAQQVCINIKDLILSGVN
IFRMNLSHGDQKIHLFRTQLIKKIADELKIKVEILFDTKGPEIRVCEMSD
NNFIIKNSEVIIHCKEKVLGSFNEFSVTDATGQYNMISDVKINHRILIDD
GKLILIVKKIDFLKNIIYTTAKNSYSLKTNKRLNLPDANYSLPFLSKKDI
DDINLAVKLKIPYLALSFISNIKQINEVKQLLKKSSFIPKLIAKIETQEA
IDNLEEIIKNTDGIMVARGDLGLEVPFYKIPIYQNKIVELCHKYNKYCII
ATQMLDSLERNIIPTRAEVTDVYYAVKQKVNATMLSGETAAGIDPINAVQ
VMKSIILETENNNIENEITFKKNELLIPKEVKLKILSFHKLKINKHKLLV
VNLISKNSKHLVYDILKYDFNFNILFVIDKNQEHDLLLKNANFIISENKM
LKQEELLKSFNIDFNNHEFLFISI
>UU284 pyrG, CTP synthetase
MEIDLMKHIQKTKFIFVTGGVYSSLGKGVSASSIGRILVELGYSVAMQKL
DPYLNIDPTYLSPLQHGEVFVTKDGKEADLDLGTYERFINADLNKYASVT
SGKIYYEILTKERENGFDGKTVQTIPHVTSAVIDYIKKIKDSLKTDFIIV
EIGGTIGDIESLPFIEAISQFKTIYGVNNVMFIHCSPLIYIEKVGELKTK
PTQHSVKTLRSLGINLDLLLLRTNQKLDEVTIKKLAWSCGLDIDMIFAAY
DVESVYLLPNVLFEQGIHKTILDFFSLPLKNDNINSWIDFTDKITTFKKH
NLVIGLVGKYVELPDAYKSVLASLELAAIELNIDLKIKYIQPQNLNENNI
NEELKKINGIVIPSIAGSIKGWPGALLAASYARKNNIPFLAVGTGVNIGI
GEFINNVLKLPIEFINLGNGDFSFLKDAFVKNEIENYRIGEYCSNIQANT
ITSQIYLKQNQLNERHRHHFEFNNHYINNYFLNQNWKIGAISVDNNYIDV
LEYTKNHFYVLTIFNPEYTSKPSKANPYFINLLKMSLKIKES
>UU513 pyrH, uridylate kinase
MRKQRIVIKISGACLKQNDSSIIDFIKINDLAEQIEKISKKYIVSIVLGG
GNIWRGSIAKELDMDRNLADNMGMMATIINGLALENALNHLNVNTIVLSA
IKCDKLVHESSANNIKKAIEKEQVMIFVAGTGFPYFTTDSCAAIRAAETE
SSIILMGKNGVDGVYDSDPKINPNAQFYEHITFNMALTQNLKVMDATALA
LCQENNINLLVFNIDKPNAIVDVLEKKNKYTIVSK
>UU321 rbfA, ribosome binding factor A
MANEVRVARLESLIKDVINNALANEINDKIAKLARVTAVRLSNDLSVAKI
FLDAHKRESMLKVLENVNKVSGLLRSKLAAEWTSYKVPELRFVIDETIDY
ANHIDELFKKIKQQEN
>UU014 rbsC-1, ribose/galactose ABC transporter (N-term domain)
MLKFKTLLSYDSFLKGQERKTITKKFLSTVFAIFVAIVVSAILVGILGYN
IRDFFIRLFTKWIGSPDIYLTKVAILGIAALSFIFAFKAGLFNIGISGQM
LGSGLIMLLVVKNMQIANINMPNVLGQFFLLIIAMLAGAMFAVFIGILKV
FLKINEVVSSILLNWIMFYITRYVVFTAQSKMYNPTPDQVGSRSIPFADN
YSLFHLASGYGYLFALLIFISLSIIIWVILKYTVFGHKVLSVGKSFDAAK
YAGYRTKIISLATFAISGALAGALAMVNYTSTTTNAIVISQAADALPTQG
YDGIAMGLISLAHPLATIPVSFLMGLLQQSADNLGGSFPQDLSGIIISFV
MLGAAMFILFERISPVYWIYHLIYTYKGKDYYRDYENKNNNIISEYKAIY
SEINKKRNQYLQELKKLRKELDQFKNHEQYNKVNQQYEYTISYIKTTYNA
WLKVEYDKYLKQLKNNAMQLKKHLIIERATLVYYPEINTTRKIKNKLKHF
ENISAKKLSRIKDKIHNEDFLIKNLVAKEISKYAQSKSFDYNKLKYLLQE
YENNNSVLTTELVNELSLVLKDEQAQLMFSEFKQASFENNLDHMIDLKNQ
IMTYINSLLDSRLEQLSITLKSKNLVHDEQMDKIILLLNPNDKILNKIII
SRNKHLENYTKEITKLELRNISQDDEIKKNTKQRSSSYLTKHYEKTKQHI
NKINLDQEQKLLLEDWLTTAYQKAIINQQNMKEVIS
>UU013 rbsC-2, ribose/galactose ABC transporter
MPSLSLINDASIYAAILILGALSGFFCERVGIANISINGQMIIGALVFTL
FSTIIYKYMGTKTETEYTFIVCLIIAGILTIPTSLLFGFLTIKLKTNQII
AGTAINLLASGVATFVTYPLGDKIADKTSLSSDYLGLMKIGDGINTIYIG
SILILIAVVLITIGLMIMMKKTPFGLRLYAIGENPNAADAQGINVYKYQW
IAVSISGFIAGIGGGLYMYASRSPFAGEVGGIGFLALAILIAGAWRIPLI
AVVSIAFAVITKTFSQIDKIPQEIGKLIPYVITLIALISFSKYSVAPKNV
GIPFDKTKR
>UU084 recA, recombination protein
MKENNNLEKLDPIATLETKFAKSSYFIADEIKDEKINAISTGSIHIDQIT
GINGIPVGKITEIYGNESSGKTTIALQTIAECQKTGGTVVLLDLEGSFDI
NYAKSLKVDLTKLIITQPQTGEQAFDMIETLIKTNSIDLIVIDSVAAMLP
ESEYQANMNEALMGAHARLMSKGLRKIQPLINKSKTAIIFINQLREKINT
FFGNPEMTTGGKALKFYASLRIETKKADLIKEGINKIGIKTKVTTVKNKL
APPLQTCFIDIFFGSGFDYNNEIIDFAIQYGVLKKNGSWFYFNDNKIGQG
REQLKNTLSKNNELFIQISEKTLEFVNNEKSNWQ
>UU089 recR, recombinational DNA repair protein
MSKPVEFEMLVDALKSLPGVGTKNANKWAFFLLQQDQKYIDDLIKRIKEA
KTNILKCKYCANFTNKDECDICLNEYRDFTKLMIVTTNEDLERIESANIY
NGLYHITNGEISLRKNVVIEHTNIKTIKERVLNGSFKEIIIATSYTHDGE
VTADYIIRMLEDIKDLQIYRIGFGIPLNSSIDYADDETLKQSLINKRKIR
N
>UU355 ribF, riboflavin kinase/FAD synthetase
MIIEITSTNIYKIKQQFVINELIIGFFDGIHLGHMNLLSDPNNQTILTFK
NIPRKIKKLYDFNERIQQLEDLGFKRIFIYDIDQNNLSGEEFIDQILKPL
TPKKIIVGANFTYGNNFCNASSLKQYFNVEIKIITNDVSTTKIKELIINK
QVEIANKLLIKPYYRVGNVVRGDQIARNIGFNTANILCDNNLIDIAEGVY
KAQVIFNNKKYDSVVYLGIPKTINTRSFSMIEAHILDFNQNIYDERIKIV
FLKYLAPNLKFNNIDELITAIKNYIKLVLDKTN
>UU145 ripX, integrase-recombinase protein
MERQSMINKFLQSIKKRNLSKNTYLTYESHLRKFKVQEQSFKQIIKQLLN
NNYKPKSLKLAKSILSEYWKFSKQYQYVQELEQIKLSKEQKSYKKVFSLD
DIKKCLKINKQDTKQIKFYKTILLFYATTGIRAMEIYQLKQINNDLFVIS
GKGNKNRQICYIEHLWNNIKNKKLPSTKTLRKYLKVFFDNKNVSLHTLRR
SFITNFLTSNENYKRGDMLKIVQDLVGHENIQTTLQYVQITKEQVDDVYK
EFFKEFENDK
>UU313 rluD, pseudouridine synthase (uracil hydrolase)
MKILYSLMSSQRIDKFLVENTNYSRTLIKKMLDQNLILVNDNFISKASYL
LKKNDYIQINNELPIVQEQKKLLPFVYSLEIIFEDQDLLIVNKPSGMLVH
PTSFHEQNTLANALKYYLKTDNFYITHRLDKNTSGLIIICKNQIALNSLQ
QQFMQKTIRKSYYAIVHNRFDMQHLHFMINEPIGHSYQDKLRMKTGNSKN
TKEAISIVKVLEQYKNTALVEVSIITGRTHQIRVHMRYINHPVYNDPLYG
ISKHTTEYEQYLHSFYISFNHPSTNKKVEFKINMPKEFMELIRELKANE
>UU205 rnc, ribonuclease III
MDNKKFLDFLKQNRIEPKNLSIYLEALTHKSYANEHKLTKNYQRLEFLGD
ACVEWVISNFIFNYKIKDNEKMRSLDEGEMTRARSNMVRSEILSYAAKDL
GLTDFLMIGVGLEQDQSARMEKIYEDIFEAFIGAVAQDQGIKKVSLILEK
TLIKYFREGQINYQKDYKTIFQEQAQRINKKPIMYKLVRNEGDKKEVHLV
WNDLIYGIGIASTRKEAEILAAKNAILKLDDYTKKA
>UU397 rnhB, ribonuclease HII
MAIVSVKLTSNQVDKFLILWRPYLVHNNHNYAKYTFKIDGTLIIIYNTNT
CTINTHDINSFLNTFLKREDLTLFNVIKQQVNTKKNNQNVMSQSEIYESA
QVIIGSDEVGVGDLFGGIVVCAVSLKKSDFKKINHLKIIDSKKLNDQQMQ
EIYQQIKNQISYTIVSYNPKEYNELIKEYNNAHILKTILHYKALQSEIHK
HAKYSIFSVVDAFSSLKNWNQYLQKVNFQPYEPNLLIPKAESIYTSVALA
SIIARVMFLKMIAIIEEQFNVKIPLGSSNPLVNDVASNIFQKFGLKILKQ
VAKEHFSNFQQIIKNK
>UU603 rnpA, ribonuclease p-protein component
MANFISLKKNEDILDTIKKQQKIHSNQIVVYFRKTNLKNVRLAISISKKK
FKLATQRNRIRRLIKAWFIAADIPIKSYDIVVLVKPSFIDGSFVLNCNNL
KIILQRIINKEKR
>UU540 rpL1, ribosomal protein L1
MAKISKKLFAAYEGIDKQKAYPLFDAIKLAQEKSITKFDGSINIAIKLNL
DTTKVEQQLRGSISLPNGNGKNVRVLVLSEDITKEEAASVGADYFGGADY
IQNIEKMLNQIDVIITNQKMMPLLAKLGKVLGPRGLMPNPKIGTVTNDVL
KAVEEFKRGRIEYRTDTYGNIHMSIGRVSFETTKIEENANALLNLIKSKK
PATVKGQYIQNIAVSPTMGPGIKVVINNN
>UU010 rpL10, ribosomal protein L10
MANVRPSVVFKQQEVNHMADILKNSKSFIVFEYHGLTAANILALRNVLHS
SNSKLYVLKNNITARAFEKAGVSGFENQLTGPNAVAVAMDDEIAAIKAVN
DVAKEFDFVKIKGAYLENKFADTHKIDQLAAIPGREGLYSMLLSCFTAPL
RNVMYGLKAVAEQKGE
>UU541 rpL11, ribosomal protein L11
MAPKKKEVTRIAKLNLIGGQAKPGPALASVGINMAEFTKSFNDKTKDQNG
KVIPVIITAYKDKSFDYVIKTTPVTFLLKDIAKIKSGAKDPKKQTVATIS
KEQALEIARYKLIDMTAYDEEAALRMIAGSAKQMGIVIEGVSAYKEKKGN
>UU577 rpL13, ribosomal protein L13
MQKSSMLKKEVAIARRQWYLVDATDLVLGRLSVKVADILRGKNKVDYTPN
VDAGDYVVVINSDKVVLTGQKALRENWYNHSHYIGGLRTRSGEEMISKYS
DELIRRSVKGMLPKNKLAKQILNKLFIYKNDKHPHEAQQPTILELKLK
>UU241 rpL14, ribosomal protein L14
MIQHMTRLKVADNTGAKEVGVIKVLGGSKKRYASVGDIVVVSVKKATPAG
LIAKGQMAKAVIVRTKKSIRRESGLLIRFDENACVLIKEDKTPRGSRIFG
PVAREIRDRGYTKIASLAPEVL
>UU249 rpL15, ribosomal protein L15
MQLHNLEYKKGSRNHKEKRVGRGHGSGLGKTSGRGQDGQKARKSGMVRLA
FEGGQTPLYRRVPKVGFNNDRFANKYNVVTLISLVKYETKELTVEFMYAN
KIAKNEDLPIKVIGNAVLPSGTVVSAHKFSKGALESISNSKAKAQILE
>UU238 rpL16, ribosomal protein L16
MLQPKRTKFRKPHKVSYEGKAKGNKQVDFGEFGLMALEGAWIDARQIESA
RIAISKRLLKTGKMWIRIFPHMSLTKKPLEVRMGSGKGSPEKWVAVVKAG
TVMFEIANVSEELMCEALRAAGNKLPIKVKIVKKGEAN
>UU258 rpL17, ribosomal protein L17
MSYINKPGKTRAWRKMVSRQQVSDVISHGSIVTTKTKAKESQRHVDHLIT
LAKKNTLASRRAAAAILLGTNQHSADDLLRKLFNELGPKYANRAGGYTRV
IKLGNRPGDNTEEAVLQLV
>UU247 rpL18, ribosomal protein L18
MKRINFSRAKQRALRAKRLHVKIRNLQLAANKPVLVITKTNAHIWAQLIC
YNKNITLASSSSVQLDLQNGNKDNARLVGVDIAKKALAQGFKQVIFNKNG
AKYHGRIKALADAAREAGLEF
>UU566 rpL19, ribosomal protein L19
MALFKINKGEIMNFVNSTQLKTDIPNFDSGDTIIVHNRIVEGKKSRIQKF
EGVVLRRRGSGSSETVIVRKESSGIGVEQSFNIHSPLVEKIEVIKYGKVR
RAYISYMRNRSGKSARIKELNKQ
>UU234 rpL2, ribosomal protein L2
MAVKRIKNHSSGKRQTVVVDYKSILTTSKPEKSLLVTLPKKAGRNNQGKI
TIRHHGGGHKRKYRIIDFKRNKDNIYGTIKSIEYDPNRTSFISLVVYADG
EKRYIIAPKGIKVGDKIISGNENIDILLGNSLPLEFIPEGTLVHNIELSP
NAGGQITRSAGASAQILGFDETKKYILVKLNSGEVRKFRKECRATIGTVS
NDEHILENLGKAGKSRHLGVRPTVRGSAMNPNDHPHGGGEGRSPVGMDAP
RTPWGKRHMGVKTRNNKKSSTSMIVRRRK
>UU229 rpL20, ribosomal protein L20
MRVKGGSVTRQRRKRWLEKAEGSWGTRNTSYRIARQTVIRAAEYAYRDRR
NKKRDFRKLWISRINAAVRELGYTYSQFMNALVKANVVTKDGQGLNRKML
SELAINNPEAFNQLVDKVMK
>UU212 rpL21, ribosomal protein L21
MFAIFQTGGKQYKVQQGEKIYVEKLDLEVGSKISFDQVIMVEGSVGTPFV
KNAVVNATVIKQGKQKKINIIKFKSKKHHLKRQGHRQPYTQLVIDSISVK
>UU236 rpL22, ribosomal protein L22
MTNKVIQRNIHISHRKASLVIDLVRNKPVHEAIRILSNTPKKFAPIVLKL
LNSAISNVQHNSKDMDPSKLYIYKIVANQGPTMKRTLPRAKGSADQLFKR
TTHLEIVLSDDVNEREKELAAIKAKKSKKPLAVEPIAKVETKKVAKPSKV
EIKPVEKDENVDPELLKREQQVLKVVEKTASQKEEETTETIMISTSPKNA
QVLFDDLEKNVIFYKTTPINKVLRVLVYVTSPTKKVVGEFDLESVEIGAI
SSIWRKYSKQSVISKKEYDAYYEGKDKAHALVSKKAYKYRNPKDLSEYNM
TKGPSGFQYLK
>UU233 rpL23, ribosomal protein L23
MELTRVILHPYTTEKTYSIRNKSEHETLTFIVDKNANKYQIREAFIAIFG
LKPLKIRTTNRRPAKIRTSTARPGYTKAKKIAYVVMPVGVKVAVSKEEVE
AANAK
>UU242 rpL24, ribosomal protein L24
MNRIKKGDTVVVISGKNKNKSGVVIQVNPKEQTALVEGVNKIKRHQKKDQ
THEQSGIIEKEAPIRLCKLALVDPKGKDKGKATKVKYLLKDNKKVRVARK
SGSELDVNKK
>UU210 rpL27, ribosomal protein L27
MNKLYWLTDLQLFASKKGVGSSKNGRDSNPKYLGAKLGDGQSTKAGQIIY
RQRGNKIYPGLNVGQGKDHTLFAKTAGVVKYTKFMGDKTKVSVLPKEDNN
>UU209.1 rpL28, ribosomal protein L28
MAKRDQLTGKGPLSGNTRSHAMNHSKRRWNVNLQKATIKTENGSQRVLVS
AKTLKTLKKHNLLA
>UU239 rpL29, ribosomal protein L29
MSSIAQDLRKKDSLELEKIVIELKAKLLELRFAAANGEAEKLHTAKEIRK
TIARALTILNERELAEKLNNKEANK
>UU231 rpL3, ribosomal protein L3
MKSLLGTKVGMTQVFTETGKAVAATVIYVEPNKVLAVKTNEKDGYSAIQI
GYETVKEKALNKPLLGQFKKANSDPKRHIKEFRDVVAEVGAELTVSEFEP
GQLVNAQAYTKGHGFTGSIKRHNFSMGPMGHGAGYPHRYVGSIAKGRGGS
QAQRVFKGTKLPGHYGHELVTTKNLLVLDVKANENLILIKGAIPGPKGSI
VLLKSAKKVGHIVSDPQVVNYLANKASSSEANE
>UU002 rpL31, ribosomal protein L31
MRDIHPVSKPCVYNCVTCKKEFIIDSAAKNTEVAIEVCSNCHTFFIGKQN
ATTTLRGRAEKLNNRFEAGLNNINKKPEKKKIQGKSEPRKSLNEL
>UU333 rpL32, ribosomal protein L32
MAVQQRRVSKSRKGMRRSHDHLTISNTVACNECGKALLPHRACRDCKTYR
SIKLSIK
>UU533 rpL33, ribosomal protein L33
MAIKRGVRLQCNESKSINYITTKNAKNNPDRLSLNKFCPKCRKVTTHVEI
KKK
>UU604 rpL34, ribosomal protein L34
MKRTFQPNNRKRAKVHGFRARMKTKNGRNVLARRRLKGRHSLTVSSEK
>UU228 rpL35, ribosomal protein L35
MAKIRQKTKRAVAKRFSITKNGKLKRKHAYRSHLALGRSTKAKRHLRKDA
IMSTSDTKRYTQCL
>UU254 rpL36, ribosomal protein L36
MKVRASVKAICKDCKIVKRSGVVRVICANSKHKQRQG
>UU232 rpL4, ribosomal protein L4
MAKIKLLSIDGNFAKELEVTSDLFVEVPHKQAMFDSVLAENAAERQGTHS
TLTKGEVRGGGKKPWRQKHTGKARTGSTRNPHWTGGGVVFGPKPNRNYNL
KVNAKVRLLAFKSALTIKLNEGKMLGLVANSDLETPSTKKMVNFINNANL
ENQKVLLVIVDNFSNIKKSTNNLQKVTTKLWYQVSVRDLMHANVVVVAEE
AFTNYARKVSK
>UU243 rpL5, ribosomal protein L5
MAFLKDLYKNKVAKDLQKEFAYSSVMQIPKIEKVVINAGIGNAVADKKHL
EAAISELTLITGQRPVETKAKKSIATFKLRAGQSIGAKVTLRGDRMWAFI
ETLFNIALPRVRDFKGISNNSFDNQGNYTLGIKEQIIFPQVVYDDVKSVR
GFDVTFVTTAKTAQEAKALLVGLGAPFQKVRGDK
>UU246 rpL6, ribosomal protein L6
MSRIGNRKLTIPANVNVSVESGKVHIVSQTAKLSVDFPVNLISVDVVDNT
VKVSRANDEKQTKMFHGTVNANIANALVGVTTGWKKELEVKGVGFRAKVE
GSKLNLGLGFSHPLLIQIPTGLKVETPSATEISINGADKAAVGAFAAVVR
AYRKPEPYKGKGVMYKGERIVRKAGKTADKKK
>UU011 rpL7/L12, ribosomal protein L7/L12
MSKLTIEQFIAAIKEMSMLELNDLVKAIETEFGVSAAAPVAAAAAPVAAE
APTEVTIKLVEAGTNKVGVIKLIREITGLGLMEAKTAAETAGSVIKEDVK
TEEANEIKKKFDELGAKVQLV
>UU551 rpL9, ribosomal protein L9
MKVILLEDIASLGKKNEIIDVSDGYAKNFLIRQKKAVALTNKSQEVLNKD
LAILEAQEQQAILDATLLKDKLEQKPLQFFLKTNNLQTFGSISNKQIIDE
INKEQKFITKHMITKPHALGIGEHIVEILLHKKVTAKLHVIVSKE
>UU230 rpS10, ribosomal protein S10
MNQELRIRLESYDHRLLDDTVKTIVNISNSTGSKLRGPIPLPTKKEIFTI
LRSPHVNKSSREQFERRTHKRLIILENPQPKTMEALKRLSVPFGVEVTFK
I
>UU256 rpS11, ribosomal protein S11
MAKKKKLSFTNGIAYIHATKNNTIITLADEQGSVLSWASSGSIGYKGTKK
KTPYSAGIAAEAAAKAVIDMGLKSVEVHVNGTGASRDTAIRSLQAAGLEV
TKIKDVTPIPHNGCRPPKKPR
>UU525 rpS12, ribosomal protein S12
MPTIAQLIRNKRAPKVKKTKSPALLFTYNSLHKKTTKNPSPLKSGVCTRV
GTMTPKKPNSALRKYAKVRLSNGFEVLAYIPGEGHNLQEHSVVVIRGGRV
KDLPGVRYHIVRGAGDASGVEKRRQQRSLYGAKRPKKEASK
>UU255 rpS13, ribosomal protein S13
MARILGVDIPNDKRVVISLTYIFGIGKSTSQQILKLANIDENIRVKDLAD
EQIAEIRRVALNFVKANGEKLQLEGDLRRTVAMDIKRLMEIGSYRGIRHR
RGLPVRGQRTKTNARTRKGPRKTVANKKIETR
>UU244 rpS14, ribosomal protein S14
MAKKSLIAKQKKHQKFAVREYTRCVRCGRPHAVNRKFGVCRLCFRDLAYA
GAIPGIKKASW
>UU568 rpS16, ribosomal protein S16
MKILVKIRLTRVGTHKKPFFRIVVMDAKTKANGAYIENLGHYDPVLGQVV
LKKEAILAQLQNGAQPSETVKNILSQEGIWKEFIALKDANKKRKAALSKA
K
>UU240 rpS17, ribosomal protein S17
MERSRRKVLEGLVVSDKMQKTVVVSVETKSKHPIYRKLVISHKKYHAHND
NDDAKVGDLVEITETRPLSATKNWRVSKILERAR
>UU552 rpS18, ribosomal protein S18
MAKVTNNRNRKPRKKVCILSAKGIEHVDYKDVELLQRFINNNNKIASRRV
TGASARMQRRIANAIKRARFVGLLPYVKE
>UU235 rpS19, ribosomal protein S19
MSRSLKKGAYADPSLLKKVEAANASVSKKPIKTWSRRSQIFPNFVGLTFE
VHNGKTFLKVYVTEDMIGHKLGEFAPTRNFKNHTEAKR
>UU026 rpS2, ribosomal protein S2
MSQMENSTKKVESVANVEVVTTENAKVEQKPTSPADAIQLKVNANSTIKN
LKTLVSIVKLTESGAHIGLNPKKWNPKMASYIHAKRSNNHVIDILKTILF
LDRAYKFLQEVSQNGGTVMFVGTRGRVVKELIKAEAERTNSFYVTQRWLG
GTLTNFTNISRSLKKFNSNLALLESEEINKYSKKEQIAINKETAKLEKFY
GGIKNMKQRPDVLILVDPVNDVNAIKEARKLNIPVIALANTNADPQLIDY
IIPVNNYSVKSITLILGVLADSIAELHGEPTKIVGRPDSEIVLPETKSNW
KQNNYDPSKRGYNPKYVNHKSTFNKFNNKKPVDSTTNEIKTNVIKAETK
>UU310 rpS20, ribosomal protein S20
MANIVSNEKTYRHTQKVRKENHAKMSKLRTIVKKTRSSNEQAQLNEAYKV
IDTTASKGVIHKNKANRLKSRTAKAFKTNLEVTA
>UU277 rpS21, ribosomal protein S21
MSRGVSVEGDLEKALKKFKRISNETKKDSKRHEYYLSPRIRRKEKIKEAN
KYRSF
>UU237 rpS3, ribosomal protein S3
MGQKVNPNGLRFGINKQWLSRWVPTDQLQMAKWLVEDDKIRKYLSTKYKN
AGIDHVEIERDQQRVNVYVYAVQSGLLIGTEASEKKLIELAINKIVGRKQ
LVSLKVVEVQIPELQASLMAREIADAIENRVSFRIAQKMVIKKVLKAGAR
GIKTHVSGRLGGVEMAREEGYTQGVMTLHTLRADIDYSMQEAHTTYGIIG
VKVWINRGELFGNKLVNSVAHAANKEFSRSSKPKKGSFNRSSRSKNTKPA
PKQAVSE
>UU498 rpS4, ribosomal protein S4
MSRYTGSIYKKSRRLGFSLLENNKEFNSGKKRTYGPGQHGNKKVKLSNYG
QQLVEKQKLMFLYGLNDRQFRRLYRVALGRPGVLTLNLLQVLESRLDSLV
YRAGFAPTRRAARQLVNHSHVLVNNKKVNIPSALVEVGSTIALKAKSLEI
PLIKNTLNKPADFIELIDKEKKVAKLARLPERNELPADVNEAYVVEWYNR
LM
>UU248 rpS5, ribosomal protein S5
MENNVKKETIVDSEKVEKQQLVTAPVVNKKENTEPKAKTFKRETTTSNFE
ERVVKIKRISKTTKGGRMMRFSALVVIGDKNGTVGFGMGKSIEVPDAIKK
AIKNANNNLIKVKQTKKGSIYHDVNGRHGAAKVMLLPAPEGTGIIAGGPV
RAVVELAGFTDIYTKSRGANAPMNVIRATINGLLQQLTPKEIARLRDKSL
REI
>UU554 rpS6, ribosomal protein S6
MAKYEIMLVVRGDLDQEQANKVANELKATLKNTEVKENNYDGVQQLAYEI
NKLKTAYRYVYNFETTDVSLINEFRRLAIINKNVLRHIIINLEKDYGYKA
TVNTKKVQRNEKRAEVYARQKEEAERRAVERQAAYEAMKAEREAAGLPVK
EFVKNTNSKR
>UU524 rpS7, ribosomal protein S7
MRKLKPQKRQVLADPVYNSRLVTKLINAIMYDGKKGLAQSIIYSAFEIVE
QKTGKPALEVFNKAIDNVMPIIELKVRRVGGSNFQVPTEVTPERRQTLGL
RWITLYARLRHEHTMIEKLAHEIIDASNNVGAAIKKKEDTHKMAEANKAF
AHLRW
>UU245 rpS8, ribosomal protein S8
MYLDPIAELITKINNGRKAHKAEVSFATSKLKTAILELLVKEGYIKSYDI
RPTENNKSETVVKLKYKNQTTSSINGFKQISKPGLRIYSTHLNLPKVLNG
LGIAIITTSKGVMSDKQARKENVGGEVIAYVW
>UU576 rpS9, ribosomal protein S9
MQKSNIVEYKGLGRRKSSIARVKLVPGSGKVLVNDRQPENYFPNKLVIQD
MMQPLVLTKTAETYDVYVKVIGGGFNGQAGAIRLGITRALIQTREDLKTD
LRKAGLVTRDSRVKERKKFGLYGARRAPQFTKR
>UU456 rpe, d-ribulose-5-phosphate 3 epimerase
MNKQLVPSLLAFDKKYPYEQLKIFKKHHLQTIHYDVMDLTYVNNTAFETE
HLEWLLKNDFLVHIHLMVINPLEKIKQYFIYKPTRISFHFEMNDYQTNLL
IINEIKKHHVLAGIAIHPCLSLNDYASYLKEVDYITFMSVIPGKGGQIFL
EESLLKLKKLYEYKIKNNFKFKIEIDGGITLEVIKKINIPIDFFVSGSYL
VKNIEKLEQTVNEFNQLVN
>UU257 rpoA, DNA-directed RNA polymerase alpha chain
MRKFLKYQLDVPSINSEDKNRTVVKIAPLEIGFGDTLGNALRRICLSSIP
GASMFAVKFGGYSHEFQPYEGVKEDITHIILNLKNLAIKIDELIYSEDYF
NNLLIDKWPKMKINFKGPGVITAKDIVCPVGFEIVNQDLYIAEVTKPIDV
EIEIFAKTGRGRVDFNTNKDFVSTLHIIATDSNYSPVLHYAYNVEMIKDS
KSSMSEILTIDIATNGTISGSEAIAIAAKIMQAHLEPIVNIDKTINEMII
MREREEEEKRQNASISIDDLDLTVRAYNALKQSGINTTAELIELTKSQLE
KIKNLGRKSVTEIIQKLTERSLELKKD
>UU187 rpoB, DNA-directed RNA polymerase beta subunit
MQNNKNYTEKFITDKVMRRDYSKIKSNFEGPNLLEIQVESFKRFMEKDLK
EVISSIFPLKSPQGKYTLAFKGLKIKQPTKDESACRDEGKTFETPIYIDL
ELTDNYTGEVKRAQRNTKTGEDGIYLGAIPKMTEKGTFVINGIEKFVISQ
IVRSPGIYVLGKSSIKLNGSRKRLFEGKICEIYPSKGTLMLGYIPKDRHN
IQIVARDSSGDNAQTFSVTTLLKAFGLTSAEILKIFNNEKEIRESLEIEK
YAPEYIFENSQENEIIFKIYSDAHDIHEKADRRESNNKLKEEYIEQGSPL
LSKLKQLIFNYVEKNDEIDALLHENKDVEDASFIKNNKKLYDEREEIINC
IISEKAAKDIVELLGINIKNIETLRHLGKASYQIALQQHFFNKRLYDISS
AGRYKFEKKLLLSERLYQKVIANDIIDKKNNILIPKDTLITKEHIELIKK
ESRDKNIKWTKKINLLPTALESEIEQFLEYESIAVYKDNDLRDETTEIVG
LASGCKLQTLTVADLVATTSYIYNLNYEIGEFDDIDHLGNKRLKLIHELL
RARIATSMARIEKFINEKLAISDGSSNNITNVNDKGIDTELDREIEESDM
SDEEKKKAISVKSIINTKQFQSLVKDFFNSHQLIQFIDQQNPLAELTNKR
RISAMGPGGISREDPNLDIRDVHHSHSSRICPIETPEGMNIGLIMSLASL
AKVDENGFIVAPYYVVEDGVVKEDYKYLTAHEDDNYIIAESSVQLDENKR
ILDEQVVARYRGSTGLFSPNEVDFIDIVPKQVVSIAASAIPFIENDDGAR
ALMGSNMQRQATPLIKPYAPIVGTGTEFKIAHDSGMAVVAKNDGVVEFVD
SQKIIIRNDNDKLDDYKLIKYRKSNQDTCNNQIPIVKVGQRVHKSETIGD
GPAMQNGELALGRNILVGYTTWRGYNFEDAIIISERLVDQDVFTSIHIDE
HTIQCMKTKNGDEEITRDMPNVSDTAKRFLDNQGIVLVGAEVHEGDVLVG
KTTPRGNVETAPEDRLLQTIFGDKSKTVKDSSLKVKHGQEGIVAAVKRIK
SSDENGSELPDDVIEIIKVYIVQKRKIQVGDKMAGRHGNKGIVSKVVPIQ
DMPFLKDGTPLDIMLNPLGVPSRMNIGQILELHLGYAAAEIGKKQLIQIA
IDQLGYEKYISLFGINEIIAKKLYENISNLIKHKQAKQAKDIDLIDVTII
LKELGLSYDDIGIKISTPVFDGANHDDIVSIMNEANIDIENNKGKQVLYD
GRTGEPFDGLISVGLTYMLKLDHMVDDKIHSRSVGPYSKITQQPLGGKSQ
NGGQRFGEMEVWALEAYGAAYNLLEILTIKSDDVQGRNQAYNAIIKGHDV
VADGMPESFKLLTKQMQGLGLCITVETKDDRMVDINEYTLNQNRLNNDDD
EVILDENLKEINDSNEEIFNTNFNNNDYDDEENF
>UU188 rpoC, DNA-directed RNA polymerase beta' chain
MSQKGIKSLTISIASPEQILNWSKGEITKPETINYKSLKPEPNGLFDESI
FGPSKDYECYCGKYRKVKHKGKICERCHVEITESIVRRERMGHIELAAPV
AHIWFTKELPSPSKISLLLDITYKEVDQVVYFVNYIVLDEGNNVYDGKSI
FNKKEVLDLTSPKNSIRSRNKLRRTLRNIQERIEDELNHEREALIQDFDY
RLAVTYDQMLKDSNIPFSVKDVMAFIEKHTGVRFGIGAEAIRELLEKLNL
EEEHEKIKQAIQNSPNAYDQKTKRLLRRLECVRWIKDSGSKPEWMVMTRI
PVTPSETRPIISLDGGRFTTSDTNNFYRKIIIRNERLKQMQATDAPEILL
DNEKRLLQEAVDSLFDNNSRKKPVVGKDKRPLKSLSNHLKGKQGLFRQNL
LGKRVDYSGRSVIVVGPELKMYEVGIPALMILKLFRPYIISELIRKRDEL
GNEIQPICANIKLAEQKILAQDNEIWPVVEKVIKQRPVILNRAPTLHRLG
IQAFEPKMVDGKAIRLHPLVTTAFNADFDGDQMAVHIPLSKEAVAEARSI
LLASWHILGPKDGKPIITPTQDMILGIYYLTKEKFPQVIEEMMAKDPTQA
RVEFINNFHIFSTQDEAIRAYKLKTIRINDVIGITTKAFNNKTFSKEGIL
VTTVGKIIFNQAFPVNFPYINDVKNLYGENQFEIIGMHESILDYLKAYNL
KEPLTKKTLSTVIDYLYKVSEIEVVPQTMDKIKALGFKYSMISATSISAF
DIPSYDQKYEYFKETDELVSKLREFYLDGKLTDDERYTKVVQAWSQTKDK
VTHDIEKLINSNEYKDNPIVIMAKSGARGNTSNFTQLAGMRGLMSKSYNY
DQKNNNGVIKDTIEIPIKHSFIEGLSVSEYFNSSFGARKGMTDTAMKTAK
SGYMTRKLVDSTQAVVIKDHDCGTKEGIIVREIRNTKDNTSIESLKDRIV
GRYSINTIYDTKNKLIIESDKLITSEIANIIQNSGIREVEVRSPLHCASL
YGVCQKCFGLDLSTNKLIETGTAIGVIAAQSIGEPGTQLTMRTFHTGGVA
GDTNITQGFERIKQLFDCIQPQENEKAVISQVKGTVERIEKDSNTNGYNV
VIKYNKDNYVNYPTRSNAVLRVKTGDEIIAGQKITEGSIDVNDLLKYAGI
ENVRHYIIKEVQKVYRMQGIEISDKYIEVIISQLTNKITITNPGDSGLFV
GETISINEFTEVAQNMLVNKKKPPSAINQVFGLDHAPSKSGSFLSAASFQ
DTKKILTDAAARSQKDMLIGLKENVILGNLIPAGTGLKDVEEVIAYGEEM
YKKQY
>UU349 rpoD, RNA polymerase sigma factor
MSTKQNEPLFVNLEDLKQKVKLSFTEEFSFSYALSELEAGIFESRNLKGA
DAGDPEEILLNVVLDVSKKKRSRNEIKFNKLQNYFIHMNLREEHFSEIID
VLEAIGIRVPDYDLVMQSKSKTNTKKKDEYGIDDTLEISTSKIGFSSTTT
EKVDDGIKAYLGVLGESKMLRSDEETEYAKMVISDDPSLVKIGKNQLYTS
NMRLVTSIAKKYLNRGLDLEDLIQEGSSGLLKAIDKFDHEKGHKFSTYAT
WWIRQSITRAIADQARQIRIPVHMVETINKLTKAERNLIQELGRDPTAEE
IAQAMNKVSQAKNQKEQLITAQKVVEIKKLNVDPVSLDKQIGHDEESQFS
DFISDDEIISPEKYTEKKALNDQINEMFEKVLNDNEQRVIKMRYGLLPFE
RPYTLEEVGEYLGVTRERARQIESKAIRKLKHPSKTAKLRSFIGESEN
>UU597 rpoE, DNA-directed RNA polymerase delta subunit
MSRQLVDIAYNAIKNNKIYNKKPFTFDDIINEIVKNSNVNLVEVNSQLGV
LYTTLIQDTRFISIGDLEWNLRERLSLDEITKINNAMYEVGLYKDSDREE
DEHEIVKNDKLTQSKEQEESDEVSSLSDFVGYEDEDEEFKNNNTSNKDEI
EDEEELEEEE
>UU204 rps15, ribosomal protein S15
MAVSKQQKHDLTVKFGGSASNTGKTEVQVAILSAEIDSLTTHMIENKKDK
ASKRGLYKKVAQRKKLLSYLQRVDIERYRALIKELNLRG
>UU449 ruvA, holliday-junction binding protein
MNYLIFKVIYANANIVVGEHNFIGYQIRIPKDYELEINKFCKLYLYEYIS
IMPNKNLIIKDLYGFRTYNERLLFIDLISINSIGPKTAINILKYDIDTII
DAIATKNIDYLITIKGINQRNANLICDQLNYKYINKVNDKNNWAKELSIG
LENLGYTKKDIEYAITKVKINSQQDIDISEIISSAIKEISLRHEN
>UU438 ruvB-1, holliday junction DNA helicase (fragment)
MIANNAKGIPRLANRLLKRVVDFKINGFNDIKSIFKKIQIYEFGLDEQDI
NYLNVLYRQDNEIGLKSIAQILRLDQYTIETKIEPYLIQHHFINKNLRGR
KITIEGIDF
>UU448 ruvB-2, holliday junction DNA helicase
MKTNYEFRPQYLKDFIGKEQLKNNLKVYLTASKRLENSFDHTLLHGLSGT
GKTTLALIIANEMNVNCHITQGNLLNKPIDIINLLSLIKENDVVFIDEIH
ACGLGAFETLYSVLEDFCIDINIGKDFNSKMTRLKIPHFTLIGATTIFGK
IPKSLEERFGHIFHLNEYEPSEISAIILKNNQMHFQIDLNEEEIDLIANN
AKGIPRLANRLLKRVVDFKINGFNDIKNIFKKIQIYEFGLDEQDINYLNV
LYRQDNEIGLKSIAQILRLDQYTIETKIEPYLIQHHFINKNLRGRKITIE
GIDFLKNNQLIK
>UU119 secA, preprotein translocase
MNLISKISPQNRILNRARLIAEEVLKKEEEYEHFSDQELINKSDDIIEYL
ANNNPLDDKLVEALCIIREVIYRVHNKRAFKVQIIGAIIVYFGDFAEMMT
GEGKTLTLVLVAYLNALYKKGVHMVTVNEYLVKVGAEFATPVLNFLNMSV
GQITANMNEYEKRNNYNCDITYTTNSELGFDYLRDNMVTNYANKVQRGLW
FAIVDEGDSVLIDEARTPLIISGEPQEEIGNYVKADRFVKTLYPQDFTLD
PESQSVALTESGVEKAQKFFNTKNYYNFENSDIIHKVTNALRANFTFFNG
REYIVKKDDDGEDIIALVDQSTGRIMEGRSYSAGLQQAIQAKEQIKIEPE
NLTVATITYQSLFRLYKKLAAVSGTAITEAEEFLNIYNMVVVTIPTNKPI
KRIDHPDYVFDNKRTKWKYVIADVIRRHENGQPILIGTASVEDSEILHQL
LERVNIPHEVLNAKNHAREAEIIACAGEYKAVTIATNMAGRGTDIKLSPE
SLEAGGLCVIGTERSDSRRIDNQLRGRAGRQGDIGESRFFISMEDTLFSR
FATDNLAKADDKLSEDVISTKFFTRLLNNTQKKVESLNYDTRKNLIDYDH
VLSNQRELIYKQRDKILISSDNKDILYRMLDSVIDDLIYQSHNKPNEDII
DIKKLIDLATQNIFYDNYLNQDEYYGLKFEQIKTKLKKDCINFFEQKEQL
MTPTIFNQILSEIMISNIDEEWTKHLDITSKIREGVNLRAYEQKAPLNIY
VEDSDKLFEKLKHNVAWKTVCSIGKINYVHQDYSDLNSEFIVNDNEINEN
NNSIDFENFNESIPTDQTIQESFDDNQSDNEDDKNNN
>UU250 secY, preprotein translocase
MTNKQKKKNAFRQLLMIFKNKKVLVALIVTLSILILFRIGSVIPMPYIKL
NGNFGNQGSFFSIINLLGGGGLSQFSLFAIGIGPYITAQIIMQLLSSELV
PPLAKLSKSGERGRKKIEVITRIITLPLAVMQAVIIINLMTRANGFISIV
SNAPFAIGSPLFYVTYIFLMVGGTYISLFLADLISKKGVGNGITLLILTG
IVASLFNHFIAIFSNLGSLTSSKVSQIIGFILYILFYIMILIGVVFVNNS
TRKIPVQQTGQALILDHEKLPFLPIKIMTAGVMPVIFASSVLAIPAQVAE
FLDKQSMGYYVIHNYFIVDSWTGLAIYVVLILLFTFFFSYVQLNPPKMAE
DIKKAGRFIPGVQVGMDTEKHITKVIYRVNWIGAPILAFLACLPHLVALV
AKTINHGIPVIQPSTIFGGTSIIIMVTATLELWNAIKSTSTSTSYAYQRK
ELETSITVSAESDKSSKSQIW
>UU106 serS, seryl-tRNA synthetase
MFDINLIRKDIATTKEKMLNKKVPSNLFDQIFDLDVLVRSLMQQEQNLNA
KKNQLSKEIGILAKNKDPKLQQTLDLVNNIKNELQDISLTLSNKQDELNK
LLLVIPNMPDDSVPIGNDENDNVEIKKVFKPKKFDFLPLAHWDLAVKNKL
IDFDKSTKITGSRFIIYTNFGARLYRALQQFCLDMNVKAGFSEIWAPVIV
NQESLIGSGNLPKFADDLFKLENSNYYLSPTAEVQLTNLHRNEILKASDL
PLYYTALTPCFRSEAGSAGRDVRGVIRQHQFHKVELVKLCKPEDSFKELE
SMTRQAESILEALELPYRRIVLCTGDLGFSSAKTYDLEVWLPSYNAYKEI
SSCSNCTNFQARRAKIRYKETIDATTELVHTLNGSSLAIDRLWAAIVENY
QQEDGSINIPKVLKKYIY
>UU113 sfhB, pseudouridine synthase (uracil hydrolase)
MNLKEIKIKINDANQRLDRFLLKNFPNLSRIAVYKIIRTKDVKVNHKKVD
HNYLLKENDVVSIYAKENFLEKKVDLSFANAKDELDIIYEDKNILVVHKP
IGLIVHEDNRYKNDTLQNRIKKYLVKKDEYHPFDESAFVPSLCHRLDLNT
SGLIVAAKTANALRVITEMFKNNDVIRIYKCLTYNQLPKNNDVIYNFMYK
ADDNTMIVQNFKTKFNKTAITKYTYIDKYKKYFIYDIELLTGRTHQIRAV
LNFLHAPIVGEQKYITKDIDKNQNYMYQCLVSYKIKFINLKKYQCEELNY
LENKEFRIKNIWFLK
>UU058 smpB, small protein B
MIVSNKHARRNYELLDFFECGIVLKGTEVKSISRANCSINEAYVQIIKNQ
ALILNMHVANFFEGNNFNQDPYRNRKLLLHKKEIIRLQHLVKTQHMTIVP
TKIYWKNNKLKIEIALGKGKQLHDKREDIKKRDLARETRLF
>UU283 spoT/relA, ppGpp 3'-pyrophosphohydrolase
MNELVKKKLDDLYDFLKQKKYSSQTIELVHKSFDFANYYHGDQTRKSGEP
YIIHPIATVRILASWDMDESTLVAGMLHDVLEDTNCPEEVMEKTFGKEVT
QLVCFVTKVSLYSKNRRNKVSHTNLEEKYSIQVFMSMTQDIRAMIIKIAD
RYHNMQTIQYLRLEKAKRIATETLEIYANISGRLGMYRVKTDLLDMSFKI
LDPQNYQLVNDSINKLVENNQKKWNEILARLKNILIANNIKAEFEWRLKG
IYSTYKKITSGYEVKDIHDIYAIRVILDDVYLCYQTLGLVHMNFTYIINT
FKDYISTPKWNLYQSIHTTISYEGTLVEIQIRTTKMNLFANNGLAAHWKY
KEQKDNKTEILLTVNNVLLRDFLLSTDKGIKTIKDVTTGTIFDVLILNSN
KWITVSNGSTLLDVAYKYDINNFFNILAIYRNGERSHFDTHVETGDTIKI
SYSNGIETIRPNWITLANNDVVKLHINNHLKKYELNKQITKEQFLANAEF
FLEGKIMSEEHAIKRLEKEFQVNSINTFLDNIANTDIDLQTKYKVFSENK
QVSREAINTIKNQAWKWLADSSYFSGLENLYFTDFEISPCCSKIPGINCV
AKIVRNKVEIHRNDCSKVKNSRSKTIVIEWSKEKLENRPRYFKVNLTLKG
NWSESVGNVLCNTLIRMKANISKVDISKNKTARTHDTFLKIYVKNLDHLQ
KIILELQAKNVINEWRLI
>UU124 spoU-1, rRNA methylase
MNYNFGKKALLDAIGNKQSISKVYLLSKNYELINLINKNKITYEIVNEAW
FKQFDHSLNHQNIAFKLVKKNFQKTSLESFLKLIKDKKNALVLILDEIED
PRNFGAIIRTANGFGVDAIIYKKHHQASINDLVIKTSMGAINYIYMIEVN
NLSNTIKNLQDEGFWVYATSLLKSQPYEKVDYANKTVFIVGNENKGVSPL
ILKNADQSIRIDMFGDVQSLNVGVATGIILAHYRTKIKP
>UU268 spoU-2, rRNA methylase
MLNIVLFEPEIILNTGNIARMCVGFDANLHLVRPYGFILDKKRFHKDFIR
ASTNHLNALKLYEYDDFNEFINKNNISGDEIYFFTRYGTKTPCDYQYQNI
IQHNVYLVFGKESTGIDHNILKKYPHNWIRIPTSINLRSLNIANSVAMGI
YEVVRQNNFKDLFKYEPHKKFE
>UU327 spoU-3, rRNA methylase
MLKIITSNKNEEIIHFYRLIHDKKYREANKLFIIEGFKLLDEALQNQQTI
VSIIINEHVYNKEFETIFKYTLYDNIQIYKVSGNIIKKLSVNIEPSPILA
VVKIKQEMCDINDNILLLDNIQDPGNLGTILRTCFAFNIKQVIFNNCVDL
YNPKTIKASMGAIFKINFLRFNDSKLALNFLLKNKFYLIATILDKNAISL
NEITIKQKYCLMVGNEGHGLVQTFIDHAHIKTMIKMNQTESLNVAVAAAI
FLYELNK
>UU553 ssb, single-strand binding protein
MNKVILIGNLVRDPEARQIPSGRLVTNFTIAVNDNTPNANANFIRCVAWN
NQANFLTTYLKKGDAIAIEGRIVSRSYVDNNGKTNYVTEVYADQVQSLSR
RNQSPSDNNKVNVDTMMESYTGINTDAAFSSNKPQTTLSSTTSNLNKNND
EEDEITSWINLDDDLE
>UU594 tdk, thymidine kinase
MAKVNAFSKKIGWIELITGPMFAGKTAELIRRLHRLEYADVKYLVFKPKI
DTRSIRNIQSRTGTSLPSVEVESAPEILNYIMSNSFNDETKVIGIDEVQF
FDDRICEVANILAENGFVVIISGLDKNFKGEPFGPIAKLFTYADKITKLT
AICNECGAEATHSLRKIDGKHADYNDDIVKIGCQEFYSAVCRHHHKVPNR
PYLNSNSEEFIKFFKNKKRNKNI
>UU018 thdF, GTP-binding protein in thiophene and furan oxidation
MSTIVALATAPMNCAIHIIRVSGPKAFEIINKISTIKIKKETFKIWYTIL
KDDNQILDEVLINTFVAPKTFTGEDLVEINCHGGIVVANLIIKTLIKYGC
QPAQRGEFSRRALLNKKMDLSKIEAINNLVNAKNELSVKGVIGALLGRVS
QSIAEFRHELFMIIGQIEVNIDYPEYDDVEQVDAIILKQRLLSLDKKITK
IIDQSKKFLPINKGIRVLIIGKPNVGKSTLLNALCNEQKAIVTDIPGTTR
DVIESSINIDNITLNILDTAGIHLTNDFVENLGINKAKALIDKVDLILYL
IPANEQQDLELYDLIKKQKHLLVYTKKDLVDQYDDKQIYINAKNNDIQSL
IDEIKKLFYVQEFDNANIDVLQSQRQIGILENVHYLINNAILNLEKGDTL
DLIVADLEFCNLRLNELLGISSEYDFLDDLFKNFCIGK
>UU418 thiI, thiamin biosynthesis protein
MKPIIYIKYGELTLKGKNRTQFIKVLVHNIKQILIQYQNLTYCVGYDNLK
IINLENYNLKQIIDDLKEVYGIAFICIAYQVDKELSEIQLACKEFINDYE
QTFKIEARRSDKSFKYNSMEIKQMCAAYLLQNSPLLKVDVHRPQLLINIE
IKYDCAIVYGHKIMGAKGLPVGINGKALVLLSGGIDSPVASRLIMKRGIS
IDFITFITPPHTSQKALDKTIALAKQITLDNKLTKANLYVCNFTKLQDEI
AHISKESYRITLMRRYFMRIAKRLAISVKANALVTGEALGQVASQTLNSM
QTISSVLDNFLVLRPLIAYDKEEIISLAKRFNTYELSILPYDDSCSLFAP
KNPTTNPNVQTAAKLEEESLVLDAIYELVYTKEITKINLS
>UU534 thrS, threonyl-tRNA synthetase
MYKFDQKLNHSAAHLLAMALTKFYPNLSLAIGPTIDEGFYYDFNLNDPNT
SITPLDLLKIEKEMKKITTQALTFDYEQVTYEKAKELFKHNKYKLDIIEQ
NKNNSLSIYHSGKWFDLCKGPHVQNTKEIKAIKLLNIAGSYWRGDANNDQ
LIRIYGVAFSDQDQLDAYLKDLQERKERDHRKIGKDLNLFTFNNLAGQGL
PIWLPNGTIIKNQVQKFINEVEFQFNFDTVITPILGSIDLYKTSGHWDHY
KDNIFSPVQIDNEILVLRPMTCPHHTLVYSNELRSYRSLPIRLSEHSILH
RYESSGGLTGFERVREMILEDCHVFCRFDQIEHEVINAFKMIQEAQEGLG
IKTFEIHLSLNDPNDKEKYYDDPQMWEQSQNVLRKMLKDHNIPYKEMVGE
AAFYGPKIDFQVKTVLNRIITVSTIQLDFLLPNRFNLTYINESNEQSVPV
MIHIGIIGTYERLLAILLEQTKGILPLWLSPIQVVIIPVNENLHTDYVKE
LNIKLRKHLIRSNVDLRNERLSKKIREAQIQKIPYQIVIGDEEIKNNKMV
TYRCYGSEKTTTVSITDFINMLENKIRLKK
>UU347 tig, FKBP-type peptidyl-prolyl cis-trans isomerase (trigger factor)
MKLLNKIKNENAIEFQILIEKSEWEKKHKESFEKIAKKTASKLKIPGFRP
GKVPVEEAKKHVNEIEVFETTTNDLIPQVLTFLEQDESFINDDSETVDTP
SVDILDFKDGELSLKVVYDLYPVATIESYNDLILTPIVNEAFEHEVNAEI
EHALNSKSQRRVKDDNEFIEKGDEVRFDFKGMIDSVPFEGGSAKDHLLTI
GSNQFIPGFEDQMIGLKKDERKNINVKFPDDYHATDLAGKAAVFEVFIKE
ITNVKPQELNDEFAKSFNLPNVNTVQELKDYIHNQIVLAKQEKNSERAWL
EIAQQLLAKAKITPIPQSLIDREVSTLRQQVLSQLSQYKIELKQYLEFSK
KSEAQFQEDLIRQAKETITLALLVDDIAETQNIVVSDEEVKERVAEMAKL
YQGEEQAVIEQLSKNPDAVKEFLLHKKVVNYLIDLNKNNQPKNTTLSSK
>UU586 tktA, transketolase I
MNRYVNAMRSLALQAINKAKQGHSGMSISAAPIVYTLYKGLMTISKSHPK
WFNRDRLVLSAGHGSMALYPVFYFSSLLTLDDIKNFRNDNYLTPGHPEVL
ANNYIDASTGPLGQGVANAVGMAITESYLRTEFATLKGVIDHYTYCIVGD
GDLQEGICYEAMSIAGKLKLSKLIILHDSNDYQLDSAVSDVNIEDLKMRV
ESMGWNYLKTDNNPENIFKAIAEAKWKKNVKPTFIEVKTIIGEGTSFENS
NEAHAAAISNDELEKFSKRFHIKTNNFEFHQEIFDHFFFNVVARGESAYN
QWQQLVDQYMQTNPEQMQRLLNYINGNYEDLNKLLDENKITNLNDSTRSY
LKQYFNQLKDLKSALVLSADLAKSTFTKIGEGAFNDNHKNPYIKFGIREF
AMAGAMNGISLHQGVKAIGGTFLAFSDYMKPAIRLAAISNLANLFIFSHD
SYAVGGDGPTHQPVDQLPMLRAIPNVEVIRPADHYEVKYALSYSFKQKQK
PICLITSRQTIKQINDQKPQDFSKGAYIINSPFSFCKDVDYTIIASGSEV
SLANDAAKELFEKHKLKIKVISAFNLNLFLRQKPEDIKSLLASKNGLLAI
EASSEMLWWKLSIYTNKFIQIAANQFGRSADGDKLMNEFGFSVKNIINQL
LNQ
>UU020 tmk, thymidylate kinase
MITMILTKNSNEKKPLKKGLFIVFEGIDGAGKTSILKQLLEVLKEPKLVN
KIFLTREPGGKNNNAAEMIREFFLKNLEVFDPLTLAYLYASSRAEHVKKT
INPHLEKDHIVISDRFVHSSYIYQGIVQNQSLDVIYQINQQAIGELEIDY
VFYFDVNVNNALNRMKNRFDNTNAFDSQNKQFYEKLLKQYPSVFKVYNQP
KKIIFIDANKNENEVLCEVKEQLLKIFKEHKYI
>UU372 tnp-1, integrase-recombinase protein
MNKLGLLCEIRRSKRKREIKNVNATFKNLANRDYDGQMNDIYATDVTYIP
SPTDVIENHVYLSVLLHHKTKKIVSWNLSKYNDTNLVLKHFKLTKFPKKF
IVHSDHGYQYSSKEFLDYIDSINGTISMSRVGNSLDNREVEYFFSILKTE
IFSNFFQKAKSLTFNELQIEIDKFINLYNNERFIKKFDLKTPQQMWDVYM
NNKSIWV
>UU404 tnp-2, integrase-recombinase protein
MDKKNIFTILEKLVKKYKYLHKPILDDYISTFTRTFLEYILTIEMKYHLN
YERFERYLSSNSKNYRNGFSKKQLYMNDLKVSINIPRDRNGAFESKIISK
YQVDISHFEYRLLSLGINNLQLNEYEKILEDIYNIYNDKMVDKLCNEIAL
KIFDYLENKKQELNNIDVDQIFIDGFNLSSNKWLTIVITKDLEKRLTILG
FWVINNLEDKWWNDIIIKISKYHPQVINYKVIFKDNDELLMSLKNHTSNN
FERARFVFINKSILNQKN
>UU590 topA, DNA topoisomerase I
MQKDLIVVESPNKIKSIQSYLGDSYNVIATCGHLRELAKKSGYDPKTYDL
KWEIIKTTNKKLSKKQQIKTIIDLAKKSNNIYLATDPDREGEAISWHVYD
LLPKKDKERVKRITFNEITQKAILKSIDEKHDIDFNLVDSQFARRILDRV
IGYKLSGLVKKNLHGLSAGRVQSIALLFVVERELERRSFVKEEWYQIEGI
IEKNIFVSLRKIPYDVELYNQKDNSDSDLKFLHKKDAQRVIDDLSDIFKV
YSIDDLKITKGDVQLPLTTDKLLQIASNNFGWSANKTTLIAQQMFEGLEI
NNQQLALITYPRTDSERLSDDFLQEANAFIENNFGKEYLENFKNKKINRK
EVNIQDAHEAIRPVDINLKPEEIKDYVSLDIYKLYNLVWNKTLSALMKVP
TFNKQVIRFINNEYKFYTAYKTIRTLGYWILDFYKKQRDELEFQPPIINV
GDEFKKEKIDLIQKETTPPPYYTEASLIAALKNAGVGRPSTYATMATIGT
TRGYINKDKSKLIPTELGIKVIQELKEAFPKVISIKFTSEMEERLDVIAN
GKLFWKDLVSTFIPIFEEEVKQAYTKIEKVPDEKINRLCPICAHDLLIKR
SRMNTRFIACSNFPTCRFTESLEKPEILNELCPNCSKSLVKRKNRKNKYF
IGCTGYPECNFIRNLDESNNDKNDFNQ
>UU181 tpiA, triosephosphate isomerase
MKYIIANFKMNATQELINHFLNNLTLFDEQKIIIGLAPGDLYLKTFVNLA
EIKKVNLYAQNPSLHNKGPYTGQISCLQLLDINIKNALVGHSEIRIDFSQ
SIIDQKIKISMDLLEQVIICVGETFDAYKQNKSLNFVLNQLANIINYKGL
KKIIIAYEPIWAIGTDLELDFKHINYMIEGIKTYLYNCTGINIPILYGGS
VNDNNINELCNQKLIDGFLIGNASLDVNVFNKIIDKCK
>UU567 trmD, tRNA (guanine-N1)-methyltransferase
MKISILSLFPELYETWIKHSIISNAIKNNQVIIEVIDFRLYTNDKHKKVD
DYQYGGGAGMVLRIEPIVAAIRAIRSSNSYVILTTPKGQVFNQELANNFV
SKYDHIIIIAGHYEGFDERINYYIDAQYSIGDFVLTGGELPSMVISDAVI
RLLDGVISPSSLETESFNNYLLDYPVYTRPLVFEGHKVPDILLSGHHKNI
ADFRKQQQETITKKNRPDLYQKYLNNKK
>UU402 trmU, tRNA-(5-methylaminomethyl-2-thiouridylate)methyl transferase
MEVKVKKRVVVGLSGGVDSSVSALLLKQEGYEVIGLFMSNWDTIANFENN
HEFNKTHQGCESELDYQDAQAVAQKIGIPLYRVEFIKEYWDNVFEYFLSE
YQKNRTPNPDILCNQFIKFDSFLNYAKNELQADYIAMGHYARVKHDRNSS
FLLKAIDTNKDQTYFLCNLNQNQLQNVLFPIGHLTKLQVRAIAKKHGLIT
ANKKDSTGICFIGERNFKTFLQNYIPNQPGQIINIVNNQIIGHHIGTMYY
TIGQRKGLNLGGMNERMFVCDKDIDKKIIYVAPSSFEKQYLISTQALIEN
INFIEPYNPQIPIMVRFRHRQDLIIVNDFLPIKNTKNVLINYESARAITP
GQYAVFYQNDHCIGGGIVSKTNIGHQKVDFLVYKS
>UU175 trpS, tryptophanyl-tRNA synthetase
MKRLISGIQPTNNLTLGNYLGAIKNFVDLQDDYEVFLFVADLHSLTPNIF
DNTDFSTTKRQIIATYLAAGIDPKKTCLFYQSDILSIPLLAHILLCSTSI
GELTRMTQFKDKSIKATKMANNTEMIPSGLLTYPTLMAADILTFNADVVP
VGQDQKQHLELTRTLADRFNKRYGNTFKLPQVYIPKIGAKIMDLLDPNIK
MSKSSKNLKGVIFLNDSKDIIFKKIKGALTDNLNKVKYDLTLQPGVSNLM
TIYACLTNLSFKEIELKYQQQNYGVFKNDLANIVADFLEKLQQKISYWLN
SPELDIMIDNSCERANDIAYQNVQLVLKHMQLK
>UU354 truB, tRNA pseudouridine 55 synthase
MSAISKNIIIINKPIKWTSNDVVQKVKRVIGAKKVGHAGTLDPNASGVLV
LGINEGTKLLTKLILDNKSYIAEIKFGTSTNTYDAAGEIVSSTNRMVTLT
EVTKIVKDFYKNDYWQKPPQFSALKINGQKAYVLARQKVDFEIAPRLVKI
FKYQIMDFNYEKQILKISLHVSKGFYVRSFAVDLATKINNLAHLLTLIRT
QSGPFEIKDAIEIEQVYDYWNNINKYL
>UU589 trx, thioredoxin
MLIKLESNQNLNELLKENHSKPILIDFYADWCPPCRMLIPVLDSIEKKHG
DEFTIIKINVDHFPELSTQYQVKSIPALFYLKNGDIKATSLGFIDENSLV
NKLRSI
>UU074 trxB, thioredoxin reductase
MNQEVYDLVIIGAGPAGLAAAVYAKRSGLNVIIVEKQFPGGKIALTSNVE
NYLGINSIPGPELAYKMYEQVLNLNVSIIYEAADEISLKEKYKKIKLTTQ
TLITKTVIIATGTENRRLNILGELEFENKGISYCAICDGPLYKNKAVSVI
GSGNSAVEEAIYLATIAKEVHLIANKPQFKAEQQLVQIANNTPNIKIYYN
KQTFEFFGHQFLEGLKFRDLITNEVTTLNIEANFTFIGLLPSRINTNNLC
IFNEVNGFITTDKNMQTSVCGIFAAGDIVDKNVRQIATATNDGVIAALYA
KEYITRNNW
>UU514 tsf, protein chain elongation factor EF-ts
MTKAELVKELRIRTQASMSECIKALDASENDIEKAIVWLRENGAIKAANK
LKNAATDGVVLAKKINNKAILIEVNCQTDFVAKNENFLAYANQILEEALA
KVENKEDFDKLIINGKPIAESGLDLTAYIGEKIVFRRGEILKANDDQTLG
VYTHNNNRVAAIILVDGKVEDEVVRNVAMHAAAMRPRYLNEKVVDKLWLA
KEREIIVNQLEHEGKPAAFAAKIIDGRLNKILKENCLVDQSYFKQPELTI
EKYLKNNNAVAVGYFSYEVGEGIEKAPQMSFADEVAAQMKK
>UU596 tsr, fructose-bisphosphate aldolase
MSPLVNAKKMIQNAYENHYAVAAININNLEWIKAALLAAQETNSPLLLAT
SEGAVKYMGGYDNCYAMVVNLIKQMNIKTPVCLHLDHGTYEGCIKAINAG
YSSIMYDGSKLSIEENIKNTKELLTITKLKGVSVEVEVGSIGGTEDGITS
EGELANIDDCYQMCLLDIDMLACGIGNIHGIYPKNWKGLNFNLLKEINNK
VNKPIVLHGGSGISDEQILKAINLGVAKININTECQIAFSNALQDHLTKA
GDLILSKQYDPRKILAYGVDAIKNTIIDKFTKFNSLNKIK
>UU522 tuf, translation elongation factor tu (EF-tu)
MAKAKFERTKPHVNIGTIGHVDHGKTTLTAAISTVLAKKGQAIAQSYADV
DKTPEERERGITINASHVEYETKTRHYAHVDCPGHADYVKNMITGAAQMD
GAILVIAASDGVMAQTKEHILLARQVGVPKIVVFLNKCDFMTDPDMQDLV
EMEVRELLSKYGFDGDNTPVIRGSGLKALEGDPVWEAKIDELMDAVDSWI
PLPERSTDKPFLLAIEDVFTISGRGTVVTGRVERGVLKVNDEVEIVGLKD
TQKTVVTGIEMFRKSLDQAEAGDNAGILLRGIKKEDVERGQVLVKPGSIK
PHRTFTAKVYILKKEEGGRHTPIVSGYRPQFYFRTTDVTGAISLPAGVDL
VMPGDDVEMTVELIAPVAIEDGSKFSIREGGKTVGHGSVIKTSN
>UU117 tyrS, tyrosyl tRNA synthetase
MHSLIKDLKARNLINNITNEEKLIKALEKNKGIYVGFDPSADSLHLGNYI
MIMLLKRFRLYNIKTLALVGGATGMIGDPSGKSAERNLLDKTILEKNIAK
IKFQLEKFTNSQVINNYVFYENMTFLDFLRDVGKLININYLLEKEIINSR
LSVGISYTEFSYNLLQGYDFLQLYKNDNIAIQAGGSDQWGNITTGIEMIR
KNLGDDNIACGLTINLLTNSEGKKFGKSEKGAIYLDENKSTVYEMYQFLI
NQSDADVEKLLNFLTLIDVEEIKKIMQAHKNNPALRVAQKALAKAVVVDI
HGQQKYEQALHISEVLFNGSISTLNQEELEIAIKSLPATKLDKDEIKIID
LLNLANISSSNRIARDFLNTGSILINDIKINDENFLVKKQDAINQKFSII
RKGKRNYFLILWNKD
>UU332 udk, uridine kinase
MNTKSPILILIAGASGSGKTTFANEIIARIPKNTTSVVICQDSYYISNSQ
LNKKERRLINYDHPSSFEWELMREQLSDIKKRKKIKVPIYDYKTEIRLDK
TIDISDVDVIVLEGIYAIYDDVINQIADLKIFIETPKDECLIRRILRDVN
ERNRSFESVITQWRSTVSPMYDQFVEPSKKNANVSVLWNEHNRVALHLIH
KWINNIH
>UU548 ung, uracil-DNA glycosylase
MKWKEFIINETKQSYLKNIIKKINNIENHQVVFPLKKQRFRCFDFFDIEQ
TKVVILGQDPYHTPKIANGLCFSVDLGNNLPGSLINIFKALEYDLQIKRT
NPDLSDWAKQGVLLLNTVLTVNAHQPNSHKNFGYEELIKNVFNELRKQKH
VVYLLWGKQAMSYINLIDQKQNLILCASHPSPLSAHRGFLTCKHFSKCND
YLIKHLRTPIKW
>UU116 upp, uracil phosphoribosyltransferase
MHKIINHPLIKDKLTRMRKVSTVSTVFRTNLEELTQLMVYEATKDLELNE
IEIETPVVKVAKGYKLKNKICLIPILRAGIGMVDGVKSLIPTATIGHIGL
YRNEQTLKPVEYFKKFPKNISESDVIILDPMLATGGSVVEAVNIIKKYNP
KSIKFVCIVAAPEGLKYVQEVHPEVDVYIAALDDKLNENGYITPGLGDAG
DRIFGTK
>UU434 ureA, urease complex component
MNLSLREVQKLLITVAADVARRRLARGLKLNYSEAVALITDHVMEGARDG
KLVADLMQSAREVLRVDQVMEGVDTMVSIIQVEVTFPDGTKLVSVHDPIY
K
>UU433 ureB, urease complex component
MSGSSSQFSPGKLVPGAINFASGEIVMNEGREAKVISIKNTGDRPIQVGS
HFHLFEVNSALVFFDEKGNEDKERKVAYGRRFDIPSGTAIRFEPGDKKEV
SIIDLAGTREVWGVNGLVNGKLKK
>UU432 ureC, urease complex component
MFKISRKNYSDLYGITTGDSVRLGDTNLWVKVEKDLTTYGEESVFGGGKT
LREGMGMNSTMKLDDKLGNAEVMDLVITNALIVDYTGIYKADIGIKNGKI
AAIGKSGNPHLTDNVDMIVGISTEISAGEGKIYTAGGLDTHVHWLEPEIV
PVALDGGITTVIAGGTGMNDGTKATTVSPGKFWVKSALQAADGLSINAGF
LAKGQGMEDPIFEQIAAGACGLKIHEDWGATGNAIDLALTVADKTDVAVA
IHTDTLNEAGFVEHTIAAMKGRTIHAYHTEGAGGGHAPDILETVKYAHIL
PASTNPTIPYTVNTIAEHLDMLMVCHHLNPKVPEDVAFADSRIRSQTIAA
EDLLHDMGAISIMSSDTLAMGRIGEVATRTWQMAHKMKAQFGSLKGDSEF
SDNNRVKRYISKYTINPAIAHGVDSYIGSLEVGKLADIVAWEPKFFGAKP
YYVVKMGVIARCVAGDPNASIPTCEPVIMRDQFGTYGRLLTNTSVSFVSK
IGLENGIKEEYKLEKELLPVKNCRSVNKKSMKWNSATPNLEVDPQTFDAA
VDFNDLENWLEQSASELAKKLKKTSSGKYILDAEPLTEAPLAQRYFLF
>UU428 ureD, urease complex component
MILNKEKIKNYAAYLYIKVAYDQAHSKMAHTVYFTNFYRSSKPLFLDEED
PINPCFQTISMGGGYVSGEIYRSDFEINDDARCIITTQSSAKAYKTVDGK
TSEQHTNITLGKNSILEYISDNVIVYEDGKFAQFNNFKMDSSATLIYTEC
FGPGWSPHGSAYQYEKMYLNTKIYYDDKLVLFDNLKFQPRKNDESAFGIM
DGYHYCGTMIVINQQVIEDDVIKIRDLVKEKYPDMDMIFGVSRMDIPGLG
LRVLANTYYHVEKINAVAHDYFRRKLFNKKPLILRKP
>UU431 ureE, urease complex component
MTVFKEILDNIANIKNVESYQIENIHLTSDDVLKRVIIISSDQNVEYGIR
LEEDKKLMDGDILYKDDYKLVVIRLELSDVLIITAHTIGEMAKIAHNLGN
RHMPAQFTETQMIVPYDYLVEEYLQDNKALYERKKIKLKEAFKHCSDAK
>UU430 ureF, urease complex component
MKEKKLNLKKHLNTVVTLNSDYLNLLDLMQITNANFPIGTFSHSFGVETY
IRKDIVFDGESLIKALLLYMNEQLLHGDLLAIYQIFKLLPKQKINAIWEI
DQMINFQGLARETREGQRRIGQQMVKIYNELFNCELLVEYAERIKNKKSY
GNPAVAFALLAMHLKIDLKTALYTHLYSTVAALTQNCVRAIPLGQVKGQK
IIYQLKHVYFDDIVNKVFTLDFKTDFCKNIPGLEIAQMEHEDTPVRLFMS
>UU429 ureG, urease complex component
MKRPLIIGVGGPVGAGKTMLIERLTRYLSTKGYSMAAITNDIYTKEDARI
LLNTSVLPADRIAGVETGGCPHTAIREDASMNFAAIEEMCDKHPDLQLLF
LESGGDNLSATFSPDLVDFSIYIIDVAQGEKIPRKGGQGMIKSDLFIINK
VDLAPYVGANVEVMKADTLKSRGNKDFFVTNLKTDEGLKSVADWIEKRLQ
LALLEE
>UU102 uvrA, excinuclease ABC sununit A
MDKIIIKGARENNLKNIDLEIPKNKLVVITGVSGSGKSSLAFDTIFAEGK
RRYFESLSSYARQFLGGNDKADVESIEGLSPTIAVDQKSTNQNPRSIVGT
ITEIYDYLRVLFARVGTPFCPNGHGQIKSQTPKQIADFLFSLSPKSKIQI
LAPIEIKKGYKINDVLNNLRNQGYLRVLVNNEVYQLDENLPQFLDNKKTD
VAIIVDRLILNIDHQTKTRALDAIEFALNYSGGEIAFKVNDDIHYFTQND
VCQVCGFKIKEIEPTLFSFNSPIGACEQCKGLGYNYVPDERKMIPNPNLS
INEGGLDYFKNTVNTTNLDWQRFNSIIKHYKIDKTKPLKELDRKEIDLLL
YGSDEAIEIDITSANNKKYSSIDYVEGVLELVNRRYQETSSELAREHYNK
YMSEKVCKSCKGKKLSSQALSVLINKINIIDFIEKNIDEAIDFLLHLDLN
EAQTKIANPILKEVLDRLGFLKNVGLEYLTLARPASSLSGGEAQRIRLAT
QIGSKLTGILYVLDEPSIGLHQRDNDKLINTLKEMRDLGNTVIVVEHDEE
TMLAADYLIDIGPQAGVNGGYVIAAGTPQEVMQNPNSLTGQYLSKQKDIL
VPKTRRSGNGHKVILKGAKHNNLKNVDLTIPLGKFICVTGVSGSGKSSLI
LETLVKAIEYTNFNPFVIPGEYKDLIGASNVDKIVVVNQDAIGRTTRSNP
ATYVGVFDDIRTVFENTIEAKARGYSKSRFSFNIKGGRCERCWGDGTIRI
EMHFLPDVYISCEECHGKRYNDETLQVKFKGKSIYDVLKMPIDEALVFFE
NYPGIHRKLQLLVDVGLGYLELGASSTSLSGGEAQRIKLAKFLQRKPTGK
TLFVLDEPTTGLHIDDVAKLIKILDKIVDGGDTVLVIEHNLDLIKVADYI
IDIGPEGGNKGGKIIATGTPEQLLSKKDISYTAQYLEKYLKKN
>UU120 uvrB, excinuclease ABC subunit B
MDDFKKFELISDYKPAGDQQKAIDEMVNNINQGIQRQVLLGATGTGKTFS
VANVIAKTQLKTLVLAHNKTLAAQLFAELKEMFPHNKVEYFVSYFDYYQP
EAYKPITDTYIEKDSVTNAEIEMMRLSTINSLATRNDVIVVASVACIYAS
VSPIEFTKKNLYLHVGELIEFEQIKYKLVQLGYERKDYDLVPGTFRIRGD
LIEIMSGYSDKFKIRISMFGNEVESIDLCDPITNNIISKEQRFILRSASE
YIFDDSRLAIAIENIKNELDERVKFFLKNNQLIEAQRIEQRTKQDLESIV
EFGFCSGVENYYRHLEHREPFQTPWTIFDFFSYNNQDWLLIVDESHISLP
QVKGMHNTDRSRKQTLVEYGFRLPSALDNRPLNYDEFNKKLSKTIYVSAT
PNDEEIALSDNHIVSQIVRPTGLLDPIIEIRKTEHQIDDLINELMLLKNK
NQRAFITVMTIRMAEDLTNYLNNTKIKAAYLHNELKTLERSVIINKLRKG
IYDCVVGINLLREGLDVPEVAGVFIFDADKPGFFRSDKSLIQIIGRAARN
ADGKVIMYADVITQAMQTAINETKRRREIQLAFNLKHNIIPKTIIKPIHE
DLSGHDYKQNAELYAAKASKNEYNQKIKELKKKMEEAAKKREYEVAAQYR
DMIVELEAIKQSVKSK
>UU381 uvrC, excinuclease ABC subunit c
MNDLLKNKLKLIPHKPGCYLWKDQFNQIIYIGKAKDLYNRTHSYFNGCKD
NKTSKLVNNINDLEYIVVNNVNEALILENNLIKTHLPKYNILLKDGSNYP
YIMITNEQYPRLKYVRTYDKNKGIYFGPLADSTNKYQLFNLLNSIFPFNK
CNHQPYKKCIYYDLHQCINQVQQSTYQEAISEVKEIFKGNLDHILMILQT
KEQHAVTKLDFENAQKYAEQQKALTSIINSGLVQLDNNESFDIIGFYEKN
NYLVIIIFNYVKGKLLNKSADTFAIYDYEINELITSFLMQYYSQNKISSK
IIVSLDDDNLLALSQRFHTKFINAQTKFHKRILKLALDNAILYFESNIKN
VINKQNELDDALNQLKQILKLPDLNIIECFDNSNINLSLPIAGMIVYQNG
KLNNKLNRKYNLMTTKNASDYHFMIEVITRRYQRLVSQHQKLPNLIVVDG
GKLQVNAALYALAQLQINIPLIGLKKDQKHKTDAIVLTNGDEIVLDRKSI
LYKFLANMQNDVHNYAISFLRDKHTKSIFNSLLDNVQGLGKKRFNELLKY
YDSINDLKSASDQELLQFLPKNVLVNLREKLNKI
>UU501 uvrD, DNA helicase II
MGLGIDYSRLNQEQKEAVTADLGPQLVIAGAGTGKTSVLTLRIAYLITEK
NIHPSRILGFTFTNKAADEMKERVGKTIGVSIPYLSTFHSMCVKILQQDI
HYLNYHNNIKIIDTDDQEVLLKEIFDQLNIEKKSQVIKKIIKTISKVKNK
FFDQNDMLNEKNHKYLELVDLNDAQRLVDIYKIYCDRCFKLNYVDFDDLI
NLTHKLFIEFPEVLEKWQNKFDYILVDEFQDTNKIQYDLISLLATKHQNL
FVVGDPDQMIYSFRGAEQWIINNFSQNFKNTKVTILKTNYRSTQPILNTA
NRLIDANNNNYKKNLTAFNTNDNNLPIYLRGQNPIDEANWIARKIRELLE
EGTPANQIAVLFRSNHYSRTIEQSMMRESIPYTILGSKKFYERAEIKDMI
AYLKVVNDLDELSFLRIINTPRRAIGPTTFEHVKHYAINNNLFLFEALAE
VEKNHLINNTQKKNILNFVNLIKEIRDEMEDLKIHEILELIYKKVNYEAY
LLENEKAEDKIDNVYELKRAMKMYVDRHPDDTINDYLNSIALYLNKDGKD
SKENVLLMTVHNSKGLEYENVFVAGMNEGLLPSDRAINDDPIKGVEEERR
IAYVALTRAKKNLYISSACCYDPLARRQVFESRFINEIGFNNLKIINSSF
KNNKPEDMPLKSFLKQQEERSWFDSKQKQKEVEDNFYQTMKNDFEIGERI
VHTSFGDGVIIGIDGDILTIAFSKYRQPKQINFNHKTIVRRIG
>UU057 vacB, virulence associated protein-Exoribonucleases
MSDFTKQTITEVISKEERPIPAAILAKKVLEKIPTLNKTDVYKLIDLLIQ
ENTIKKLENNRLVIGYLDYEFDHEIKQGIITINSKGDGFIKEDNTEIEYY
VNKKYLNGALKKDSVKFVKLKKEPKNNLQDAAVIEIVGHAKDHYVGQFIT
LPNGGYYIFVDDPLFYLNINLKDTTGLVNGHKILFKIISQTTKDAIAELV
HIIGHKNDVGSDVLSIVYDNGIDPTFDPQVVDLASKLEFYVDEHQNKIRR
SIIDREIISIDPVGSKDIDDAVYVKKLNDQRYFLGISIADVSFYVQPNTI
LDADAFKRGTSTYLVDRVIPMLPHNISNNICSLNEGEFRMCITCDMVIDK
DGKICWKDVYPAIMKNYRQMSYDEVNDFYEGKSRFESATLTMKEMLLEAK
ELHHILRNKKIKDGYVDFDIKEPKIILDETGVPIDIKIYERKTAQMMVED
FMIAANEAVTMFAEEHMDKTLKEFNLEMPFIYRVHDKPSIINLQKFEIEA
KKLSFNISHDFENIQPNTISNWLKMNDNHVNLPLISKLLLRSMAKASYEI
INTGHFGLASDNYTHFTSPIRRYPDLIVHRLLWMFIFDSQSYTDKQRVEL
VNKLKLITEESNKNEIIAVKTERDVNAAKFAEYMNLHIGKEFIGVVTTVS
SFGVFVELENTIEGLIRIKNLKDDFYDFIPENMTLVGQKRKKIITVGNKV
RVRVIEANKLTRKIDFELVAQ
>UU267 valS, valyl-tRNA synthetase
MKKKLSKKYSFKEVEANKLLFWQENNLFKAQINSTKKPFTIVLPPPNVTG
HLHIGHAYDFTLSDILMRYKKLKGYDSFIIPGTDHAGIATQTKFEKNLKV
NAQTNRFNLGRELFLEKLKIWKDEQINYIHKQWNALGLGLDYSNYLFTLD
PIVVQTVREVFVKMFNEHIIYRDKKLVNWDIQLKTAISNIEVIHKEVEQK
LYYIKYLSQDQKDFVVVATSRPETMFGDKYLVINPKDKRYFHLHNKIFIN
PINNIEMTVILDDYIDIEFGTGVMKCTPAHDFNDYELAKKHNLEIINIMN
ADGTLNEKCGEFKGLDRLEARSLIIDKLQKNNHLLKVESYRTSVGFSERT
NEIVEPYLSHQWFIKMDSLIKDTIKMQDDCNNKVDFYPNRFNKTLLTWLK
NTEDWCISRQLWWGHQIPVWYHKKTNQIYCDTIPPKDLENWIQDEDVLDT
WFSSGMWPLLTTKWNYNSHFFDRYFPTSLIVTGMDILFFWVSRMMNFSQY
LVEKKPFKDVLIHGLIRDSQGRKMSKSLGNGIDPFDIIDKYGLDAMRLFF
ASCTTIGEDLNFSTERLGANWNYLNKIWNIAKYIENLDEINDNLNFEDVD
KFCDVNKWILTELSKLTLEINKNMDKYNLVVATKYLYDFIWNTFASYYLE
YTKVLLQDLTLKNETIKTIRYVFNKILIMLQPFAPNISEEIWLCLNQTNN
SILLQEYPIINFEFETIIIDKIAKIILEIRKLRLEENINNRINLCFELIS
PNDAFYKSKIKLVNLLLILVNAEINEIKKTSSNNYTYELVIDDFILKTSY
EKPIDYVFQMKKASEQLNYLENEIQRATNLLNNSGFINKAPAQLIIKEKN
KLINLKKEHANLLKTLTDLKQKVK
>UU223 xasA, amino acid antiporter
MGFVLLTASAIIAFYTFPSLSTAGWIAIIFAFITAMCWFIPIGIAAAEMA
TIKGWAEGGIFTWVRNLLGPRNGFIVTWLQFQVTFGFVAMILFVLSSFSF
AFAGADGYNYFNTLKLGTTLNQATSVNFSKNFSNGALYGIGIVVVAGLIF
MSLLGQKRTHQFGQVALIIGILLPFFIILGFQIYTVATMPDPLYFIGKHF
QKEPHLDPSVTGTSYELNKTFMSSVVMASFMAFSFSLHGVEVSAIAANRM
DNPSKKYPQAMMIVVISALVCIIIGSIMISMTVPTSTLSFNGGLVQTIMF
NLSVGGIDVKLPDGTVAHYKTLAHAYSVIETQYGTAAANQVMYQFVYGHP
INTGSDLARSDLLTLTSEVNDPLKNPSLFISVMNIETNKMAMQGLQAITF
FIGIGVFVEVSVWMSNLSTGLNYAMRKAHFPAWVTYRLKNGSALTVAILW
IVLLMCIFAIYMFGYNSLMQYKGQTISDILANEIRINQDQKEPMALLSNQ
NLDEIKLMARSIYEHSHAPGAQANVLHFDFNKHANSEVKAIYDKIKDYIG
INAVASGTPASITNISFISNVVSQISMYYIGYNIFLIGYLRYVFKANWLR
REFRVKWSWLQISLALLAMGVNTFAVVATYLPAAPELYPGQEAYYVFISI
ALPMFICTLLLGLFIYLINYAWNKKRGINLSEHSNLTNVDQNVLDVINNW
HLYKDQKEFAKFERHVQLLQQKQVIVRTTKDKAQRELVANEMQYLAAEIA
TRFAPEEEH
>UU222 xerC, integrase-recombinase protein
MKDFIRYTKKRNLSLNTIRTYESVLKHYEPVLDSWIKIRNKIINSNFKPR
TIHLHKNVLLSFFEFKKLKRYLQNLKLLKLPQIEMKYFDVISKNNLYKKT
DILDDDSLEIKKYKTIIRFLFETGIRAHELFFLESINNRLYVLGKGNKKR
QIFFVKQTFEQLQKFYENLKGFETTKTLRLYIKKIIGKNFTPHSLRRSFA
TFMLIKGANPKTVMLQMGHANIQTTFSYLNLNEQTNRRIYNKIMYQNDAE